0001213809-19-000074.txt : 20191113 0001213809-19-000074.hdr.sgml : 20191113 20191113170343 ACCESSION NUMBER: 0001213809-19-000074 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 53 CONFORMED PERIOD OF REPORT: 20190930 FILED AS OF DATE: 20191113 DATE AS OF CHANGE: 20191113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DYADIC INTERNATIONAL INC CENTRAL INDEX KEY: 0001213809 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 450486747 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-32513 FILM NUMBER: 191214794 BUSINESS ADDRESS: STREET 1: 140 INTRACOASTAL POINTE DRIVE STREET 2: SUITE 404 CITY: JUPITER STATE: FL ZIP: 33477 BUSINESS PHONE: 561-743-8333 MAIL ADDRESS: STREET 1: 140 INTRACOASTAL POINTE DRIVE STREET 2: SUITE 404 CITY: JUPITER STATE: FL ZIP: 33477 FORMER COMPANY: FORMER CONFORMED NAME: CCP WORLDWIDE INC DATE OF NAME CHANGE: 20030110 10-Q 1 dyai-20190930.htm 10-Q Document
00012138099/30/20192019Q3false140 Intracoastal Pointe DriveSuite 404JupiterFlorida☒☐--12-31P2YP1YP1YP1Y00012138092019-01-012019-09-30xbrli:shares00012138092019-11-12iso4217:USD00012138092019-09-3000012138092018-12-31iso4217:USDxbrli:shares00012138092019-07-012019-09-3000012138092018-07-012018-09-3000012138092018-01-012018-09-300001213809us-gaap:CommonStockMember2018-12-310001213809us-gaap:TreasuryStockMember2018-12-310001213809us-gaap:AdditionalPaidInCapitalMember2018-12-310001213809us-gaap:RetainedEarningsMember2018-12-310001213809us-gaap:AdditionalPaidInCapitalMember2019-01-012019-09-300001213809us-gaap:CommonStockMember2019-01-012019-09-300001213809us-gaap:RetainedEarningsMember2019-01-012019-09-300001213809us-gaap:CommonStockMember2019-09-300001213809us-gaap:TreasuryStockMember2019-09-300001213809us-gaap:AdditionalPaidInCapitalMember2019-09-300001213809us-gaap:RetainedEarningsMember2019-09-3000012138092017-12-3100012138092018-09-300001213809dyai:IndustrialTechnologyBusinessMemberdyai:DuPontDaniscoMember2015-12-312015-12-31dyai:segmentdyai:customer0001213809us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2019-07-012019-09-300001213809us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2018-07-012018-09-300001213809us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2019-01-012019-09-300001213809us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2018-01-012018-09-300001213809us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2019-01-012019-09-300001213809us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2018-01-012018-12-310001213809us-gaap:NonUsMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2019-07-012019-09-300001213809us-gaap:NonUsMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2019-01-012019-09-30xbrli:pure0001213809us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMembercountry:US2018-07-012018-09-300001213809us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMembercountry:US2018-01-012018-09-300001213809us-gaap:NonUsMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2019-07-012019-09-300001213809us-gaap:NonUsMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2019-09-300001213809us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMembercountry:US2018-01-012018-12-310001213809us-gaap:BilledRevenuesMember2019-09-300001213809us-gaap:BilledRevenuesMember2018-12-310001213809us-gaap:UnbilledRevenuesMember2019-09-300001213809us-gaap:UnbilledRevenuesMember2018-12-3100012138092017-12-222017-12-220001213809us-gaap:CashMember2019-09-300001213809us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2019-09-300001213809us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2019-09-300001213809us-gaap:CashMember2018-12-310001213809us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2018-12-310001213809us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2018-12-310001213809us-gaap:CorporateDebtSecuritiesMember2019-07-012019-09-300001213809us-gaap:CorporateDebtSecuritiesMember2018-07-012018-09-300001213809us-gaap:CorporateDebtSecuritiesMember2019-01-012019-09-300001213809us-gaap:CorporateDebtSecuritiesMember2018-01-012018-09-300001213809us-gaap:CorporateDebtSecuritiesMember2018-01-012018-12-3100012138092017-06-302017-06-30iso4217:EUR0001213809dyai:ResearchServicesAgreementMember2017-06-302017-06-300001213809dyai:ResearchServicesAgreementMemberdyai:BDIHoldingsMember2017-06-302017-06-300001213809dyai:ResearchServicesAgreementMemberdyai:VLPbioMember2017-06-302017-06-300001213809dyai:ResearchServicesAgreementMemberdyai:BDIMember2017-06-300001213809dyai:ResearchServicesAgreementMemberdyai:BDIMember2017-06-302017-06-300001213809dyai:ResearchServicesAgreementMembersrt:MinimumMember2017-06-302017-06-300001213809dyai:ResearchServicesAgreementMembersrt:MaximumMember2017-06-302017-06-300001213809dyai:ResearchServicesAgreementMemberdyai:BDIMembersrt:MinimumMember2017-06-302017-06-300001213809dyai:ResearchServicesAgreementMemberdyai:BDIMembersrt:MaximumMember2017-06-302017-06-300001213809dyai:ResearchServicesAgreementMember2017-06-300001213809dyai:ServiceFrameworkAgreementMember2017-06-300001213809dyai:ServiceFrameworkAgreementMember2017-06-302017-06-30dyai:collaboration_project0001213809dyai:ServiceFrameworkAgreementMember2019-09-300001213809dyai:NovovetMember2019-04-260001213809dyai:AlphazymeMember2019-05-050001213809dyai:AlphazymeMemberus-gaap:CollaborativeArrangementMember2019-05-052019-05-05dyai:antibody_and_vaccine0001213809dyai:SerumMemberus-gaap:CollaborativeArrangementMember2019-05-07dyai:protein0001213809dyai:SerumMemberus-gaap:CollaborativeArrangementMember2019-05-072019-05-070001213809dyai:SerumMemberus-gaap:CollaborativeArrangementMember2019-01-012019-09-300001213809dyai:SerumMemberus-gaap:CollaborativeArrangementMember2019-07-012019-09-300001213809dyai:SerumMemberus-gaap:CollaborativeArrangementMember2019-09-30utr:sqft0001213809dyai:JupiterFloridaHeadquartersLeaseMember2019-09-300001213809dyai:JupiterFloridaHeadquartersLeaseMember2019-01-012019-09-300001213809dyai:NetherlandsOfficeLeaseMember2019-09-300001213809dyai:NetherlandsOfficeLeaseMember2019-01-012019-09-300001213809dyai:NetherlandsOfficeLeaseMember2019-02-010001213809dyai:NetherlandsOfficeLeaseMember2019-02-012019-02-010001213809dyai:VTTTechnicalResearchCentreofFinlandLtdMember2019-06-280001213809dyai:VTTTechnicalResearchCentreofFinlandLtdMember2019-06-282019-06-280001213809us-gaap:SubsequentEventMemberdyai:VTTTechnicalResearchCentreofFinlandLtdMember2019-10-250001213809us-gaap:SubsequentEventMemberdyai:VTTTechnicalResearchCentreofFinlandLtdMember2019-10-252019-10-250001213809dyai:A2006PlanMember2019-09-300001213809dyai:A2011PlanMember2019-09-300001213809dyai:A2011PlanMember2019-01-012019-01-010001213809dyai:A2011PlanMember2018-12-310001213809us-gaap:EmployeeStockOptionMemberdyai:A2011PlanMember2019-01-012019-09-300001213809us-gaap:EmployeeStockOptionMemberdyai:A2011PlanMemberus-gaap:ChiefExecutiveOfficerMember2019-01-012019-09-300001213809dyai:ContractorMemberus-gaap:EmployeeStockOptionMemberdyai:A2011PlanMember2019-01-012019-09-300001213809us-gaap:EmployeeStockOptionMember2019-01-012019-09-300001213809us-gaap:EmployeeStockOptionMembersrt:MinimumMember2019-01-012019-09-300001213809us-gaap:EmployeeStockOptionMembersrt:MaximumMember2019-01-012019-09-3000012138092018-01-012018-12-310001213809dyai:ExecutivesandKeyPersonnelMemberus-gaap:EmployeeStockOptionMember2019-01-022019-01-020001213809dyai:ExecutivesandKeyPersonnelMember2019-01-022019-01-020001213809us-gaap:DirectorMember2019-01-022019-01-020001213809us-gaap:ShareBasedCompensationAwardTrancheOneMemberus-gaap:EmployeeStockOptionMemberus-gaap:DirectorMember2019-01-022019-01-020001213809us-gaap:EmployeeStockOptionMemberdyai:SharebasedCompensationAwardTrancheTwothroughFiveMemberus-gaap:DirectorMember2019-01-022019-01-020001213809dyai:EmployeeMember2019-01-022019-01-020001213809us-gaap:EmployeeStockOptionMemberdyai:EmployeeMember2019-01-022019-01-020001213809dyai:ContractorMemberus-gaap:EmployeeStockOptionMember2019-01-020001213809dyai:ContractorMember2019-01-022019-01-020001213809dyai:ContractorMemberus-gaap:EmployeeStockOptionMember2019-03-070001213809dyai:ContractorMember2019-03-072019-03-070001213809us-gaap:EmployeeStockOptionMemberus-gaap:DirectorMember2019-06-250001213809us-gaap:DirectorMember2019-06-252019-06-25dyai:board_of_director00012138092019-06-250001213809us-gaap:EmployeeStockOptionMemberus-gaap:ChiefFinancialOfficerMember2019-06-280001213809us-gaap:ChiefFinancialOfficerMember2019-06-282019-06-280001213809us-gaap:GeneralAndAdministrativeExpenseMember2019-07-012019-09-300001213809us-gaap:GeneralAndAdministrativeExpenseMember2018-07-012018-09-300001213809us-gaap:GeneralAndAdministrativeExpenseMember2019-01-012019-09-300001213809us-gaap:GeneralAndAdministrativeExpenseMember2018-01-012018-09-300001213809us-gaap:ResearchAndDevelopmentExpenseMember2019-07-012019-09-300001213809us-gaap:ResearchAndDevelopmentExpenseMember2018-07-012018-09-300001213809us-gaap:ResearchAndDevelopmentExpenseMember2019-01-012019-09-300001213809us-gaap:ResearchAndDevelopmentExpenseMember2018-01-012018-09-300001213809us-gaap:AdditionalPaidInCapitalMember2019-01-012019-03-3100012138092019-01-012019-03-310001213809us-gaap:RetainedEarningsMember2019-01-012019-03-310001213809us-gaap:CommonStockMember2019-03-310001213809us-gaap:TreasuryStockMember2019-03-310001213809us-gaap:AdditionalPaidInCapitalMember2019-03-310001213809us-gaap:RetainedEarningsMember2019-03-3100012138092019-03-310001213809us-gaap:CommonStockMember2019-04-012019-06-300001213809us-gaap:AdditionalPaidInCapitalMember2019-04-012019-06-3000012138092019-04-012019-06-300001213809us-gaap:RetainedEarningsMember2019-04-012019-06-300001213809us-gaap:CommonStockMember2019-06-300001213809us-gaap:TreasuryStockMember2019-06-300001213809us-gaap:AdditionalPaidInCapitalMember2019-06-300001213809us-gaap:RetainedEarningsMember2019-06-3000012138092019-06-300001213809us-gaap:CommonStockMember2019-07-012019-09-300001213809us-gaap:AdditionalPaidInCapitalMember2019-07-012019-09-300001213809us-gaap:RetainedEarningsMember2019-07-012019-09-300001213809us-gaap:CommonStockMember2017-12-310001213809us-gaap:TreasuryStockMember2017-12-310001213809us-gaap:AdditionalPaidInCapitalMember2017-12-310001213809us-gaap:RetainedEarningsMember2017-12-310001213809us-gaap:TreasuryStockMember2018-01-012018-03-3100012138092018-01-012018-03-310001213809us-gaap:AdditionalPaidInCapitalMember2018-01-012018-03-310001213809us-gaap:RetainedEarningsMember2018-01-012018-03-310001213809us-gaap:CommonStockMember2018-03-310001213809us-gaap:TreasuryStockMember2018-03-310001213809us-gaap:AdditionalPaidInCapitalMember2018-03-310001213809us-gaap:RetainedEarningsMember2018-03-3100012138092018-03-310001213809us-gaap:AdditionalPaidInCapitalMember2018-04-012018-06-3000012138092018-04-012018-06-300001213809us-gaap:RetainedEarningsMember2018-04-012018-06-300001213809us-gaap:CommonStockMember2018-06-300001213809us-gaap:TreasuryStockMember2018-06-300001213809us-gaap:AdditionalPaidInCapitalMember2018-06-300001213809us-gaap:RetainedEarningsMember2018-06-3000012138092018-06-300001213809us-gaap:TreasuryStockMember2018-07-012018-09-300001213809us-gaap:AdditionalPaidInCapitalMember2018-07-012018-09-300001213809us-gaap:CommonStockMember2018-07-012018-09-300001213809us-gaap:RetainedEarningsMember2018-07-012018-09-300001213809us-gaap:CommonStockMember2018-09-300001213809us-gaap:TreasuryStockMember2018-09-300001213809us-gaap:AdditionalPaidInCapitalMember2018-09-300001213809us-gaap:RetainedEarningsMember2018-09-3000012138092016-02-162016-02-1600012138092016-02-1600012138092017-08-162017-08-1600012138092017-08-1600012138092016-01-122016-01-120001213809dyai:PubliclyAnnouncedRepurchasePlansMember2016-01-122016-01-1200012138092017-01-112017-01-110001213809dyai:PubliclyAnnouncedRepurchasePlansMember2017-01-112017-01-1100012138092017-01-012017-02-280001213809dyai:PubliclyAnnouncedRepurchasePlansMember2017-01-012017-02-2800012138092017-02-2800012138092017-09-012017-12-310001213809dyai:PubliclyAnnouncedRepurchasePlansMember2017-09-012017-12-3100012138092018-01-012018-08-310001213809dyai:PubliclyAnnouncedRepurchasePlansMember2018-01-012018-08-3100012138092018-08-3100012138092016-01-012018-12-310001213809dyai:PubliclyAnnouncedRepurchasePlansMember2016-01-012018-12-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q
(Mark One)
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the quarterly period ended September 30, 2019
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _____ to ______
Commission File Number: 000-55264
dyai-20190930_g1.jpg DYADIC INTERNATIONAL, INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware 45-0486747
State or Other Jurisdiction of Incorporation or Organization I.R.S. Employer Identification No.
140 Intracoastal Pointe Drive, Suite 404
 Jupiter, Florida
 33477
Address of Principal Executive OfficesZip Code

(561) 743-8333
Registrant’s Telephone Number, Including Area Code
N/A
Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☐
Accelerated filer ☐
Non-accelerated filer ☒
 
Smaller reporting company ☒
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.001 per shareDYAIThe NASDAQ Stock Market LLC
The number of shares outstanding of each of the registrant’s Common Stock as of November 12, 2019 was 27,213,157.






CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
Information (other than historical facts) set forth in this Quarterly Report contains forward-looking statements within the meaning of the Federal securities laws, which involve many risks and uncertainties that could cause our actual results to differ materially from those reflected in the forward-looking statements. Forward-looking statements generally can be identified by use of the words “expect,” “should,” “intend,” “anticipate,” “will,” “project,” “may,” “might,” “potential,” or “continue” and other similar terms or variations of them or similar terminology. Such forward-looking statements are included under Item 2 “Management’s Discussion and Analysis”. Dyadic International, Inc., and its subsidiaries cautions readers that any forward-looking information is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking information. Such statements reflect the current views of our management with respect to our operations, results of operations and future financial performance. Forward-looking statements involve many risks, uncertainties or other factors within and/or beyond Dyadic’s control. These factors include, but are not limited to, (1) general economic, political and market conditions; (2) our ability to generate the required productivity, stability, purity, performance, cost, safety and other data necessary to carry out and implement our biopharmaceutical research and business plans and strategic initiatives; (3) our ability to retain and attract employees, consultants, directors and advisors; (4) our ability to implement and successfully carry out Dyadic’s and third parties’ research and development efforts; (5) our ability to obtain new license and research agreements; (6) our ability to maintain our existing access to, and/or expand access to third party contract research organizations in order to carry out our research projects for ourselves and third parties; (7) competitive pressures and reliance on our key customers and collaborators; (8) the pharmaceutical and biotech industry, governmental regulatory and other agencies’ willingness to adopt, utilize and approve the use of the C1 gene expression platform; (9) speculative nature and illiquidity of equity securities received as consideration from sub-licenses; and (10) other factors discussed in Dyadic’s publicly available filings, including information set forth under the caption “Risk Factors” in our Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 27, 2019 and our Form 10-Q filed with the SEC on May 9, 2019. We caution you that the foregoing list of important factors is not exclusive. The forward-looking statements are based on our beliefs, assumptions and expectations of future performance, considering the information currently available to us. These statements are only predictions based upon our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Moreover, we operate in a highly regulated, competitive and rapidly changing environment. Our competitors have far greater resources, infrastructure and market presence than we do which makes it difficult for us to enter certain markets, and/or to gain or maintain customers. New risks emerge from time to time and it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Before investing in our common stock, investors should carefully read the information set forth under the caption “Risk Factors” and elsewhere on our Form 10-K filed with the SEC on March 27, 2019 and our Form 10-Q filed with the SEC on May 9, 2019 which could have a material adverse effect on our business, results of operations and financial condition.
You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. Except as required by law, we undertake no obligation to publicly update any forward-looking statements for any reason after the date of this Quarterly Report to conform these statements to actual results or to changes in our expectations.
We qualify all our forward-looking statements by these cautionary statements. In addition, with respect to all our forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

PART I

Item 1.Financial Statements

3

DYADIC INTERNATIONAL, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
September 30, 2019December 31, 2018
(Unaudited)(Audited)
Assets
Current assets:
Cash and cash equivalents$4,662,327  $2,386,314  
Short-term investment securities30,793,472  38,816,441  
Interest receivable235,440  294,240  
Accounts receivable418,945  318,744  
Income tax receivable9,406  506,866  
Prepaid research and development—  253,446  
Prepaid expenses and other current assets336,868  172,001  
Total current assets36,456,458  42,748,052  
Non-current assets:
Long-term investment securities1,514,153  —  
Long-term income tax receivable500,616  500,616  
Other assets50,232  52,139  
Total assets$38,521,459  $43,300,807  
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable$713,395  $309,060  
Accrued expenses470,117  399,576  
Deferred research and development obligations93,276  141,002  
Total current liabilities1,276,788  849,638  
Commitments and contingencies (See Note 4)
Stockholders’ equity:
Preferred stock, $.0001 par value:
Authorized shares - 5,000,000; none issued and outstanding
—  —  
Common stock, $.001 par value:
Authorized shares - 100,000,000; issued shares - 39,466,659 and 38,966,988, outstanding shares - 27,213,157 and 26,713,486 as of September 30, 2019 and December 31, 2018
39,467  38,967  
Additional paid-in capital95,747,666  94,385,230  
Treasury stock, shares held at cost - 12,253,502
(18,929,915) (18,929,915) 
Accumulated deficit(39,612,547) (33,043,113) 
Total stockholders’ equity37,244,671  42,451,169  
Total liabilities and stockholders’ equity$38,521,459  $43,300,807  

The accompanying notes are an integral part of these unaudited consolidated financial statements.

4

DYADIC INTERNATIONAL, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
Three Months Ended September 30,Nine Months Ended September 30,
2019201820192018
Revenues:
Research and development revenue$454,507  $262,960  $1,247,908  $608,576  
Costs and expenses:
Costs of research and development revenue384,803  243,406  1,034,934  519,331  
Research and development841,343  476,633  2,351,953  1,654,716  
Research and development - related party101,849  288,175  827,632  1,021,573  
General and administrative1,056,196  1,023,606  4,354,941  3,238,145  
Foreign currency exchange loss (gain), net13,727  12,279  24,693  1,921  
Total costs and expenses2,397,918  2,044,099  8,594,153  6,435,686  
Loss from operations(1,943,411) (1,781,139) (7,346,245) (5,827,110) 
Interest income245,027  241,644  777,711  647,686  
Loss before income taxes(1,698,384) (1,539,495) (6,568,534) (5,179,424) 
Provision for income taxes—  —  900  —  
Net loss$(1,698,384) $(1,539,495) $(6,569,434) $(5,179,424) 
Basic and diluted net loss per common share$(0.06) $(0.06) $(0.24) $(0.19) 
Basic and diluted weighted-average common shares outstanding27,181,003  27,774,436  26,909,205  27,996,754  
The accompanying notes are an integral part of these unaudited consolidated financial statements.


5

DYADIC INTERNATIONAL, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(Unaudited)
Common StockTreasury StockAdditionalAccumulated
SharesAmountSharesAmountPaid-in CapitalDeficit Total
Balance at December 31, 201838,966,988   $38,967  (12,253,502) $(18,929,915) $94,385,230  $(33,043,113) $42,451,169  
Stock-based compensation—  —  —  —  1,034,346  —  1,034,346  
Exercise of stock options499,671  500  —  —  328,090  —  328,590  
Net loss—  —  —  —  —  (6,569,434) (6,569,434) 
Balance at September 30, 201939,466,659  $39,467  (12,253,502) $(18,929,915) $95,747,666  $(39,612,547) $37,244,671  

The accompanying notes are an integral part of these unaudited consolidated financial statements.


6

DYADIC INTERNATIONAL, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
Nine Months Ended September 30,
20192018
Cash flows from operating activities
 Net loss $(6,569,434) $(5,179,424) 
 Adjustments to reconcile net loss to net cash used in operating activities:
 Stock-based compensation expense 1,034,346  413,640  
 Amortization of held-to-maturity securities, net 141,362  598,464  
 Foreign currency exchange loss (gain), net24,693  1,921  
 Changes in operating assets and liabilities:
 Interest receivable58,800  176,617  
 Accounts receivable(110,807) 66,574  
 Income tax receivable497,460  —  
 Prepaid research and development253,446  705,836  
 Prepaid expenses and other current assets(164,590) (39,732) 
 Accounts payable429,955  35,345  
 Accrued expenses70,541  92,616  
 Deferred research and development obligation(47,726) 51,786  
 Income taxes payable—  (102,000) 
 Net cash used in operating activities(4,381,954) (3,178,357) 
Cash flows from investing activities
 Purchases of held-to-maturity investment securities(37,585,548) (39,320,144) 
 Proceeds from maturities of investment securities43,953,000  40,739,000  
 Net cash provided by investing activities6,367,452  1,418,856  
Cash flows from financing activities
 Repurchases of common stock—  (2,304,042) 
 Proceeds from exercise of options328,590  4,500  
 Net cash provided by (used in) financing activities328,590  (2,299,542) 
 Effect of exchange rate changes on cash(38,075) (12,600) 
 Net increase (decrease) in cash and cash equivalents2,276,013  (4,071,643) 
 Cash and cash equivalents at beginning of period2,386,314  5,786,348  
 Cash and cash equivalents at end of period$4,662,327  $1,714,705  
 Supplemental cash flow information
 Cash received from income tax refund$506,866  $—  

The accompanying notes are an integral part of these unaudited consolidated financial statements.

7

Notes to Consolidated Financial Statements

Note 1: Organization and Summary of Significant Accounting Policies
Description of Business
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our” or the “Company”) is a global biotechnology platform company based in Jupiter, Florida with operations in the United States, a satellite office in the Netherlands and research organizations performing services under contract to Dyadic in Finland and Spain. Over the past two decades, the Company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has previously licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Myceliophthora thermophila fungus, which the Company named C1. The C1 technology is a robust and versatile fungal expression system for the development and production of enzymes and other proteins.
On December 31, 2015, the Company sold its industrial technology business to DuPont Danisco (“DuPont”), the industrial biosciences business of DuPont (NYSE: DD) for $75 million (the “DuPont Transaction”). As part of the DuPont Transaction, Dyadic retained co-exclusive rights to the C1 technology for use in all human and animal pharmaceutical applications, and currently has the exclusive ability to enter into sub-license agreements (subject to the terms of the license and to certain exceptions). DuPont retained certain rights to utilize the C1 technology in pharmaceutical applications, including the development and production of pharmaceutical products, for which it will be required to make royalty payments to Dyadic upon commercialization. In certain circumstances, Dyadic may owe a royalty to either DuPont or certain licensors of DuPont, depending upon whether Dyadic elects to utilize certain patents either owned by DuPont or licensed in by DuPont.
After the DuPont Transaction, the Company has been focused on the biopharmaceutical industry, specifically in further improving and applying the proprietary C1 technology into a safe and efficient gene expression platform to help accelerate the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. We believe that the C1 technology could be beneficial in the development and manufacturing of human and animal vaccines (such as virus-like particles (VLPs) and antigens), monoclonal antibodies (mAbs), Bi-Specific antibodies, Fab antibody fragments, Fc-Fusion proteins, metabolites, and other therapeutic enzymes and proteins.
Effective April 17, 2019, our common stock began trading on the NASDAQ Stock Market LLC’s NASDAQ Capital Market, under the symbol “DYAI”. Prior to the Company’s uplisting to the NASDAQ, the Company’s common stock traded on the OTCQX market.
Summary of Significant Accounting Policies
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements, including the accounts of the Company and its wholly owned subsidiaries, have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and footnote disclosures normally included in consolidated financial statements have been condensed or omitted pursuant to such rules and regulations. All significant intra-entity transactions and balances have been eliminated in consolidation. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and footnotes as of and for the year ended December 31, 2018, included in our Form 10-K which was filed with the SEC on March 27, 2019.
In the opinion of management, the accompanying unaudited interim consolidated financial statements reflect all adjustments, which are of a normal recurring nature, considered necessary for a fair presentation of all periods presented. The results of the Company’s operations for any interim periods are not necessarily indicative of the results of operations for any other interim period or for a full fiscal year.
Since concluding the DuPont Transaction, the Company has conducted business in one operating segment, which is identified by the Company based on how resources are allocated, and operating decisions are made. Management evaluates performance and allocates resources based on the Company as a whole.
Use of Estimates
8

The preparation of these consolidated financial statements in accordance with GAAP requires management to make estimates and judgments that affect the reported amount of assets and liabilities and related disclosure of contingent assets and liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the applicable period. Actual results may differ from these estimates under different assumptions or conditions. Such differences could be material to the consolidated financial statements.
Concentrations
The Company’s financial instruments that are potentially subject to concentrations of credit risk consist primarily of cash and cash equivalents, and investment securities. At times, the Company has cash, cash equivalents, and investment securities at financial institutions exceeding the Federal Depository Insurance Company (“FDIC”) and the Securities Investor Protection Corporation (“SIPC”) insured limit on domestic currency and the Netherlands’ FDIC counterpart for foreign currency. The Company only deals with reputable financial institutions and has not experienced any losses in such accounts.
For the three months ended September 30, 2019 and 2018, the Company’s revenue was generated from five and four customers, respectively. For the nine months ended September 30, 2019 and 2018, the Company’s revenue was generated from eight and five customers, respectively. As of September 30, 2019 and December 31, 2018, the Company’s accounts receivable was from three and four customers, respectively. The loss of business from one or a combination of the Company’s customers could adversely affect its operations.
The Company generates a portion of its revenues from customers that are located outside of the United States. For the three months ended September 30, 2019, the Company had three customers outside of the United States (i.e. European and Indian customers) that accounted for approximately 77.0% or $351,000 of total revenue. For the nine months ended September 30, 2019 the Company had three customers outside of the United States that accounted for approximately 73.6% or $918,000 of total revenue. For the three and nine months ended September 30, 2018, 100% of the Company’s revenue was from the United States.
As of September 30, 2019, the Company had one customer outside of the United States that accounted for approximately 79.3% or $332,000 of accounts receivable. As of December 31, 2018, 100% of the Company’s accounts receivable was from the United States.
Cash and Cash Equivalents
We treat highly liquid investments with original maturities of three months or less when purchased as cash equivalents, including money market funds, which are unrestricted for withdrawal or use.
Investment Securities
The Company invests excess cash balances in short-term and long-term investment grade securities. Short-term investment securities mature within 12 months or less, and long-term investment securities mature between 12 and 18 months from the applicable reporting date. Management determines the appropriate classification of its investments at the time of purchase and reevaluates the classifications at each balance sheet date. The Company’s investments in debt securities have been classified and accounted for as held-to-maturity. Held-to-maturity securities are those securities that the Company has the ability and intent to hold until maturity. Held-to-maturity securities are recorded at amortized cost, adjusted for the amortization or accretion of premiums or discounts. Premiums and discounts are amortized over the life of the related held-to-maturity security. When a debt security is purchased at a premium, both the face value of the debt and premium amount are reflected as investing outflow. Other-than-temporary impairment charges, if incurred, will be included in other income (expense).
The Company’s investments in money market funds have been classified and accounted for as available-for-sale securities and presented as cash equivalents on the consolidated balance sheets. As of September 30, 2019 and December 31, 2018, all of our money market funds were invested in U.S. Government money market funds. The Company did not have any investment securities classified as trading as of September 30, 2019 or December 31, 2018.
Accounts Receivable
Accounts receivable consist of billed receivables currently due from customers and unbilled receivables. Unbilled receivables represent the excess of contract revenue (or amounts reimbursable under contracts) over billings to date. Such amounts become billable in accordance with the contract terms, which usually consider the passage of time, achievement of certain milestones or completion of the project.
9

Outstanding account balances are reviewed individually for collectability. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing accounts receivable. Substantially all of our accounts receivable were current and include unbilled amounts that will be billed and collected over the next twelve months. There was no allowance for doubtful accounts as of September 30, 2019 and December 31, 2018.
Accounts receivable consist of the following:
September 30, 2019December 31, 2018
(Unaudited)(Audited)
Billed receivable $66,988  $193,065  
Unbilled receivable351,957  125,679  
$418,945  $318,744  
Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets consist of the following:
September 30, 2019December 31, 2018
(Unaudited) (Audited) 
Prepaid expenses - various$81,320  $91,725  
Prepaid insurance254,997  77,249  
Prepaid taxes551  3,027  
$336,868  $172,001  
Equity Method Investment
The Company follows Accounting Standards Codification (“ASC”) Subtopic 323-10, Investments - Equity Methods and Joint Ventures, which requires the accounting for investments where the Company can exercise significant influence, but not control of a joint venture or equity investment. See Note 3 for the Company’s investments recorded under the equity method of accounting.
Equity method investments are assessed for impairment whenever events or changes in circumstances indicate that the carrying amount of the investment may not be recoverable. If the decline in value is considered to be other than temporary, the investment is written down to its estimated fair value, which establishes a new cost basis in the investment.
Accounts Payable
Accounts payable consist of the following:
September 30, 2019December 31, 2018
(Unaudited) (Audited) 
Research and development expenses$636,428  $240,064  
Legal expenses17,283  —  
Other59,684  68,996  
$713,395  $309,060  
Accrued Expenses
Accrued expenses consist of the following:
10

September 30, 2019December 31, 2018
(Unaudited) (Audited) 
Employee wages and benefits$353,552  $268,287  
Research and development expenses77,855  49,666  
Other38,710  81,623  
$470,117  $399,576  

Revenue Recognition
The Company has no pharmaceutical products approved for sale at this point, and all of our revenue to date has been research revenue from third-party collaborations and government grants. The Company is expected to generate future revenue from license agreements and collaborative arrangements, which may include upfront payments for licenses or options to obtain a license, payment for research and development services and milestone payments, in the form of cash or non-cash considerations (e.g., minority equity interest).
Revenue related to research collaborations and agreements: The Company typically performs research and development services as specified in each respective agreement on a best efforts basis, and recognizes revenue from research funding under collaboration agreements in accordance with the 5-step process outlined in ASC Topic 606 (“Topic 606”): (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We recognize revenue when we satisfy a performance obligation by transferring control of the service to a customer in an amount that reflects the consideration that we expect to receive. Since the performance obligation under our collaboration agreements is generally satisfied over time, we elected to use the input method under Topic 606 to measure the progress toward complete satisfaction of a performance obligation.
Under the input methods, revenue will be recognized on the basis of the entity’s efforts or inputs to the satisfaction of a performance obligation (e.g., resources consumed, labor hours expended, costs incurred, or time elapsed) relative to the total expected inputs to the satisfaction of that performance obligation. The Company believes that the cost-based input method is the best measure of progress to reflect how the Company transfers its performance obligation to a customer. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to budgeted costs to fulfill the performance obligation. These costs consist primarily of full-time equivalent effort and third-party contract costs. Revenue will be recognized based on actual costs incurred as a percentage of total budgeted costs as the Company completes its performance obligations.
A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company’s performance obligations. In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete the Company’s performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.
Revenue related to sublicensing agreements: If the sublicense to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue allocated to the license when technology is transferred to the customer and the customer is able to use and benefit from the license.
Milestone payments: At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Company evaluates whether the achievement of the milestones is considered probable and estimates the amount to be included in the transaction price. If the milestone payment is in exchange for a sublicense and is based on the sublicensee’s subsequent sale of product, the Company recognizes milestone payment by applying the accounting guidance for royalties. To date, the Company has not recognized any milestone payment revenue resulting from any of its sublicensing arrangements.
Royalties: With respect to licenses deemed to be the predominant item to which the sales-based royalties relate, including milestone payments based on the level of sales, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or
11

partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its sublicensing arrangements.
We invoice customers based on our contractual arrangements with each customer, which may not be consistent with the period that revenues are recognized. When there is a timing difference between when we invoice customers and when revenues are recognized, we record either a contract asset (unbilled accounts receivable) or a contract liability (deferred research and development obligations), as appropriate. If upfront fees or considerations related to sublicensing agreement are received prior to the technology transfer, the Company will record the amount received as deferred revenue from licensing agreement.
We are not required to disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.

The Company adopted a practical expedient to expense sales commissions when incurred because the amortization period would be one year or less.

Research and Development Costs
Research and development (“R&D”) costs are expensed as incurred. R&D costs are for the Company’s internally funded pharmaceutical programs and other governmental and commercial projects.
Research and development costs consist of personnel-related costs, facilities, research-related overhead, services from independent contract research organizations, and other external costs. Research and development costs, including related party, during the three and nine months ended September 30, 2019 and 2018 were as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2019201820192018
(Unaudited) (Unaudited) (Unaudited) (Unaudited) 
Outside contracted services$730,190  $365,689  $1,974,176  $1,316,581  
Contracted services - related party101,849  288,175  827,632  1,021,573  
Personnel related costs95,269  87,307  312,321  277,856  
Facilities, overhead and other15,884  23,637  65,456  60,279  
$943,192  $764,808  $3,179,585  $2,676,289  

Foreign Currency Transaction Gain or Loss
The Company’s foreign subsidiary uses the U.S. dollar as its functional currency, and it initially measures the foreign currency denominated assets and liabilities at the transaction date. Monetary assets and liabilities are then re-measured at exchange rates in effect at the end of each period, and property and non-monetary assets and liabilities are converted at historical rates.
Fair Value Measurements
The Company applies fair value accounting for certain financial instruments that are recognized or disclosed at fair value in the financial statements. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:
•Level 1 – Quoted prices in active markets for identical assets or liabilities.
•Level 2 – Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
12

•Level 3 – Inputs that are generally unobservable and typically reflect management’s estimate of assumptions that market participants would use in pricing the asset or liability.

Certain assets and liabilities on the balance sheets are measured at carrying values, which approximate fair values due to the short-term nature of these balances. Such items include cash and cash equivalents, accounts receivable, accounts payable, prepaid expenses, and accrued expenses. Investments in debt securities are recorded at amortized cost, and their estimated fair value amounts are provided by the third-party broker service for disclosure purposes.
The Company utilized various methods, including income, cost and market approaches to determine the fair value of its investments in equity interest, which may fall into Level 3 of the fair value hierarchy because of the significant unobservable inputs utilized in these valuation approaches. These inputs can be readily observable, market corroborated, or generally unobservable inputs. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. Our key inputs included, but were not limited to, significant management judgments and estimates, including projections of the timing and amount of the project’s cash flows, determination of a discount rate for the income approach, market multipliers, probability weighting of potential outcomes of legal and regulatory proceedings, and weighting of the valuations produced by the income, cost and market approaches.
Income Taxes
The Tax Cuts and Jobs Act (“TCJA”) was enacted on December 22, 2017 and became effective January 1, 2018. The TCJA contains several key provisions, including a reduction in the U.S. Federal corporate income tax rate from 35% to 21% and a change to the corporate alternative minimum tax (“AMT”). The TCJA’s reduction in the U.S. statutory tax rate had no additional impact on the consolidated financial statement for the year ended December 31, 2018.
The TCJA eliminated the corporate AMT and permits existing AMT credit carryforwards to be used to reduce the regular tax obligation in 2018, 2019, and 2020. Any AMT credit carryforwards that do not reduce regular taxes are eligible for a 50% refund in 2018 through 2020, and a 100% refund in 2021. Accordingly, we reclassified the balance of the AMT credit from the deferred tax asset to an income tax receivable in 2018. The corresponding balance in the valuation allowance has been reversed into income tax benefit in the amount of $1,001,233. As of September 30, 2019, we have received 50% or approximately $0.5 million refund for tax year 2018 and expect to receive the remaining 50% for tax years 2019 through 2021.
For the nine months ended September 30, 2019, the Company recorded a provision for income taxes of $900. There were no unrecognized tax benefits as of September 30, 2019 and December 31, 2018.
Deferred tax assets as of September 30, 2019 and December 31, 2018 were approximately $6.9 million and $4.6 million, respectively. Due to the Company’s history of operating losses and the uncertainty regarding our ability to generate taxable income in the future, the Company has established a 100% valuation allowance against deferred tax assets as of September 30, 2019 and December 31, 2018.
On June 20, 2019, the Company received a letter from the United States Internal Revenue Service (the “IRS”) informing the Company that its 2016 federal tax return was selected for examination. In August 2019, the Company had a meeting with the IRS agent and provided the IRS with all requested information. Thus far, the Company has not been informed of any assessment. As the IRS audit is still in progress, we are unable to predict when the audit will be concluded or whether any assessment will be proposed.
Comprehensive Income (Loss)
Comprehensive income (loss) includes net income (loss) and other revenue, expenses, gains and losses that are recorded as an element of shareholders’ equity but are excluded from net income (loss) under GAAP. The Company does not have any significant transactions that are required to be reported in other comprehensive income (loss), and therefore, does not separately present a statement of comprehensive income (loss) in its consolidated financial statements.

Stock-Based Compensation

We recognize all share-based payments to employees and our board of directors (“Board of Directors”), as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statement of operations based on the grant date fair values of such payments. Stock-based compensation expense recognized each period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are recorded as they occur.
13

Net Loss Per Share
Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common stock outstanding during the reporting period. Diluted net loss per share adjusts the weighted average number of common stock outstanding for the potential dilution that could occur if common stock equivalents, such as stock options were exercised or converted into common stock, calculated by applying the treasury stock method.
For each of the three and nine months ended September 30, 2019 and 2018, the effect of the potential exercise of options to purchase 4,006,390 and 3,411,890 shares of common stock, respectively, were excluded from the computation of diluted net loss per share as their effect would have been anti-dilutive.
Recent Accounting Pronouncements Not Adopted as of September 30, 2019
In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which modifies the measurement of expected credit losses of certain financial instruments. ASU 2016-13 will be effective for the Company beginning in the first quarter of 2020. The Company is currently evaluating the impact, if any, of this newly issued guidance.
In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820) which modifies the disclosure requirements on fair value measurements. The effective date for the standard is fiscal years beginning after December 15, 2019, which for the Company is January 1, 2020. Early adoption is permitted. The new disclosure requirements for changes in unrealized gains and losses in other comprehensive income for recurring Level 3 measurements, the range and weighted average of significant unobservable inputs and the amended requirements for the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively. The Company does not expect ASU 2018-13 to have a material impact on our consolidated financial statements.
Other pronouncements issued by the FASB or other authoritative accounting standards group with future effective dates are either not applicable or not significant to our consolidated financial statements.
Recently Adopted Accounting Pronouncements
In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). Under the new guidance, lessees will be required to recognize the assets and liabilities that arise from operating leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. Companies are required to recognize and measure leases using a modified retrospective approach at either the beginning of the earliest comparative period presented or the beginning of the reporting period in which the entity first applies the new standard. ASU 2016-02 was effective for the Company beginning in the first quarter of 2019. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements and related disclosures, as the Company’s leases are one year or less and not required to recognize lease assets or liabilities under the new guidance.
In March 2017, the FASB issued ASU 2017-08, Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization of Purchased Callable Debt Securities. The amendments in this ASU shorten the amortization period for certain callable debt securities held at a premium. The amendments require the premium to be amortized to the earliest call date. The amendments do not require an accounting change for securities held at a discount; the discount continues to be amortized to maturity. The Company adopted the standard on January 1, 2019. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements and related disclosures.
In February 2018, the FASB issued ASU 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. The new guidance allows a reclassification from accumulated other comprehensive income to retained earnings for any stranded tax effects resulting from TCJA that was enacted on December 22, 2017. The new guidance will be effective for the Company beginning in the first quarter of 2019. The Company adopted the standard on January 1, 2019. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements and related disclosures.
14

In June 2018, the FASB issued ASU 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Non-employee Share-based Payment Accounting. The standard expands the scope of Topic 718 to include share-based payments issued to non-employees for goods or services, simplifying the accounting for share-based payments to non-employees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years with early adoption permitted, including adoption in an interim period. The Company adopted the standard on January 1, 2019. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements and related disclosures.

Note 2: Cash, Cash Equivalent, and Investments
The Company’s investments in debt securities are classified as held-to-maturity and are recorded at amortized cost, and its investments in money market funds are classified as cash equivalents. The following table shows the Company’s cash, available-for-sale securities, and short-term and long-term investment securities by major security type as of September 30, 2019 and December 31, 2018:
September 30, 2019 (Unaudited)
GrossGross
LevelUnrealizedUnrealized
(1)
Fair ValueHolding GainsHolding LossesAdjusted Cost
Cash and Cash Equivalents
Cash$552,569  $—  $—  $552,569  
Money Market Funds1  4,109,758  —  —  4,109,758  
Subtotal4,662,327  —  —  4,662,327  
Short-Term Investment Securities (2)
Corporate Bonds (4)
2  30,794,626  16,862  (15,708) 30,793,472  
Long-Term Investment Securities (3)
Corporate Bonds (4)
2  1,527,865  13,712  —  1,514,153  
Total$36,984,818  $30,574  $(15,708) $36,969,952  

December 31, 2018 (Audited)
GrossGross
LevelUnrealizedUnrealized
(1)
Fair ValueHolding GainsHolding LossesAdjusted Cost
Cash and Cash Equivalents
Cash$1,048,272  $—  $—  $1,048,272  
Money Market Funds1  1,338,042  —  —  1,338,042  
Subtotal2,386,314  —  —  2,386,314  
Short-Term Investment Securities (2)
Corporate Bonds (4)
2  38,731,120  —  (85,321) 38,816,441  
Total$41,117,434  $—  $(85,321) $41,202,755  
_________________
Notes:
(1) Definition of the three-level fair value hierarchy:
•Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities
•Level 2 - Other inputs that are directly or indirectly observable in the markets
•Level 3 - Inputs that are generally unobservable
(2) Short-term investment securities will mature within 12 months or less, from the applicable reporting date.
(3) Long-term investment securities will mature between 12 and 18 months, from the applicable reporting date.
(4) The premium paid to purchase held-to-maturity investment securities was $54,385 and $0 for the three months ended September 30, 2019 and 2018, respectively. The premium paid to purchase held-to-maturity investment securities was $158,548
15

and $205,038 for the nine months ended September 30, 2019 and 2018, respectively. The premium paid to purchase held-to-maturity investment securities was $378,681 for the year ended December 31, 2018.

The Company considers the declines in market value of its investment portfolio to be temporary in nature. The Company’s investment policy requires investment securities to be investment grade and held to maturity with the primary objective to maintain a high degree of liquidity while maximizing yield. When evaluating an investment for other-than-temporary impairment, the Company reviews factors such as the length of time and extent to which fair value has been below its cost basis, the financial condition of the issuer and any changes thereto, changes in market interest rates, and whether it is more likely than not the Company will be required to sell the investment before recovery of the investment’s cost basis. As of September 30, 2019, the Company does not consider any of its investments to be other-than-temporarily impaired.

Note 3: Research Collaboration and Sub-licensing Agreements
BDI Agreements
On June 30, 2017, the Company entered into a strategic Research Services Agreement (the “RSA”) with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U. (“BDI Pharma”), and a Service Framework Agreement (the “SFA”, and together with the RSA, the “R&D Agreements”), with VLP The Vaccines Company, S.L.U. (“VLPbio”), both of which are subsidiaries of Biotechnology Developments for Industry, S.L., a Spanish biotechnology company (“BDI Holdings” and together with BDI Pharma and VLPbio, “BDI”).

The R&D Agreements provide a framework under which the parties will engage in a research and development collaboration encompassing several different projects over approximately a two-year period, with a focus on advancing Dyadic’s proprietary C1 technology in the development of next generation biological vaccines and drugs. Dyadic expects to leverage the BDI team’s previous C1 gene expression and industrial fermentation scale-up and commercialization experience with yeast and filamentous fungi processes to further advance Dyadic’s proprietary C1 technology with the potential to commercialize certain biopharmaceutical product(s). All of the data and any products developed from the funded research projects will be owned by Dyadic.

Upon closing of the BDI transaction, the Company paid EUR €1 million (the “RSA Initial Payment”) in cash to engage BDI to develop designated C1 based product candidates and further improve the C1 manufacturing process, in consideration of which Dyadic also received a 16.1% equity interest in BDI Holdings and a 3.3% equity interest in VLPbio. BDI is obligated to spend a minimum amount of EUR €936,000 over two years in the conduct of the research and development project under the RSA. If the research and development activities produce a product that is selected for additional development and commercialization, then Dyadic expects to share with BDI a range of between 50% and 75% of the net income from such selected product, depending upon the amount of BDI’s aggregate spend in the development of the selected product, with a minimum aggregate spend by BDI of EUR €1 million for a 50% share and EUR €8 million for a 75% share. If BDI does not enter into an agreement with Dyadic for such additional development and commercialization of the selected product, then Dyadic will pay to BDI EUR €1.5 million of the net income from Dyadic’s commercialization, if any, of the selected product. In addition, under the SFA, Dyadic agreed to purchase from BDI at least USD $1 million (the “SFA Commitment”) in contract research services specified by Dyadic over two years since the closing of the BDI transaction.

The Company has concluded that BDI is not a Variable Interest Entity (“VIE”), because BDI has sufficient equity to finance its activities without additional subordinated financial support and its at-risk equity holders have the characteristics of a controlling financial interest. Additionally, Dyadic is not the primary beneficiary of BDI as Dyadic does not have the power to control or direct the activities of BDI or its operations. As a result, the Company does not consolidate its investments in BDI, and the financial results of BDI are not included in the Company’s consolidated financial results. Dyadic has fulfilled its SFA commitment, however it is and may in the future continue to provide funding to BDI for certain research and commercialization projects.

The Company performed a valuation analysis of the components of the transaction and allocated the consideration based on the relative fair value of each component. As the fair value of BDI equity interest was considered immaterial, the RSA Initial Payment of approximately USD $1.1 million (EUR €1 million) was accounted for as a prepaid research and development collaboration payment on our consolidated balance sheet, and both the collaboration payment under the RSA and the remaining SFA Commitment of USD $1 million paid by Dyadic will be expensed as the related research services are performed by BDI. BDI has completed its services under the RSA in June 2019, and the entire amount of the RSA Initial Payment was expensed. Under the SFA, there were four research projects completed and three research projects in progress, and we do not have any outstanding commitment under the SFA as of September 30, 2019.

16

As of September 30, 2019 and December 31, 2018, the prepaid research and development collaboration related to BDI recorded on our consolidated balance sheets were none and approximately $0.3 million, respectively. For the three months ended September 30, 2019 and 2018, research and development expenses related to BDI were recorded as research and development - related party in our consolidated statements of operations in the amount of approximately $0.1 million and $0.3 million, respectively. For the nine months ended September 30, 2019 and 2018, research and development expenses related to BDI were recorded as research and development - related party in our consolidated statements of operations in the amount of approximately $0.8 million and $1.0 million, respectively.

Novovet and Luina Bio Sub-License Agreement
On April 26, 2019, the Company entered into a sub-license agreement (the “Luina Bio Sub-License Agreement”) with Luina Bio Pty Ltd. (“Luina Bio”) and Novovet Pty Ltd (“Novovet”). Under the terms of the Luina Bio Sub-License Agreement, the Company has granted to Novovet, subject to the terms of the license agreement entered into between the Company and Danisco US, Inc. on December 31, 2015, a worldwide sub-license to certain patent rights and know-how related to Dyadic’s proprietary C1 gene expression platform for the exclusive and sole purpose of commercializing certain targeted antigen and biological products for the prevention and treatment of various ailments for companion animals.

In consideration of the license granted pursuant to the Luina Bio Sub-License Agreement, Dyadic received a 20% equity interest in Novovet (“Novovet Up-Front Consideration”) in accordance with the terms of Novovet’s Shareholder Agreement (“Shareholders Agreement”), and will receive a percentage of royalties on future net sales and non-sales revenue, if any, which incorporates Dyadic's proprietary C1 gene expression platform.

The Company evaluated the nature of its equity interest investment in Novovet and determined that Novovet is a Variable Interest Entity (“VIE”), because Novovet does not have sufficient equity to finance its activities without additional financial support from third party investors or lenders. However, the Company is not the primary beneficiary of Novovet as Dyadic does not have the power to control or direct the activities of Novovet that most significantly impact the VIE. As a result, the Company will not consolidate its investment in Novovet, but account for under the equity method investment, given that it has the ability to exercise significant influence, but not control, over Novovet.

As of September 30, 2019, the technology transfer of the Company’s C1 platform has not been completed and Novovet has not raised sufficient capital to support its required research and drug development activities. Therefore, the Novovet Up-Front Consideration received under the Luina Bio Sub-License Agreement, in the form of a 20% equity interest in Novovet, does not yet meet the revenue recognition criteria under ASC 606. The Company will account for its investment in Novovet and the related income under the equity method of accounting, once the transfer of its C1 technology is completed and Novovet receives adequate financing required to commence its research and development activities.

The Shareholder Agreement provides that, for as long as the Company has a respective proportion of Novovet equal to or more than 20% it may designate one individual to serve on the Board of Directors of Novovet. The Dyadic appointee is Mark Emalfarb, Dyadic’s CEO. Pursuant to the terms of the Shareholders Agreement, the Company agreed, subject to certain exceptions, not to sell, transfer, assign, convey or otherwise dispose of its interests in Novovet. In addition, the Company is entitled to or subject to, as applicable, anti-dilution rights, tag along rights and drag along rights, each as described in the Shareholders Agreement.

Alphazyme Sub-License Agreement
On May 5, 2019, the Company entered into a sub-license agreement (the “Alphazyme Sub-License Agreement”) with Alphazyme, LLC (“Alphazyme”). Under the terms of the Alphazyme Sub-License Agreement, the Company has granted to Alphazyme, subject to the terms of the license agreement entered into between the Company and Danisco US, Inc. on December 31, 2015, a sub-license to certain patent rights and know-how related to Dyadic’s proprietary C1 gene expression platform for the purpose of commercializing certain pharmaceutical products that are used as reagents to catalyze a chemical reaction to detect, measure, or be used as a process intermediate to produce a nucleic acid as a therapeutic or diagnostic agent.

In consideration of the license granted pursuant to the Alphazyme Sub-License Agreement, Dyadic will receive a 7.5% ownership interest in Alphazyme (“Alphazyme Up-Front Consideration”) upon the successful transfer of C1 technology, additional milestone payments and a percentage of royalties on net sales, if any, which incorporate Dyadic's proprietary C1 gene expression platform. The Alphazyme Sub-License Agreement has an initial exclusivity period of 18 months (“Exclusivity Period”) beginning on the date the technology transfer has been completed. Following the Exclusivity Period, the sub-license will be nonexclusive. At any time prior to the expiration of the Exclusivity Period,
17

Alphazyme has the option to extend the Exclusivity Period for an additional twelve (12) months in return for an additional 2.5% ownership interest in Alphazyme.

The Company evaluated the nature of its equity interest investment in Alphazyme and determined that Alphazyme is a Variable Interest Entity (“VIE”) due to the capital structure of the entity. However, the Company is not the primary beneficiary of Alphazyme as Dyadic does not have the power to control or direct the activities of Alphazyme that most significantly impact the VIE. As a result, the Company does not consolidate its investments in Alphazyme. The Company will account for its investment in Alphazyme under the equity method, given that it has the ability to exercise significant influence, but not control, over Alphazyme.

As of September 30, 2019, the technology transfer of the C1 platform has not completed and Dyadic has not received the Alphazyme Up-Front Consideration. Therefore, no revenue form the Alphazyme Sub-Licensing Agreement was recorded at September 30, 2019.

Upon receipt of the Alphazyme Up-Front Consideration, Dyadic will become a party to the Alphazyme Limited Liability Company Agreement pursuant to which the Company will agree to certain customary rights, covenants and obligations.

Research and Commercialization Collaboration with Serum
On May 7, 2019, the Company entered into a research and commercialization collaboration with Serum Institute of India Pvt., Ltd (“Serum”). Under the terms of this collaboration, Serum anticipates applying Dyadic’s C1 technology to express up to twelve (12) antibodies and vaccines and will undertake commercially best efforts to fully develop and commercialize the proteins expressed from Dyadic’s C1 technology. Dyadic has agreed to grant Serum the option to obtain an exclusive commercial sub-license for each of the twelve (12) proteins in return for certain research funding, milestone payments and royalties for 15 years from the date of the first commercial sale.
For the three and nine month ended September 30, 2019, the Company recognized approximately $13,000 in research revenue from Serum. As of September 30, 2019, the Company has approximately $70,000 in deferred revenue related to this agreement.

Note 4: Commitments and Contingencies
Leases
Jupiter, Florida Headquarters
The Company’s corporate headquarters are located in Jupiter, Florida. The Company occupies approximately 4,900 square feet with a monthly rental rate and common area maintenance charges of approximately $9,700. The lease expires on June 30, 2020, and thereafter, the Company will reconsider the square footage of the leased space to align with the staffing requirements of the future operations of the Company.
The Netherlands Office
The Company maintains a small satellite office in Wageningen, The Netherlands. In 2018, the Company occupied approximately 258 square feet with annual rentals and common area maintenance charges of approximately $4,700. The lease expired on January 31, 2019, and thereafter, the Company entered into a new lease with the same lessor (the “New Lease”). The New Lease has a one-year term and includes a flexible office space with annual rentals of approximately $4,000.
VTT Research Contract Extension
On June 28, 2019, the Company extended its research contract (“Contract”) through June 2022 with VTT Technical Research Centre of Finland Ltd. (“VTT”). Under the terms of this Contract, Dyadic will pay VTT a total of EUR €2.52 million over the next three years to continue developing Dyadic’s C1 fungal expression system for therapeutic protein production, including C1 host system improvement, glycoengineering, and management of third-party target protein projects. VTT is subject to an additional success bonus up to EUR €450,000 based on the technical targets stipulated in the Contract. Dyadic and its sublicensees will also have the right to use synthetic promoters developed by VTT with an access fee. On October 25, 2019, the Company expanded the Contract to pay an additional EUR €690,000 over the next 1.5 years to reinforce the glycoengineering work. Dyadic retains the right to terminate the Contract with 90 days’ notice.
18

Legal Proceedings
From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. The Company does not believe that any of these claims or proceedings against us is likely to have, individually or in the aggregate, a material adverse effect on the financial condition or results of operations.

Note 5: Share-Based Compensation
Description of Equity Plans
The 2011 Equity Incentive Plan (the “2011 Plan”) was adopted by the Company’s Board of Directors on April 28, 2011 and approved by the Company’s stockholders on June 15, 2011. The 2011 Plan serves as the successor to the Company’s 2006 Stock Option Plan (the “2006 Plan”). Since the effective date of the 2011 Plan, all equity awards were made from the 2011 Plan, and no additional awards will be granted under the 2006 plan. Under the 2011 Plan, 3,000,000 shares of the Company’s common stock have been initially reserved for issuance pursuant to a variety of share-based compensation awards, plus any shares available for issuance under the 2006 Plan or are subject to awards under the 2006 Plan which are forfeited or lapse unexercised and which following the effective date are not issued under the 2006 Plan. In accordance with the provisions of the 2011 Plan, the Board of Directors approved an increase of 1,500,000 shares to the plan on January 1, 2019.
As of September 30, 2019, the Company had 4,006,390 stock options outstanding and an additional 1,547,211 shares of common stock available for grant under the 2011 Plan. As of December 31, 2018, there were 3,552,890 stock options outstanding and 1,136,211 shares of common stock available for grant under the 2011 Plan.
Stock Options
Options are granted to purchase common stock at prices that are equal to the fair value of the common stock on the date the option is granted. Vesting is determined by the Board of Directors at the time of grant. The term of any stock option awards under the Company’s 2011 Plan is no more than ten years except for qualified options granted to the CEO (five years) and certain contractors (two years).
The grant-date fair value of each option grant is estimated using the Black-Scholes option pricing model and amortized on a straight-line basis over the requisite service period, which is generally the vesting period, for each separately vesting portion of the award as if the award was, in substance, multiple awards. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs, including the following:
Risk-free interest rate. The risk-free interest rate is based on U.S. Treasury rates with securities approximating the expected lives of options at the date of grant.
Expected dividend yield. The expected dividend yield is zero, as the Company has never paid dividends to common shareholders and does not currently anticipate paying any in the foreseeable future.
Expected stock price volatility. The expected stock price volatility was calculated based on the Company’s own volatility after the DuPont Transaction. The Company reviews its volatility assumption on an annual basis and has used the Company’s historical volatility since 2016, as the DuPont Transaction resulted in significant changes in the Company’s business and capital structure.
Expected life of option. The expected life of option was based on the contractual term of the option and expected employee exercise and post-vesting employment termination behavior. The Company uses the weighted average vesting period and contractual term of the option as the best estimate of the expected life of a new option, except for the qualified options granted to the CEO (i.e., 5 years) and certain contractors (i.e., 2 years).
Discount for lack of marketability. The Company applied a discount to reflect the lack of marketability due to the holding period restriction of its shares under Rule 144 prior to its April 2019 uplisting to the NASDAQ. The discount for lack of marketability is no longer applicable since the uplisting of the Company’s common stock.
The assumptions used in the Black-Scholes option pricing model for stock options granted through the nine months ended September 30, 2019 are as follows:
19

Risk-Free interest rate
1.69% - 2.50%
Expected dividend yield— %
Expected stock price volatility
28.59% - 37.29%
Expected life of options
2 - 6.25 Years
Discount for lack of marketability
0.0% - 8.48%

The following table summarizes the stock option activities for the nine months ended September 30, 2019: 
SharesWeighted-Average Exercise PriceWeighted-Average Remaining Contractual Term (Years)Aggregate Intrinsic Value
Outstanding at December 31, 20183,552,890  $1.575.06$1,149,461
Granted (1)
1,089,000  2.26  
Exercised (2)
(635,500) 1.62  
Expired—  —  
Canceled —  —  
Outstanding at September 30, 20194,006,390  $1.755.89$17,556,185
Exercisable at September 30, 20192,764,073  $1.644.65$12,408,351
_________________
Notes:
(1) Represents the following stock options granted:
•Annual share-based compensation awards on January 2, 2019, including: (a) 600,000 stock options with an exercise price of $1.87 per share granted to executives and key personnel, vesting upon grant, or one year anniversary, or vest annually in equal installments over four years, (b) 300,000 stock options with an exercise price of $1.87 per share granted to the Board of Directors, vesting 25% upon grant and the remaining 75% will vest annually in equal installments over four years, and (c) 24,000 stock options with an exercise price of $1.87 per share granted to employees, vesting annually in equal installments over four years. 
•One-time awards granted on (a) January 2, 2019 of 50,000 stock options with an exercise price of $1.87 per share granted to a contractor, vesting upon one year anniversary, (b) March 7, 2019 of 15,000 stock options with an exercise price of $3.00 per share granted to a contractor, vesting upon one year anniversary, (c) June 25, 2019 of 75,000 stock options with an exercise price of $5.83 per share granted to three members of the Board of Directors, vesting upon one year anniversary, and (d) June 28, 2019 of 25,000 stock options with an exercise price of $6.26 per share granted to the Chief Financial Officer, vesting immediately.
(2) Represents the following stock options exercised:
•A total of 635,500 stock options exercised with a weighted average market price of $1.62, including (a) net share exercise of 440,000 stock options resulting in the issuance of 304,171 shares of common stock, and surrender of 135,829 shares, and (b)195,500 stock options exercised with cash payment.

Compensation Expenses
We recognize all share-based payments to employees and our Board of Directors, as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statement of operations, and these charges had no impact on the Company’s reported cash flows. Stock-based compensation expense is calculated on the grant date fair values of such awards, and recognized each period based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are recorded as they occur.
Total non-cash stock option compensation expense was allocated among the following expense categories: 
20

Three Months Ended September 30,Nine Months Ended September 30,
2019201820192018
General and administrative$118,754  $51,887  $957,843  $356,024  
Research and development25,426  18,733  76,503  57,616  
Total $144,180  $70,620  $1,034,346  $413,640  

Note 6: Shareholders’ Equity
Issuances of Common Stock
For the nine months ended September 30, 2019, there were 499,671 shares of the Company’s common stock issued as a result of the exercise of stock options with a weighted average issue price of $1.62 per share. For the nine months ended September 30, 2018, no shares were issued.
Nine Months Ended September 30, 2019 (Unaudited) 
Common Stock  Treasury Stock  Additional Paid-In Capital  Accumulated Deficit  Total  
January 1, 2019$38,967  $(18,929,915) $94,385,230  $(33,043,113) $42,451,169  
Stock-based compensation—  —  309,563  —  309,563  
Net loss—  —  —  (2,175,258) (2,175,258) 
March 31, 201938,967  (18,929,915) 94,694,793  (35,218,371) 40,585,474  
Stock issued398  —  148,782  —  149,180  
Stock-based compensation—  —  580,603  —  580,603  
Net loss—  —  —  (2,695,792) (2,695,792) 
June 30, 201939,365  (18,929,915) 95,424,178  (37,914,163) 38,619,465  
Stock issued102  —  179,308  —  179,410  
Stock-based compensation—  —  144,180  —  144,180  
Net loss—  —  —  (1,698,384) (1,698,384) 
September 30, 2019$39,467  $(18,929,915) $95,747,666  $(39,612,547) $37,244,671  
Nine Months Ended September 30, 2018 (Unaudited) 
Common Stock  Treasury Stock  Additional Paid-In Capital  Accumulated Deficit  Total
January 1, 2018$38,937  $(16,625,873) $93,913,557  $(27,351,357) $49,975,264  
Stock repurchased—  (374,820) —  —  (374,820) 
Stock-based compensation—  —  269,596  —  269,596  
Net loss—  —  —  (2,043,292) (2,043,292) 
March 31, 201838,937  (17,000,693) 94,183,153  (29,394,649) 47,826,748  
Stock-based compensation—  —  73,425  —  73,425  
Net loss—  —  —  (1,596,637) (1,596,637) 
June 30, 201838,937  (17,000,693) 94,256,578  (30,991,286) 46,303,536  
Stock repurchased(1,929,222) —  (1,929,222) 
Stock-based compensation—  70,619  —  70,619  
Stock issued30  —  4,470  4,500  
Net loss—  —  —  (1,539,495) (1,539,495) 
September 30, 2018$38,967  $(18,929,915) $94,331,667  $(32,530,781) $42,909,938  

21

Stock Repurchase Programs
On February 16, 2016, the Board of Directors authorized a one-year stock repurchase program, under which the Company was authorized to repurchase up to $15,000,000 of its outstanding common stock (the “2016 Stock Repurchase Program”). The 2016 Stock Repurchase Program ended on February 15, 2017.
On August 16, 2017, the Board of Directors authorized a new one-year stock repurchase program, under which the Company may repurchase up to $5,000,000 of its outstanding common stock (the “2017 Stock Repurchase Program”). On August 6, 2018, the Board of Directors authorized an extension of this stock repurchase program through August 15, 2019. The 2017 Stock Repurchase Program ended on August 15, 2019.
The following table summarizes the Company’s stock repurchase activities: 
PeriodTotal Number of Shares PurchasedAverage Price Paid per ShareAmountTotal Number of Treasury Shares Purchased as Part of Publicly Announced PlanMaximum Dollar Value of Shares that May Yet Be Purchased Under the Plan
Privately Negotiated Transactions:
January 12, 2016 - Abengoa repurchased and retired shares2,136,752  $1.35  $2,884,615  —  N/A
January 11, 2017 - Pinnacle Family Office Investments L.P. repurchased shares2,363,590  1.54  3,639,929  2,363,590  N/A
$15,000,000  
2016 Stock Repurchase Program:
January through February 20177,863,980  1.58  12,448,283  7,863,980  $2,551,717  
2017 Stock Repurchase Program:$5,000,000  
September through December 2017381,607  1.41  537,661  381,607  $4,462,339  
January through August 20181,644,325  1.40  2,304,042  1,644,325  $2,158,297  
Total open market and privately negotiated purchases14,390,254  $1.52  $21,814,530  12,253,502  

Treasury Stock
As of September 30, 2019 and December 31, 2018, there were 12,253,502 shares of common stock held in treasury, at a cost of approximately $18.9 million, representing the purchase price on the date the shares were surrendered to the Company.

Note 7: Subsequent Events
For purpose of disclosure in the consolidated financial statements, the Company has evaluated subsequent events through November 13, 2019, the date the consolidated financial statements were available to be issued. Management is not aware of any material events that have occurred subsequent to the balance sheet date that would require adjustment to, or disclosure in the accompanying financial statements.
On November 12, 2019, the Company entered into an amendment (the “Amendment”) to the Employment Agreement between the Company and Mark A. Emalfarb, dated as of June 16, 2016, as previously amended (the “Agreement”). The Amendment contains a technical correction clarifying the exercise period and date of grant of certain stock awarded, or to be awarded, to Mr. Emalfarb.


22


Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis of financial condition and results of operations should be read in conjunction with the financial statements and the notes to those statements appearing in this Quarterly Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks, assumptions and uncertainties. Important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis include, but not limited to those set forth in “Item 1A. Risk Factors” in this Quarterly Report. All forward-looking statements included in this Quarterly Report are based on information available to us as of the time we file this Quarterly Report and, except as required by law, we undertake no obligation to update publicly or revise any forward-looking statements.

Overview
Description of Business
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our” or the “Company”) is a global biotechnology platform company based in Jupiter, Florida with operations in the United States, a satellite office in the Netherlands and research organizations performing services under contract to Dyadic in Finland and Spain. Over the past two decades, the Company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has previously licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Myceliophthora thermophila fungus, which the Company named C1. The C1 technology is a robust and versatile fungal expression system for the development and production of enzymes and other proteins.
On December 31, 2015, the Company sold its industrial technology business to DuPont Danisco (“DuPont”), the industrial biosciences business of DuPont (NYSE: DD) for $75.0 million (the “DuPont Transaction”). As part of the DuPont Transaction, Dyadic retained co-exclusive rights to the C1 technology for use in all human and animal pharmaceutical applications, and currently has the exclusive ability to enter into sub-license agreements (subject to the terms of the license and certain exceptions). DuPont retained certain rights to utilize the C1 technology in pharmaceutical applications, including the development and production of pharmaceutical products, for which it will be required to make royalty payments to Dyadic upon commercialization. In certain circumstances, Dyadic may owe a royalty to either DuPont or certain licensors of DuPont, depending upon whether Dyadic elects to utilize certain patents either owned by DuPont or licensed in by DuPont.
After the DuPont Transaction, the Company has been focused on the biopharmaceutical industry, specifically in further improving and applying the proprietary C1 technology into a safe and efficient gene expression platform to help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. We believe that the C1 technology could be beneficial in the development and manufacturing of human and animal vaccines and drugs (such as virus-like particles (VLPs) and antigens), monoclonal antibodies (mAbs), Bi-Specific antibodies, Fab antibody fragments, Fc-Fusion proteins, and other therapeutic enzymes and proteins. The Company is aiming to develop such products as innovative vaccines and drugs, biosimilars and/or biobetters. Additionally, in early 2018, we began to conduct certain funded research activities to further understand if, or how the C1 technology may be applied for use in developing and manufacturing certain metabolites. The initial data from this metabolite project, where the Phase I data milestone was achieved, demonstrated that C1 has the potential to be engineered to produce certain metabolites. The Company is evaluating if, and how it may further develop and commercialize this potential metabolite product which may include the Company fully funding this on its own, or in collaboration with third parties.

Recent Developments
The Company continues to develop relationships with business and research partners in the biopharmaceutical industry. In the first nine months of 2019, the Company entered into new proof of concept research collaborations with four top 25 biopharmaceutical companies to express different types of biologic vaccines and drugs of interest for human and animal health application. In addition, the Company initiated four new internally funded research projects, including engineering C1 to explore the potential of C1 to express adeno-associated viral (AAV) vectors which are widely used in gene therapy and are in high demand and short supply, and to explore the development and commercialization of one or more secondary metabolites.
23

Novovet and Luina Bio Sub-License Agreement
On April 26, 2019, the Company entered into a sub-license agreement (the “Luina Bio Sub-License Agreement”) with Luina Bio Pty Ltd. (“Lunia Bio”) and Novovet Pty Ltd (“Novovet”). Under the terms of the Luina Bio Sub-License Agreement, the Company has granted to Novovet, subject to the terms of the license agreement entered into between the Company and Danisco US, Inc. on December 31, 2015, a worldwide sub-license to certain patent rights and know-how related to Dyadic’s proprietary C1 gene expression platform for the exclusive and sole purpose of commercializing certain targeted antigen and biological products for the prevention and treatment of various ailments for companion animals.

In consideration of the license granted pursuant to the Luina Bio Sub-License Agreement, Dyadic received a 20% equity interest in Novovet (“Novovet Up-Front Consideration”) in accordance with the terms of Novovet’s Shareholder Agreement (“Shareholders Agreement”), and will receive a percentage of royalties on future net sales and non-sales revenue, if any, which incorporates Dyadic’s proprietary C1 gene expression platform.

The Company evaluated the nature of its equity interest investment in Novovet and determined that Novovet is a Variable Interest Entity (“VIE”), because Novovet does not have sufficient equity to finance its activities without additional financial support from third party investors or lenders. However, the Company is not the primary beneficiary of Novovet, as Dyadic does not have the power to control or direct the activities of Novovet that most significantly impact the VIE. As a result, the Company will not consolidate its investment in Novovet, but account for under the equity method investment, given that it has the ability to exercise significant influence, but not control, over Novovet.

As of September 30, 2019, the technology transfer of the Company’s C1 platform has not been completed and Novovet has not raised sufficient capital to support its required research and drug development activities. Therefore, the Novovet Up-Front Consideration received under the Luina Bio Sub-License Agreement, in the form of a 20% equity interest in Novovet, does not yet meet the revenue recognition criteria under ASC 606. The Company will account for its investment in Novovet and the related income under the equity method of accounting, once the transfer of its C1 technology is completed and Novovet receives adequate financing required to commence its research and development activities.

The Shareholder Agreement provides that, for as long as the Company has a respective proportion of Novovet equal to or more than 20% it may designate one individual to serve on the Board of Directors of Novovet. The Dyadic appointee is Mark Emalfarb, Dyadic’s CEO. Pursuant to the terms of the Shareholders Agreement, the Company agreed, subject to certain exceptions, not to sell, transfer, assign, convey or otherwise dispose of its interests in Novovet. In addition, the Company is entitled to or subject to, as applicable, anti-dilution rights, tag along rights and drag along rights, each as described in the Shareholders Agreement.

Alphazyme Sub-License Agreement
On May 5, 2019, the Company entered into a sub-license agreement (the “Alphazyme Sub-License Agreement”) with Alphazyme, LLC (“Alphazyme”). Under the terms of the Alphazyme Sub-License Agreement, the Company has granted to Alphazyme, subject to the terms of the license agreement entered into between the Company and Danisco US, Inc. on December 31, 2015, a sub-license to certain patent rights and know-how related to Dyadic’s proprietary C1 gene expression platform for the purpose of commercializing certain pharmaceutical products that are used as reagents to catalyze a chemical reaction to detect, measure, or be used as a process intermediate to produce a nucleic acid as a therapeutic or diagnostic agent.

In consideration of the license granted pursuant to the Alphazyme Sub-License Agreement, Dyadic will receive a 7.5% ownership interest in Alphazyme (“Alphazyme Up-Front Consideration”) upon the successful transfer of C1 technology, additional milestone payments and a percentage of royalties on net sales, if any, which incorporate Dyadic’s proprietary C1 gene expression platform. The Alphazyme Sub-License Agreement has an initial exclusivity period of 18 months (“Exclusivity Period”) beginning on the date the technology transfer has been completed. Following the Exclusivity Period, the sub-license will be nonexclusive. At any time prior to the expiration of the Exclusivity Period, Alphazyme has the option to extend the Exclusivity Period for an additional twelve (12) months in return for an additional 2.5% ownership interest in Alphazyme.

The Company evaluated the nature of its equity interest investment in Alphazyme and determined that Alphazyme is a Variable Interest Entity (“VIE”) due to the capital structure of the entity. However, the Company is not the primary beneficiary of Alphazyme, as Dyadic does not have the power to control or direct the activities of Alphazyme that most significantly impact the VIE. As a result, the Company does not consolidate its investments in Alphazyme. The Company will account for its investment in Alphazyme under the equity method, given that it has the ability to exercise significant influence, but not control, over Alphazyme.

24

As of September 30, 2019, the technology transfer of the C1 platform has not completed and Dyadic has not received the Alphazyme Up-Front Consideration. Therefore, no revenue form the Alphazyme Sub-Licensing Agreement was recorded at September 30, 2019.

Upon receipt of the Alphazyme Up-Front Consideration, Dyadic will become a party to the Alphazyme Limited Liability Company Agreement pursuant to which the Company will agree to certain customary rights, covenants and obligations.

Research and Commercialization Collaboration with Serum
On May 7, 2019, the Company entered into a research and commercialization collaboration with Serum Institute of India Pvt., Ltd (“Serum”). Under the terms of this collaboration, Serum anticipates applying Dyadic’s C1 technology to express up to twelve (12) antibodies and vaccines and will undertake commercially best efforts to fully develop and commercialize the proteins expressed from Dyadic’s C1 technology. Dyadic has agreed to grant Serum the option to obtain an exclusive commercial sub-license for each of the twelve (12) proteins in return for certain research funding, milestone payments and royalties for 15 years from the date of the first commercial sale.
VTT Research Contract Extension
On June 28, 2019, the Company extended its research contract (“Contract”) through June 2022 with VTT Technical Research Centre of Finland Ltd. (“VTT”). Under the terms of this Contract, Dyadic will pay VTT a total of EUR €2.52 million over the next three years to continue developing Dyadic’s C1 fungal expression system for therapeutic protein production, including C1 host system improvement, glycoengineering, and management of third-party target protein projects. VTT is subject to an additional success bonus up to EUR €450,000 based on the technical targets stipulated in the Contract. Dyadic and its sublicensees will also have the right to use synthetic promoters developed by VTT with an access fee. On October 25, 2019, the Company expanded the Contract to pay an additional EUR €690,000 over the next 1.5 years to reinforce the glycoengineering work. Dyadic retains the right to terminate the Contract with 90 days’ notice.
C1 Platform and Collaboration Update

•Through our continued collaboration with VTT, the Company has generated more data on C1 cell line development that exceeded initial expectations on several fronts, including in certain cases the pace of development and level of protein productivity, stability and structure. This was demonstrated recently by the very high expression level reached of a full-length monoclonal antibody (mAb) of 22 grams per liter in seven days.
•With regard to the ZAPI program, we demonstrated further success with fermentation results of the ZAPI antigen against the Schmallenberg virus (SMV) with a yield of 1,780 mg/l (time point 121h) or 17 times the initially stated expression level. The high productivity level reached with C1 expressed SMV antigen has significant contribution to the next step of animal trails as well as to achieve the goal of ZAPI project, which is to produce a sufficient number of doses quickly, at low cost and reduced fermentation capacity.
•On August 12, 2019, Dyadic signed a fully funded research collaboration with a top tier pharmaceutical company to express three different types and classes of proteins for human health. Under the terms of the agreement, Dyadic will apply its proprietary and patented C1 gene expression platform to express three different types of proteins to be evaluated by our collaborator for its potential use in their research and commercial projects.

•On October 28, 2019, Dyadic entered into a fully funded collaboration with one of the leading animal health companies to demonstrate the C1 technology for expression and production of therapeutic proteins for companion and farm animal health diseases. Dyadic will apply its proprietary and patented C1 gene expression platform to express three different types of proteins to be evaluated by our collaborator for its potential use in their research and commercial projects.

•On October 28, 2019, Dyadic expanded an existing research collaboration with a top tier animal health company to express one additional protein.

Critical Accounting Policies, Estimates, and Judgments
The preparation of these consolidated financial statements in accordance with GAAP requires management to make
25

estimates and judgments that affect the reported amount of assets and liabilities and related disclosure of contingent assets and liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the applicable period. Actual results may differ from these estimates under different assumptions or conditions. Such differences could be material to the consolidated financial statements.
We define critical accounting policies as those that are reflective of significant judgments and uncertainties and which may potentially result in materially different results under different assumptions and conditions. In applying these critical accounting policies, our management uses its judgment to determine the appropriate assumptions to be used in making certain estimates. These estimates are subject to an inherent degree of uncertainty. Our critical accounting policies include the following:
Revenue Recognition
The Company has no pharmaceutical products approved for sale at this point, and all of our revenue to date has been research revenue from third party collaborations and government grants. The Company is expected to generate future revenue from license agreements and collaborative arrangements, which may include upfront payments for licenses or options to obtain a license, payment for research and development services and milestone payments, in the form of cash or non-cash considerations (e.g., minority equity interest).
Revenue related to research collaborations and agreements: The Company typically performs research and development services as specified in each respective agreement on a best efforts basis, and recognizes revenue from research funding under collaboration agreements in accordance with the 5-step process outlined in Topic 606: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We recognize revenue when we satisfy a performance obligation by transferring control of the service to a customer in an amount that reflects the consideration that we expect to receive. Since the performance obligation under our collaboration agreements is generally satisfied over time, we elected to use the input method under Topic 606 to measure the progress toward complete satisfaction of a performance obligation.
Under the input methods, revenue will be recognized on the basis of the entity’s efforts or inputs to the satisfaction of a performance obligation (e.g., resources consumed, labor hours expended, costs incurred, or time elapsed) relative to the total expected inputs to the satisfaction of that performance obligation. The Company believes that the cost-based input method is the best measure of progress to reflect how the Company transfers its performance obligation to a customer. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to budgeted costs to fulfill the performance obligation. These costs consist primarily of full-time equivalent effort and third-party contract costs. Revenue will be recognized based on actual costs incurred as a percentage of total budgeted costs as the Company completes its performance obligations.
A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company’s performance obligations. In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete the Company’s performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.
Revenue related to sublicensing agreements: If the sublicense to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue allocated to the license when technology is transferred to the customer and the customer is able to use and benefit from the license.
Milestone payments: At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Company evaluates whether the achievement of the milestones is considered probable and estimates the amount to be included in the transaction price. If the milestone payment is in exchange for a sublicense and is based on the sublicensee’s subsequent sale of product, the Company recognizes milestone payment by applying the accounting guidance for royalties. To date, the Company has not recognized any milestone payment revenue resulting from any of its sublicensing arrangements.
Royalties: With respect to licenses deemed to be the predominant item to which sales-based royalties relate, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation
26

to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its sublicensing arrangements.
We invoice customers based on our contractual arrangements with each customer, which may not be consistent with the period that revenues are recognized. When there is a timing difference between when we invoice customers and when revenues are recognized, we record either a contract asset (unbilled accounts receivable) or a contract liability (deferred research and development obligations), as appropriate.
We are not required to disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.
The Company adopted a practical expedient to expense sales commissions when incurred because the amortization period would be one year or less.

Accrued Research and Development Expenses
In order to properly record services that have been rendered but not yet billed to the Company, we review open contracts and purchase orders, communicate with our personnel and we estimate the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. The majority of our service providers invoice us monthly or quarterly in arrears for services performed or when contractual milestones are met. We make estimates of our accrued expenses as of each balance sheet date in our consolidated financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary. Examples of accrued research and development expenses include amounts owed to contract research organizations, to service providers in connection with commercialization and development activities.
Stock-Based Compensation
We have granted stock options and restricted stock to employees, directors and consultants. The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes model considers volatility in the price of our stock, the risk-free interest rate, the estimated life of the option, the closing market price of our stock and the exercise price. For purposes of the calculation, we assumed that no dividends would be paid during the life of the options and restricted stock and applied a discount to reflect the lack of marketability due to the holding period restriction of its shares under Rule 144 prior to the Company April 2019 uplisting to NASDAQ. We also used the weighted-average vesting period and contractual term of the option as the best estimate of the expected life of a new option (except for our CEO which is 5 years). The Company performs a review of assumptions used in the Black-Scholes option-pricing model on an annual basis. During the Company’s annual review of its volatility assumption in 2018, the Company determined that it would be appropriate to use the Company’s historical volatility since 2016, as the DuPont Transaction resulted in significant changes in the Company’s business and capital structure. The change in assumption was effective January 1, 2018 and only impacts new options granted in 2018 and thereafter.
The estimates utilized in the Black-Scholes calculation involve inherent uncertainties and the application of management judgment. These estimates are neither predictive nor indicative of the future performance of our stock. As a result, if other assumptions had been used, our recorded share-based compensation expense could have been materially different from that reported. In addition, because some of the options and restricted stock issued to employees, consultants and other third-parties vest upon the achievement of certain milestones, the total ultimate expense of share-based compensation is uncertain.
In connection with board member and employee terminations, the Company may modify certain terms to outstanding share-based awards. We have recorded charges related to these modifications based on the estimated fair value of the share-based options immediately prior to and immediately after the modification occurs, with any incremental value being charged to expense. We have used the Black-Scholes pricing model in this valuation process, and this requires management to use various assumptions and estimates. Future modifications to share-based compensation transactions may result in significant expenses being recorded in our consolidated financial statements.
Accounting for Income Taxes
The Company accounts for income taxes under the asset and liability method in accordance with ASC Topic 740 (“Topic 740”), “Income Taxes”. Under this method, income tax expense/(benefit) is recognized for: (i) taxes payable or
27

refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all the deferred tax assets will not be realized.
In determining taxable income for the Company’s consolidated financial statements, we are required to estimate our income taxes in each of the jurisdictions in which we operate. This process requires the Company to make certain estimates of our actual current tax exposure and assessment of temporary differences between the tax and financial statement recognition of revenue and expense. In evaluating the Company’s ability to recover its deferred tax assets, the Company must consider all available positive and negative evidence including its past operating results, the existence of cumulative losses in the most recent years and its forecast of future taxable income. Significant management judgment is required in determining our provision for income taxes, deferred tax assets and liabilities and any valuation allowance recorded against our net deferred tax assets.
The Company is required to evaluate the provisions of Topic 740 related to the accounting for uncertainty in income taxes recognized in a company’s financial statements. Topic 740 prescribes a comprehensive model for how a company should recognize, present, and disclose uncertain positions that the company has taken or expects to take in its tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. Differences between tax positions taken or expected to be taken in a tax return and the net benefit recognized and measured pursuant to the interpretation are referred to as “unrecognized benefits.” A liability should be recognized (or amount of net operating loss carry forward or amount of tax refundable is reduced) for unrecognized tax benefit because it represents a company’s potential future obligation to the taxing authority for a tax position that was not recognized because of applying the provision of Topic 740. TCJA was enacted on December 22, 2017 and is effective January 1, 2018. The new legislation includes, among other things a reduction of the U.S. Federal corporate income tax rate from 35% to 21%, and a change to alternative minimum taxes. The TCJA eliminated the corporate Alternative Minimum Tax (AMT) and permits existing AMT credit carryforwards to be used to reduce the regular tax obligation in 2018, 2019, and 2020. Any AMT credit carryforwards that do not reduce regular taxes are eligible for a 50% refund in 2018 through 2020, and a 100% refund in 2021.
Fair Value Measurements
Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company utilized various methods, including income, cost and market approaches to determine the fair value of its investments in equity interest, which may fall into Level 3 of the fair value hierarchy because of the significant unobservable inputs utilized in these valuation approaches. These inputs can be readily observable, market corroborated, or generally unobservable inputs. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. Our key inputs included, but were not limited to, significant management judgments and estimates, including projections of the timing and amount of the project’s cash flows, determination of a discount rate for the income approach, market multipliers, probability weighting of potential outcomes of legal and regulatory proceedings, and weighting of the valuations produced by the income, cost and market approaches.
The Company bases its fair value estimates on assumptions it believes to be reasonable, but which are unpredictable and inherently uncertain. Actual future results may differ from those estimates.
Off-Balance Sheet Arrangements
We do not have any off-balance sheet arrangements.
Recent Accounting Pronouncements
See Note 1 to the Consolidated Financial Statements for information about recent accounting pronouncements.

Results of Operations
Three and Nine Months Ended September 30, 2019 Compared to the Same Periods in 2018
28

Revenue and Cost of Revenue
The following table summarizes the Company’s revenue and cost of research and development revenue for the three and nine months ended September 30, 2019 and 2018:
Three Months Ended September 30,Nine Months Ended September 30,
2019201820192018
Revenue$454,507  $262,960  $1,247,908  $608,576  
Cost of research and development revenue$384,803  $243,406  $1,034,934  $519,331  

The increase in revenue and cost of research and development revenue for the three months ended September 30, 2019 reflect five on-going research collaborations compared to four collaborations for the same period a year ago. The increase in revenue and cost of research and development revenue for the nine months ended September 30, 2019 reflect eight on-going research collaborations compared to five collaborations for the same period a year ago.
Research and Development Expenses
Research and development costs are expensed as incurred and primarily include salary and benefits of research personnel, third-party contract research organization services and supply costs.
Research and development expenses for the three months ended September 30, 2019 increased to approximately $841,000 compared to $477,000 for the same period a year ago. The increase primarily reflects the costs of additional internal research projects.
Research and development expenses for the nine months ended September 30, 2019 increased to approximately $2,352,000 compared to $1,655,000 for the same period a year ago. The increase primarily reflects the costs of additional internal research projects.
Research and development expenses - related party, for the three months ended September 30, 2019, was approximately $102,000 compared to $288,000 for the same period a year ago. The decrease primarily reflects the reduced cost incurred in connection with the Research Service Agreement with BDI, which was completed in June 2019.
Research and development expenses - related party, for the nine months ended September 30, 2019, was approximately $828,000 compared to $1,022,000 for the same period a year ago. The decrease primarily reflects the reduced cost incurred in connection with the Research Service Agreement with BDI, which was completed in June 2019.
General and Administrative Expenses
General and administrative expenses for the three months ended September 30, 2019, increased 3.1% to approximately $1,056,000 compared to $1,024,000 for the same period a year ago. The increase principally includes increases in noncash share-based compensation expenses of $67,000, accrued annual bonuses and incentives for employees of $86,000, insurance and other costs of $86,000, and business development and investor relations costs of $28,000, offset by reductions in executive compensation costs, including the separation of the Company's former CFO, of $171,000 and SEC registration and NASDAQ uplisting expenses of $63,000.
General and administrative expenses for the nine months ended September 30, 2019, increased 34.5% to approximately $4,355,000 compared to $3,238,000 for the same period a year ago. The increase principally includes increases in noncash share-based compensation expenses of $640,000 related to stock options granted in 2019 and options vested upon the April 2019 uplisting to the NASDAQ, accrued annual bonuses and incentives for employees of $257,000, SEC registration and NASDAQ uplisting expenses of $244,000, business development and investor relations costs of $159,000, and insurance costs and others of $89,000, offset by reductions in executive compensation costs, including the separation of the Company's former CFO, of $273,000.
Interest Income
29

Interest income for the three months ended September 30, 2019, increased 1.2% to approximately $245,000 compared to $242,000 for the same period a year ago. The increase reflects higher yield on the Company’s investment grade securities, which are classified as held-to-maturity.
Interest income for the nine months ended September 30, 2019, increased 20.1% to approximately $778,000 compared to $648,000 for the same period a year ago. The increase reflects higher yield on the Company’s investment grade securities, which are classified as held-to-maturity.
Net Loss
Net loss for the three months ended September 30, 2019 was approximately $1,698,000 compared to $1,539,000 for the same period a year ago.
Net loss for the nine months ended September 30, 2019 was approximately $6,569,000 compared to $5,179,000 for the same period a year ago.

Liquidity and Capital Resources
Our primary source of cash has been the cash received from the DuPont Transaction in December 2015, interest income received from investment grade securities, and funding from our research collaboration agreements. On August 16, 2017, the Board of Directors authorized the 2017 Stock Repurchase Program, under which the Company may repurchase up to $5 million of its outstanding common stock. On August 6, 2018, the Board of Directors authorized an extension of the 2017 Stock Repurchase Program through August 15, 2019. The Company financed the 2017 Stock Repurchase Program from its existing cash on hand. Between January 2016 and August 2018, the Company repurchased a total of 14,390,254 shares of its common stock at a weighted average price of $1.52 for an aggregate purchase price of $21,814,530. In June 2019, the Company’s liquidity was further improved with the receipt of approximately $0.5 million tax refund resulting from the elimination of corporate Alternative Minimum Tax (AMT) under the TCJA. An additional $0.5 million AMT tax refund is expected over the next three years through 2021.
Our ability to achieve profitability depends on a number of factors, including our scientific results and our ability to continue to obtain funded research and development collaborations from industry and government programs, as well as sub-license agreements. We may continue to incur substantial operating losses even if we begin to generate revenues from research and development and licensing. Our primary future cash needs are expected to be for general operating activities, including additional costs and expenses as an SEC reporting and NASDAQ listed company, and our business development and research expenses. We believe that our existing cash position and investments in investment grade securities will be adequate to meet our operational, business, and other liquidity requirements for the next twelve months.
At September 30, 2019, cash and cash equivalents were approximately $4.7 million compared to $2.4 million at December 31, 2018. The carrying value of investment grade securities, including accrued interest at September 30, 2019 was approximately $32.5 million compared to $39.1 million at December 31, 2018.
Net cash used in operating activities for the nine months ended September 30, 2019 of approximately $4.4 million was principally attributable to a net loss of $6.6 million, partially offset by share-based compensation expense of approximately $1.0 million, changes in tax receivable of approximately $0.5 million, changes in other operating assets and liabilities of approximately $0.5 million, and amortization of held-to-maturity securities and foreign currency exchange gain of approximately $0.2 million.
Net cash used in operating activities for the nine months ended September 30, 2018 of approximately $3.2 million was principally attributable to a net loss of $5.2 million, partially offset by changes in operating assets and liabilities of approximately $1.0 million, share-based compensations expense of approximately $0.4 million and amortization of held-to-maturity securities of approximately $0.6 million.
Net cash provided by investing activities for the nine months ended September 30, 2019 was approximately $6.4 million compared to net cash provided by investing activities of $1.4 million for the nine months ended September 30, 2018. Cash flows from investing activities in 2019 and 2018 were primarily related to proceeds from maturities and purchases of investment grade debt securities.
30

Net cash provided by financing activities for the nine months ended September 30, 2019 was approximately $0.3 million compared to net cash used in financing activities of $2.3 million for the nine months ended September 30, 2018. Cash flows from financing activities in 2019 were primarily related to proceeds from exercise of options. Cash flows from financing activities in 2018 were primarily related to repurchases of common stock.


Item 3.Quantitative and Qualitative Disclosures about Market Risk
We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.


Item 4.Controls and procedures
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms. Based on the evaluation of our disclosure controls and procedures as of the end of the period covered by this report, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective.
Changes in Internal Controls Over Financial Reporting
There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d- 15(d) of the Exchange Act that occurred during the three months ended September 30, 2019 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Inherent Limitation on Effectiveness of Controls
A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

PART II

Item 1.Legal Proceedings
31

From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. The Company does not believe that any of these claims or proceedings against us is likely to have, individually or in the aggregate, a material adverse effect on the financial condition or results of operations.



Item 1A.Risk Factors
There have been no changes to our risk factors from those disclosed in our Form 10-K for the 2018 fiscal year filed on March 27, 2019 and our 10-Q filed on May 9, 2019.


Item 2.Unregistered Sales of Equity Securities and Use of Proceeds
None.


Item 3.Defaults Upon Senior Securities
Not applicable.


Item 4.Mine Safety Disclosures
Not applicable.


Item 5.Other Information
Nasdaq Uplisting 
Effective April 17, 2019, our common stock began trading on the NASDAQ Stock Market LLC’s NASDAQ Capital Market, under the symbol “DYAI”. Prior to the Company’s uplisting to the NASDAQ Capital Market, the Company’s common stock traded on the OTCQX market.


Item 6.Exhibits
Following Exhibits are filed as part of this report pursuant to Item 601 of Regulation S-K:
32

Incorporated by Reference
Exhibit No.Description of ExhibitFormOriginal No.Date FiledFiled Herewith
10.1
Sub-License Agreement among Dyadic International (USA), Inc., Luina Bio Pty Ltd. and Novovet Pty Ltd, dated April 26, 2019. Specific items in this exhibit have been redacted, as marked by three asterisks [***]
8-K10.1May 2, 2019
10.28-K10.2May 2, 2019
10.3
Non-Exclusive Sublicense Agreement among Dyadic International, Inc., Alphazyme, LLC, dated May 5, 2019. Specific items in this exhibit have been redacted, as marked by three asterisks [***]
8-K10.1May 8, 2019
10.4
Research and Commercialization Collaboration Agreement with Serum Institute of India Pvt,. Ltd., dated May 7, 2019. Specific items in this exhibit have been redacted, as marked by three asterisks [***].
8-K10.1May 8, 2019
10.5
Commission Contract with VTT Technical Research Centre of Finland Ltd., dated June 28, 2019. Specific items in this exhibit have been redacted, as marked by three asterisks [***]
8-K10.1July 5, 2019
10.68-K10.1November 13, 2019 
31.1x
31.2x
32.1x
32.2x

Exhibit No. Description
101.INS XBRL Instance Document
101.SCH XBRL Taxonomy Extension Schema Document
101.CAL XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF XBRL Taxonomy Extension Definition Linkbase Document
101.LAB XBRL Taxonomy Extension Labels Linkbase Document
101.PRE XBRL Taxonomy Extension Presentation Linkbase Document

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
33

 DYADIC INTERNATIONAL, INC.
   
November 13, 2019By:/s/ Mark A. Emalfarb
  Mark A. Emalfarb
  President and Chief Executive Officer
(Principal Executive Officer)
November 13, 2019By:/s/ Ping W. Rawson
 Ping W. Rawson
 Chief Financial Officer
(Principal Financial Officer and Principal Accounting Officer)

34
 EX-31.1 2 exhibit311certificatio.htm EX-31.1 Document

Exhibit 31.1
 
Certification of Principal Executive Officer
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
and Securities and Exchange Commission Release 34-46427
 
 
 I, Mark A. Emalfarb, certify that:
 
1.I have reviewed this quarterly report on Form 10-Q of Dyadic International Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:

5.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:
a.designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
d.disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

6.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and



a.any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date: November 13, 2019
By:  
          
Name:              
Title:                 		/s/   Mark A. Emalfarb

Mark A. Emalfarb
Chief Executive Officer
 


 EX-31.2 3 exhibit312certificatio.htm EX-31.2 Document

Exhibit 31.2
 
Certification of Principal Executive Officer
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
and Securities and Exchange Commission Release 34-46427
 
 
 I, Ping W. Rawson, certify that:
 
1. I have reviewed this quarterly report on Form 10-Q of Dyadic International Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:

a.designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
d.disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b.any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 


Date: November 13, 2019
By:  
          
Name:              
Title:                 		/s/   Ping W. Rawson

Ping W. Rawson
Chief Financial Officer
 


 EX-32.1 4 exhibit321sec1350certi.htm EX-32.1 Document

Exhibit 32.1
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Quarterly Report of Dyadic International Inc. (the "Company") on Form 10-Q for the quarter ended September 30, 2019 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Mark A. Emalfarb, certify, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
 
(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
 
Date:November 13, 2019
By:  
          
Name:              
Title:                 		/s/   Mark A. Emalfarb

Mark A. Emalfarb
Chief Executive Officer
 


 EX-32.2 5 exhibit322sec1350certi.htm EX-32.2 Document

Exhibit 32.2
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Quarterly Report of Dyadic International Inc. (the "Company") on Form 10-Q for the quarter ended September 30, 2019 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Ping W. Rawson, certify, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
 
(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
 
Date:November 13, 2019
By:  
          
Name:              
Title:                 		/s/   Ping W. Rawson

Ping W. Rawson
Chief Financial Officer
 


 EX-101.SCH 6 dyai-20190930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Organization and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 2404401 - Disclosure - Organization and Summary of Significant Accounting Policies - Textual (Details) link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Organization and Summary of Significant Accounting Policies - Accounts Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - Organization and Summary of Significant Accounting Policies - Prepaid Expenses and Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2407404 - Disclosure - Organization and Summary of Significant Accounting Policies - Accounts Payable (Details) link:presentationLink link:calculationLink link:definitionLink 2408405 - Disclosure - Organization and Summary of Significant Accounting Policies - Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 2409406 - Disclosure - Organization and Summary of Significant Accounting Policies - Research and Development Costs (Details) link:presentationLink link:calculationLink link:definitionLink 2110102 - Disclosure - Cash, Cash Equivalent, and Investments link:presentationLink link:calculationLink link:definitionLink 2311302 - Disclosure - Cash, Cash Equivalent, and Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 2412407 - Disclosure - Cash, Cash Equivalent, and Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2412407 - Disclosure - Cash, Cash Equivalent, and Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2113103 - Disclosure - Research Collaboration and Sub-licensing Agreements link:presentationLink link:calculationLink link:definitionLink 2414408 - Disclosure - Research Collaboration and Sub-licensing Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 2115104 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2416409 - Disclosure - Commitments and Contingencies - Textual (Details) link:presentationLink link:calculationLink link:definitionLink 2117105 - Disclosure - Share-Based Compensation link:presentationLink link:calculationLink link:definitionLink 2318303 - Disclosure - Share-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2419410 - Disclosure - Share-Based Compensation - Textual (Details) link:presentationLink link:calculationLink link:definitionLink 2420411 - Disclosure - Share-Based Compensation - Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 2421412 - Disclosure - Share-Based Compensation - Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2422413 - Disclosure - Share-Based Compensation - Stock Option Activity - Textual (Details) link:presentationLink link:calculationLink link:definitionLink 2423414 - Disclosure - Share-Based Compensation - Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2124106 - Disclosure - Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 2325304 - Disclosure - Shareholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2426415 - Disclosure - Shareholders' Equity - Textual (Details) link:presentationLink link:calculationLink link:definitionLink 2427416 - Disclosure - Shareholders' Equity - Changes in Shareholders’ Equity (Details) link:presentationLink link:calculationLink link:definitionLink 2428417 - Disclosure - Shareholders' Equity - Stock Repurchase (Details) link:presentationLink link:calculationLink link:definitionLink 2129107 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 dyai-20190930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 dyai-20190930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 dyai-20190930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Range [Domain] Range [Domain] Common stock, par value (USD per share) Common Stock, Par or Stated Value Per Share Income Statement Location [Domain] Income Statement Location [Domain] Accounting Policies [Abstract] Accounting Policies [Abstract] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Research and development expense, related party, net Research And Development Expense, Including Related Party Research And Development Expense, Including Related Party Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Research and development expenses Accrued Research and Development in Process, Current Accrued Research and Development in Process, Current Concentrations Concentration Risk, Credit Risk, Policy [Policy Text Block] Prepaid expenses and other current assets Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current SFA Service Framework Agreement [Member] Service Framework Agreement [Member] Tax cuts and jobs act, change in alternative minimum tax, income tax benefit Tax Cuts and Jobs Act, Change In Alternative Minimum Tax, Income Tax Benefit Tax Cuts and Jobs Act, Change In Alternative Minimum Tax, Income Tax Benefit Additional paid-in capital Additional Paid-in Capital [Member] Duration of agreement Collaborative Arrangement, Duration Of Agreement Collaborative Arrangement, Duration Of Agreement Income tax receivable Income Taxes Receivable, Current Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Cash and Cash Equivalents Cash and Cash Equivalents, Fair Value Disclosure Commitment to pay Commitment To Pay Commitment To Pay Long term Investments, gross unrealized holding loss Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss, Noncurrent Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss, Noncurrent Income Taxes Income Tax, Policy [Policy Text Block] Repurchases of common stock Payments for Repurchase of Common Stock Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Risk-Free interest rate, maximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Aggregate intrinsic value, exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Aggregate intrinsic value, outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Costs and expenses: Costs and Expenses [Abstract] Level 2 Fair Value, Inputs, Level 2 [Member] Billing Status, Type [Axis] Billing Status, Type [Axis] Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Collaborative Arrangement Collaborative Arrangement [Member] Exercise of stock options, cash (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Cash Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Cash Stock Option Employee Stock Option [Member] Expected life of options Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Canceled (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Statement [Table] Statement [Table] Obligation for payment for research and development, maximum Collaborative Arrangement, Maximum Obligation For Research And Development Collaborative Arrangement, Maximum Obligation For Research And Development Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Number of shares available for grant (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Schedule of Accrued Expenses Schedule of Accrued Liabilities [Table Text Block] Accumulated deficit Retained Earnings (Accumulated Deficit) Commitments, right to terminate contract notice period Commitments, Right To Terminate Contract Notice Period Commitments, Right To Terminate Contract Notice Period Prepaid insurance Prepaid Insurance New Accounting Pronouncements or Change in Accounting Principle [Table] New Accounting Pronouncements or Change in Accounting Principle [Table] Expected stock price volatility, maximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Document Quarterly Report Document Quarterly Report Cash and Cash Equivalents [Abstract] Cash and Cash Equivalents [Abstract] Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Long term Investments, fair value Debt Securities, Held-to-maturity, Fair Value, Noncurrent Debt Securities, Held-to-maturity, Fair Value, Noncurrent Investment Securities Investment, Policy [Policy Text Block] Award requisite service period Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period Investment, Name [Axis] Investment, Name [Axis] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Supplemental cash flow information Supplemental Cash Flow Information [Abstract] Legal expenses Accrued Professional Fees, Current Schedule of Cash, Available-for-sale Securities, Short-term and Long-term Investment Securities Cash, Cash Equivalents and Investments [Table Text Block] Exclusivity period Collaborative Arrangement, Exclusivity Period Collaborative Arrangement, Exclusivity Period Jupiter, Florida Headquarters Lease Jupiter, Florida Headquarters Lease [Member] Jupiter, Florida Headquarters Lease [Member] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Revenue from collaborative arrangement, recognized Revenue from Collaborative Arrangement, Recognized Revenue from Collaborative Arrangement, Recognized Netherlands Office Lease Netherlands Office Lease [Member] Netherlands Office Lease [Member] Stock-based compensation Allocated Share-based Compensation Expense Financial Instruments [Domain] Financial Instruments [Domain] Proceeds from maturities of investment securities Proceeds from Sale and Maturity of Held-to-maturity Securities Deferred tax assets, net Deferred Tax Assets, Net Assets Assets [Abstract] Range [Axis] Range [Axis] Organization and Summary of Significant Accounting Policies Business Description and Accounting Policies [Text Block] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Accounts payable Increase (Decrease) in Accounts Payable Accrued expenses Increase (Decrease) in Accrued Liabilities Deferred tax assets, valuation allowance coverage, percent Deferred Tax Assets, Valuation Allowance Coverage, Percent Deferred Tax Assets, Valuation Allowance Coverage, Percent Document Fiscal Year Focus Document Fiscal Year Focus Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Period under program Stock Repurchase Program, Period in Force Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Commitment to pay, expanded, period Commitment To Pay, Expanded, Period Commitment To Pay, Expanded, Period Title of Individual [Axis] Title of Individual [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Other assets Other Assets, Noncurrent Long-term income tax receivable Income Taxes Receivable, Noncurrent Equity, Class of Treasury Stock [Line Items] Equity, Class of Treasury Stock [Line Items] Entity Current Reporting Status Entity Current Reporting Status Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Entity Emerging Growth Company Entity Emerging Growth Company Accumulated deficit Retained Earnings [Member] Net cash provided by investing activities Net Cash Provided by (Used in) Investing Activities Receivables Billing Status [Domain] Receivables Billing Status [Domain] Stock repurchased Stock Issued During Period, Value, Share-based Compensation, Gross Schedule of Accounts Payable Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Contractor Contractor [Member] Contractor [Member] Contracted services - related party Research And Development Expense, Contracted Services, Related Party Research And Development Expense, Contracted Services, Related Party Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Payment for research and development agreement Collaborative Arrangement, Payment for Research and Development Agreement Collaborative Arrangement, Payment for Research and Development Agreement Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Proceeds from sales of business Proceeds from Sales of Business, Affiliate and Productive Assets Long term Investments, gross unrealized holding gain Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain, Noncurrent Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain, Noncurrent Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Risk-Free interest rate, minimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Option to extend exclusivity period Collaborative Arrangement, Option To Extend Exclusivity Period Collaborative Arrangement, Option To Extend Exclusivity Period Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Entity Address, State or Province Entity Address, State or Province Schedule of stock option activity Share-based Compensation, Stock Options, Activity [Table Text Block] Serum Serum [Member] Serum [Member] Share-based Compensation Award, Tranche One Share-based Compensation Award, Tranche One [Member] Short-term investment securities Short term investments, adjusted cost Debt Securities, Held-to-maturity, Current Subsequent Event Type [Axis] Subsequent Event Type [Axis] Number of collaboration project, in progress Collaborative Arrangement, Number of Collaboration Project, In Progress Collaborative Arrangement, Number of Collaboration Project, In Progress Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Monthly rental rate Operating Leases, Monthly Rental Rate Operating Leases, Monthly Rental Rate Accounts Receivable Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block] Document Transition Report Document Transition Report Obligation for payment for research and development, minimum Collaborative Arrangement, Minimum Obligation For Research And Development Collaborative Arrangement, Minimum Obligation For Research And Development Revenue Sales Revenue, Net [Member] Vesting [Domain] Vesting [Domain] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Weighted average exercise price, granted (USD per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Weighted-average remaining contractual term, outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Stock-based compensation expense Share-based Compensation Area of building rented Area of Real Estate Property Expiration period Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Arrangements and Non-arrangement Transactions [Domain] Arrangements and Non-arrangement Transactions [Domain] Geographical [Axis] Geographical [Axis] Accounts receivable Increase (Decrease) in Accounts Receivable Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Approved (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Entity Address, City or Town Entity Address, City or Town Prepaid taxes Prepaid Taxes Entity Filer Category Entity Filer Category Equity [Abstract] Equity [Abstract] Short term investments, gross unrealized holding loss Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss, Current Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss, Current Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Schedule of Accounts Receivable Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Research and Development Costs Research and Development Expense, Policy [Policy Text Block] BDI BDI [Member] BDI [Member] Loss before income taxes Income (Loss) Attributable to Parent, before Tax Number of board of directors Share-based Compensation Arrangement by Share-based Payment Award, Number of Board of Directors Share-based Compensation Arrangement by Share-based Payment Award, Number of Board of Directors Type of Arrangement and Non-arrangement Transactions [Axis] Type of Arrangement and Non-arrangement Transactions [Axis] Statement [Line Items] Statement [Line Items] Schedule of stock repurchase activity Class of Treasury Stock [Table Text Block] Entity Registrant Name Entity Registrant Name Share Repurchase Program [Domain] Share Repurchase Program [Domain] Equity Method Investment Equity Method Investments [Policy Text Block] Authorized repurchase amount Stock Repurchase Program, Authorized Amount Cash received from income tax refund Proceeds from Income Tax Refunds Treasury Stock Treasury Stock [Member] Chief Financial Officer Chief Financial Officer [Member] VTT Technical Research Centre of Finland Ltd VTT Technical Research Centre of Finland Ltd [Member] VTT Technical Research Centre of Finland Ltd [Member] Amendment Flag Amendment Flag VLPbio VLPbio [Member] VLPbio [Member] Expired (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Number of collaboration project, completed Collaborative Arrangement, Number of Collaboration Project, Completed Collaborative Arrangement, Number of Collaboration Project, Completed City Area Code City Area Code Vesting [Axis] Vesting [Axis] Common stock reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Entity Central Index Key Entity Central Index Key Other Other Accrued Liabilities, Current Rent expense Operating Leases, Annual Rental Rate Operating Leases, Annual Rental Rate Basic and diluted weighted-average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic and Diluted Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Maximum Dollar Value of Shares that May Yet Be Purchased Under the Plan Stock Repurchase Program, Remaining Authorized Repurchase Amount Exercise of stock options, common stock (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Common Stock Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Common Stock 2006 Plan 2006 Plan [Member] 2006 Plan [Member] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Billed receivable Billed Revenues [Member] Entity Shell Company Entity Shell Company Expected stock price volatility, minimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Amortization of held-to-maturity securities, net Investment Income, Amortization of Premium Other Accounts Payable, Other, Current Outside of the United States Non-US [Member] Stock-Based Compensation Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Long-term investment securities Long term investments, adjusted cost Debt Securities, Held-to-maturity, Noncurrent Industrial Technology Business Industrial Technology Business [Member] Industrial Technology Business [Member] Total stockholders’ equity Beginning balance Ending balance Stockholders' Equity Attributable to Parent Research and development - related party Research and Development Expense, Related Party Research and Development Expense, Related Party Plan Name [Axis] Plan Name [Axis] Disposal Group Name [Domain] Disposal Group Name [Domain] Equity Component [Domain] Equity Component [Domain] Facilities, overhead and other Research And Development Expense, Facilities, Overhead and Other Research And Development Expense, Facilities, Overhead and Other Weighted average exercise price, exercisable (USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Common Stock Common Stock [Member] Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Lease Arrangement, Type [Axis] Lease Arrangement, Type [Axis] Geographical [Domain] Geographical [Domain] Held-to-maturity, premium paid on purchase Debt Securities, Held-to-maturity, Premium Paid on Purchase Debt Securities, Held-to-maturity, Premium Paid on Purchase Exercise of stock options, net (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Net Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Net Exercisable (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Accounts payable Accounts payable Accounts Payable, Current Relationship to Entity [Domain] Relationship to Entity [Domain] Executives and Key Personnel Executives and Key Personnel [Member] Executives and Key Personnel [Member] Current Fiscal Year End Date Current Fiscal Year End Date Equity Award [Domain] Equity Award [Domain] Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Cash Cash [Member] Schedule of Prepaid Expenses and Other Current Assets Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Granted (in shares) Options granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Interest receivable Increase (Decrease) in Accrued Interest Receivable, Net Level 1 Fair Value, Inputs, Level 1 [Member] Schedule of stockholders equity Schedule of Stockholders Equity [Table Text Block] Share-Based Compensation Disclosure of Compensation Related Costs, Share-based Payments [Text Block] General and administrative General and Administrative Expense [Member] Research and Development [Abstract] Research and Development [Abstract] Interest income Interest Income (Expense), Nonoperating, Net Number of antibodies and vaccines for development and commercialization Collaborative Arrangement, Number of Antibodies and Vaccines For Development And Commercialization Collaborative Arrangement, Number of Antibodies and Vaccines For Development And Commercialization Payment for additional development and commercialization Collaborative Arrangement, Payment for Additional Development and Commercialization Collaborative Arrangement, Payment for Additional Development and Commercialization Income Statement Location [Axis] Income Statement Location [Axis] Prepaid research and development Prepaid Research and Development Prepaid Research and Development Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Chief Executive Officer Chief Executive Officer [Member] Outstanding commitment Collaborative Arrangement, Outstanding Commitment Collaborative Arrangement, Outstanding Commitment Research and Development Arrangement, Contract to Perform for Others [Line Items] Research and Development Arrangement, Contract to Perform for Others [Line Items] Cash and Investment, adjusted cost Investments and Cash, Amortized Cost Investments and Cash, Amortized Cost Outstanding (in shares) Outstanding, beginning (in shares) Outstanding, ending (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Long-term Purchase Commitment [Line Items] Long-term Purchase Commitment [Line Items] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Investment, Name [Domain] Investment, Name [Domain] Average Price Paid per Share (in usd per share) Treasury Stock Acquired, Average Cost Per Share Equity percentage Equity Method Investment, Ownership Percentage Foreign Currency Transaction Gain or Loss Foreign Currency Transactions and Translations Policy [Policy Text Block] Loss from operations Operating Income (Loss) Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Foreign currency exchange loss (gain), net Foreign Currency Transaction Gain (Loss), before Tax Allowance for doubtful accounts receivable Allowance for Doubtful Accounts Receivable Revenue from collaborative arrangement, contract liability Revenue from Collaborative Arrangement, Contract Liability Revenue from Collaborative Arrangement, Contract Liability Basic and diluted net loss per common share (USD per share) Earnings Per Share, Basic and Diluted Short term investments, fair value Debt Securities, Held-to-maturity, Fair Value, Current Debt Securities, Held-to-maturity, Fair Value, Current Publicly Announced Repurchase Plans Publicly Announced Repurchase Plans [Member] Publicly Announced Repurchase Plans [Member] Subsequent Event [Member] Subsequent Event [Member] Employee wages and benefits Employee-related Liabilities, Current Interest receivable Interest Receivable, Current Income taxes payable Increase (Decrease) in Income Taxes Payable Commitments and contingencies (See Note 4) Commitments and Contingencies Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Cover page. Exercise of stock options, forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Forfeited Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Forfeited Research and development Research and Development Expense Unbilled receivable Unbilled Revenues [Member] Trading Symbol Trading Symbol United States UNITED STATES Document Period End Date Document Period End Date Accounts receivable Accounts Receivable, Net Effect of exchange rate changes on cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Class of Treasury Stock [Table] Class of Treasury Stock [Table] Share Repurchase Program [Axis] Share Repurchase Program [Axis] Project [Axis] Project [Axis] Common stock Common Stock, Value, Issued Comprehensive Income (Loss) Comprehensive Income, Policy [Policy Text Block] Research and development Research and Development Expense [Member] 2011 Plan 2011 Plan [Member] 2011 Plan [Member] Expected dividend rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Accounts Receivable Accounts Receivable [Member] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Subsequent Events Subsequent Events [Text Block] Costs of research and development revenue Cost of Goods and Services Sold Board of Directors Director [Member] Stock-based compensation Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Revenues: Revenues [Abstract] Treasury stock, shares held at cost Treasury stock, shares held at cost Treasury Stock, Value Total assets Assets Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Project [Domain] Project [Domain] Weighted-average remaining contractual term, exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Plan Name [Domain] Plan Name [Domain] Revenue sharing, percentage Collaborative Arrangement, Revenue Sharing, Percentage Collaborative Arrangement, Revenue Sharing, Percentage Discount for lack of marketability Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Lack of Marketability Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Lack of Marketability Document Fiscal Period Focus Document Fiscal Period Focus Weighted average exercise price, expired (USD per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Document Type Document Type Concentration risk, number of customers Concentration Risk, Number of Customers Concentration Risk, Number of Customers Alphazyme Alphazyme [Member] Alphazyme [Member] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Tax Identification Number Entity Tax Identification Number Purchases of held-to-maturity investment securities Payments to Acquire Held-to-maturity Securities Income Statement [Abstract] Income Statement [Abstract] Prepaid research and development Prepaid Research and Development in Process, Current Prepaid Research and Development in Process, Current Total costs and expenses Costs and Expenses Entity Interactive Data Current Entity Interactive Data Current Corporate bonds Corporate Debt Securities [Member] Number of operating segments Number of Operating Segments Use of Estimates Use of Estimates, Policy [Policy Text Block] Provision for income taxes Income Tax Expense (Benefit) Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Total current assets Assets, Current Stock issued Stock Issued Net increase (decrease) in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Total current liabilities Liabilities, Current Non-current assets: Assets, Noncurrent [Abstract] Commitment development period Commitment Development Period Commitment Development Period General and administrative General and Administrative Expense Local Phone Number Local Phone Number Total liabilities and stockholders’ equity Liabilities and Equity Additional paid-in capital Additional Paid in Capital Accounts receivable Accounts Receivable, Net, Current Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Equity Components [Axis] Equity Components [Axis] Cash, Cash Equivalent, and Investments Cash, Cash Equivalents, and Marketable Securities [Text Block] Schedule of valuation assumptions Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Award Type [Axis] Award Type [Axis] Counterparty Name [Domain] Counterparty Name [Domain] Commitment success bonus award Commitment Success Bonus Award Commitment Success Bonus Award Common stock, shares issued (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Issued Exercise of stock options, common stock issued (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Common Stock Issued Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Common Stock Issued Commitment to pay, expanded Commitment To Pay, Expanded Commitment To Pay, Expanded Preferred stock, par value (USD per share) Preferred Stock, Par or Stated Value Per Share Personnel related costs Research And Development Expense, Personnel Related Costs Research And Development Expense, Personnel Related Costs Subsequent Events [Abstract] Subsequent Events [Abstract] Weighted average exercise price, outstanding, beginning (USD per share) Weighted average exercise price, outstanding, ending (USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Preferred stock Preferred Stock, Value, Issued Schedule of non-cash stock option compensation expense Share-based Compensation, Activity [Table Text Block] Percentage of options that will vest Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Net loss Net loss Net Income (Loss) Attributable to Parent Long-term Purchase Commitment [Table] Long-term Purchase Commitment [Table] Total Number of Shares Purchased (in shares) Treasury Stock, Shares, Acquired Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Entity Small Business Entity Small Business Entity File Number Entity File Number Cash and Investment, fair value Investments and Cash Ownership [Axis] Ownership [Axis] Customer Concentration Risk Customer Concentration Risk [Member] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Schedule of Research and Development Costs Schedule of Research and Development Costs [Table Text Block] Schedule of Research and Development Costs [Table Text Block] Research funding, milestone payments and royalties, period Collaborative Arrangement, Research Funding, Milestone Payments And Royalties, Period Collaborative Arrangement, Research Funding, Milestone Payments And Royalties, Period Income tax receivable Increase (Decrease) in Income Taxes Receivable Weighted average exercise price, canceled (USD per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Accrued expenses Accrued expenses Accrued Liabilities, Current Outside contracted services Research And Development Expense, Outside Contracted Services Research And Development Expense, Outside Contracted Services Counterparty Name [Axis] Counterparty Name [Axis] Award vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Financial Instrument [Axis] Financial Instrument [Axis] RSA Research Services Agreement [Member] Research Services Agreement [Member] Option to obtain exclusive commercial sub-license for number of proteins Collaborative Arrangement, Option to Obtain Exclusive Commercial Sub-License For Number of Proteins Collaborative Arrangement, Option to Obtain Exclusive Commercial Sub-License For Number of Proteins Novovet Novovet [Member] Novovet [Member] Lease Arrangement, Type [Domain] Lease Arrangement, Type [Domain] Short term investments, gross unrealized holding gain Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain, Current Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain, Current Deferred research and development obligation Increase (Decrease) in Contract with Customer, Liability Treasury stock (in shares) Treasury Stock, Common, Shares Current liabilities: Liabilities, Current [Abstract] Foreign currency exchange loss (gain), net Foreign Currency Transaction Gain (Loss), Realized Investment, gross unrealized holding gain Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Exercise of stock options (in shares) Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Liabilities and stockholders’ equity Liabilities and Equity [Abstract] Prepaid research and development Increase (Decrease) in Prepaid Research and Development Increase (Decrease) in Prepaid Research and Development Research and development revenue Revenues Revenue from Contract with Customer, Excluding Assessed Tax Money Market Funds Money Market Funds [Member] Ownership [Domain] Ownership [Domain] DuPont Danisco DuPont Danisco [Member] DuPont Danisco [Member] Term of contract Lessee, Operating Lease, Term of Contract BDI Holdings BDI Holdings [Member] BDI Holdings [Member] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Investment, gross unrealized holding losses Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Employee Employee [Member] Employee [Member] Share-based Compensation Award, Tranche Two through Five Share-based Compensation Award, Tranche Two through Five [Member] Share-based Compensation Award, Tranche Two through Five [Member] Net Loss Per Share Earnings Per Share, Policy [Policy Text Block] Deferred research and development obligations Contract with Customer, Liability, Current Weighted average exercise price, exercised (in USD per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Equity interest acquired Collaborative Arrangement, Equity Interest Acquired Collaborative Arrangement, Equity Interest Acquired Minimum Minimum [Member] Concentration risk, percentage Concentration Risk, Percentage Amount Treasury Stock, Value, Acquired, Cost Method Security Exchange Name Security Exchange Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Address Line Two Entity Address, Address Line Two Ownership interest consideration receivable upon extension of exclusivity period Collaborative Arrangement, Ownership Interest Consideration Receivable Upon Extension Of Exclusivity Period Collaborative Arrangement, Ownership Interest Consideration Receivable Upon Extension Of Exclusivity Period Entity Address, Address Line One Entity Address, Address Line One Current assets: Assets, Current [Abstract] Unrecognized tax benefits Unrecognized Tax Benefits Exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Proceeds from exercise of options Proceeds from Stock Options Exercised Research and development expenses Research And Development In Process, Current Research And Development In Process, Current Research Collaboration and Sub-licensing Agreements Collaborative Arrangement Disclosure [Text Block] Prepaid expenses - various Other Prepaid Expense, Current Disposal Group Name [Axis] Disposal Group Name [Axis] Maximum Maximum [Member] Title of 12(b) Security Title of 12(b) Security EX-101.PRE 10 dyai-20190930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 11 dyai-20190930_g1.jpg begin 644 dyai-20190930_g1.jpg M_]C_X 02D9)1@ ! 0$ > !X #_X1"617AI9@ 34T *@ @ ! $[ ( M , (2H=I 0 ! (5IR= $ 8 0=NH< < @, /@ M G)E4WI.5&-Z:V,Y9"<_/@T*/'@Z>&UP;65T M82!X;6QN&UL;G,Z&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT M"UN#IX;7!M971A M/@T*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" * M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @ M(" @(" @(" @(" @(" @(" @(" @(" @(" \/WAP86-K970@96YD/2=W)S\^ M_]L 0P '!04&!00'!@4&" <'" H1"PH)"0H5#Q ,$1@5&AD8%1@7&QXG(1L= M)1T7&"(N(B4H*2LL*QH@+S,O*C(G*BLJ_]L 0P$'" @*"0H4"PL4*AP8'"HJ M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ M*BHJ_\ $0@ XP$= P$B (1 0,1 ?_$ !\ $% 0$! 0$! ! M @,$!08'" D*"__$ +40 (! P,"! ,%!00$ !?0$" P $$042(3%!!A-1 M80'EZ@X2%AH>(B8J2DY25EI>8 MF9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R;G MZ.GJ\?+S]/7V]_CY^O_$ !\! ,! 0$! 0$! 0$ ! @,$!08'" D* M"__$ +41 (! @0$ P0'!00$ $"=P ! @,1! 4A,08205$'87$3(C*!"!1" MD:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)BH*#A(6&AXB)BI*3E)66EYB9FJ*CI*6F MIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V M]_CY^O_: P# 0 "$0,1 #\ ^D:*\-^-_C;Q'X9\6V%IH6JRV4$EB)'1%4Y; MS'&>0>P%>;?\+:\=?]#%<_\ ?"?_ !-;QH2DKW,W42=CZ[HKY$_X6UXY_P"A MBN?^^$_^)JQ;?&;QY;=-<,H]);>)O_9:KZO+N+VD3ZSHKQ'P)\?/MU]%IWC* M&&V,A"I?P_*@/^VIZ?[PX'ICFO;00R@J001D$'K6$X2@[,T33V%HKP'XO^)/ M&W@[QB?[/UNYBTN^3S;8!5(0C =,E>QY^C"N2T+XR>++'7[*XU;5Y[RQ24?: M(&1/G3HW0=<#_ BB:9/Y.J7\GEV[@ F-5P7?GCI@?\"KP7_A;7CG_H8K MC_OA/_B:VA1E-71$IJ+L?7E%UO?%%[+=7U[^_'F@ QQG[BX '; MG\:Z^LI*SL6M0HKQ+XW?$36/#^OV&D^'-0:S=(#- M8?\ "V?'7_0Q7'_?"?\ Q-;1H2DKD.HD['UY16)X-UP>)/!FEZL&W-7/[ M#JT:;GMF;*R#NR'N/;J/?K6R45\P>"OB9XQU+QUHEE?:[/-;7%[%'+&R)A ME+ $=*^GZJI3<'9BC)26@45B^*_%>F>#]"DU/5Y=J+\L<:_?F?LJCN?Y5\Y^ M)OC?XKUR>1=.N!H]F3\D5M_K,>\AYS],"G"E*>P2DH[GU-17Q--XEUVXF,L^ MM:A)(3GVA4O)+(V%4>YKCOAS\3].\>VK0^7]CU6!-TUJ3D,.F]# MW&3TZC/XU'\0(H]5\7^#M!U YTN\NIYKB(_=F:&,-&A]02>G>L.1\W*S2^ET M+_PMW0MGVD:=KATW=C^TQIS_ &?'][=UQ^%=GI^H6FJZ?#?:=<1W-K.N^.6- MLJPKP31]8UR;6=%A6]UB![S6)(5NKK4-UC+$DC!H1%SSMPH'&>U>A>#$&B>- M_&&B:4G_ !+;>>WN(H%^[ \T9:15]!D X[5I.FEL)-GF7[1O_(]:;_V#1_Z- M>O-?#F@W/B?Q#::/8/%'<73%4:8D*, GG )[>E>E?M&_\CUIO_8-'_HUZY7X M1?\ )6-"_P"NK_\ HMJZH.U*YA+69TA_9V\6@<7VDGV\Z3_XBL36_@SXTT2V M>X?3DO84Y9K*3S"!Z[>&/X"OK"BN98B9K[.)\)U]"_ 'QK-J6GW'AK4IO,EL M4$MHSG+&+."OOM.,>S>U<5\=?",'A[Q=%J5A$L5KJRM(448"S*1OP/?*GZDU MRGPZUH^'_B'H]]NVQ_:%BE/^P_R-^AS^%=,DJM.Z,HWA*Q]+_$[P>OC/P5U?(9!5B&!!!P0>U?==?+WQM\&?\ "->,#J5I M'MT_5BTJA1Q'+_&OXD[A]3Z5AAY_99I4CU/1_@#XM.K>%YM!NY-USI9!AR>6 MA8\?]\G(^A6O6Z^-? ?BF3P=XRLM67<8%;R[E%_CB;AA]1U'N!7T/\6_&T7A M[X>M)I\X:ZU=/)M'0_P,N6D'T4\'U84JM-\^G4<)>[J>#?%'Q8?%_CN[NHG+ M65L?LUH,\;%/WO\ @1R?Q'I4OPI\'_\ "8>.+>&XCW6%GBYN\]&4'A/^!' ^ MF:XFOJ_X/^#/^$1\%1O=Q[=1U'%QU+7(?%/6_[!^&NKW*.$FEA^SQ9ZEI#MX]P"3^%<$5=V M.AZ:GR_XVUT^)?&VJZKN+1SW#>3GM&ORI_XZ!6%2=*ZSQOX-E\)6^@R2 _\ M$QTY)Y"1]V7.67\ RUZFBLCDU>IZQ^SIX@\_1=2T&9_GM91P8# M_OJO::^2/A%KAT+XFZ6[/MANW-I+DX!#\#/_ +:?PKZWKAKQM._*5#@J17VQJ^DVFN:/=:9J4?F6MU&8Y%]CW'N.H/J*^ M+]=TF70?$%_I-P0TEG.\)8=&P< _B.:UI5/:*S)G'EU1]=^!/%47C'P?9ZN@ M5)779<1K_!*O##Z=Q[$5Y'^TG_R$M _ZY3?S2IOV<-:;S-8T.1B5PMW$,\+_ M /^?R?E4/[2?_(2T#_KE-_-*QA'EK6+D[PN>:?#S_DI7AW_ +",/_H8K['D M=8HV>1E1%!+,QP !W-?''P\_Y*5X=_[",/\ Z&*^C?C-KK:%\,;\PL5FOBMG M&1VW_>_\<#4ZZYII"INT6SY[^)'C.X\:^+KB[,A-A QBLHNRQ@_>QZMU/Y=J MRO#7A;5_%NJC3]"M3/-C<[$X2-?[S-T _GVK'KZX^%/A.'PIX#LT\M1>WJ+< MW3XY+,,A?^ @@8]<^M;5)*E'0B*YWJ>8Q?LW:D;/=/XAM4N\:NFK:'R)HFLWGA_6K75=,E,5S:R!T(/!]5/J M"."/0U]97EAIWQ+\$V%Y;SR6CR!+RRNX3^\M)AW'N#D$=^?K7SYH?P7\::UM M9M-&FQ'_ ):7[^7C_@(RWZ5]"?#?PK?^#/!\>CZG>Q7 M%8/"NER0+<27MY\O9O]9<2GJQ]!Z#M6]17-*;:L:V/G#]HW_D M>M-_[!H_]&O7*_"+_DK&A?\ 75__ $6U=5^T;_R/6F_]@T?^C7KE?A%_R5C0 MO^NK_P#HMJ[8_P +Y&#^,^N:***\\Z#R#]HRT63P5IMWCYH;\(#[,C9_]!%? M.:.8Y%=>"I##\*^EOVAR!\.+;/4ZE'C_ +XDKYG/2O0H? <]3XC[GLY_M5C! M=:L?X95Y'Y\K]&K9T(%?#NG!NHM8 M@?\ O@5?-<%^5W1T;GPI)&\4C1RJ4="596&"".H-7]2US4-6L].M;^?""Z'XKCUJS0+:ZMN:10.%G'WO^^@0?KNKRJO3C M)22D#T\(>" M+:&2,"_O +B[;'.XCA/^ C ^N?6NU%<%:?/(Z(1L@KP;]HWQ 3)I7AZ)N #> M3@'ZJG_L_P"8KWDU\^?'S01J?P^748ES+I4ZR? M]LV^5A^94_A7$?LZ:,+CQ+J>KR1AEL[=88V/9W.3C_@*D?C7OFL:9#K.BWFF MW(S%=P/"W&S5\0ZY_P C%J7_ %]R_P#H9K[> MKXAUS_D8M2_Z^Y?_ $,U&&W8ZNQ[?^S7_P @_P 0_P#7:#_T%Z]OKQ#]FO\ MY!_B'_KM!_Z"]>WUE6_B,N'PH*^4?C;;+;_%G4R@P)4AD./4QJ#^HKZNKY9^ M.Y!^*MT!VMH0?^^:K#_&*I\(_P" MTT'Q2AB4X%Q:S1M[@ -_P"RUTO[2?\ MR$M _P"N4W\TKD?@>"?BWIF.T<^?^_35UW[2?_(2T#_KE-_-*V?\9>A"_AGF MGP\_Y*5X=_[",/\ Z&*]=_:2NF32-!M ?EEGED(]U50/_0S7D7P\_P"2E>'? M^PC#_P"ABO4OVE0<^'&_A_T@?^BZQT'DW[2&HJFAZ+IH8;IKAYRN>R+M!_\ 'Z\$L;5[[4;: MTA7=)<2I$H'I\1]TT445YYT'.^/=?'AGP+JNJ!ML ML4!6$@\^8WRI^I!_"OC7KU.3ZU[Y^T;K_EV6E>'XFYFV<#\:\\BE>"9)H6*R1L'1AV(.0:OW9QLA:Q>I]U"OB'7/^1BU+_K[E_] M#-?9'A;6X_$?A73M7BQB[MUD8#HK8PP_!@1^%?&^N?\ (Q:E_P!?5_Y9QY&0?=BWY5@?M)_P#(2T#_ *Y3?S2GS7KA:U,\T^'G_)2O M#O\ V$8?_0Q7LO[1VGM-X6TF_496VNVC;VWK_BE>-?#S_DI7AW_L(P_^ABOJ M;Q_X<_X2OP-J6E(!Y\D6^ D?\M%.Y?IDC'XTZLN6I%B@KQ:/CF"8V]Q',GWH MW#CZ@YK[AT^]BU'3;:]MSF&YB69#ZJP!'Z&OAQD:-V212K*<,I'(/I7T#\$/ MB3:SZ7#X4UJ98+JV&VRED; F3/\ J\G^(9X]1].7B(MQNN@4W9V/:JK:E?1: M9I=U?7)Q#:PO,Y_V5!)_E5BO'/C=\1K2RT6X\+:3,LU]=#9=LC9%O'GE3_M' MICL,^U<<(NKZ)KVE^(] M-%_HE[%>6Q8KYD9Z,.H(/(/(X-?$5?7/PE\/-X;^&^G6\R[;BY4W4P/9GY ^ MH7:/PKHK4X15T9PDWN=I1117*:GSA^T9_P CUIO_ _P"C7KR-69&#*2I' M0@XKZK\??">R\?:S;ZC=:G<6C06X@"11JP(W%L\_[U ?:9_P#GO)_WV:C9BS98ECZDYKZ#_P"&;M*_Z&"]_P"_ M*5:L_P!G/P[$^;W5=1N1_=0I&#^AJ_;TQ>SD?/6GZ?=ZMJ$-CIMO)&O)EVR:E=XDO)5.1D=$'LN3]22:V/#O@S0/"D'EZ# MID-LQ&&EQND?ZN<&B0,6.TC'/UKA$_9PTM)%;^ MW[P[2#_J4KLI581A9F,H-NY[/113)E9X76-_+=E(5P,[3ZXKC-CY)^+>MC7? MB;JLT;;H;9Q:Q\Y&(QM./8MN/XUK? G0_P"UOB1'=R+F'3(6N#G^^?E7]6)_ MX#7=M^SAICN7?Q#>LS'+$PIR:[?X??#JQ^']M>QV=W+=R7CJSR2J%("@X Q] M2?QKLE5@H1ZS^S]I&K:W>Z@FKW5J+J9IO)CB4JA8Y('MDUT4:BA=2 M,YQ?+=DSUVL1FE-Q,1@S2$>[FOH#_AF[2O M^A@O?^_*4O\ PS=I7_0?O?\ ORE:^WI]R?9R/GJNL^'_ ("O_'>O+;6X:*PA M(:[NL<1KZ#U8]A^/05[AI7P \(V$J2WK7NI,IR4GE"H?P4 _K7I%AI]GI=FE MIIMK#:VZ?=BA0*H_ 5E/$*WNE1I]Q--T^UTG3+?3]/B$-M;1B.*,?PJ!C_)K MPO\ :3_Y"7A__KE-_-*]^KA_B#\,K3X@7%C+=ZC/9FS5U41(&W;B.N?I7/2D MHSNS22O&R/F[X>?\E*\._P#81A_]#%?9->3:%\ ]-T+Q!8:K%K=W,]E.DZQM M$H#%3G!KUFKK3C-JPH1<5J?.GQK^&DNEZC/XHT2 O87+%[R-.?(D)Y?_ '6/ MY'ZBO'J^ZI(UEC:.15='!5E89!!Z@BO+O%/P%\.ZY+?$<5C]CCU[4UML8\D7;A<>F,UD$EB2Q)). M23WKV1_V;]:$N(]=L#'G[S1N#^7_ ->NF\._L\:18W"3^(-1FU,J0?L\:>5& M3Z$Y+$?B*V=:FB.23/.?A#\/9/&'B)+[4(&_L:Q.WMXAM2*)0JJ/8"IZXJE1S=S>,>56"BBBLRCSGXB?%&; MP+K=M81:4EZ)[?SB[3%,?,5QC!]*Y+_AH>Z_Z%V'_P "C_\ $UG_ +0/_(Z: M=_V#Q_Z,>O*:X9U)J329]!AL+1G1C*4=3V;_ (:'NO\ H78?_ H__$T?\-#W M7_0NP_\ @4?_ (FO&:*CVL^YT?4L/_+^9[-_PT/=?]"[#_X%'_XFC_AH>Z_Z M%V'_ ,"C_P#$UXS11[6?,T4>UGW#ZEA_Y?S/9O^&A[K_H78?\ P*/_ ,31_P -#W7_ $+L M/_@4?_B:\9HH]K/N'U+#_P OYGLW_#0]U_T+L/\ X%'_ .)H_P"&A[K_ *%V M'_P*/_Q->,T4>UGW#ZEA_P"7\SV;_AH>Z_Z%V'_P*/\ \31_PT/=?]"[#_X% M'_XFO&:*/:S[A]2P_P#+^9[-_P -#W7_ $+L/_@4?_B:/^&A[K_H78?_ */ M_P 37C-%'M9]P^I8?^7\SV;_ (:'NO\ H78?_ H__$T?\-#W7_0NP_\ @4?_ M (FO&:*/:S[A]2P_\OYGLW_#0]U_T+L/_@4?_B:/^&A[K_H78?\ P*/_ ,37 MC-%'M9]P^I8?^7\SV;_AH>Z_Z%V'_P "C_\ $T?\-#W7_0NP_P#@4?\ XFO& M:*/:S[A]2P_\OYGLW_#0]U_T+L/_ (%'_P")H_X:'NO^A=A_\"C_ /$UXS11 M[6?S?\-#W7_0NP_P#@4?\ XFC_ (:'NO\ H78?_ H__$UXS11[ M6?,T4>UGW# MZEA_Y?S/HCP-\7Y_&'BJ'2)-'CM5DC=_-6; M_P!!KZ9KJHR7L26(1GMX&< ^8 MQP2!UY%>:?\ "%^*/^A=U7_P#D_PKZ^HI2H*3O .YK8_X0OQ1_P!"[JO_ (!R?X5'X3_Y'31?^O\ @_\ 1@K[ M"JZ5/GN88O%O#M)*]SY!_P"$+\4?]"[JO_@')_A1_P (7XH_Z%W5?_ .3_"O MKZBMOJZ[G%_:D_Y3Y!_X0OQ1_P!"[JO_ (!R?X5#=^%]>L+5[F^T74+:WC&7 MEEMG55YQR2,#FOL2N-^+7_)*]:_ZYQ_^C4J94$HMW+IYC*2_M!_\BII M?_7[_P"R-7@%>_\ [0?_ "*FE_\ 7[_[(U> 5Y];^(SZ7+_]W7S-?PG_ ,CI MHO\ U_P?^C!7V%7Q[X3_ .1TT7_K_@_]&"OL*ML/U.+-/BB%%%%=1XX5QOQ: M_P"25ZU_USC_ /1J5V5<;\6O^25ZU_USC_\ 1J5%3X&;8?\ C0]5^9\L4AZ& MEI#T->8?6GV3X>_Y%G2_^O.+_P! %:-9WA[_ )%G2_\ KSB_] %:->I'X4?' MS^)A1115$!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 >2_M!_\ (J:7_P!?O_LC5X!7O_[0?_(J:7_U^_\ LC5X!7GUOXC/ MIM?]AI:0]#7F'UI]D^'O\ D6=+_P"O.+_T 5HUG>'O^19TO_KS MB_\ 0!6C7J1^%'Q\_B844451 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% 'DO[0?_(J:7_U^_\ LC5X!7O_ .T'_P BII?_ M %^_^R-7@%>?6_B,^ER__=U\S7\)_P#(Z:+_ -?\'_HP5]A5\>^$_P#D=-%_ MZ_X/_1@K["K;#]3BS3XHA11174>.%<;\6O\ DE>M?]M?]AI:0]#7F'UI]D^'O^19TO_KSB_\ M0!6C6=X>_P"19TO_ *\XO_0!6C7J1^%'Q\_B844451 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'DO[0?_ "*FE_\ 7[_[ M(U> 5[_^T'_R*FE_]?O_ +(U> 5Y];^(SZ7+_P#=U\S7\)_\CIHO_7_!_P"C M!7V%7Q[X3_Y'31?^O^#_ -&"OL*ML/U.+-/BB%%%%=1XX5QOQ:_Y)7K7_7./ M_P!&I795QOQ:_P"25ZU_USC_ /1J5%3X&;8?^-#U7YGRQ2'H:6D/0UYA]:?9 M/A[_ )%G2_\ KSB_] %:-9WA[_D6=+_Z\XO_ $ 5HUZD?A1\?/XF%%%%40%% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y+^ MT'_R*FE_]?O_ +(U> 5[_P#M!_\ (J:7_P!?O_LC5X!7GUOXC/I'O\ D6=+_P"O.+_T 5HU MZD?A1\?/XF%%%%40%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110!Y+^T'_P BII?_ %^_^R-7@%>__M!_\BII?_7[_P"R-7@% M>?6_B,^ER_\ W=?,U_"?_(Z:+_U_P?\ HP5]A5\>^$_^1TT7_K_@_P#1@K[" MK;#]3BS3XHA11174>.%<;\6O^25ZU_USC_\ 1J5V5<;\6O\ DE>M?]8?6GV3X>_P"19TO_ *\XO_0!6C6=X>_Y M%G2_^O.+_P! %:->I'X4?'S^)A1115$!1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 >2_M!?\BII?_7[_P"R-7@%?5?Q#\#G MQWI-K9+?_8?L\_F[S%YF[Y2,8R/6O/O^&=G_ .AE7_P"_P#LZXJM.YRX^M3JRBX.X4445T'FA7&_%K_DE>M?]O>'O^19T MO_KSB_\ 0!6C5;3K3[!I=K:;]_V>%(MV,;MJ@9Q^%6:]".B1\U)WDV@HHHID MA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 %44 ?_]D! end XML 12 R9.htm IDEA: XBRL DOCUMENT v3.19.3
Research Collaboration and Sub-licensing Agreements
 9 Months Ended
Sep. 30, 2019
Research and Development [Abstract]  
Research Collaboration and Sub-licensing Agreements Research Collaboration and Sub-licensing Agreements
BDI Agreements
On June 30, 2017, the Company entered into a strategic Research Services Agreement (the “RSA”) with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U. (“BDI Pharma”), and a Service Framework Agreement (the “SFA”, and together with the RSA, the “R&D Agreements”), with VLP The Vaccines Company, S.L.U. (“VLPbio”), both of which are subsidiaries of Biotechnology Developments for Industry, S.L., a Spanish biotechnology company (“BDI Holdings” and together with BDI Pharma and VLPbio, “BDI”).

The R&D Agreements provide a framework under which the parties will engage in a research and development collaboration encompassing several different projects over approximately a two-year period, with a focus on advancing Dyadic’s proprietary C1 technology in the development of next generation biological vaccines and drugs. Dyadic expects to leverage the BDI team’s previous C1 gene expression and industrial fermentation scale-up and commercialization experience with yeast and filamentous fungi processes to further advance Dyadic’s proprietary C1 technology with the potential to commercialize certain biopharmaceutical product(s). All of the data and any products developed from the funded research projects will be owned by Dyadic.

Upon closing of the BDI transaction, the Company paid EUR €1 million (the “RSA Initial Payment”) in cash to engage BDI to develop designated C1 based product candidates and further improve the C1 manufacturing process, in consideration of which Dyadic also received a 16.1% equity interest in BDI Holdings and a 3.3% equity interest in VLPbio. BDI is obligated to spend a minimum amount of EUR €936,000 over two years in the conduct of the research and development project under the RSA. If the research and development activities produce a product that is selected for additional development and commercialization, then Dyadic expects to share with BDI a range of between 50% and 75% of the net income from such selected product, depending upon the amount of BDI’s aggregate spend in the development of the selected product, with a minimum aggregate spend by BDI of EUR €1 million for a 50% share and EUR €8 million for a 75% share. If BDI does not enter into an agreement with Dyadic for such additional development and commercialization of the selected product, then Dyadic will pay to BDI EUR €1.5 million of the net income from Dyadic’s commercialization, if any, of the selected product. In addition, under the SFA, Dyadic agreed to purchase from BDI at least USD $1 million (the “SFA Commitment”) in contract research services specified by Dyadic over two years since the closing of the BDI transaction.

The Company has concluded that BDI is not a Variable Interest Entity (“VIE”), because BDI has sufficient equity to finance its activities without additional subordinated financial support and its at-risk equity holders have the characteristics of a controlling financial interest. Additionally, Dyadic is not the primary beneficiary of BDI as Dyadic does not have the power to control or direct the activities of BDI or its operations. As a result, the Company does not consolidate its investments in BDI, and the financial results of BDI are not included in the Company’s consolidated financial results. Dyadic has fulfilled its SFA commitment, however it is and may in the future continue to provide funding to BDI for certain research and commercialization projects.

The Company performed a valuation analysis of the components of the transaction and allocated the consideration based on the relative fair value of each component. As the fair value of BDI equity interest was considered immaterial, the RSA Initial Payment of approximately USD $1.1 million (EUR €1 million) was accounted for as a prepaid research and development collaboration payment on our consolidated balance sheet, and both the collaboration payment under the RSA and the remaining SFA Commitment of USD $1 million paid by Dyadic will be expensed as the related research services are performed by BDI. BDI has completed its services under the RSA in June 2019, and the entire amount of the RSA Initial Payment was expensed. Under the SFA, there were four research projects completed and three research projects in progress, and we do not have any outstanding commitment under the SFA as of September 30, 2019.
As of September 30, 2019 and December 31, 2018, the prepaid research and development collaboration related to BDI recorded on our consolidated balance sheets were none and approximately $0.3 million, respectively. For the three months ended September 30, 2019 and 2018, research and development expenses related to BDI were recorded as research and development - related party in our consolidated statements of operations in the amount of approximately $0.1 million and $0.3 million, respectively. For the nine months ended September 30, 2019 and 2018, research and development expenses related to BDI were recorded as research and development - related party in our consolidated statements of operations in the amount of approximately $0.8 million and $1.0 million, respectively.

Novovet and Luina Bio Sub-License Agreement
On April 26, 2019, the Company entered into a sub-license agreement (the “Luina Bio Sub-License Agreement”) with Luina Bio Pty Ltd. (“Luina Bio”) and Novovet Pty Ltd (“Novovet”). Under the terms of the Luina Bio Sub-License Agreement, the Company has granted to Novovet, subject to the terms of the license agreement entered into between the Company and Danisco US, Inc. on December 31, 2015, a worldwide sub-license to certain patent rights and know-how related to Dyadic’s proprietary C1 gene expression platform for the exclusive and sole purpose of commercializing certain targeted antigen and biological products for the prevention and treatment of various ailments for companion animals.

In consideration of the license granted pursuant to the Luina Bio Sub-License Agreement, Dyadic received a 20% equity interest in Novovet (“Novovet Up-Front Consideration”) in accordance with the terms of Novovet’s Shareholder Agreement (“Shareholders Agreement”), and will receive a percentage of royalties on future net sales and non-sales revenue, if any, which incorporates Dyadic's proprietary C1 gene expression platform.

The Company evaluated the nature of its equity interest investment in Novovet and determined that Novovet is a Variable Interest Entity (“VIE”), because Novovet does not have sufficient equity to finance its activities without additional financial support from third party investors or lenders. However, the Company is not the primary beneficiary of Novovet as Dyadic does not have the power to control or direct the activities of Novovet that most significantly impact the VIE. As a result, the Company will not consolidate its investment in Novovet, but account for under the equity method investment, given that it has the ability to exercise significant influence, but not control, over Novovet.

As of September 30, 2019, the technology transfer of the Company’s C1 platform has not been completed and Novovet has not raised sufficient capital to support its required research and drug development activities. Therefore, the Novovet Up-Front Consideration received under the Luina Bio Sub-License Agreement, in the form of a 20% equity interest in Novovet, does not yet meet the revenue recognition criteria under ASC 606. The Company will account for its investment in Novovet and the related income under the equity method of accounting, once the transfer of its C1 technology is completed and Novovet receives adequate financing required to commence its research and development activities.

The Shareholder Agreement provides that, for as long as the Company has a respective proportion of Novovet equal to or more than 20% it may designate one individual to serve on the Board of Directors of Novovet. The Dyadic appointee is Mark Emalfarb, Dyadic’s CEO. Pursuant to the terms of the Shareholders Agreement, the Company agreed, subject to certain exceptions, not to sell, transfer, assign, convey or otherwise dispose of its interests in Novovet. In addition, the Company is entitled to or subject to, as applicable, anti-dilution rights, tag along rights and drag along rights, each as described in the Shareholders Agreement.

Alphazyme Sub-License Agreement
On May 5, 2019, the Company entered into a sub-license agreement (the “Alphazyme Sub-License Agreement”) with Alphazyme, LLC (“Alphazyme”). Under the terms of the Alphazyme Sub-License Agreement, the Company has granted to Alphazyme, subject to the terms of the license agreement entered into between the Company and Danisco US, Inc. on December 31, 2015, a sub-license to certain patent rights and know-how related to Dyadic’s proprietary C1 gene expression platform for the purpose of commercializing certain pharmaceutical products that are used as reagents to catalyze a chemical reaction to detect, measure, or be used as a process intermediate to produce a nucleic acid as a therapeutic or diagnostic agent.

In consideration of the license granted pursuant to the Alphazyme Sub-License Agreement, Dyadic will receive a 7.5% ownership interest in Alphazyme (“Alphazyme Up-Front Consideration”) upon the successful transfer of C1 technology, additional milestone payments and a percentage of royalties on net sales, if any, which incorporate Dyadic's proprietary C1 gene expression platform. The Alphazyme Sub-License Agreement has an initial exclusivity period of 18 months (“Exclusivity Period”) beginning on the date the technology transfer has been completed. Following the Exclusivity Period, the sub-license will be nonexclusive. At any time prior to the expiration of the Exclusivity Period,
Alphazyme has the option to extend the Exclusivity Period for an additional twelve (12) months in return for an additional 2.5% ownership interest in Alphazyme.

The Company evaluated the nature of its equity interest investment in Alphazyme and determined that Alphazyme is a Variable Interest Entity (“VIE”) due to the capital structure of the entity. However, the Company is not the primary beneficiary of Alphazyme as Dyadic does not have the power to control or direct the activities of Alphazyme that most significantly impact the VIE. As a result, the Company does not consolidate its investments in Alphazyme. The Company will account for its investment in Alphazyme under the equity method, given that it has the ability to exercise significant influence, but not control, over Alphazyme.

As of September 30, 2019, the technology transfer of the C1 platform has not completed and Dyadic has not received the Alphazyme Up-Front Consideration. Therefore, no revenue form the Alphazyme Sub-Licensing Agreement was recorded at September 30, 2019.

Upon receipt of the Alphazyme Up-Front Consideration, Dyadic will become a party to the Alphazyme Limited Liability Company Agreement pursuant to which the Company will agree to certain customary rights, covenants and obligations.

Research and Commercialization Collaboration with Serum
On May 7, 2019, the Company entered into a research and commercialization collaboration with Serum Institute of India Pvt., Ltd (“Serum”). Under the terms of this collaboration, Serum anticipates applying Dyadic’s C1 technology to express up to twelve (12) antibodies and vaccines and will undertake commercially best efforts to fully develop and commercialize the proteins expressed from Dyadic’s C1 technology. Dyadic has agreed to grant Serum the option to obtain an exclusive commercial sub-license for each of the twelve (12) proteins in return for certain research funding, milestone payments and royalties for 15 years from the date of the first commercial sale.
For the three and nine month ended September 30, 2019, the Company recognized approximately $13,000 in research revenue from Serum. As of September 30, 2019, the Company has approximately $70,000 in deferred revenue related to this agreement.
XML 13 R5.htm IDEA: XBRL DOCUMENT v3.19.3
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($)
Total
Common Stock
Treasury Stock
Additional paid-in capital
Accumulated deficit
Beginning balance at Dec. 31, 2017 $ 49,975,264 $ 38,937 $ (16,625,873) $ 93,913,557 $ (27,351,357)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation 269,596     269,596  
Net loss (2,043,292)       (2,043,292)
Ending balance at Mar. 31, 2018 47,826,748 38,937 (17,000,693) 94,183,153 (29,394,649)
Beginning balance at Dec. 31, 2017 49,975,264 38,937 (16,625,873) 93,913,557 (27,351,357)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss (5,179,424)        
Ending balance at Sep. 30, 2018 42,909,938 38,967 (18,929,915) 94,331,667 (32,530,781)
Beginning balance at Mar. 31, 2018 47,826,748 38,937 (17,000,693) 94,183,153 (29,394,649)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation 73,425     73,425  
Net loss (1,596,637)       (1,596,637)
Ending balance at Jun. 30, 2018 46,303,536 38,937 (17,000,693) 94,256,578 (30,991,286)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation 70,619     70,619  
Net loss (1,539,495)       (1,539,495)
Ending balance at Sep. 30, 2018 $ 42,909,938 $ 38,967 $ (18,929,915) 94,331,667 (32,530,781)
Beginning balance (in shares) at Dec. 31, 2018 38,966,988 38,966,988 (12,253,502)    
Beginning balance at Dec. 31, 2018 $ 42,451,169 $ 38,967 $ (18,929,915) 94,385,230 (33,043,113)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation 309,563     309,563  
Net loss (2,175,258)       (2,175,258)
Ending balance at Mar. 31, 2019 $ 40,585,474 $ 38,967 $ (18,929,915) 94,694,793 (35,218,371)
Beginning balance (in shares) at Dec. 31, 2018 38,966,988 38,966,988 (12,253,502)    
Beginning balance at Dec. 31, 2018 $ 42,451,169 $ 38,967 $ (18,929,915) 94,385,230 (33,043,113)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation $ 1,034,346     1,034,346  
Exercise of stock options (in shares) 635,500 499,671      
Exercise of stock options $ 328,590 $ 500   328,090  
Net loss $ (6,569,434)       (6,569,434)
Ending balance (in shares) at Sep. 30, 2019 39,466,659 39,466,659 (12,253,502)    
Ending balance at Sep. 30, 2019 $ 37,244,671 $ 39,467 $ (18,929,915) 95,747,666 (39,612,547)
Beginning balance at Mar. 31, 2019 40,585,474 38,967 (18,929,915) 94,694,793 (35,218,371)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation 580,603     580,603  
Net loss (2,695,792)       (2,695,792)
Ending balance at Jun. 30, 2019 38,619,465 $ 39,365 $ (18,929,915) 95,424,178 (37,914,163)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation 144,180     144,180  
Net loss $ (1,698,384)       (1,698,384)
Ending balance (in shares) at Sep. 30, 2019 39,466,659 39,466,659 (12,253,502)    
Ending balance at Sep. 30, 2019 $ 37,244,671 $ 39,467 $ (18,929,915) $ 95,747,666 $ (39,612,547)
XML 14 R1.htm IDEA: XBRL DOCUMENT v3.19.3
Document and Entity Information - shares
 9 Months Ended
Sep. 30, 2019
Nov. 12, 2019
Cover page.    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2019  
Document Transition Report false  
Entity File Number 000-55264  
Entity Registrant Name DYADIC INTERNATIONAL, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 45-0486747  
Entity Address, Address Line One 140 Intracoastal Pointe Drive  
Entity Address, Address Line Two Suite 404  
Entity Address, City or Town Jupiter  
Entity Address, State or Province FL  
Entity Address, Postal Zip Code 33477  
City Area Code 561  
Local Phone Number 743-8333  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Title of 12(b) Security Common Stock, par value $0.001 per share  
Trading Symbol DYAI  
Security Exchange Name NASDAQ  
Entity Common Stock, Shares Outstanding   27,213,157
Entity Central Index Key 0001213809  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2019  
Document Fiscal Period Focus Q3  
Amendment Flag false  
XML 15 R22.htm IDEA: XBRL DOCUMENT v3.19.3
Organization and Summary of Significant Accounting Policies - Accounts Payable (Details) - USD ($)
Sep. 30, 2019
Dec. 31, 2018
Accounting Policies [Abstract]    
Research and development expenses $ 636,428 $ 240,064
Legal expenses 17,283 0
Other 59,684 68,996
Accounts payable $ 713,395 $ 309,060
XML 16 R26.htm IDEA: XBRL DOCUMENT v3.19.3
Research Collaboration and Sub-licensing Agreements (Details)
€ in Thousands
 3 Months Ended 9 Months Ended
May 07, 2019
protein
antibody_and_vaccine
May 05, 2019
Jun. 30, 2017
EUR (€)
Jun. 30, 2017
USD ($)
Sep. 30, 2019
USD ($)
collaboration_project
Sep. 30, 2018
USD ($)
Sep. 30, 2019
USD ($)
collaboration_project
Sep. 30, 2018
USD ($)
Apr. 26, 2019
Dec. 31, 2018
USD ($)
Jun. 30, 2017
USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Duration of agreement     2 years 2 years              
Payment for research and development agreement     € 1,000 $ 1,100,000              
Prepaid research and development         $ 0   $ 0     $ 300,000  
Research and development - related party         101,849 $ 288,175 827,632 $ 1,021,573      
Alphazyme                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Equity percentage   7.50%                  
Ownership interest consideration receivable upon extension of exclusivity period   2.50%                  
Novovet                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Equity percentage                 20.00%    
Collaborative Arrangement | Alphazyme                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Exclusivity period   18 months                  
Option to extend exclusivity period   12 months                  
Collaborative Arrangement | Serum                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Number of antibodies and vaccines for development and commercialization | antibody_and_vaccine 12                    
Option to obtain exclusive commercial sub-license for number of proteins | protein 12                    
Research funding, milestone payments and royalties, period 15 years                    
Revenue from collaborative arrangement, recognized         13,000   13,000        
Revenue from collaborative arrangement, contract liability         $ 70,000   $ 70,000        
RSA                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Payment for research and development agreement | €     1,000                
Payment for additional development and commercialization | €     € 1,500                
RSA | Minimum                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Revenue sharing, percentage     50.00% 50.00%              
RSA | Maximum                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Revenue sharing, percentage     75.00% 75.00%              
RSA | BDI Holdings                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Equity interest acquired     16.10% 16.10%              
RSA | VLPbio                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Equity interest acquired     3.30% 3.30%              
RSA | BDI                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Duration of agreement     2 years 2 years              
Obligation for payment for research and development, minimum | €     € 936                
Obligation for payment for research and development, maximum | €     € 8,000                
RSA | BDI | Minimum                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Revenue sharing, percentage     50.00% 50.00%              
RSA | BDI | Maximum                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Revenue sharing, percentage     75.00% 75.00%              
SFA                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Duration of agreement     2 years 2 years              
Obligation for payment for research and development, minimum                     $ 1,000,000
Number of collaboration project, completed | collaboration_project         4   4        
Outstanding commitment                     $ 1,000,000
Number of collaboration project, in progress | collaboration_project         3   3        
XML 17 R18.htm IDEA: XBRL DOCUMENT v3.19.3
Shareholders' Equity (Tables)
 9 Months Ended
Sep. 30, 2019
Equity [Abstract]  
Schedule of stockholders equity
Nine Months Ended September 30, 2019 (Unaudited) 
Common Stock  Treasury Stock  Additional Paid-In Capital  Accumulated Deficit  Total  
January 1, 2019$38,967  $(18,929,915) $94,385,230  $(33,043,113) $42,451,169  
Stock-based compensation—  —  309,563  —  309,563  
Net loss—  —  —  (2,175,258) (2,175,258) 
March 31, 201938,967  (18,929,915) 94,694,793  (35,218,371) 40,585,474  
Stock issued398  —  148,782  —  149,180  
Stock-based compensation—  —  580,603  —  580,603  
Net loss—  —  —  (2,695,792) (2,695,792) 
June 30, 201939,365  (18,929,915) 95,424,178  (37,914,163) 38,619,465  
Stock issued102  —  179,308  —  179,410  
Stock-based compensation—  —  144,180  —  144,180  
Net loss—  —  —  (1,698,384) (1,698,384) 
September 30, 2019$39,467  $(18,929,915) $95,747,666  $(39,612,547) $37,244,671  
Nine Months Ended September 30, 2018 (Unaudited) 
Common Stock  Treasury Stock  Additional Paid-In Capital  Accumulated Deficit  Total
January 1, 2018$38,937  $(16,625,873) $93,913,557  $(27,351,357) $49,975,264  
Stock repurchased—  (374,820) —  —  (374,820) 
Stock-based compensation—  —  269,596  —  269,596  
Net loss—  —  —  (2,043,292) (2,043,292) 
March 31, 201838,937  (17,000,693) 94,183,153  (29,394,649) 47,826,748  
Stock-based compensation—  —  73,425  —  73,425  
Net loss—  —  —  (1,596,637) (1,596,637) 
June 30, 201838,937  (17,000,693) 94,256,578  (30,991,286) 46,303,536  
Stock repurchased(1,929,222) —  (1,929,222) 
Stock-based compensation—  70,619  —  70,619  
Stock issued30  —  4,470  4,500  
Net loss—  —  —  (1,539,495) (1,539,495) 
September 30, 2018$38,967  $(18,929,915) $94,331,667  $(32,530,781) $42,909,938  
Schedule of stock repurchase activity
The following table summarizes the Company’s stock repurchase activities: 
PeriodTotal Number of Shares PurchasedAverage Price Paid per ShareAmountTotal Number of Treasury Shares Purchased as Part of Publicly Announced PlanMaximum Dollar Value of Shares that May Yet Be Purchased Under the Plan
Privately Negotiated Transactions:
January 12, 2016 - Abengoa repurchased and retired shares2,136,752  $1.35  $2,884,615  —  N/A
January 11, 2017 - Pinnacle Family Office Investments L.P. repurchased shares2,363,590  1.54  3,639,929  2,363,590  N/A
$15,000,000  
2016 Stock Repurchase Program:
January through February 20177,863,980  1.58  12,448,283  7,863,980  $2,551,717  
2017 Stock Repurchase Program:$5,000,000  
September through December 2017381,607  1.41  537,661  381,607  $4,462,339  
January through August 20181,644,325  1.40  2,304,042  1,644,325  $2,158,297  
Total open market and privately negotiated purchases14,390,254  $1.52  $21,814,530  12,253,502  
XML 18 R10.htm IDEA: XBRL DOCUMENT v3.19.3
Commitments and Contingencies
 9 Months Ended
Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Leases
Jupiter, Florida Headquarters
The Company’s corporate headquarters are located in Jupiter, Florida. The Company occupies approximately 4,900 square feet with a monthly rental rate and common area maintenance charges of approximately $9,700. The lease expires on June 30, 2020, and thereafter, the Company will reconsider the square footage of the leased space to align with the staffing requirements of the future operations of the Company.
The Netherlands Office
The Company maintains a small satellite office in Wageningen, The Netherlands. In 2018, the Company occupied approximately 258 square feet with annual rentals and common area maintenance charges of approximately $4,700. The lease expired on January 31, 2019, and thereafter, the Company entered into a new lease with the same lessor (the “New Lease”). The New Lease has a one-year term and includes a flexible office space with annual rentals of approximately $4,000.
VTT Research Contract Extension
On June 28, 2019, the Company extended its research contract (“Contract”) through June 2022 with VTT Technical Research Centre of Finland Ltd. (“VTT”). Under the terms of this Contract, Dyadic will pay VTT a total of EUR €2.52 million over the next three years to continue developing Dyadic’s C1 fungal expression system for therapeutic protein production, including C1 host system improvement, glycoengineering, and management of third-party target protein projects. VTT is subject to an additional success bonus up to EUR €450,000 based on the technical targets stipulated in the Contract. Dyadic and its sublicensees will also have the right to use synthetic promoters developed by VTT with an access fee. On October 25, 2019, the Company expanded the Contract to pay an additional EUR €690,000 over the next 1.5 years to reinforce the glycoengineering work. Dyadic retains the right to terminate the Contract with 90 days’ notice.
Legal Proceedings
From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. The Company does not believe that any of these claims or proceedings against us is likely to have, individually or in the aggregate, a material adverse effect on the financial condition or results of operations.
XML 19 R14.htm IDEA: XBRL DOCUMENT v3.19.3
Organization and Summary of Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2019
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements, including the accounts of the Company and its wholly owned subsidiaries, have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and footnote disclosures normally included in consolidated financial statements have been condensed or omitted pursuant to such rules and regulations. All significant intra-entity transactions and balances have been eliminated in consolidation. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and footnotes as of and for the year ended December 31, 2018, included in our Form 10-K which was filed with the SEC on March 27, 2019.
In the opinion of management, the accompanying unaudited interim consolidated financial statements reflect all adjustments, which are of a normal recurring nature, considered necessary for a fair presentation of all periods presented. The results of the Company’s operations for any interim periods are not necessarily indicative of the results of operations for any other interim period or for a full fiscal year.
Since concluding the DuPont Transaction, the Company has conducted business in one operating segment, which is identified by the Company based on how resources are allocated, and operating decisions are made. Management evaluates performance and allocates resources based on the Company as a whole.
Use of Estimates Use of EstimatesThe preparation of these consolidated financial statements in accordance with GAAP requires management to make estimates and judgments that affect the reported amount of assets and liabilities and related disclosure of contingent assets and liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the applicable period. Actual results may differ from these estimates under different assumptions or conditions. Such differences could be material to the consolidated financial statements.
Concentrations ConcentrationsThe Company’s financial instruments that are potentially subject to concentrations of credit risk consist primarily of cash and cash equivalents, and investment securities. At times, the Company has cash, cash equivalents, and investment securities at financial institutions exceeding the Federal Depository Insurance Company (“FDIC”) and the Securities Investor Protection Corporation (“SIPC”) insured limit on domestic currency and the Netherlands’ FDIC counterpart for foreign currency. The Company only deals with reputable financial institutions and has not experienced any losses in such accounts.
Cash and Cash Equivalents Cash and Cash EquivalentsWe treat highly liquid investments with original maturities of three months or less when purchased as cash equivalents, including money market funds, which are unrestricted for withdrawal or use.
Investment Securities
Investment Securities
The Company invests excess cash balances in short-term and long-term investment grade securities. Short-term investment securities mature within 12 months or less, and long-term investment securities mature between 12 and 18 months from the applicable reporting date. Management determines the appropriate classification of its investments at the time of purchase and reevaluates the classifications at each balance sheet date. The Company’s investments in debt securities have been classified and accounted for as held-to-maturity. Held-to-maturity securities are those securities that the Company has the ability and intent to hold until maturity. Held-to-maturity securities are recorded at amortized cost, adjusted for the amortization or accretion of premiums or discounts. Premiums and discounts are amortized over the life of the related held-to-maturity security. When a debt security is purchased at a premium, both the face value of the debt and premium amount are reflected as investing outflow. Other-than-temporary impairment charges, if incurred, will be included in other income (expense).
The Company’s investments in money market funds have been classified and accounted for as available-for-sale securities and presented as cash equivalents on the consolidated balance sheets.
Accounts Receivable
Accounts Receivable
Accounts receivable consist of billed receivables currently due from customers and unbilled receivables. Unbilled receivables represent the excess of contract revenue (or amounts reimbursable under contracts) over billings to date. Such amounts become billable in accordance with the contract terms, which usually consider the passage of time, achievement of certain milestones or completion of the project.
Outstanding account balances are reviewed individually for collectability. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing accounts receivable. Substantially all of our accounts receivable were current and include unbilled amounts that will be billed and collected over the next twelve months.
Equity Method Investment
Equity Method Investment
The Company follows Accounting Standards Codification (“ASC”) Subtopic 323-10, Investments - Equity Methods and Joint Ventures, which requires the accounting for investments where the Company can exercise significant influence, but not control of a joint venture or equity investment. See Note 3 for the Company’s investments recorded under the equity method of accounting.
Equity method investments are assessed for impairment whenever events or changes in circumstances indicate that the carrying amount of the investment may not be recoverable. If the decline in value is considered to be other than temporary, the investment is written down to its estimated fair value, which establishes a new cost basis in the investment.
Revenue Recognition
Revenue Recognition
The Company has no pharmaceutical products approved for sale at this point, and all of our revenue to date has been research revenue from third-party collaborations and government grants. The Company is expected to generate future revenue from license agreements and collaborative arrangements, which may include upfront payments for licenses or options to obtain a license, payment for research and development services and milestone payments, in the form of cash or non-cash considerations (e.g., minority equity interest).
Revenue related to research collaborations and agreements: The Company typically performs research and development services as specified in each respective agreement on a best efforts basis, and recognizes revenue from research funding under collaboration agreements in accordance with the 5-step process outlined in ASC Topic 606 (“Topic 606”): (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We recognize revenue when we satisfy a performance obligation by transferring control of the service to a customer in an amount that reflects the consideration that we expect to receive. Since the performance obligation under our collaboration agreements is generally satisfied over time, we elected to use the input method under Topic 606 to measure the progress toward complete satisfaction of a performance obligation.
Under the input methods, revenue will be recognized on the basis of the entity’s efforts or inputs to the satisfaction of a performance obligation (e.g., resources consumed, labor hours expended, costs incurred, or time elapsed) relative to the total expected inputs to the satisfaction of that performance obligation. The Company believes that the cost-based input method is the best measure of progress to reflect how the Company transfers its performance obligation to a customer. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to budgeted costs to fulfill the performance obligation. These costs consist primarily of full-time equivalent effort and third-party contract costs. Revenue will be recognized based on actual costs incurred as a percentage of total budgeted costs as the Company completes its performance obligations.
A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company’s performance obligations. In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete the Company’s performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.
Revenue related to sublicensing agreements: If the sublicense to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue allocated to the license when technology is transferred to the customer and the customer is able to use and benefit from the license.
Milestone payments: At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Company evaluates whether the achievement of the milestones is considered probable and estimates the amount to be included in the transaction price. If the milestone payment is in exchange for a sublicense and is based on the sublicensee’s subsequent sale of product, the Company recognizes milestone payment by applying the accounting guidance for royalties. To date, the Company has not recognized any milestone payment revenue resulting from any of its sublicensing arrangements.
Royalties: With respect to licenses deemed to be the predominant item to which the sales-based royalties relate, including milestone payments based on the level of sales, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or
partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its sublicensing arrangements.
We invoice customers based on our contractual arrangements with each customer, which may not be consistent with the period that revenues are recognized. When there is a timing difference between when we invoice customers and when revenues are recognized, we record either a contract asset (unbilled accounts receivable) or a contract liability (deferred research and development obligations), as appropriate. If upfront fees or considerations related to sublicensing agreement are received prior to the technology transfer, the Company will record the amount received as deferred revenue from licensing agreement.
We are not required to disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.

The Company adopted a practical expedient to expense sales commissions when incurred because the amortization period would be one year or less.
Research and Development Costs Research and Development Costs Research and development (“R&D”) costs are expensed as incurred. R&D costs are for the Company’s internally funded pharmaceutical programs and other governmental and commercial projects.
Foreign Currency Transaction Gain or Loss Foreign Currency Transaction Gain or LossThe Company’s foreign subsidiary uses the U.S. dollar as its functional currency, and it initially measures the foreign currency denominated assets and liabilities at the transaction date. Monetary assets and liabilities are then re-measured at exchange rates in effect at the end of each period, and property and non-monetary assets and liabilities are converted at historical rates.
Fair Value Measurements
Fair Value Measurements
The Company applies fair value accounting for certain financial instruments that are recognized or disclosed at fair value in the financial statements. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:
•Level 1 – Quoted prices in active markets for identical assets or liabilities.
•Level 2 – Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
•Level 3 – Inputs that are generally unobservable and typically reflect management’s estimate of assumptions that market participants would use in pricing the asset or liability.

Certain assets and liabilities on the balance sheets are measured at carrying values, which approximate fair values due to the short-term nature of these balances. Such items include cash and cash equivalents, accounts receivable, accounts payable, prepaid expenses, and accrued expenses. Investments in debt securities are recorded at amortized cost, and their estimated fair value amounts are provided by the third-party broker service for disclosure purposes.
The Company utilized various methods, including income, cost and market approaches to determine the fair value of its investments in equity interest, which may fall into Level 3 of the fair value hierarchy because of the significant unobservable inputs utilized in these valuation approaches. These inputs can be readily observable, market corroborated, or generally unobservable inputs. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. Our key inputs included, but were not limited to, significant management judgments and estimates, including projections of the timing and amount of the project’s cash flows, determination of a discount rate for the income approach, market multipliers, probability weighting of potential outcomes of legal and regulatory proceedings, and weighting of the valuations produced by the income, cost and market approaches.
Income Taxes Income TaxesThe Tax Cuts and Jobs Act (“TCJA”) was enacted on December 22, 2017 and became effective January 1, 2018. The TCJA contains several key provisions, including a reduction in the U.S. Federal corporate income tax rate from 35% to 21% and a change to the corporate alternative minimum tax (“AMT”).
Stock-Based Compensation
Stock-Based Compensation

We recognize all share-based payments to employees and our board of directors (“Board of Directors”), as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statement of operations based on the grant date fair values of such payments. Stock-based compensation expense recognized each period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are recorded as they occur.
Comprehensive Income (Loss)
Comprehensive Income (Loss)
Comprehensive income (loss) includes net income (loss) and other revenue, expenses, gains and losses that are recorded as an element of shareholders’ equity but are excluded from net income (loss) under GAAP. The Company does not have any significant transactions that are required to be reported in other comprehensive income (loss), and therefore, does not separately present a statement of comprehensive income (loss) in its consolidated financial statements.
Net Loss Per Share Net Loss Per ShareBasic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common stock outstanding during the reporting period. Diluted net loss per share adjusts the weighted average number of common stock outstanding for the potential dilution that could occur if common stock equivalents, such as stock options were exercised or converted into common stock, calculated by applying the treasury stock method.
Recent Accounting Pronouncements
Recent Accounting Pronouncements Not Adopted as of September 30, 2019
In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which modifies the measurement of expected credit losses of certain financial instruments. ASU 2016-13 will be effective for the Company beginning in the first quarter of 2020. The Company is currently evaluating the impact, if any, of this newly issued guidance.
In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820) which modifies the disclosure requirements on fair value measurements. The effective date for the standard is fiscal years beginning after December 15, 2019, which for the Company is January 1, 2020. Early adoption is permitted. The new disclosure requirements for changes in unrealized gains and losses in other comprehensive income for recurring Level 3 measurements, the range and weighted average of significant unobservable inputs and the amended requirements for the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively. The Company does not expect ASU 2018-13 to have a material impact on our consolidated financial statements.
Other pronouncements issued by the FASB or other authoritative accounting standards group with future effective dates are either not applicable or not significant to our consolidated financial statements.
Recently Adopted Accounting Pronouncements
In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). Under the new guidance, lessees will be required to recognize the assets and liabilities that arise from operating leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. Companies are required to recognize and measure leases using a modified retrospective approach at either the beginning of the earliest comparative period presented or the beginning of the reporting period in which the entity first applies the new standard. ASU 2016-02 was effective for the Company beginning in the first quarter of 2019. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements and related disclosures, as the Company’s leases are one year or less and not required to recognize lease assets or liabilities under the new guidance.
In March 2017, the FASB issued ASU 2017-08, Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization of Purchased Callable Debt Securities. The amendments in this ASU shorten the amortization period for certain callable debt securities held at a premium. The amendments require the premium to be amortized to the earliest call date. The amendments do not require an accounting change for securities held at a discount; the discount continues to be amortized to maturity. The Company adopted the standard on January 1, 2019. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements and related disclosures.
In February 2018, the FASB issued ASU 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. The new guidance allows a reclassification from accumulated other comprehensive income to retained earnings for any stranded tax effects resulting from TCJA that was enacted on December 22, 2017. The new guidance will be effective for the Company beginning in the first quarter of 2019. The Company adopted the standard on January 1, 2019. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements and related disclosures.
In June 2018, the FASB issued ASU 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Non-employee Share-based Payment Accounting. The standard expands the scope of Topic 718 to include share-based payments issued to non-employees for goods or services, simplifying the accounting for share-based payments to non-employees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years with early adoption permitted, including adoption in an interim period. The Company adopted the standard on January 1, 2019. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements and related disclosures.
EXCEL 20 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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htm IDEA: XBRL DOCUMENT v3.19.3
Shareholders' Equity - Textual (Details) - USD ($)
 9 Months Ended
Aug. 16, 2017
Feb. 16, 2016
Sep. 30, 2019
Sep. 30, 2018
Dec. 31, 2018
Equity [Abstract]          
Exercise of stock options, common stock issued (in shares)     499,671 0  
Weighted average exercise price, exercised (in USD per share)     $ 1.62    
Period under program 1 year 1 year      
Authorized repurchase amount $ 5,000,000 $ 15,000,000      
Treasury stock (in shares)     12,253,502   12,253,502
Treasury stock, shares held at cost     $ 18,929,915   $ 18,929,915
XML 22 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3 html 184 315 1 false 47 0 false 12 false false R1.htm 0001001 - Document - Document and Entity Information Sheet http://www.dyadic.com/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001002 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETSParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 1004005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY Sheet http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY Statements 5 false false R6.htm 1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 2101101 - Disclosure - Organization and Summary of Significant Accounting Policies Sheet http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPolicies Organization and Summary of Significant Accounting Policies Notes 7 false false R8.htm 2110102 - Disclosure - Cash, Cash Equivalent, and Investments Sheet http://www.dyadic.com/role/CashCashEquivalentandInvestments Cash, Cash Equivalent, and Investments Notes 8 false false R9.htm 2113103 - Disclosure - Research Collaboration and Sub-licensing Agreements Sheet http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreements Research Collaboration and Sub-licensing Agreements Notes 9 false false R10.htm 2115104 - Disclosure - Commitments and Contingencies Sheet http://www.dyadic.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 10 false false R11.htm 2117105 - Disclosure - Share-Based Compensation Sheet http://www.dyadic.com/role/ShareBasedCompensation Share-Based Compensation Notes 11 false false R12.htm 2124106 - Disclosure - Shareholders' Equity Sheet http://www.dyadic.com/role/ShareholdersEquity Shareholders' Equity Notes 12 false false R13.htm 2129107 - Disclosure - Subsequent Events Sheet http://www.dyadic.com/role/SubsequentEvents Subsequent Events Notes 13 false false R14.htm 2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies) Sheet http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies Organization and Summary of Significant Accounting Policies (Policies) Policies http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPolicies 14 false false R15.htm 2303301 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables) Sheet http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables Organization and Summary of Significant Accounting Policies (Tables) Tables http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPolicies 15 false false R16.htm 2311302 - Disclosure - Cash, Cash Equivalent, and Investments (Tables) Sheet http://www.dyadic.com/role/CashCashEquivalentandInvestmentsTables Cash, Cash Equivalent, and Investments (Tables) Tables http://www.dyadic.com/role/CashCashEquivalentandInvestments 16 false false R17.htm 2318303 - Disclosure - Share-Based Compensation (Tables) Sheet http://www.dyadic.com/role/ShareBasedCompensationTables Share-Based Compensation (Tables) Tables http://www.dyadic.com/role/ShareBasedCompensation 17 false false R18.htm 2325304 - Disclosure - Shareholders' Equity (Tables) Sheet http://www.dyadic.com/role/ShareholdersEquityTables Shareholders' Equity (Tables) Tables http://www.dyadic.com/role/ShareholdersEquity 18 false false R19.htm 2404401 - Disclosure - Organization and Summary of Significant Accounting Policies - Textual (Details) Sheet http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails Organization and Summary of Significant Accounting Policies - Textual (Details) Details http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables 19 false false R20.htm 2405402 - Disclosure - Organization and Summary of Significant Accounting Policies - Accounts Receivable (Details) Sheet http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsReceivableDetails Organization and Summary of Significant Accounting Policies - Accounts Receivable (Details) Details 20 false false R21.htm 2406403 - Disclosure - Organization and Summary of Significant Accounting Policies - Prepaid Expenses and Other Current Assets (Details) Sheet http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPrepaidExpensesandOtherCurrentAssetsDetails Organization and Summary of Significant Accounting Policies - Prepaid Expenses and Other Current Assets (Details) Details 21 false false R22.htm 2407404 - Disclosure - Organization and Summary of Significant Accounting Policies - Accounts Payable (Details) Sheet http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsPayableDetails Organization and Summary of Significant Accounting Policies - Accounts Payable (Details) Details 22 false false R23.htm 2408405 - Disclosure - Organization and Summary of Significant Accounting Policies - Accrued Expenses (Details) Sheet http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccruedExpensesDetails Organization and Summary of Significant Accounting Policies - Accrued Expenses (Details) Details 23 false false R24.htm 2409406 - Disclosure - Organization and Summary of Significant Accounting Policies - Research and Development Costs (Details) Sheet http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesResearchandDevelopmentCostsDetails Organization and Summary of Significant Accounting Policies - Research and Development Costs (Details) Details 24 false false R25.htm 2412407 - Disclosure - Cash, Cash Equivalent, and Investments (Details) Sheet http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails Cash, Cash Equivalent, and Investments (Details) Details http://www.dyadic.com/role/CashCashEquivalentandInvestmentsTables 25 false false R26.htm 2414408 - Disclosure - Research Collaboration and Sub-licensing Agreements (Details) Sheet http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails Research Collaboration and Sub-licensing Agreements (Details) Details http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreements 26 false false R27.htm 2416409 - Disclosure - Commitments and Contingencies - Textual (Details) Sheet http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails Commitments and Contingencies - Textual (Details) Details 27 false false R28.htm 2419410 - Disclosure - Share-Based Compensation - Textual (Details) Sheet http://www.dyadic.com/role/ShareBasedCompensationTextualDetails Share-Based Compensation - Textual (Details) Details 28 false false R29.htm 2420411 - Disclosure - Share-Based Compensation - Assumptions (Details) Sheet http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails Share-Based Compensation - Assumptions (Details) Details 29 false false R30.htm 2421412 - Disclosure - Share-Based Compensation - Stock Option Activity (Details) Sheet http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails Share-Based Compensation - Stock Option Activity (Details) Details 30 false false R31.htm 2422413 - Disclosure - Share-Based Compensation - Stock Option Activity - Textual (Details) Sheet http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails Share-Based Compensation - Stock Option Activity - Textual (Details) Details 31 false false R32.htm 2423414 - Disclosure - Share-Based Compensation - Compensation Expense (Details) Sheet http://www.dyadic.com/role/ShareBasedCompensationCompensationExpenseDetails Share-Based Compensation - Compensation Expense (Details) Details 32 false false R33.htm 2426415 - Disclosure - Shareholders' Equity - Textual (Details) Sheet http://www.dyadic.com/role/ShareholdersEquityTextualDetails Shareholders' Equity - Textual (Details) Details 33 false false R34.htm 2427416 - Disclosure - Shareholders' Equity - Changes in Shareholders??? Equity (Details) Sheet http://www.dyadic.com/role/ShareholdersEquityChangesinShareholdersEquityDetails Shareholders' Equity - Changes in Shareholders??? Equity (Details) Details 34 false false R35.htm 2428417 - Disclosure - Shareholders' Equity - Stock Repurchase (Details) Sheet http://www.dyadic.com/role/ShareholdersEquityStockRepurchaseDetails Shareholders' Equity - Stock Repurchase (Details) Details 35 false false All Reports Book All Reports dyai-20190930.htm dyai-20190930.xsd dyai-20190930_cal.xml dyai-20190930_def.xml dyai-20190930_lab.xml dyai-20190930_pre.xml exhibit311certificatio.htm exhibit312certificatio.htm exhibit321sec1350certi.htm exhibit322sec1350certi.htm dyai-20190930_g1.jpg http://fasb.org/srt/2018-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2018-01-31 http://xbrl.sec.gov/country/2017-01-31 true true JSON 23 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "dyai-20190930.htm": { "axisCustom": 0, "axisStandard": 23, "contextCount": 184, "dts": { "calculationLink": { "local": [ "dyai-20190930_cal.xml" ] }, "definitionLink": { "local": [ "dyai-20190930_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-eedm-def-2018-01-31.xml", "http://xbrl.fasb.org/srt/2018/elts/srt-eedm1-def-2018-01-31.xml" ] }, "inline": { "local": [ "dyai-20190930.htm" ] }, "labelLink": { "local": [ "dyai-20190930_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-doc-2018-01-31.xml" ] }, "presentationLink": { "local": [ "dyai-20190930_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-ref-2018-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "dyai-20190930.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-types-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-roles-2018-01-31.xsd", "http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-parts-codification-2018-01-31.xsd" ] } }, "elementCount": 387, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2018-01-31": 3, "http://www.dyadic.com/20190930": 1, "http://xbrl.sec.gov/dei/2019-01-31": 12, "total": 16 }, "keyCustom": 56, "keyStandard": 259, "memberCustom": 20, "memberStandard": 27, "nsprefix": "dyai", "nsuri": "http://www.dyadic.com/20190930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i340263fc1e5b41b5af90808913d871a1_D20190101-20190930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Document and Entity Information", "role": "http://www.dyadic.com/role/DocumentandEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i340263fc1e5b41b5af90808913d871a1_D20190101-20190930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i340263fc1e5b41b5af90808913d871a1_D20190101-20190930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2115104 - Disclosure - Commitments and Contingencies", "role": "http://www.dyadic.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i340263fc1e5b41b5af90808913d871a1_D20190101-20190930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i340263fc1e5b41b5af90808913d871a1_D20190101-20190930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2117105 - Disclosure - Share-Based Compensation", "role": "http://www.dyadic.com/role/ShareBasedCompensation", "shortName": "Share-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i340263fc1e5b41b5af90808913d871a1_D20190101-20190930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i340263fc1e5b41b5af90808913d871a1_D20190101-20190930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2124106 - Disclosure - Shareholders' Equity", "role": "http://www.dyadic.com/role/ShareholdersEquity", "shortName": "Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i340263fc1e5b41b5af90808913d871a1_D20190101-20190930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i340263fc1e5b41b5af90808913d871a1_D20190101-20190930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2129107 - Disclosure - Subsequent Events", "role": "http://www.dyadic.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i340263fc1e5b41b5af90808913d871a1_D20190101-20190930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i340263fc1e5b41b5af90808913d871a1_D20190101-20190930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)", "role": "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies", "shortName": "Organization and Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i340263fc1e5b41b5af90808913d871a1_D20190101-20190930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i340263fc1e5b41b5af90808913d871a1_D20190101-20190930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2303301 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)", "role": "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables", "shortName": "Organization and Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i340263fc1e5b41b5af90808913d871a1_D20190101-20190930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i340263fc1e5b41b5af90808913d871a1_D20190101-20190930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2311302 - Disclosure - Cash, Cash Equivalent, and Investments (Tables)", "role": "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsTables", "shortName": "Cash, Cash Equivalent, and Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i340263fc1e5b41b5af90808913d871a1_D20190101-20190930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i340263fc1e5b41b5af90808913d871a1_D20190101-20190930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2318303 - Disclosure - Share-Based Compensation (Tables)", "role": "http://www.dyadic.com/role/ShareBasedCompensationTables", "shortName": "Share-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i340263fc1e5b41b5af90808913d871a1_D20190101-20190930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i340263fc1e5b41b5af90808913d871a1_D20190101-20190930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2325304 - Disclosure - Shareholders' Equity (Tables)", "role": "http://www.dyadic.com/role/ShareholdersEquityTables", "shortName": "Shareholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i340263fc1e5b41b5af90808913d871a1_D20190101-20190930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i340263fc1e5b41b5af90808913d871a1_D20190101-20190930", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404401 - Disclosure - Organization and Summary of Significant Accounting Policies - Textual (Details)", "role": "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails", "shortName": "Organization and Summary of Significant Accounting Policies - Textual (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i340263fc1e5b41b5af90808913d871a1_D20190101-20190930", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i26fe0708f0ab4b64ae8b33c60b2f574c_I20190930", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - CONSOLIDATED BALANCE SHEETS", "role": "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS", "shortName": "CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i26fe0708f0ab4b64ae8b33c60b2f574c_I20190930", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i26fe0708f0ab4b64ae8b33c60b2f574c_I20190930", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405402 - Disclosure - Organization and Summary of Significant Accounting Policies - Accounts Receivable (Details)", "role": "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsReceivableDetails", "shortName": "Organization and Summary of Significant Accounting Policies - Accounts Receivable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i974b2bc40516464dbf96986a0310b6a2_I20190930", "decimals": "0", "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i26fe0708f0ab4b64ae8b33c60b2f574c_I20190930", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherPrepaidExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406403 - Disclosure - Organization and Summary of Significant Accounting Policies - Prepaid Expenses and Other Current Assets (Details)", "role": "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPrepaidExpensesandOtherCurrentAssetsDetails", "shortName": "Organization and Summary of Significant Accounting Policies - Prepaid Expenses and Other Current Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i26fe0708f0ab4b64ae8b33c60b2f574c_I20190930", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherPrepaidExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i26fe0708f0ab4b64ae8b33c60b2f574c_I20190930", "decimals": "0", "first": true, "lang": null, "name": "dyai:ResearchAndDevelopmentInProcessCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407404 - Disclosure - Organization and Summary of Significant Accounting Policies - Accounts Payable (Details)", "role": "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsPayableDetails", "shortName": "Organization and Summary of Significant Accounting Policies - Accounts Payable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i26fe0708f0ab4b64ae8b33c60b2f574c_I20190930", "decimals": "0", "first": true, "lang": null, "name": "dyai:ResearchAndDevelopmentInProcessCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i26fe0708f0ab4b64ae8b33c60b2f574c_I20190930", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408405 - Disclosure - Organization and Summary of Significant Accounting Policies - Accrued Expenses (Details)", "role": "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccruedExpensesDetails", "shortName": "Organization and Summary of Significant Accounting Policies - Accrued Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i26fe0708f0ab4b64ae8b33c60b2f574c_I20190930", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i3e91660dbd4c4bd2a0f1e20072efd95b_D20190701-20190930", "decimals": "0", "first": true, "lang": null, "name": "dyai:ResearchAndDevelopmentExpenseOutsideContractedServices", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409406 - Disclosure - Organization and Summary of Significant Accounting Policies - Research and Development Costs (Details)", "role": "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesResearchandDevelopmentCostsDetails", "shortName": "Organization and Summary of Significant Accounting Policies - Research and Development Costs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i3e91660dbd4c4bd2a0f1e20072efd95b_D20190701-20190930", "decimals": "0", "first": true, "lang": null, "name": "dyai:ResearchAndDevelopmentExpenseOutsideContractedServices", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i26fe0708f0ab4b64ae8b33c60b2f574c_I20190930", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412407 - Disclosure - Cash, Cash Equivalent, and Investments (Details)", "role": "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails", "shortName": "Cash, Cash Equivalent, and Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i30aa6c3f8b5746c297fb0fda0cde8930_I20181231", "decimals": "0", "lang": null, "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i2fe8da1d4040471f90791b1ecb59adcd_D20170630-20170630", "decimals": "-6", "first": true, "lang": null, "name": "dyai:CollaborativeArrangementPaymentforResearchandDevelopmentAgreement", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414408 - Disclosure - Research Collaboration and Sub-licensing Agreements (Details)", "role": "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails", "shortName": "Research Collaboration and Sub-licensing Agreements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i2fe8da1d4040471f90791b1ecb59adcd_D20170630-20170630", "decimals": "-6", "first": true, "lang": null, "name": "dyai:CollaborativeArrangementPaymentforResearchandDevelopmentAgreement", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i38ad242f12e941ceb69d173aa38880b3_I20190628", "decimals": "-4", "first": true, "lang": null, "name": "dyai:CommitmentToPay", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416409 - Disclosure - Commitments and Contingencies - Textual (Details)", "role": "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails", "shortName": "Commitments and Contingencies - Textual (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i38ad242f12e941ceb69d173aa38880b3_I20190628", "decimals": "-4", "first": true, "lang": null, "name": "dyai:CommitmentToPay", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i26fe0708f0ab4b64ae8b33c60b2f574c_I20190930", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419410 - Disclosure - Share-Based Compensation - Textual (Details)", "role": "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails", "shortName": "Share-Based Compensation - Textual (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i00fff323dbbb408d934122e27a388a3b_I20190930", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "ia1e0ee8f34d7457a9203fa9e5264845e_D20190101-20190930", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420411 - Disclosure - Share-Based Compensation - Assumptions (Details)", "role": "http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails", "shortName": "Share-Based Compensation - Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "ia1e0ee8f34d7457a9203fa9e5264845e_D20190101-20190930", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i26fe0708f0ab4b64ae8b33c60b2f574c_I20190930", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i26fe0708f0ab4b64ae8b33c60b2f574c_I20190930", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i30aa6c3f8b5746c297fb0fda0cde8930_I20181231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421412 - Disclosure - Share-Based Compensation - Stock Option Activity (Details)", "role": "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails", "shortName": "Share-Based Compensation - Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i340263fc1e5b41b5af90808913d871a1_D20190101-20190930", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i340263fc1e5b41b5af90808913d871a1_D20190101-20190930", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422413 - Disclosure - Share-Based Compensation - Stock Option Activity - Textual (Details)", "role": "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails", "shortName": "Share-Based Compensation - Stock Option Activity - Textual (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i90b8edbd9cbd4f6dabe478f8cdf6ff17_I20190625", "decimals": "INF", "lang": null, "name": "dyai:SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofBoardofDirectors", "reportCount": 1, "unique": true, "unitRef": "board_of_director", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i3e91660dbd4c4bd2a0f1e20072efd95b_D20190701-20190930", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423414 - Disclosure - Share-Based Compensation - Compensation Expense (Details)", "role": "http://www.dyadic.com/role/ShareBasedCompensationCompensationExpenseDetails", "shortName": "Share-Based Compensation - Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i3e91660dbd4c4bd2a0f1e20072efd95b_D20190701-20190930", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i340263fc1e5b41b5af90808913d871a1_D20190101-20190930", "decimals": "INF", "first": true, "lang": null, "name": "dyai:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCommonStockIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2426415 - Disclosure - Shareholders' Equity - Textual (Details)", "role": "http://www.dyadic.com/role/ShareholdersEquityTextualDetails", "shortName": "Shareholders' Equity - Textual (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i340263fc1e5b41b5af90808913d871a1_D20190101-20190930", "decimals": "INF", "first": true, "lang": null, "name": "dyai:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCommonStockIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "iae63df3c3c9c41cabd667f41d7b09d2d_I20190630", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2427416 - Disclosure - Shareholders' Equity - Changes in Shareholders\u2019 Equity (Details)", "role": "http://www.dyadic.com/role/ShareholdersEquityChangesinShareholdersEquityDetails", "shortName": "Shareholders' Equity - Changes in Shareholders\u2019 Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i20adaf91f13b4ea0beb7d653d038a2b4_D20180701-20180930", "decimals": "0", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfTreasuryStockByClassTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "id9709febbf494a1e95807aa25c193e17_D20170111-20170111", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:TreasuryStockSharesAcquired", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428417 - Disclosure - Shareholders' Equity - Stock Repurchase (Details)", "role": "http://www.dyadic.com/role/ShareholdersEquityStockRepurchaseDetails", "shortName": "Shareholders' Equity - Stock Repurchase (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfTreasuryStockByClassTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "id9709febbf494a1e95807aa25c193e17_D20170111-20170111", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:TreasuryStockSharesAcquired", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i3e91660dbd4c4bd2a0f1e20072efd95b_D20190701-20190930", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS", "role": "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i3e91660dbd4c4bd2a0f1e20072efd95b_D20190701-20190930", "decimals": "0", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "ic896c9f242b8449893684208683b30ca_I20171231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY", "role": "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i61dbe381446447d0a65623b974e0e096_D20190101-20190930", "decimals": "0", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i340263fc1e5b41b5af90808913d871a1_D20190101-20190930", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i340263fc1e5b41b5af90808913d871a1_D20190101-20190930", "decimals": "0", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i340263fc1e5b41b5af90808913d871a1_D20190101-20190930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Organization and Summary of Significant Accounting Policies", "role": "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPolicies", "shortName": "Organization and Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i340263fc1e5b41b5af90808913d871a1_D20190101-20190930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i340263fc1e5b41b5af90808913d871a1_D20190101-20190930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110102 - Disclosure - Cash, Cash Equivalent, and Investments", "role": "http://www.dyadic.com/role/CashCashEquivalentandInvestments", "shortName": "Cash, Cash Equivalent, and Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i340263fc1e5b41b5af90808913d871a1_D20190101-20190930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i340263fc1e5b41b5af90808913d871a1_D20190101-20190930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2113103 - Disclosure - Research Collaboration and Sub-licensing Agreements", "role": "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreements", "shortName": "Research Collaboration and Sub-licensing Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dyai-20190930.htm", "contextRef": "i340263fc1e5b41b5af90808913d871a1_D20190101-20190930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 47, "tag": { "country_US": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r227" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r228" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r229" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r229" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r229" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r230" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r229" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r229" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r229" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r229" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r225" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r226" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/role/DocumentandEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dyai_A2006PlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2006 Plan [Member]", "label": "2006 Plan [Member]", "terseLabel": "2006 Plan" } } }, "localname": "A2006PlanMember", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails" ], "xbrltype": "domainItemType" }, "dyai_A2011PlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2011 Plan [Member]", "label": "2011 Plan [Member]", "terseLabel": "2011 Plan" } } }, "localname": "A2011PlanMember", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails" ], "xbrltype": "domainItemType" }, "dyai_AccruedResearchandDevelopmentinProcessCurrent": { "auth_ref": [], "calculation": { "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccruedExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued Research and Development in Process, Current", "label": "Accrued Research and Development in Process, Current", "terseLabel": "Research and development expenses" } } }, "localname": "AccruedResearchandDevelopmentinProcessCurrent", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "dyai_AlphazymeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Alphazyme [Member]", "label": "Alphazyme [Member]", "terseLabel": "Alphazyme" } } }, "localname": "AlphazymeMember", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "domainItemType" }, "dyai_BDIHoldingsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "BDI Holdings [Member]", "label": "BDI Holdings [Member]", "terseLabel": "BDI Holdings" } } }, "localname": "BDIHoldingsMember", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "domainItemType" }, "dyai_BDIMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "BDI [Member]", "label": "BDI [Member]", "terseLabel": "BDI" } } }, "localname": "BDIMember", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "domainItemType" }, "dyai_CollaborativeArrangementDurationOfAgreement": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangement, Duration Of Agreement", "label": "Collaborative Arrangement, Duration Of Agreement", "terseLabel": "Duration of agreement" } } }, "localname": "CollaborativeArrangementDurationOfAgreement", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "durationItemType" }, "dyai_CollaborativeArrangementEquityInterestAcquired": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangement, Equity Interest Acquired", "label": "Collaborative Arrangement, Equity Interest Acquired", "terseLabel": "Equity interest acquired" } } }, "localname": "CollaborativeArrangementEquityInterestAcquired", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "percentItemType" }, "dyai_CollaborativeArrangementExclusivityPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangement, Exclusivity Period", "label": "Collaborative Arrangement, Exclusivity Period", "terseLabel": "Exclusivity period" } } }, "localname": "CollaborativeArrangementExclusivityPeriod", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "durationItemType" }, "dyai_CollaborativeArrangementMaximumObligationForResearchAndDevelopment": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangement, Maximum Obligation For Research And Development", "label": "Collaborative Arrangement, Maximum Obligation For Research And Development", "terseLabel": "Obligation for payment for research and development, maximum" } } }, "localname": "CollaborativeArrangementMaximumObligationForResearchAndDevelopment", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangement, Minimum Obligation For Research And Development", "label": "Collaborative Arrangement, Minimum Obligation For Research And Development", "terseLabel": "Obligation for payment for research and development, minimum" } } }, "localname": "CollaborativeArrangementMinimumObligationForResearchAndDevelopment", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "dyai_CollaborativeArrangementNumberofAntibodiesandVaccinesForDevelopmentAndCommercialization": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangement, Number of Antibodies and Vaccines For Development And Commercialization", "label": "Collaborative Arrangement, Number of Antibodies and Vaccines For Development And Commercialization", "terseLabel": "Number of antibodies and vaccines for development and commercialization" } } }, "localname": "CollaborativeArrangementNumberofAntibodiesandVaccinesForDevelopmentAndCommercialization", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "integerItemType" }, "dyai_CollaborativeArrangementNumberofCollaborationProjectCompleted": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangement, Number of Collaboration Project, Completed", "label": "Collaborative Arrangement, Number of Collaboration Project, Completed", "terseLabel": "Number of collaboration project, completed" } } }, "localname": "CollaborativeArrangementNumberofCollaborationProjectCompleted", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "integerItemType" }, "dyai_CollaborativeArrangementNumberofCollaborationProjectInProgress": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangement, Number of Collaboration Project, In Progress", "label": "Collaborative Arrangement, Number of Collaboration Project, In Progress", "terseLabel": "Number of collaboration project, in progress" } } }, "localname": "CollaborativeArrangementNumberofCollaborationProjectInProgress", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "integerItemType" }, "dyai_CollaborativeArrangementOptionToExtendExclusivityPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangement, Option To Extend Exclusivity Period", "label": "Collaborative Arrangement, Option To Extend Exclusivity Period", "terseLabel": "Option to extend exclusivity period" } } }, "localname": "CollaborativeArrangementOptionToExtendExclusivityPeriod", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "durationItemType" }, "dyai_CollaborativeArrangementOptiontoObtainExclusiveCommercialSubLicenseForNumberofProteins": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangement, Option to Obtain Exclusive Commercial Sub-License For Number of Proteins", "label": "Collaborative Arrangement, Option to Obtain Exclusive Commercial Sub-License For Number of Proteins", "terseLabel": "Option to obtain exclusive commercial sub-license for number of proteins" } } }, "localname": "CollaborativeArrangementOptiontoObtainExclusiveCommercialSubLicenseForNumberofProteins", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "integerItemType" }, "dyai_CollaborativeArrangementOutstandingCommitment": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangement, Outstanding Commitment", "label": "Collaborative Arrangement, Outstanding Commitment", "terseLabel": "Outstanding commitment" } } }, "localname": "CollaborativeArrangementOutstandingCommitment", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "dyai_CollaborativeArrangementOwnershipInterestConsiderationReceivableUponExtensionOfExclusivityPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangement, Ownership Interest Consideration Receivable Upon Extension Of Exclusivity Period", "label": "Collaborative Arrangement, Ownership Interest Consideration Receivable Upon Extension Of Exclusivity Period", "terseLabel": "Ownership interest consideration receivable upon extension of exclusivity period" } } }, "localname": "CollaborativeArrangementOwnershipInterestConsiderationReceivableUponExtensionOfExclusivityPeriod", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "percentItemType" }, "dyai_CollaborativeArrangementPaymentforAdditionalDevelopmentandCommercialization": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangement, Payment for Additional Development and Commercialization", "label": "Collaborative Arrangement, Payment for Additional Development and Commercialization", "terseLabel": "Payment for additional development and commercialization" } } }, "localname": "CollaborativeArrangementPaymentforAdditionalDevelopmentandCommercialization", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "dyai_CollaborativeArrangementPaymentforResearchandDevelopmentAgreement": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangement, Payment for Research and Development Agreement", "label": "Collaborative Arrangement, Payment for Research and Development Agreement", "terseLabel": "Payment for research and development agreement" } } }, "localname": "CollaborativeArrangementPaymentforResearchandDevelopmentAgreement", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "dyai_CollaborativeArrangementResearchFundingMilestonePaymentsAndRoyaltiesPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangement, Research Funding, Milestone Payments And Royalties, Period", "label": "Collaborative Arrangement, Research Funding, Milestone Payments And Royalties, Period", "terseLabel": "Research funding, milestone payments and royalties, period" } } }, "localname": "CollaborativeArrangementResearchFundingMilestonePaymentsAndRoyaltiesPeriod", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "durationItemType" }, "dyai_CollaborativeArrangementRevenueSharingPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangement, Revenue Sharing, Percentage", "label": "Collaborative Arrangement, Revenue Sharing, Percentage", "terseLabel": "Revenue sharing, percentage" } } }, "localname": "CollaborativeArrangementRevenueSharingPercentage", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "percentItemType" }, "dyai_CommitmentDevelopmentPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commitment Development Period", "label": "Commitment Development Period", "terseLabel": "Commitment development period" } } }, "localname": "CommitmentDevelopmentPeriod", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails" ], "xbrltype": "durationItemType" }, "dyai_CommitmentSuccessBonusAward": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Commitment Success Bonus Award", "label": "Commitment Success Bonus Award", "terseLabel": "Commitment success bonus award" } } }, "localname": "CommitmentSuccessBonusAward", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails" ], "xbrltype": "monetaryItemType" }, "dyai_CommitmentToPay": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Commitment To Pay", "label": "Commitment To Pay", "terseLabel": "Commitment to pay" } } }, "localname": "CommitmentToPay", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails" ], "xbrltype": "monetaryItemType" }, "dyai_CommitmentToPayExpanded": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Commitment To Pay, Expanded", "label": "Commitment To Pay, Expanded", "terseLabel": "Commitment to pay, expanded" } } }, "localname": "CommitmentToPayExpanded", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails" ], "xbrltype": "monetaryItemType" }, "dyai_CommitmentToPayExpandedPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commitment To Pay, Expanded, Period", "label": "Commitment To Pay, Expanded, Period", "terseLabel": "Commitment to pay, expanded, period" } } }, "localname": "CommitmentToPayExpandedPeriod", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails" ], "xbrltype": "durationItemType" }, "dyai_CommitmentsRightToTerminateContractNoticePeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commitments, Right To Terminate Contract Notice Period", "label": "Commitments, Right To Terminate Contract Notice Period", "terseLabel": "Commitments, right to terminate contract notice period" } } }, "localname": "CommitmentsRightToTerminateContractNoticePeriod", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails" ], "xbrltype": "durationItemType" }, "dyai_ConcentrationRiskNumberofCustomers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Concentration Risk, Number of Customers", "label": "Concentration Risk, Number of Customers", "terseLabel": "Concentration risk, number of customers" } } }, "localname": "ConcentrationRiskNumberofCustomers", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "integerItemType" }, "dyai_ContractorMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contractor [Member]", "label": "Contractor [Member]", "terseLabel": "Contractor" } } }, "localname": "ContractorMember", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails", "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails" ], "xbrltype": "domainItemType" }, "dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainCurrent": { "auth_ref": [], "calculation": { "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails": { "order": 2.0, "parentTag": "us-gaap_HeldToMaturitySecuritiesCurrent", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain, Current", "label": "Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain, Current", "terseLabel": "Short term investments, gross unrealized holding gain" } } }, "localname": "DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainCurrent", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainNoncurrent": { "auth_ref": [], "calculation": { "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain, Noncurrent", "label": "Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain, Noncurrent", "terseLabel": "Long term Investments, gross unrealized holding gain" } } }, "localname": "DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainNoncurrent", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossCurrent": { "auth_ref": [], "calculation": { "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss, Current", "label": "Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss, Current", "negatedLabel": "Short term investments, gross unrealized holding loss" } } }, "localname": "DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossCurrent", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossNoncurrent": { "auth_ref": [], "calculation": { "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails": { "order": 3.0, "parentTag": "us-gaap_HeldToMaturitySecuritiesNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss, Noncurrent", "label": "Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss, Noncurrent", "negatedLabel": "Long term Investments, gross unrealized holding loss" } } }, "localname": "DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossNoncurrent", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "dyai_DebtSecuritiesHeldtomaturityFairValueCurrent": { "auth_ref": [], "calculation": { "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails": { "order": 3.0, "parentTag": "us-gaap_HeldToMaturitySecuritiesCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Debt Securities, Held-to-maturity, Fair Value, Current", "label": "Debt Securities, Held-to-maturity, Fair Value, Current", "terseLabel": "Short term investments, fair value" } } }, "localname": "DebtSecuritiesHeldtomaturityFairValueCurrent", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "dyai_DebtSecuritiesHeldtomaturityFairValueNoncurrent": { "auth_ref": [], "calculation": { "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails": { "order": 3.0, "parentTag": "us-gaap_InvestmentsAndCash", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Debt Securities, Held-to-maturity, Fair Value, Noncurrent", "label": "Debt Securities, Held-to-maturity, Fair Value, Noncurrent", "terseLabel": "Long term Investments, fair value" } } }, "localname": "DebtSecuritiesHeldtomaturityFairValueNoncurrent", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "dyai_DebtSecuritiesHeldtomaturityPremiumPaidonPurchase": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Debt Securities, Held-to-maturity, Premium Paid on Purchase", "label": "Debt Securities, Held-to-maturity, Premium Paid on Purchase", "terseLabel": "Held-to-maturity, premium paid on purchase" } } }, "localname": "DebtSecuritiesHeldtomaturityPremiumPaidonPurchase", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "dyai_DeferredTaxAssetsValuationAllowanceCoveragePercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Deferred Tax Assets, Valuation Allowance Coverage, Percent", "label": "Deferred Tax Assets, Valuation Allowance Coverage, Percent", "terseLabel": "Deferred tax assets, valuation allowance coverage, percent" } } }, "localname": "DeferredTaxAssetsValuationAllowanceCoveragePercent", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "percentItemType" }, "dyai_DuPontDaniscoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "DuPont Danisco [Member]", "label": "DuPont Danisco [Member]", "terseLabel": "DuPont Danisco" } } }, "localname": "DuPontDaniscoMember", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "domainItemType" }, "dyai_EmployeeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Employee [Member]", "label": "Employee [Member]", "terseLabel": "Employee" } } }, "localname": "EmployeeMember", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails" ], "xbrltype": "domainItemType" }, "dyai_ExecutivesandKeyPersonnelMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Executives and Key Personnel [Member]", "label": "Executives and Key Personnel [Member]", "terseLabel": "Executives and Key Personnel" } } }, "localname": "ExecutivesandKeyPersonnelMember", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails" ], "xbrltype": "domainItemType" }, "dyai_IncreaseDecreaseinPrepaidResearchandDevelopment": { "auth_ref": [], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Increase (Decrease) in Prepaid Research and Development", "label": "Increase (Decrease) in Prepaid Research and Development", "negatedTerseLabel": "Prepaid research and development" } } }, "localname": "IncreaseDecreaseinPrepaidResearchandDevelopment", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "dyai_IndustrialTechnologyBusinessMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Industrial Technology Business [Member]", "label": "Industrial Technology Business [Member]", "terseLabel": "Industrial Technology Business" } } }, "localname": "IndustrialTechnologyBusinessMember", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "domainItemType" }, "dyai_InvestmentsandCashAmortizedCost": { "auth_ref": [], "calculation": { "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Investments and Cash, Amortized Cost", "label": "Investments and Cash, Amortized Cost", "totalLabel": "Cash and Investment, adjusted cost" } } }, "localname": "InvestmentsandCashAmortizedCost", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "dyai_JupiterFloridaHeadquartersLeaseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Jupiter, Florida Headquarters Lease [Member]", "label": "Jupiter, Florida Headquarters Lease [Member]", "terseLabel": "Jupiter, Florida Headquarters Lease" } } }, "localname": "JupiterFloridaHeadquartersLeaseMember", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails" ], "xbrltype": "domainItemType" }, "dyai_NetherlandsOfficeLeaseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Netherlands Office Lease [Member]", "label": "Netherlands Office Lease [Member]", "terseLabel": "Netherlands Office Lease" } } }, "localname": "NetherlandsOfficeLeaseMember", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails" ], "xbrltype": "domainItemType" }, "dyai_NovovetMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Novovet [Member]", "label": "Novovet [Member]", "terseLabel": "Novovet" } } }, "localname": "NovovetMember", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "domainItemType" }, "dyai_OperatingLeasesAnnualRentalRate": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Operating Leases, Annual Rental Rate", "label": "Operating Leases, Annual Rental Rate", "terseLabel": "Rent expense" } } }, "localname": "OperatingLeasesAnnualRentalRate", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails" ], "xbrltype": "monetaryItemType" }, "dyai_OperatingLeasesMonthlyRentalRate": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Operating Leases, Monthly Rental Rate", "label": "Operating Leases, Monthly Rental Rate", "terseLabel": "Monthly rental rate" } } }, "localname": "OperatingLeasesMonthlyRentalRate", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails" ], "xbrltype": "monetaryItemType" }, "dyai_PrepaidResearchandDevelopment": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Prepaid Research and Development", "label": "Prepaid Research and Development", "terseLabel": "Prepaid research and development" } } }, "localname": "PrepaidResearchandDevelopment", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "dyai_PrepaidResearchandDevelopmentinProcessCurrent": { "auth_ref": [], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Prepaid Research and Development in Process, Current", "label": "Prepaid Research and Development in Process, Current", "terseLabel": "Prepaid research and development" } } }, "localname": "PrepaidResearchandDevelopmentinProcessCurrent", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "dyai_PubliclyAnnouncedRepurchasePlansMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Publicly Announced Repurchase Plans [Member]", "label": "Publicly Announced Repurchase Plans [Member]", "terseLabel": "Publicly Announced Repurchase Plans" } } }, "localname": "PubliclyAnnouncedRepurchasePlansMember", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/ShareholdersEquityStockRepurchaseDetails" ], "xbrltype": "domainItemType" }, "dyai_ResearchAndDevelopmentExpenseContractedServicesRelatedParty": { "auth_ref": [], "calculation": { "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesResearchandDevelopmentCostsDetails": { "order": 2.0, "parentTag": "dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Research And Development Expense, Contracted Services, Related Party", "label": "Research And Development Expense, Contracted Services, Related Party", "terseLabel": "Contracted services - related party" } } }, "localname": "ResearchAndDevelopmentExpenseContractedServicesRelatedParty", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesResearchandDevelopmentCostsDetails" ], "xbrltype": "monetaryItemType" }, "dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadandOther": { "auth_ref": [], "calculation": { "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesResearchandDevelopmentCostsDetails": { "order": 4.0, "parentTag": "dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Research And Development Expense, Facilities, Overhead and Other", "label": "Research And Development Expense, Facilities, Overhead and Other", "terseLabel": "Facilities, overhead and other" } } }, "localname": "ResearchAndDevelopmentExpenseFacilitiesOverheadandOther", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesResearchandDevelopmentCostsDetails" ], "xbrltype": "monetaryItemType" }, "dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty": { "auth_ref": [], "calculation": { "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesResearchandDevelopmentCostsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Research And Development Expense, Including Related Party", "label": "Research And Development Expense, Including Related Party", "totalLabel": "Research and development expense, related party, net" } } }, "localname": "ResearchAndDevelopmentExpenseIncludingRelatedParty", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesResearchandDevelopmentCostsDetails" ], "xbrltype": "monetaryItemType" }, "dyai_ResearchAndDevelopmentExpenseOutsideContractedServices": { "auth_ref": [], "calculation": { "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesResearchandDevelopmentCostsDetails": { "order": 1.0, "parentTag": "dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Research And Development Expense, Outside Contracted Services", "label": "Research And Development Expense, Outside Contracted Services", "terseLabel": "Outside contracted services" } } }, "localname": "ResearchAndDevelopmentExpenseOutsideContractedServices", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesResearchandDevelopmentCostsDetails" ], "xbrltype": "monetaryItemType" }, "dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts": { "auth_ref": [], "calculation": { "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesResearchandDevelopmentCostsDetails": { "order": 3.0, "parentTag": "dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Research And Development Expense, Personnel Related Costs", "label": "Research And Development Expense, Personnel Related Costs", "terseLabel": "Personnel related costs" } } }, "localname": "ResearchAndDevelopmentExpensePersonnelRelatedCosts", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesResearchandDevelopmentCostsDetails" ], "xbrltype": "monetaryItemType" }, "dyai_ResearchAndDevelopmentInProcessCurrent": { "auth_ref": [], "calculation": { "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsPayableDetails": { "order": 1.0, "parentTag": "us-gaap_AccountsPayableCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Research And Development In Process, Current", "label": "Research And Development In Process, Current", "terseLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentInProcessCurrent", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsPayableDetails" ], "xbrltype": "monetaryItemType" }, "dyai_ResearchServicesAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Research Services Agreement [Member]", "label": "Research Services Agreement [Member]", "terseLabel": "RSA" } } }, "localname": "ResearchServicesAgreementMember", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "domainItemType" }, "dyai_ResearchandDevelopmentExpenseRelatedParty": { "auth_ref": [], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Research and Development Expense, Related Party", "label": "Research and Development Expense, Related Party", "terseLabel": "Research and development - related party" } } }, "localname": "ResearchandDevelopmentExpenseRelatedParty", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "dyai_RevenueFromCollaborativeArrangementContractLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Revenue from Collaborative Arrangement, Contract Liability", "label": "Revenue from Collaborative Arrangement, Contract Liability", "terseLabel": "Revenue from collaborative arrangement, contract liability" } } }, "localname": "RevenueFromCollaborativeArrangementContractLiability", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "dyai_RevenueFromCollaborativeArrangementRecognized": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Revenue from Collaborative Arrangement, Recognized", "label": "Revenue from Collaborative Arrangement, Recognized", "terseLabel": "Revenue from collaborative arrangement, recognized" } } }, "localname": "RevenueFromCollaborativeArrangementRecognized", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "dyai_ScheduleofResearchandDevelopmentCostsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of Research and Development Costs [Table Text Block]", "label": "Schedule of Research and Development Costs [Table Text Block]", "terseLabel": "Schedule of Research and Development Costs" } } }, "localname": "ScheduleofResearchandDevelopmentCostsTableTextBlock", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "dyai_SerumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Serum [Member]", "label": "Serum [Member]", "terseLabel": "Serum" } } }, "localname": "SerumMember", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "domainItemType" }, "dyai_ServiceFrameworkAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Service Framework Agreement [Member]", "label": "Service Framework Agreement [Member]", "terseLabel": "SFA" } } }, "localname": "ServiceFrameworkAgreementMember", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "domainItemType" }, "dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsDiscountforLackofMarketability": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Lack of Marketability", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Lack of Marketability", "terseLabel": "Discount for lack of marketability" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsDiscountforLackofMarketability", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofBoardofDirectors": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Board of Directors", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Board of Directors", "terseLabel": "Number of board of directors" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofBoardofDirectors", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails" ], "xbrltype": "integerItemType" }, "dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCash": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Cash", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Cash", "terseLabel": "Exercise of stock options, cash (in shares)" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCash", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails" ], "xbrltype": "sharesItemType" }, "dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCommonStock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Common Stock", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Common Stock", "terseLabel": "Exercise of stock options, common stock (in shares)" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCommonStock", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails" ], "xbrltype": "sharesItemType" }, "dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCommonStockIssued": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Common Stock Issued", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Common Stock Issued", "terseLabel": "Exercise of stock options, common stock issued (in shares)" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCommonStockIssued", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/ShareholdersEquityTextualDetails" ], "xbrltype": "sharesItemType" }, "dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodForfeited": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Forfeited", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Forfeited", "terseLabel": "Exercise of stock options, forfeited (in shares)" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodForfeited", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails" ], "xbrltype": "sharesItemType" }, "dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodNet": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Net", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Net", "terseLabel": "Exercise of stock options, net (in shares)" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodNet", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails" ], "xbrltype": "sharesItemType" }, "dyai_SharebasedCompensationAwardTrancheTwothroughFiveMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Award, Tranche Two through Five [Member]", "label": "Share-based Compensation Award, Tranche Two through Five [Member]", "terseLabel": "Share-based Compensation Award, Tranche Two through Five" } } }, "localname": "SharebasedCompensationAwardTrancheTwothroughFiveMember", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails" ], "xbrltype": "domainItemType" }, "dyai_TaxCutsandJobsActChangeInAlternativeMinimumTaxIncomeTaxBenefit": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Tax Cuts and Jobs Act, Change In Alternative Minimum Tax, Income Tax Benefit", "label": "Tax Cuts and Jobs Act, Change In Alternative Minimum Tax, Income Tax Benefit", "terseLabel": "Tax cuts and jobs act, change in alternative minimum tax, income tax benefit" } } }, "localname": "TaxCutsandJobsActChangeInAlternativeMinimumTaxIncomeTaxBenefit", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "monetaryItemType" }, "dyai_VLPbioMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "VLPbio [Member]", "label": "VLPbio [Member]", "terseLabel": "VLPbio" } } }, "localname": "VLPbioMember", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "domainItemType" }, "dyai_VTTTechnicalResearchCentreofFinlandLtdMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "VTT Technical Research Centre of Finland Ltd [Member]", "label": "VTT Technical Research Centre of Finland Ltd [Member]", "terseLabel": "VTT Technical Research Centre of Finland Ltd" } } }, "localname": "VTTTechnicalResearchCentreofFinlandLtdMember", "nsuri": "http://www.dyadic.com/20190930", "presentation": [ "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r40", "r70" ], "lang": { "en-US": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails", "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails", "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "stringItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Investment, Name [Domain]", "terseLabel": "Investment, Name [Domain]" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails", "http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails", "http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Ownership [Axis]", "terseLabel": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Ownership [Domain]", "terseLabel": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Range [Axis]", "terseLabel": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails", "http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Range [Domain]", "terseLabel": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails", "http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails", "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails", "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r106" ], "lang": { "en-US": { "role": { "label": "Investment, Name [Axis]", "terseLabel": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "stringItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r93", "r126", "r128", "r221", "r223" ], "lang": { "en-US": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis": { "auth_ref": [ "r35" ], "lang": { "en-US": { "role": { "documentation": "Information by billing status of receivables.", "label": "Billing Status, Type [Axis]", "terseLabel": "Billing Status, Type [Axis]" } } }, "localname": "AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsReceivableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r26" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsPayableDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "totalLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableOtherCurrent": { "auth_ref": [ "r8", "r26" ], "calculation": { "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsPayableDetails": { "order": 3.0, "parentTag": "us-gaap_AccountsPayableCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.", "label": "Accounts Payable, Other, Current", "terseLabel": "Other" } } }, "localname": "AccountsPayableOtherCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNet": { "auth_ref": [ "r14", "r20", "r206", "r212" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "For an unclassified balance sheet, the amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business, reduced to their estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.", "label": "Accounts Receivable, Net", "terseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r14", "r127" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.", "label": "Accounts Receivable, Net, Current", "terseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r28" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccruedExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r7", "r8", "r28" ], "calculation": { "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsPayableDetails": { "order": 2.0, "parentTag": "us-gaap_AccountsPayableCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Legal expenses" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareholdersEquityChangesinShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareholdersEquityChangesinShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r15" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.dyadic.com/role/ShareholdersEquityChangesinShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r133", "r135", "r160", "r161" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.", "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.dyadic.com/role/ShareholdersEquityChangesinShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r135", "r155", "r159" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.", "label": "Allocated Share-based Compensation Expense", "terseLabel": "Stock-based compensation" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r37", "r96" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "For an unclassified balance sheet, a valuation allowance for receivables due a company that are expected to be uncollectible.", "label": "Allowance for Doubtful Accounts Receivable", "terseLabel": "Allowance for doubtful accounts receivable" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r76" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AreaOfRealEstateProperty": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area of a real estate property.", "label": "Area of Real Estate Property", "terseLabel": "Area of building rented" } } }, "localname": "AreaOfRealEstateProperty", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails" ], "xbrltype": "areaItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This item is to be populated with the collective of (i) types (categories) of arrangements of the entity applicable to its revenue-generating activities or operations and non-arrangement transactions, including but not limited to, for instance, sales of product manufactured by the entity, if such comparison of arrangements as a component of all transactions is provided by the entity.", "label": "Arrangements and Non-arrangement Transactions [Domain]", "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r92", "r204", "r213" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r4", "r6", "r39" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Noncurrent [Abstract]", "terseLabel": "Non-current assets:" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r101" ], "calculation": { "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails": { "order": 2.0, "parentTag": "dyai_InvestmentsandCashAmortizedCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "totalLabel": "Investment, gross unrealized holding gain" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r102" ], "calculation": { "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails": { "order": 4.0, "parentTag": "us-gaap_HeldToMaturitySecuritiesNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "negatedTotalLabel": "Investment, gross unrealized holding losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r136", "r156" ], "lang": { "en-US": { "role": { "documentation": "Information by award type pertaining to equity-based compensation.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails", "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails", "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BilledRevenuesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Billed amounts due for services rendered or products shipped. This element is distinct from Billed contracts receivables because this is based on noncontract transactions.", "label": "Billed Revenues [Member]", "terseLabel": "Billed receivable" } } }, "localname": "BilledRevenuesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsReceivableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r71", "r90" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Business Description and Accounting Policies [Text Block]", "terseLabel": "Organization and Summary of Significant Accounting Policies" } } }, "localname": "BusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis": { "auth_ref": [ "r200", "r201", "r202" ], "lang": { "en-US": { "role": { "documentation": "Information by project.", "label": "Project [Axis]", "terseLabel": "Project [Axis]" } } }, "localname": "CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash and Cash Equivalents [Abstract]", "terseLabel": "Cash and Cash Equivalents [Abstract]" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r0", "r23", "r60" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails": { "order": 1.0, "parentTag": "us-gaap_InvestmentsAndCash", "weight": 1.0 }, "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails_1": { "order": 1.0, "parentTag": "dyai_InvestmentsandCashAmortizedCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r10", "r61", "r67", "r94" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": { "auth_ref": [ "r95", "r105" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).", "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]", "terseLabel": "Cash, Cash Equivalent, and Investments" } } }, "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CashCashEquivalentandInvestments" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r56", "r60", "r66" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r56", "r190" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashMember": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.", "label": "Cash [Member]", "terseLabel": "Cash" } } }, "localname": "CashMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ChiefExecutiveOfficerMember": { "auth_ref": [ "r193" ], "lang": { "en-US": { "role": { "documentation": "Highest ranking executive officer, who has ultimate managerial responsibility for the entity and who reports to the board of directors. In addition, the chief executive officer (CEO) may also be the chairman of the board or president.", "label": "Chief Executive Officer [Member]", "terseLabel": "Chief Executive Officer" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ChiefFinancialOfficerMember": { "auth_ref": [ "r193" ], "lang": { "en-US": { "role": { "documentation": "Senior executive officer responsible for overseeing the financial activities of the entity.", "label": "Chief Financial Officer [Member]", "terseLabel": "Chief Financial Officer" } } }, "localname": "ChiefFinancialOfficerMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfTreasuryStockTable": { "auth_ref": [ "r116", "r117", "r118", "r119" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.", "label": "Class of Treasury Stock [Table]", "terseLabel": "Class of Treasury Stock [Table]" } } }, "localname": "ClassOfTreasuryStockTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareholdersEquityStockRepurchaseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r177" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Research Collaboration and Sub-licensing Agreements" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreements" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementMember": { "auth_ref": [ "r176" ], "lang": { "en-US": { "role": { "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.", "label": "Collaborative Arrangement [Member]", "terseLabel": "Collaborative Arrangement" } } }, "localname": "CollaborativeArrangementMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r30", "r112", "r208", "r216" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (See Note 4)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r111", "r113" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r31" ], "lang": { "en-US": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Common stock reserved for future issuance (in shares)" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.dyadic.com/role/ShareholdersEquityChangesinShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (USD per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "verboseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r13", "r114" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r13" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive Income (Loss)" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r85", "r86", "r184", "r185" ], "lang": { "en-US": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r85", "r86", "r184", "r185", "r220" ], "lang": { "en-US": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r85", "r86", "r184", "r185", "r220" ], "lang": { "en-US": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r81", "r210" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentrations" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r85", "r86", "r184", "r185" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk, percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r85", "r86", "r184", "r185" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r122", "r123", "r127" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Deferred research and development obligations" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r130", "r132" ], "lang": { "en-US": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate bonds" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r46" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Costs of research and development revenue" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r45" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total costs and expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Costs and expenses:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "stringItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r84" ], "lang": { "en-US": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "auth_ref": [ "r25" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.", "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r172" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "terseLabel": "Deferred tax assets, net" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DirectorMember": { "auth_ref": [ "r193" ], "lang": { "en-US": { "role": { "documentation": "Person serving on the board of directors (who collectively have responsibility for governing the entity).", "label": "Director [Member]", "terseLabel": "Board of Directors" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r120", "r162" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.", "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]", "verboseLabel": "Share-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]", "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r75" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Basic and Diluted", "terseLabel": "Basic and diluted net loss per common share (USD per share)" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r67", "r76", "r77", "r78" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Loss Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r190" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Effect of exchange rate changes on cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r28" ], "calculation": { "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccruedExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Employee wages and benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.", "label": "Employee Stock Option [Member]", "terseLabel": "Stock Option" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails", "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails", "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityClassOfTreasuryStockLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Equity, Class of Treasury Stock [Line Items]", "terseLabel": "Equity, Class of Treasury Stock [Line Items]" } } }, "localname": "EquityClassOfTreasuryStockLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareholdersEquityStockRepurchaseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r114" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.dyadic.com/role/ShareholdersEquityChangesinShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r106" ], "lang": { "en-US": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment, Ownership Percentage", "terseLabel": "Equity percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EquityMethodInvestmentsPolicy": { "auth_ref": [ "r24", "r55", "r67", "r107", "r186" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.", "label": "Equity Method Investments [Policy Text Block]", "terseLabel": "Equity Method Investment" } } }, "localname": "EquityMethodInvestmentsPolicy", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r178", "r179", "r180", "r181", "r182", "r183" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r130", "r131", "r132", "r180", "r196" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r130", "r131", "r132", "r180", "r197" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r130", "r131", "r132", "r180", "r198" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r187", "r188", "r189" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), before Tax", "negatedTerseLabel": "Foreign currency exchange loss (gain), net" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossRealized": { "auth_ref": [ "r187", "r188", "r189" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 5.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of foreign currency transaction realized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), Realized", "negatedTerseLabel": "Foreign currency exchange loss (gain), net" } } }, "localname": "ForeignCurrencyTransactionGainLossRealized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r67", "r189", "r191" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency Transaction Gain or Loss" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r48" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r44" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HeldToMaturitySecuritiesCurrent": { "auth_ref": [ "r100" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 7.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails_1": { "order": 2.0, "parentTag": "dyai_InvestmentsandCashAmortizedCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at amortized cost (held-to-maturity), classified as current.", "label": "Debt Securities, Held-to-maturity, Current", "terseLabel": "Short-term investment securities", "totalLabel": "Short term investments, adjusted cost" } } }, "localname": "HeldToMaturitySecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HeldToMaturitySecuritiesNoncurrent": { "auth_ref": [ "r100" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails_1": { "order": 3.0, "parentTag": "dyai_InvestmentsandCashAmortizedCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.", "label": "Debt Securities, Held-to-maturity, Noncurrent", "terseLabel": "Long-term investment securities", "totalLabel": "Long term investments, adjusted cost" } } }, "localname": "HeldToMaturitySecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossAttributableToParent": { "auth_ref": [ "r47" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.", "label": "Income (Loss) Attributable to Parent, before Tax", "totalLabel": "Loss before income taxes" } } }, "localname": "IncomeLossAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r110" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r69", "r91", "r174" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r67", "r167", "r168", "r170", "r171", "r173", "r175", "r222" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesReceivable": { "auth_ref": [ "r34", "r207", "r218" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.", "label": "Income Taxes Receivable, Current", "terseLabel": "Income tax receivable" } } }, "localname": "IncomeTaxesReceivable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesReceivableNoncurrent": { "auth_ref": [ "r11", "r211" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount due after one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.", "label": "Income Taxes Receivable, Noncurrent", "terseLabel": "Long-term income tax receivable" } } }, "localname": "IncomeTaxesReceivableNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r58" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r58" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r58" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Increase (Decrease) in Income Taxes Payable", "terseLabel": "Income taxes payable" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet": { "auth_ref": [ "r58" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.", "label": "Increase (Decrease) in Accrued Interest Receivable, Net", "negatedTerseLabel": "Interest receivable" } } }, "localname": "IncreaseDecreaseInAccruedInterestReceivableNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r58" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r58" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Deferred research and development obligation" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": { "auth_ref": [ "r58" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.", "label": "Increase (Decrease) in Income Taxes Receivable", "negatedTerseLabel": "Income tax receivable" } } }, "localname": "IncreaseDecreaseInIncomeTaxesReceivable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r58" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedTerseLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.dyadic.com/role/ShareholdersEquityChangesinShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "auth_ref": [], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_IncomeLossAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net amount of nonoperating interest income (expense).", "label": "Interest Income (Expense), Nonoperating, Net", "terseLabel": "Interest income" } } }, "localname": "InterestIncomeExpenseNonoperatingNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestReceivableCurrent": { "auth_ref": [ "r38" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.", "label": "Interest Receivable, Current", "terseLabel": "Interest receivable" } } }, "localname": "InterestReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeAmortizationOfPremium": { "auth_ref": [ "r49" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization of purchase premium on nonoperating securities.", "label": "Investment Income, Amortization of Premium", "terseLabel": "Amortization of held-to-maturity securities, net" } } }, "localname": "InvestmentIncomeAmortizationOfPremium", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r27", "r67", "r103", "r104", "r107" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for investments in financial assets, including marketable securities (debt and equity securities with readily determinable fair values), investments accounted for under the equity method and cost method, securities borrowed and loaned, and repurchase and resale agreements. For marketable securities, the disclosure may include the entity's accounting treatment for transfers between investment categories and how the fair values for such securities are determined. Also, for all investments, an entity may describe its policy for assessing, recognizing and measuring impairment of the investment.", "label": "Investment, Policy [Policy Text Block]", "terseLabel": "Investment Securities" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentsAndCash": { "auth_ref": [ "r217" ], "calculation": { "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails": { "order": 1.0, "parentTag": "dyai_InvestmentsandCashAmortizedCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of investments and unrestricted cash as of the balance sheet date.", "label": "Investments and Cash", "totalLabel": "Cash and Investment, fair value" } } }, "localname": "InvestmentsAndCash", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseArrangementTypeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.", "label": "Lease Arrangement, Type [Axis]", "terseLabel": "Lease Arrangement, Type [Axis]" } } }, "localname": "LeaseArrangementTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseArrangementTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.", "label": "Lease Arrangement, Type [Domain]", "terseLabel": "Lease Arrangement, Type [Domain]" } } }, "localname": "LeaseArrangementTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r192" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Term of contract" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r19", "r205", "r215" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r29" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermPurchaseCommitmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Long-term Purchase Commitment [Line Items]", "terseLabel": "Long-term Purchase Commitment [Line Items]" } } }, "localname": "LongTermPurchaseCommitmentLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermPurchaseCommitmentTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule setting forth key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount.", "label": "Long-term Purchase Commitment [Table]", "terseLabel": "Long-term Purchase Commitment [Table]" } } }, "localname": "LongTermPurchaseCommitmentTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r130" ], "lang": { "en-US": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money Market Funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r56" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by (used in) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r56" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r56", "r57", "r59" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r41", "r42", "r43", "r59", "r77", "r209", "r219" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.dyadic.com/role/ShareholdersEquityChangesinShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsReceivableDetails", "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r72", "r73", "r74" ], "lang": { "en-US": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Table]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsReceivableDetails", "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non-US [Member]", "terseLabel": "Outside of the United States" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_IncomeLossAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r7", "r8", "r9", "r28" ], "calculation": { "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccruedExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r25" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherPrepaidExpenseCurrent": { "auth_ref": [ "r1", "r5" ], "calculation": { "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPrepaidExpensesandOtherCurrentAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Other Prepaid Expense, Current", "terseLabel": "Prepaid expenses - various" } } }, "localname": "OtherPrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPrepaidExpensesandOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r54" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedTerseLabel": "Repurchases of common stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireHeldToMaturitySecurities": { "auth_ref": [ "r52", "r99" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow through purchase of long-term held-to-maturity securities.", "label": "Payments to Acquire Held-to-maturity Securities", "negatedTerseLabel": "Purchases of held-to-maturity investment securities" } } }, "localname": "PaymentsToAcquireHeldToMaturitySecurities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r136", "r156" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name pertaining to equity-based compensation arrangements.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the equity-based compensation arrangement plan.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (USD per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "verboseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r12" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r4", "r21", "r22" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPrepaidExpensesandOtherCurrentAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPrepaidExpensesandOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidInsurance": { "auth_ref": [ "r2", "r5", "r108", "r109" ], "calculation": { "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPrepaidExpensesandOtherCurrentAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Insurance", "terseLabel": "Prepaid insurance" } } }, "localname": "PrepaidInsurance", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPrepaidExpensesandOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidTaxes": { "auth_ref": [ "r3", "r5", "r108", "r109" ], "calculation": { "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPrepaidExpensesandOtherCurrentAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Taxes", "terseLabel": "Prepaid taxes" } } }, "localname": "PrepaidTaxes", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPrepaidExpensesandOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIncomeTaxRefunds": { "auth_ref": [ "r57", "r62" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of cash received during the period as refunds for the overpayment of taxes.", "label": "Proceeds from Income Tax Refunds", "terseLabel": "Cash received from income tax refund" } } }, "localname": "ProceedsFromIncomeTaxRefunds", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities": { "auth_ref": [ "r50", "r99" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from the sale or maturity of long-term held-to-maturity securities.", "label": "Proceeds from Sale and Maturity of Held-to-maturity Securities", "terseLabel": "Proceeds from maturities of investment securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets": { "auth_ref": [ "r51" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.", "label": "Proceeds from Sales of Business, Affiliate and Productive Assets", "terseLabel": "Proceeds from sales of business" } } }, "localname": "ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r53", "r157" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProjectMember": { "auth_ref": [ "r203" ], "lang": { "en-US": { "role": { "documentation": "Planned program of work.", "label": "Project [Domain]", "terseLabel": "Project [Domain]" } } }, "localname": "ProjectMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReceivablesBillingStatusDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Amounts due from customers (or dealers) within the next year (or operating cycle, if longer) for goods or services that have been delivered or used, but not yet paid.", "label": "Receivables Billing Status [Domain]", "terseLabel": "Receivables Billing Status [Domain]" } } }, "localname": "ReceivablesBillingStatusDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsReceivableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": { "auth_ref": [ "r20", "r67", "r97" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.", "label": "Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]", "terseLabel": "Accounts Receivable" } } }, "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Research and Development [Abstract]", "terseLabel": "Research and Development [Abstract]" } } }, "localname": "ResearchAndDevelopmentAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r163", "r224" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r67", "r163" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Costs" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r16", "r115", "r214" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.dyadic.com/role/ShareholdersEquityChangesinShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r124", "r125", "r126" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Research and development revenue", "verboseLabel": "Revenues" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r68", "r129" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "stringItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revenue from sale of goods and services rendered, in the normal course of business, after sales returns and allowances, and sales discounts, when it serves as a benchmark in a concentration of risk calculation.", "label": "Sales Revenue, Net [Member]", "terseLabel": "Revenue" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "auth_ref": [ "r35" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "terseLabel": "Schedule of Accounts Receivable" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accounts Payable" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accrued Expenses" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.", "label": "Cash, Cash Equivalents and Investments [Table Text Block]", "terseLabel": "Schedule of Cash, Available-for-sale Securities, Short-term and Long-term Investment Securities" } } }, "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": { "auth_ref": [ "r164", "r165" ], "lang": { "en-US": { "role": { "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.", "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]", "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]" } } }, "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "auth_ref": [ "r148", "r149", "r150" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure for share-based compensation plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Compensation, Activity [Table Text Block]", "terseLabel": "Schedule of non-cash stock option compensation expense" } } }, "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r136", "r156" ], "lang": { "en-US": { "role": { "documentation": "Components of an equity-based arrangement under which compensation is awarded to employees, typically comprised of compensation expense; changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan; and cash flow effects resulting from the equity-based payment arrangement. Component disclosures are by type of award and plan name.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails", "http://www.dyadic.com/role/ShareBasedCompensationCompensationExpenseDetails", "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails", "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r141", "r149", "r150" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Compensation, Stock Options, Activity [Table Text Block]", "terseLabel": "Schedule of stock option activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r152" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of valuation assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": { "auth_ref": [ "r114" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.", "label": "Schedule of Stockholders Equity [Table Text Block]", "verboseLabel": "Schedule of stockholders equity" } } }, "localname": "ScheduleOfStockholdersEquityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfTreasuryStockByClassTextBlock": { "auth_ref": [ "r116", "r117", "r118", "r119" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.", "label": "Class of Treasury Stock [Table Text Block]", "terseLabel": "Schedule of stock repurchase activity" } } }, "localname": "ScheduleOfTreasuryStockByClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r58" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.", "label": "Share-based Compensation", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": { "auth_ref": [ "r137" ], "lang": { "en-US": { "role": { "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period", "terseLabel": "Award requisite service period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r137" ], "lang": { "en-US": { "role": { "documentation": "Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "verboseLabel": "Award vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r154" ], "lang": { "en-US": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "terseLabel": "Expected stock price volatility, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "terseLabel": "Expected stock price volatility, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "terseLabel": "Risk-Free interest rate, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "terseLabel": "Risk-Free interest rate, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails", "http://www.dyadic.com/role/ShareBasedCompensationCompensationExpenseDetails", "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails", "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of additional shares authorized for issuance under an established share-based compensation plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Approved (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r156" ], "lang": { "en-US": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Number of shares available for grant (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails", "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r144" ], "lang": { "en-US": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Exercisable (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r144" ], "lang": { "en-US": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, exercisable (USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r147" ], "lang": { "en-US": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period", "negatedTerseLabel": "Expired (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r146" ], "lang": { "en-US": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedTerseLabel": "Canceled (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (in shares)", "verboseLabel": "Options granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails", "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r156" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate intrinsic value, outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r143", "r156" ], "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding, ending (in shares)", "periodStartLabel": "Outstanding, beginning (in shares)", "terseLabel": "Outstanding (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails", "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r142" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted average exercise price, outstanding, ending (USD per share)", "periodStartLabel": "Weighted average exercise price, outstanding, beginning (USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r134", "r139" ], "lang": { "en-US": { "role": { "documentation": "Equity-based compensation award.", "label": "Equity Award [Domain]", "terseLabel": "Equity Award [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails", "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails", "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "verboseLabel": "Weighted average exercise price, exercised (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails", "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails", "http://www.dyadic.com/role/ShareholdersEquityTextualDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, expired (USD per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, canceled (USD per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "verboseLabel": "Weighted average exercise price, granted (USD per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails", "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "First portion of share-based compensation award differentiated by a particular vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-based Compensation Award, Tranche One [Member]", "terseLabel": "Share-based Compensation Award, Tranche One" } } }, "localname": "ShareBasedCompensationAwardTrancheOneMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r67", "r136", "r140" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.", "label": "Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareRepurchaseProgramAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by share repurchase program.", "label": "Share Repurchase Program [Axis]", "terseLabel": "Share Repurchase Program [Axis]" } } }, "localname": "ShareRepurchaseProgramAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareholdersEquityStockRepurchaseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareRepurchaseProgramDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the share repurchase program.", "label": "Share Repurchase Program [Domain]", "terseLabel": "Share Repurchase Program [Domain]" } } }, "localname": "ShareRepurchaseProgramDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareholdersEquityStockRepurchaseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r137" ], "lang": { "en-US": { "role": { "documentation": "Percentage of vesting of share-based compensation awards.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Percentage of options that will vest" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r138" ], "lang": { "en-US": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Expiration period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r153", "r158" ], "lang": { "en-US": { "role": { "documentation": "Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected life of options" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails", "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r156" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Aggregate intrinsic value, exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r156" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted-average remaining contractual term, exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r151" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted-average remaining contractual term, outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r33", "r114" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.dyadic.com/role/ShareholdersEquityChangesinShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r63", "r64", "r65" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Stock Issued", "terseLabel": "Stock issued" } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareholdersEquityChangesinShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r12", "r13", "r114", "r115", "r145" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised (in shares)", "terseLabel": "Exercise of stock options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails", "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Gross value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP). Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.", "label": "Stock Issued During Period, Value, Share-based Compensation, Gross", "negatedLabel": "Stock repurchased" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensationGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareholdersEquityChangesinShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r33", "r114", "r115" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Authorized repurchase amount" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareholdersEquityTextualDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramPeriodInForce1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Period which shares may be purchased under a stock repurchase plan authorized by an entity's Board of Directors, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Stock Repurchase Program, Period in Force", "terseLabel": "Period under program" } } }, "localname": "StockRepurchaseProgramPeriodInForce1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareholdersEquityTextualDetails" ], "xbrltype": "durationItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "terseLabel": "Maximum Dollar Value of Shares that May Yet Be Purchased Under the Plan" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareholdersEquityStockRepurchaseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r13", "r17", "r18", "r98" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.dyadic.com/role/ShareholdersEquityChangesinShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r121" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r194" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r194" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Subsequent Events [Abstract]", "terseLabel": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r195" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental cash flow information" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_TitleOfIndividualAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.", "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails", "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Title of individual, or nature of relationship to individual or group of individuals.", "label": "Relationship to Entity [Domain]", "terseLabel": "Relationship to Entity [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails", "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r199" ], "lang": { "en-US": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockAcquiredAverageCostPerShare": { "auth_ref": [ "r116" ], "lang": { "en-US": { "role": { "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.", "label": "Treasury Stock Acquired, Average Cost Per Share", "terseLabel": "Average Price Paid per Share (in usd per share)" } } }, "localname": "TreasuryStockAcquiredAverageCostPerShare", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareholdersEquityStockRepurchaseDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_TreasuryStockCommonShares": { "auth_ref": [ "r36", "r116" ], "lang": { "en-US": { "role": { "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common, Shares", "terseLabel": "Treasury stock (in shares)" } } }, "localname": "TreasuryStockCommonShares", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.dyadic.com/role/ShareholdersEquityTextualDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r32", "r116" ], "lang": { "en-US": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.dyadic.com/role/ShareholdersEquityChangesinShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r13", "r114", "r115" ], "lang": { "en-US": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "netLabel": "Total Number of Shares Purchased (in shares)" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareholdersEquityStockRepurchaseDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r32", "r116", "r119" ], "calculation": { "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedTerseLabel": "Treasury stock, shares held at cost", "terseLabel": "Treasury stock, shares held at cost" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.dyadic.com/role/ShareholdersEquityTextualDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r114", "r115", "r116" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "Treasury Stock, Value, Acquired, Cost Method", "terseLabel": "Amount" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareholdersEquityStockRepurchaseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r176" ], "lang": { "en-US": { "role": { "documentation": "Information by category of arrangement, including but not limited to collaborative arrangements and non-collaborative arrangements.", "label": "Type of Arrangement and Non-arrangement Transactions [Axis]", "terseLabel": "Type of Arrangement and Non-arrangement Transactions [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UnbilledRevenuesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Unbilled amounts due for services rendered or products shipped. This element is distinct from unbilled contracts receivables because this is based on noncontract transactions.", "label": "Unbilled Revenues [Member]", "terseLabel": "Unbilled receivable" } } }, "localname": "UnbilledRevenuesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsReceivableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r166", "r169" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "terseLabel": "Unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r79", "r80", "r82", "r83", "r87", "r88", "r89" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r156" ], "lang": { "en-US": { "role": { "documentation": "Information by vesting schedule for share-based compensation.", "label": "Vesting [Axis]", "terseLabel": "Vesting [Axis]" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r156" ], "lang": { "en-US": { "role": { "documentation": "Vesting schedule for share-based compensation.", "label": "Vesting [Domain]", "terseLabel": "Vesting [Domain]" } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted", "terseLabel": "Basic and diluted weighted-average common shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "sharesItemType" } }, "unitCount": 12 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=d3e26626-111562" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27290-111563" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.M)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=65877573&loc=d3e87990-122713" }, "r105": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5865-108316" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r111": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349" }, "r113": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/subtopic&trid=2208855" }, "r121": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046" }, "r129": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=112275985&loc=d3e4179-114921" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=79507207&loc=d3e4534-113899" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=SL79508275-113901" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11149-113907" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11178-113907" }, "r162": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=SL37586934-109318" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e32247-109318" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e32280-109318" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "30", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r177": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "http://asc.fasb.org/topic&trid=5833765" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19190-110258" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=SL7498348-110258" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19279-110258" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13531-108611" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13537-108611" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30700-110894" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r195": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=68078379&loc=d3e122625-111746" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-10(a)(32))", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=82851474&loc=d3e511914-122862" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-10(c)(3)(ii)(A))", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=82851474&loc=d3e511914-122862" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-10(c)(7)(ii))", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=82851474&loc=d3e511914-122862" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6806780-109447" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(9))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(5)(c))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1,2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.5(c))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r225": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r226": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r227": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" }, "r228": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r229": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.2,12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.20)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6787-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "21D", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=SL94080555-108585" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6911-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r71": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22580-107794" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e7018-107765" }, "r90": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "305", "URI": "http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797" }, "r95": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "305", "URI": "http://asc.fasb.org/topic&trid=2122426" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84173941&loc=d3e5074-111524" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84173941&loc=d3e5144-111524" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=d3e26853-111562" } }, "version": "2.1" } XML 24 R11.htm IDEA: XBRL DOCUMENT v3.19.3
Share-Based Compensation
 9 Months Ended
Sep. 30, 2019
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Share-Based Compensation Share-Based Compensation
Description of Equity Plans
The 2011 Equity Incentive Plan (the “2011 Plan”) was adopted by the Company’s Board of Directors on April 28, 2011 and approved by the Company’s stockholders on June 15, 2011. The 2011 Plan serves as the successor to the Company’s 2006 Stock Option Plan (the “2006 Plan”). Since the effective date of the 2011 Plan, all equity awards were made from the 2011 Plan, and no additional awards will be granted under the 2006 plan. Under the 2011 Plan, 3,000,000 shares of the Company’s common stock have been initially reserved for issuance pursuant to a variety of share-based compensation awards, plus any shares available for issuance under the 2006 Plan or are subject to awards under the 2006 Plan which are forfeited or lapse unexercised and which following the effective date are not issued under the 2006 Plan. In accordance with the provisions of the 2011 Plan, the Board of Directors approved an increase of 1,500,000 shares to the plan on January 1, 2019.
As of September 30, 2019, the Company had 4,006,390 stock options outstanding and an additional 1,547,211 shares of common stock available for grant under the 2011 Plan. As of December 31, 2018, there were 3,552,890 stock options outstanding and 1,136,211 shares of common stock available for grant under the 2011 Plan.
Stock Options
Options are granted to purchase common stock at prices that are equal to the fair value of the common stock on the date the option is granted. Vesting is determined by the Board of Directors at the time of grant. The term of any stock option awards under the Company’s 2011 Plan is no more than ten years except for qualified options granted to the CEO (five years) and certain contractors (two years).
The grant-date fair value of each option grant is estimated using the Black-Scholes option pricing model and amortized on a straight-line basis over the requisite service period, which is generally the vesting period, for each separately vesting portion of the award as if the award was, in substance, multiple awards. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs, including the following:
Risk-free interest rate. The risk-free interest rate is based on U.S. Treasury rates with securities approximating the expected lives of options at the date of grant.
Expected dividend yield. The expected dividend yield is zero, as the Company has never paid dividends to common shareholders and does not currently anticipate paying any in the foreseeable future.
Expected stock price volatility. The expected stock price volatility was calculated based on the Company’s own volatility after the DuPont Transaction. The Company reviews its volatility assumption on an annual basis and has used the Company’s historical volatility since 2016, as the DuPont Transaction resulted in significant changes in the Company’s business and capital structure.
Expected life of option. The expected life of option was based on the contractual term of the option and expected employee exercise and post-vesting employment termination behavior. The Company uses the weighted average vesting period and contractual term of the option as the best estimate of the expected life of a new option, except for the qualified options granted to the CEO (i.e., 5 years) and certain contractors (i.e., 2 years).
Discount for lack of marketability. The Company applied a discount to reflect the lack of marketability due to the holding period restriction of its shares under Rule 144 prior to its April 2019 uplisting to the NASDAQ. The discount for lack of marketability is no longer applicable since the uplisting of the Company’s common stock.
The assumptions used in the Black-Scholes option pricing model for stock options granted through the nine months ended September 30, 2019 are as follows:
Risk-Free interest rate
1.69% - 2.50%
Expected dividend yield— %
Expected stock price volatility
28.59% - 37.29%
Expected life of options
2 - 6.25 Years
Discount for lack of marketability
0.0% - 8.48%

The following table summarizes the stock option activities for the nine months ended September 30, 2019: 
SharesWeighted-Average Exercise PriceWeighted-Average Remaining Contractual Term (Years)Aggregate Intrinsic Value
Outstanding at December 31, 20183,552,890  $1.575.06$1,149,461
Granted (1)
1,089,000  2.26  
Exercised (2)
(635,500) 1.62  
Expired—  —  
Canceled —  —  
Outstanding at September 30, 20194,006,390  $1.755.89$17,556,185
Exercisable at September 30, 20192,764,073  $1.644.65$12,408,351
_________________
Notes:
(1) Represents the following stock options granted:
•Annual share-based compensation awards on January 2, 2019, including: (a) 600,000 stock options with an exercise price of $1.87 per share granted to executives and key personnel, vesting upon grant, or one year anniversary, or vest annually in equal installments over four years, (b) 300,000 stock options with an exercise price of $1.87 per share granted to the Board of Directors, vesting 25% upon grant and the remaining 75% will vest annually in equal installments over four years, and (c) 24,000 stock options with an exercise price of $1.87 per share granted to employees, vesting annually in equal installments over four years. 
•One-time awards granted on (a) January 2, 2019 of 50,000 stock options with an exercise price of $1.87 per share granted to a contractor, vesting upon one year anniversary, (b) March 7, 2019 of 15,000 stock options with an exercise price of $3.00 per share granted to a contractor, vesting upon one year anniversary, (c) June 25, 2019 of 75,000 stock options with an exercise price of $5.83 per share granted to three members of the Board of Directors, vesting upon one year anniversary, and (d) June 28, 2019 of 25,000 stock options with an exercise price of $6.26 per share granted to the Chief Financial Officer, vesting immediately.
(2) Represents the following stock options exercised:
•A total of 635,500 stock options exercised with a weighted average market price of $1.62, including (a) net share exercise of 440,000 stock options resulting in the issuance of 304,171 shares of common stock, and surrender of 135,829 shares, and (b)195,500 stock options exercised with cash payment.

Compensation Expenses
We recognize all share-based payments to employees and our Board of Directors, as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statement of operations, and these charges had no impact on the Company’s reported cash flows. Stock-based compensation expense is calculated on the grant date fair values of such awards, and recognized each period based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are recorded as they occur.
Total non-cash stock option compensation expense was allocated among the following expense categories: 
Three Months Ended September 30,Nine Months Ended September 30,
2019201820192018
General and administrative$118,754  $51,887  $957,843  $356,024  
Research and development25,426  18,733  76,503  57,616  
Total $144,180  $70,620  $1,034,346  $413,640  
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.19.3
Organization and Summary of Significant Accounting Policies (Tables)
 9 Months Ended
Sep. 30, 2019
Accounting Policies [Abstract]  
Schedule of Accounts Receivable
Accounts receivable consist of the following:
September 30, 2019December 31, 2018
(Unaudited)(Audited)
Billed receivable $66,988  $193,065  
Unbilled receivable351,957  125,679  
$418,945  $318,744  
Schedule of Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets consist of the following:
September 30, 2019December 31, 2018
(Unaudited) (Audited) 
Prepaid expenses - various$81,320  $91,725  
Prepaid insurance254,997  77,249  
Prepaid taxes551  3,027  
$336,868  $172,001  
Schedule of Accounts Payable
Accounts payable consist of the following:
September 30, 2019December 31, 2018
(Unaudited) (Audited) 
Research and development expenses$636,428  $240,064  
Legal expenses17,283  —  
Other59,684  68,996  
$713,395  $309,060  
Schedule of Accrued Expenses Accrued expenses consist of the following:
September 30, 2019December 31, 2018
(Unaudited) (Audited) 
Employee wages and benefits$353,552  $268,287  
Research and development expenses77,855  49,666  
Other38,710  81,623  
$470,117  $399,576  
Schedule of Research and Development Costs Research and development costs, including related party, during the three and nine months ended September 30, 2019 and 2018 were as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2019201820192018
(Unaudited) (Unaudited) (Unaudited) (Unaudited) 
Outside contracted services$730,190  $365,689  $1,974,176  $1,316,581  
Contracted services - related party101,849  288,175  827,632  1,021,573  
Personnel related costs95,269  87,307  312,321  277,856  
Facilities, overhead and other15,884  23,637  65,456  60,279  
$943,192  $764,808  $3,179,585  $2,676,289  
XML 26 R19.htm IDEA: XBRL DOCUMENT v3.19.3
Organization and Summary of Significant Accounting Policies - Textual (Details)
 3 Months Ended 9 Months Ended 12 Months Ended
Dec. 22, 2017
USD ($)
Dec. 31, 2015
USD ($)
Sep. 30, 2019
USD ($)
customer
shares
Sep. 30, 2018
USD ($)
customer
shares
Sep. 30, 2019
USD ($)
customer
segment
shares
Sep. 30, 2018
USD ($)
customer
shares
Dec. 31, 2018
USD ($)
customer
New Accounting Pronouncements or Change in Accounting Principle [Line Items]              
Number of operating segments | segment         1    
Revenues     $ 454,507 $ 262,960 $ 1,247,908 $ 608,576  
Allowance for doubtful accounts receivable     0   0   $ 0
Tax cuts and jobs act, change in alternative minimum tax, income tax benefit $ 1,001,233            
Cash received from income tax refund         506,866 0  
Provision for income taxes     0 $ 0 900 $ 0  
Unrecognized tax benefits     0   0   0
Deferred tax assets, net     $ 6,900,000   $ 6,900,000   $ 4,600,000
Deferred tax assets, valuation allowance coverage, percent     100.00%   100.00%   100.00%
Antidilutive securities excluded from computation of earnings per share (in shares) | shares     4,006,390 4,006,390 3,411,890 3,411,890  
Customer Concentration Risk | Revenue              
New Accounting Pronouncements or Change in Accounting Principle [Line Items]              
Concentration risk, number of customers | customer     5 4 8 5  
Customer Concentration Risk | Accounts Receivable              
New Accounting Pronouncements or Change in Accounting Principle [Line Items]              
Concentration risk, number of customers | customer         3   4
United States | Customer Concentration Risk | Revenue              
New Accounting Pronouncements or Change in Accounting Principle [Line Items]              
Concentration risk, percentage       100.00%   100.00%  
United States | Customer Concentration Risk | Accounts Receivable              
New Accounting Pronouncements or Change in Accounting Principle [Line Items]              
Concentration risk, percentage             100.00%
Outside of the United States | Customer Concentration Risk | Revenue              
New Accounting Pronouncements or Change in Accounting Principle [Line Items]              
Concentration risk, number of customers | customer     3   3    
Concentration risk, percentage     77.00%   73.60%    
Revenues     $ 351,000   $ 918,000    
Outside of the United States | Customer Concentration Risk | Accounts Receivable              
New Accounting Pronouncements or Change in Accounting Principle [Line Items]              
Concentration risk, number of customers | customer     1        
Concentration risk, percentage     79.30%        
Accounts receivable     $ 332,000   $ 332,000    
DuPont Danisco | Industrial Technology Business              
New Accounting Pronouncements or Change in Accounting Principle [Line Items]              
Proceeds from sales of business   $ 75,000,000          
XML 27 R32.htm IDEA: XBRL DOCUMENT v3.19.3
Share-Based Compensation - Compensation Expense (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation $ 144,180 $ 70,620 $ 1,034,346 $ 413,640
General and administrative        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation 118,754 51,887 957,843 356,024
Research and development        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation $ 25,426 $ 18,733 $ 76,503 $ 57,616
XML 28 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 29 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 30 R4.htm IDEA: XBRL DOCUMENT v3.19.3
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Revenues:        
Research and development revenue $ 454,507 $ 262,960 $ 1,247,908 $ 608,576
Costs and expenses:        
Costs of research and development revenue 384,803 243,406 1,034,934 519,331
Research and development 841,343 476,633 2,351,953 1,654,716
Research and development - related party 101,849 288,175 827,632 1,021,573
General and administrative 1,056,196 1,023,606 4,354,941 3,238,145
Foreign currency exchange loss (gain), net 13,727 12,279 24,693 1,921
Total costs and expenses 2,397,918 2,044,099 8,594,153 6,435,686
Loss from operations (1,943,411) (1,781,139) (7,346,245) (5,827,110)
Interest income 245,027 241,644 777,711 647,686
Loss before income taxes (1,698,384) (1,539,495) (6,568,534) (5,179,424)
Provision for income taxes 0 0 900 0
Net loss $ (1,698,384) $ (1,539,495) $ (6,569,434) $ (5,179,424)
Basic and diluted net loss per common share (USD per share) $ (0.06) $ (0.06) $ (0.24) $ (0.19)
Basic and diluted weighted-average common shares outstanding (in shares) 27,181,003 27,774,436 26,909,205 27,996,754
XML 31 R8.htm IDEA: XBRL DOCUMENT v3.19.3
Cash, Cash Equivalent, and Investments
 9 Months Ended
Sep. 30, 2019
Cash and Cash Equivalents [Abstract]  
Cash, Cash Equivalent, and Investments Cash, Cash Equivalent, and Investments
The Company’s investments in debt securities are classified as held-to-maturity and are recorded at amortized cost, and its investments in money market funds are classified as cash equivalents. The following table shows the Company’s cash, available-for-sale securities, and short-term and long-term investment securities by major security type as of September 30, 2019 and December 31, 2018:
September 30, 2019 (Unaudited)
GrossGross
LevelUnrealizedUnrealized
(1)
Fair ValueHolding GainsHolding LossesAdjusted Cost
Cash and Cash Equivalents
Cash$552,569  $—  $—  $552,569  
Money Market Funds1  4,109,758  —  —  4,109,758  
Subtotal4,662,327  —  —  4,662,327  
Short-Term Investment Securities (2)
Corporate Bonds (4)
2  30,794,626  16,862  (15,708) 30,793,472  
Long-Term Investment Securities (3)
Corporate Bonds (4)
2  1,527,865  13,712  —  1,514,153  
Total$36,984,818  $30,574  $(15,708) $36,969,952  

December 31, 2018 (Audited)
GrossGross
LevelUnrealizedUnrealized
(1)
Fair ValueHolding GainsHolding LossesAdjusted Cost
Cash and Cash Equivalents
Cash$1,048,272  $—  $—  $1,048,272  
Money Market Funds1  1,338,042  —  —  1,338,042  
Subtotal2,386,314  —  —  2,386,314  
Short-Term Investment Securities (2)
Corporate Bonds (4)
2  38,731,120  —  (85,321) 38,816,441  
Total$41,117,434  $—  $(85,321) $41,202,755  
_________________
Notes:
(1) Definition of the three-level fair value hierarchy:
•Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities
•Level 2 - Other inputs that are directly or indirectly observable in the markets
•Level 3 - Inputs that are generally unobservable
(2) Short-term investment securities will mature within 12 months or less, from the applicable reporting date.
(3) Long-term investment securities will mature between 12 and 18 months, from the applicable reporting date.
(4) The premium paid to purchase held-to-maturity investment securities was $54,385 and $0 for the three months ended September 30, 2019 and 2018, respectively. The premium paid to purchase held-to-maturity investment securities was $158,548
and $205,038 for the nine months ended September 30, 2019 and 2018, respectively. The premium paid to purchase held-to-maturity investment securities was $378,681 for the year ended December 31, 2018.The Company considers the declines in market value of its investment portfolio to be temporary in nature. The Company’s investment policy requires investment securities to be investment grade and held to maturity with the primary objective to maintain a high degree of liquidity while maximizing yield. When evaluating an investment for other-than-temporary impairment, the Company reviews factors such as the length of time and extent to which fair value has been below its cost basis, the financial condition of the issuer and any changes thereto, changes in market interest rates, and whether it is more likely than not the Company will be required to sell the investment before recovery of the investment’s cost basis. As of September 30, 2019, the Company does not consider any of its investments to be other-than-temporarily impaired.
XML 32 R23.htm IDEA: XBRL DOCUMENT v3.19.3
Organization and Summary of Significant Accounting Policies - Accrued Expenses (Details) - USD ($)
Sep. 30, 2019
Dec. 31, 2018
Accounting Policies [Abstract]    
Employee wages and benefits $ 353,552 $ 268,287
Research and development expenses 77,855 49,666
Other 38,710 81,623
Accrued expenses $ 470,117 $ 399,576
XML 33 R27.htm IDEA: XBRL DOCUMENT v3.19.3
Commitments and Contingencies - Textual (Details)
 9 Months Ended
Oct. 25, 2019
EUR (€)
Jun. 28, 2019
EUR (€)
Feb. 01, 2019
USD ($)
Sep. 30, 2019
USD ($)
ft²
VTT Technical Research Centre of Finland Ltd        
Long-term Purchase Commitment [Line Items]        
Commitment to pay   € 2,520,000    
Commitment development period   3 years    
Commitment success bonus award   € 450,000    
Commitments, right to terminate contract notice period   90 days    
VTT Technical Research Centre of Finland Ltd | Subsequent Event [Member]        
Long-term Purchase Commitment [Line Items]        
Commitment to pay, expanded € 690,000      
Commitment to pay, expanded, period 1 year 6 months      
Jupiter, Florida Headquarters Lease        
Long-term Purchase Commitment [Line Items]        
Area of building rented | ft²       4,900
Monthly rental rate | $       $ 9,700
Netherlands Office Lease        
Long-term Purchase Commitment [Line Items]        
Area of building rented | ft²       258
Rent expense | $     $ 4,000 $ 4,700
Term of contract     1 year  
XML 34 R34.htm IDEA: XBRL DOCUMENT v3.19.3
Shareholders' Equity - Changes in Shareholders’ Equity (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Sep. 30, 2019
Sep. 30, 2018
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Beginning balance $ 38,619,465 $ 40,585,474 $ 42,451,169 $ 46,303,536 $ 47,826,748 $ 49,975,264 $ 42,451,169 $ 49,975,264
Stock repurchased       (1,929,222)   (374,820)    
Stock issued 179,410 149,180   4,500        
Stock-based compensation 144,180 580,603 309,563 70,619 73,425 269,596 1,034,346  
Net loss (1,698,384) (2,695,792) (2,175,258) (1,539,495) (1,596,637) (2,043,292) (6,569,434) (5,179,424)
Ending balance 37,244,671 38,619,465 40,585,474 42,909,938 46,303,536 47,826,748 37,244,671 42,909,938
Common Stock                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Beginning balance 39,365 38,967 38,967 38,937 38,937 38,937 38,967 38,937
Stock issued 102 398   30        
Ending balance 39,467 39,365 38,967 38,967 38,937 38,937 39,467 38,967
Treasury Stock                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Beginning balance (18,929,915) (18,929,915) (18,929,915) (17,000,693) (17,000,693) (16,625,873) (18,929,915) (16,625,873)
Stock repurchased       (1,929,222)   (374,820)    
Ending balance (18,929,915) (18,929,915) (18,929,915) (18,929,915) (17,000,693) (17,000,693) (18,929,915) (18,929,915)
Additional paid-in capital                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Beginning balance 95,424,178 94,694,793 94,385,230 94,256,578 94,183,153 93,913,557 94,385,230 93,913,557
Stock issued 179,308 148,782   4,470        
Stock-based compensation 144,180 580,603 309,563 70,619 73,425 269,596 1,034,346  
Ending balance 95,747,666 95,424,178 94,694,793 94,331,667 94,256,578 94,183,153 95,747,666 94,331,667
Accumulated deficit                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Beginning balance (37,914,163) (35,218,371) (33,043,113) (30,991,286) (29,394,649) (27,351,357) (33,043,113) (27,351,357)
Net loss (1,698,384) (2,695,792) (2,175,258) (1,539,495) (1,596,637) (2,043,292) (6,569,434)  
Ending balance $ (39,612,547) $ (37,914,163) $ (35,218,371) $ (32,530,781) $ (30,991,286) $ (29,394,649) $ (39,612,547) $ (32,530,781)
XML 35 R30.htm IDEA: XBRL DOCUMENT v3.19.3
Share-Based Compensation - Stock Option Activity (Details) - USD ($)
 9 Months Ended 12 Months Ended
Sep. 30, 2019
Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]    
Outstanding, beginning (in shares) 3,552,890  
Granted (in shares) 1,089,000  
Exercised (in shares) (635,500)  
Expired (in shares) 0  
Canceled (in shares) 0  
Outstanding, ending (in shares) 4,006,390 3,552,890
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]    
Weighted average exercise price, outstanding, beginning (USD per share) $ 1.57  
Weighted average exercise price, granted (USD per share) 2.26  
Weighted average exercise price, exercised (in USD per share) 1.62  
Weighted average exercise price, expired (USD per share) 0  
Weighted average exercise price, canceled (USD per share) 0  
Weighted average exercise price, outstanding, ending (USD per share) $ 1.75 $ 1.57
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]    
Exercisable (in shares) 2,764,073  
Weighted average exercise price, exercisable (USD per share) $ 1.64  
Weighted-average remaining contractual term, outstanding 5 years 10 months 20 days 5 years 21 days
Weighted-average remaining contractual term, exercisable 4 years 7 months 24 days  
Aggregate intrinsic value, outstanding $ 17,556,185 $ 1,149,461
Aggregate intrinsic value, exercisable $ 12,408,351  
ZIP 36 0001213809-19-000074-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213809-19-000074-xbrl.zip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
.YPU;"LYZ( $9:@,3A(/&6AE!C[$T MD8G%Q,V$09[NM*!K-QK&M@?K>@].!AWQG'6X6$;$&."R M*A!*&4962284Q-!!$LV%3VF)%(W6DG'$WRA/P_S$ M9C@VQIK D&,2:6L,A@+K#611JC11NL 6+9 [GE)YFEA[79<[712_/90*4:' =%PQD)Q%.?[!CCE@R1^-^N=/-N^1FGP9J5V) M&[A-O9"W'I:PX<%G"Q7C&L21@T/I#;/4ZV!0<%1[@IPUB%VQI,P6TC5#TO4 M\\FG,Y]\&?/=+I0MHW;41T*18\QBJZDQ'FL<, &O5LY!+#2=ITG2EM&6'.1"-!Y2/QR%KOPAPX&K.*U_1] 4.)',\HBI MEXXP+EA0\Z^#E="KATX# O_N=HRY"W.E>B[954N MCNI-"J;I:YSG##PF;3&B:5<89&F0 6GLM!6!AE%)1_AG >4S-([< /)G"EQ@ M9I$343JOF0.8A('^\\$:*R#6'AD[,M*X!4S/U3CR=(V[>>K/I&*F/<08B9@$ MS; +5FB/)36&*J5 _X8:)XB:-2@?B5K^KE:+[=53)>I1%L\GN',GM.-&WDK8 M?N[YU]8\D1$U!LV#P-(2;664F("K232U&D//5G=LP1H()>*Y]&G!1$>HQ':SF.1F-J[-#F841F;@KP:ON;ONV&__33 MA-_I+2[]S@GC2,^<05&ZI?D8960<,\6:14DE4R (CEF-C%;$!<2T<\1Y.Z@^ M5$A'MA"3N1"3.XQS2U!^S#BW3OV9O'448Z2$>FLM0\IKRC A@,Y H&G%!P1 MA8[",.>C8MA2$;U""A'GW-TQ!#R[$G/^$I>4BN$C& [8G2,ZIGI M^/L^R7KSI-&^"&&WUW;'VR=AS^>Y%)8G/Z.:]U(NYU;+YZ>Y[]_=:^]3/0]Q_3RX?IJ<'8R+==ZB MH"*M<42..O 'F+;1(!4I5]I00HAW=HX$]3N0%O+SJ9VV@7.]]F,@ODVUF$O1 M-!A,:P!Q9%XR+HTFB$:C R>"*<;G:;YY;,(RET!BB:E1DC)$#9-6: *1A^6( M,(.1$^A7!/+1)TZMO,!41(38X!P)P6C+&/8$G"23]HHBQ")"5%R(R"PMW9\. MBQC)J0P1$&-,<*RX4Y([#]ZT%%I-HRSR<_MM*G6'$9,0I(;@L-/,.VPU@%?.>M>T_/^$BR^ATVVW6J$Q+3O25OX MW3GU9P@:NP!Q0BHW;YC W$@AK DX!F%$U/H7EZ*YQ-0AX% ,MM0HPS@W2EFG M'?8^2B0$IO./Z>CP6MX)3PC^YA)%%'#00BC,'&.@B1:#.8S.*B:-I5+,$8I_ MAVXO;QW>F2FMFT[X:+JI<$'S!"XI:A(,V+AC6M#0[=;85M1./JK_A267,\MH M\)ZA %X_"(-<8B M"?.IQ8QRQS'5+F+&B;*&!!VC@_BIJ XZU&(Z>Z4V?G4MIB^NXG*[Z(KGP6K" MI',1M%B9J% 4 02"&P/Z/-1B.BJZ\M8E80Q:3)]>_X2.I_X)TQSQJ")%B#!+ MC++41@E@:N=DP/9J5<_,)HO/C-_V^B';O15#XU@W0$ "9'*\O 4)D,(PQ5PP MBGEPX#G'5RN&>#;KHC SL;1XOEBSX*JLM,?$>$9\JW:99=5 /P6RPD6%0#('G M8;7E;*$T_466D0H,BBT]:#E3&D-L:F*T@EK#A8]X#LIZC3#;:KEV$S0:>B)= M^;GM!F/:MX#=#*W0 ;1;?M4W\U;>[0U**JV?IT'P"8P_3;[^%N;"9L51' @%,E.#(4@L$3:7$ MX-AJX?@\E7R9 XBG4W]1(^28Y-IJP<#B:J5L,KM!I=UHN+Z3T;: ^&>U^.G) M=^.".%(NB-7&*&48324V#0HF4NJ-QUS-0XG-9T$\6EP.&*^%T]!HGZ1SW[ E M=JF6C'.(":48"E@9BJ.CCENNO0G^K5GB:0(\%3O,@XL2>6:BE,P1!@(#&:7(0Y >VQH")320 2ZM[:$SNXR^BMH![N-I#RO=@N^=F]#O.I]GH W MC2\F]UNMX>9/,Z6]=#RK&VP,03J.D#>:Z2B-X03,K]>42G;M8$T2W+GH-R^B M9U(+*4+:ECA:9S5347CBL+9Q&OWVRDJQ$WHF;P6_;CJMO'78?8O:H(T@P&V< M!I4\EJ UU0PS0HG"VES599]_,.'W9KM5#/6_?J[!6,J'("\QTP,'$<>J<)]8C1ATS5&M':"HZ26B,Y,V ,S'/ MX'5@\HQS;"FQTC/+J=$^8&RE(B1M0T'?#$RO;ZM>!1]B8YI=1ZDV.3/*:&*I M4?!10I8+A8*P6C@1B,6*:"/0&66[R MP>/D406\K*3!&A$\@V[6TH,>4. _QSB6H^!Q_L&<8/ HQE.[5=%@(*SGF.G M%#A5TB*?UGM3"@@I\F:@F6CP."9PA &5B=(CCR.#B%Z!$Q@T^ R*LR@U>C/@ M3"EX'!-,GBNFX?](*#!3!AG$*:%(>"R+32_?#$R3#A['A \XV-1'ZJC3CF$( MF7RJM\NP!Z[3GOC)X3.M'J#:4QV$P,@(1B375 ;+ R;(1"Z1G:-DD5FPQ--/ M#C%62J%<"#2"J7;.4H>1,Y($*;QP\Y3],VLF8OK@!G"]@O!<*RM9JKECA Q! M(QHQ8]B&MP?NY(.@*:@LC]0''*U#E 'Q6D+3-#(.-B(;U&"'(CG+I?9G@7IO MF$ O]):AGS MW"+L$>:2R8BTI>+-@#.-(&A\,!F/%0>_VIN4_D&LADB(&)E<3)>FI]\,3!,- M@L:'#\'<,J)CVF24.4LLQ<0KXHUE-B5SW$U&G/^ISEX,T?50%I99SK@,2AG&- M;#0T2@5A$T2_S@P\]+< YJ2")S6^Q!3GG,16**PCD]AH+8C#P5F(:N&7\&:@ MF5SP-#YP&!:.&N$03PM!L=(R.F.B\9(Q1S5^,^!,(W@:'TP241.#P,EPL5BD MC7!K)$^%0KGT[,W --'@:7SXQ"BYYT(3&BCC7BN%@>C KX@ $L9Q51TYTY0++*5A$6'C<,I=,T$82JAS0[*??S G&&N,*X_!@QE.^'"7MNK" MVBLC$9'%#C.2X#<#S41CC3&!8\%!"@A133QE@CL3K64$"6:]-@R)-P/.E&*- M,<&$(J.8<\Q%XCD( @WE$,(+P524VKT=F"8=:XP)'\1HL@QA!*8,Z7N03BU\G$)!P>"UC4X)$U2J>*^\YPY"2:O3 M1LQHGFI&SH+G/'U N7%<$XJ2[\:"" 9\.<6"(L78@'F#VCKYN';RJ#H2K-0Q MK1IFC'JLG0O."@,1E$[;C0T=B_D'3/03#2N'1,XF#DBP;H!W5&&,%=,\0 /D)9[%+A_,^!,*:X=$TQ*Q(!# MJA!!(Y.<6YRV)+=,":ZDTN'-P#3IN'9,^%AAG3(A,)SJFEIG@S=2(*N9T5CH MP9)X@0@6V>C## 2XM\RVR!#)L'B*V;YSZL]D^04O(.Q5$GHDU8,UD4;M B91 M$$/1@'YFI;MN2,Z='OB9]95(.2LY,XY!#_"@A8W>$!PE"C2009E%B=1 %&+,0%[K PC3Z[<5&->U=O1-.^AU7-]WPI=,^ M[)CFC3WLOO0MW*)QL=IJM?LM%_R-DQNF]=JAX%3P]1IBOIBR.!B87S#('*)Y MB#JXPYH&+(>,BC'.1A]F32]DT1E/"J'OG/HS4\-!.AR49M1Z1@.U'$=O@TYI MY(IJ/X5^>ZMZ,15\"2724\?3SD8,6V,I-=0Q)P,3WLHKO4!#?,GK[UGUHGY[ MVM"23![:6#:&\H1(RDA,"RJ@MTQ:E$($\58;0B6?1K^]:;V8-+Z2.,ML)(&' MR()!"KQ'IGU*DG%I<]NA)SD;ZG#;DR3CV+!)+!QFA$ M8'0HX7HHX9-8Y_@"R=%/EIQ;RPY_9N%&$#H0I+6QCBD@47 5!5>1&8$5YFX* M_?:&F6'R^ *F$B.(KH*RS&EGO%6$82Z,DDH,:U7<6&ZE9D\OGK>@28VGWR"V MTI;Z",XW9QAS8XPT%OZ%P LI?F^9V@3Z[:WJQ53PI28(C^%=G3&,.FPQ15(J M0GW0@9-1%L]LJ,/M\5XUGA4#0J4UYLIJC"1ST:=B]%C JWLC!-9\-(8PE/!9 MM)CB.9(S+D:53G-'(KC0$(. \"@>@2HP9IY31X:Q^63[[:TRP^OC^RX_?]\) MW3:\5.@.OM:#\47C?7[ZX4_X9P#[ 3I(.%[_VNU=-!)B(3^L]]XSLB+Y2>^/ ML]SWZN\Q0O__'TNWSDO/R_)60NT]%7!F\8-IY(>M]T?]+D!Y\4?3= [S5F;; MO5Z[^1X3. MNTCTQK0]_VLX[>/K@\Z 1]YIRXXX.'A,ZHZM')UCCC@\[@*3/ M7+O1[KSO'-K?".?+H_]*: 7]_L?@V#]0\;\_(O15%DTS;UR\_^\J"%&W5 EG MI9UVT[3^>W"TFU^&]YA!*0TIEY);$95Q6_M&%AJF43\/N3O MU]JNGX@R[7"_-!RXH7]?V+7VZ6>R5^O9FF51(F9:K M?^65RYV\5JVQRF:95];*%[5JX[B\6:G7CLIGGVFE4;ML7]:J]:/*D3^J7*Y? MU(XMEN;G.]]<^'M6^;5V6-]3Y9[)_4?OF1(V4+RO?ME"- M;.'RM[^;EKA M>?GRF,+]R &65A,G8V8B8AF+PF2:G)S_,?H^Q"3]]$1ANMO=IZ'3RYUI M#'\;W/#J_@6B&% 8_3! %%][ Z,6WJ P=$?RV%VI_09W2G?K_O<=V7[B.\"C MQ\U\L=UIFAY<#;T#WB[T0[MA3:/1[MGV^4/$^+4/#F#H-"[ #6UW>G/)D1NY MW=P3E>KZ1?D2CI,]7&GNY)6UOYO;:\? C7\WRFOU.CS_;'_M&,'?X35_P[-X M:[_:QN7JUF6EN7^T7]TC^W#ORK<:VZ[^U=S_MG>VO;D.[_KQ&-I+RW^KL\_5 MU5YY%YU_KJY?EH_*!Z!\*B)/LLAXS)BG%FB5Z$PXXKRR- K%EC[\\Q]:,O'' M=YEUJ%ESKC,/D?6/B?Z%BO-U;W6GNK[SN5;:6?^RO5,M?=G;V=U;K51+U>T2 MN)!5\!-+F):V=TJ8_^9_+VUOE*K_7B_=\"ZO/,O53]5T&&O*;L$Q#2X;NFK3 M8+-Q0?//?T"H_L?<"O;,N-!W=8G==7P& ?%&NU/JU4/I/R,B+PT"\Q+$Z\&/ M8)@==VW0ZO'[_#\SP)8,W M,GQGVVON3G#2)I6C_:,4=.QOKJ/*T2':KM;KM6_KO'RT"O?=/ZY4C]'^9B4O M-VX%)W#NU\L#+3RF\%^&!"(0G!B<*4-BYI%GQ!/J&/5+'W;#2:\8"!N0#$7+ MI20!/XY7GD+F0^E,0<',&-/)4?;T&S "[%&CL0!JYH!:Q'QS%O-5.Z;5+9:] M+(*^I]F^R]M!W]Z! LB)]2H+5NB,*:DS2[')@A-<*X,#L6@8]+%%T#KO33)]9P9VV&W?GX"=S$340Q;]@?F#M( Z[Z:Y_-)& MW@@EX&H(,]Z7)AY WVOP=R8\7G'2;+U()DC=,.B%N?0/QC5Q=D@/M'(L]5MF M6&09(XQFQG&5<2,B(<;:P&213Y)Q3@1[=/;L(>V1Y$'M23@W#TO=C@-H+DQ^ MA=?!(5XY.CE<*IE&[WN'[J13<&"_P90-E_!QZ=T,2O44].V),]6OKF\[X3#O M)H;N5>#(+ZQSE;5U>A"8-5YJDBF.9<:DYYG%5&<8"60\BLBHL/1AK;:ZMO6I MM 5AP$YE-;E_JY^7X>NGE>N5TJ246K'TK6LE$RWM'L2 M7$I;\Z6\5C$6_/VI\,?,]&Q-CDLD!2+?G1S_X00V$RN@;NK)$]C/ MG#H7@@NE7V/F'1I.&&+B!S>?^LS[Q#SC5PLI7WTPIIL*7)QTVJ>)[F_/0PQH M?ZOEVIV3=L9T_$6:CB>:# <,1 M&N;,=,)B:.8M3/HN>.A1[[)JSK>&Z>VNH)HY#NTF33!;-PAF[T!8:JS3,?," M_F&"0URH#X#K?LK?%:9U#T\HOB^]OG/[?:,[/ M&Q?HK96=E=V5TGKSI-&^ (F^S>.E2GOE.90RC"O5=";0'Y_97S3L@8;-Y13[ M4\8;4HOIA*<$GKBBX-5=LE7O.Z';'?[Y#"W "W?L,7?LYDS\>>7>J&,;E]<^ MYI6C/539W$.UZE=4NSSFM:/CU/;Z?K7>J%0WX.\>KOQ])PNMNG5Q@(TWR#N1 M!:TA>'1&939BGG'OD(J$1\_!M\,,@1O1ZQC7-A#?-TI?VCD(1VFMDY_>BRB7 M7W-YT_<$B2P$:8J"5$8'6)$0(U<9#BF=40N?I3U\,NTX#UQ'B6U*9^SG(#8, M/7/*:,Z(=.@<3D@+/L''[4ZU?=9:Z, 4=>#KQ8&CEK+ 3$:L8* #:23.,I4Q M4^S=SHQ))13_ZI^ $G0F0)O/'IH=2E014&YWOL"9>;:I %>YC*M/,Z8CUCYM#5GRA3? $++O7E"9OBX\KQ>,P298-@,CYB/(=/) MFI4O[>3I[>'QI*.%IQ#.E[1AS%[I/&-S[93GSS8@" M\%LI$=QS4T#GKC[)4ZM*O*)Y28'*:B>8N34H8\NP9 ?*A^ A0,X(HVD-O4&9 MMBIF:;].*HVA2(%UX +?M0V_O^;HRNKNUR(,%E/B!("@*Q4,6TY@8 M\QIG)GB:11NX\6EC58&7/DA&,T4IG=<,O,C4W[#J]]Y__4 3+/[JE:FB$DV2*ABM3EE,B M0Z.?FEY*7L1]M^UA_$?D ,0<'G&@GW'JC,Z+SH*POU)KAM9AM*SJA>'&+(9/ M/_E*TUXA7WFW.NE0^=5E8:KJ_?S(<\;*\X#[6RS<6"X-OXP&7$S+CW[:R+O0 M4:5:,,#L>4PK.%J'P9=VTXQ#Z;/I]DJ#M?I/6DQ&Q8_+W'[GLF(IU"3[\.[2 MJ^\L?MEJ^93L%$KVHN3JP1V7FJG8XUD]%!E^:65KYWI!S&_X]U+==$LQ;T ' MFD8##J:>Z\+?__3S#OS8:Y=L&)X ]]P-@^Q 3%,^X&#E>#L6]X5#_4[>R^$- MUL]= 4IIU?72X;1RO.3A*%C@=.I))[A0V&-,2D7UH6[I-[A?A/^Z?5OM MM"IGM/2V5S>]NVT_,[=;F9HXN'CX#K\O%U+S&QF\HPT!D.K;(WB#='YQ*ER4 M6C&\3RKXT"T:430R29)&)6\NNBN#$?32X,^$AM,_]3L=:-% F*&9:7*MW_V% M(^O*VM;%@?%8"I[FM*B5&>,Z9M9ZG45GB'7(&\39TH=:&H6]'52_TGK)&U5. MGK]6;5CJV:[C?UQCZE_41I/] ;,ULQ[/>!"B'YB M<;%<"N!;7*0DK- QKIBF6#,],UBZ?X?FKV]RTN]T^^G><&"GWTB9-WRXFK+? M&"33[F;5TF^)"N4?A)*5X0F]>MZ%)IN3M*CRM3E_T-XK*@_=WUL'0OQ!# R>:4L-T MP"4VS@%#=TQBV<19G>2F/OAK"50C>_! MPG4#D_IC%Q#X+8F=-!%,WO-+ XC/\8G?;H"=]M MWM6)R3$?GOR=MH[.S%L#^X.)S<@HU+@97ZQ\?[9A=N<6](K65P/5SYY;('B% M,"XP>Y5!=+*"*$?J!S7R?\F;\Q6JI1 OK5$PUIN_H34NCV\^-$NL__EAAIR! MTE?/L%N7&C@:VG@ZEO3O4>D?4'U4Q*T5U]3,=B'L)#A M%$@*/(3:6Z>G=HX[BRN76QO;G1V*\>LG+S*]H_VL]K1_7C\MI7 M6MZLG:>2R-O?*D?EC3L+*M8.SP])E9 M;9Y>#?V!_2JZ[&._"RWKSN?DY:3MU]?K\OF7][:.@?;NT?*:KT.?8&@?JE0_ M'FU_JYW7CO[.*]]22?XMN%>]?F]!X%H-'P1BB4JU^"4R-F.!^4PA&3*K6.!< M^&",>'P#MM=P9&F%]8NN]9NE&';1;]]6G070N+ M]YC%N[AI\2IK=R.V-BM7X3D$[M%,ZW#W4.5H%=>.BG<\KZ4ULYM_U\MK>ZB, M[UF\RX,0D?;S MBY@)A)ZH=A]\:$--]J=XEF-B_3PLQP> MG?BG!2_43B[X:=XM@NN6:;G<--*P?"H'G$[N]DS+FX[OEE+1BMS?R6BYSF+\ MS?S^\*3B8E)]/B;5N_70:%S9IM] T(JY[4&!]_LSQX#M[P!NJ08MG4&$IVW" M=E-OSK/E&E<:D[LXL(A1H:/,F*8L8UC)S%A%,Z>"=E82(^SW+<]48Q+W']]7:NQZQU_HT4^0&/A<[W+!/YS?Y^@[3>OXDEM3^7]D+E MBL!:*?H:*1B$KDB*M'Z5G)KGMGR^*K<,#XXBXGDLYE'->XUBMYA@'#BX#=-] M2A&7!0YCQZ%CBA3QW8NF;3=^Z_[^YE$8GGX%PG?.GR601CLK%;H21E$3&*VS M>EXLOQI9MCFN1O78.M$WH&NON#IBZ.=<0.A5,.M:>X<[1_M MH=I1C<,[T$ISXWA_L\:A+;S6W#BJ_'TG;>'R\"!X1"2F+E,XBHP9%3(3#,D" M(" ,0DREZ"-MQ9F6XO3:[GBY=&(ZI5/3Z(?2_P&,$4X#*1 @S]#>/0N%G(Y" M#NWJP*PNM/$)VKA^2QLA,B#4.I/A5(V1A: RS2/*L!1,.F^HB[388G%KH6GS M[^"\?NH?.$WW*RF/K.9H('IN]S:=M*YNW=#5XP/&A>"B#$Q!IU$.ILKJ[MOIU8#U+9=,Y#KW2Y\^?'B^J^O1-OF=P$"J]>:LH MC)2<^,(]Z);:_5XQ9Y*"KY%KW[X[CW-58>FFVY%V584S2Y7V:4@W'>2^8;)< M2O)?+-D=ZM-&L506KNNW\H$V#1Z^=%O#I"8!NT"\9(0%9ZV&&PH,(#Q16*5RC>8+=HQ?9U#P S M V7"Z6@NU>_%8^ I]Q4?P7P\0^*16:Z3]F .\7TGI&7JIZ.AQZ+$ MS&AW;[(B.=SQQI&EAV]B+!BK?B_\,6P(NG_-]UMU\]]ZY]K8'X;,=H(YSDP$ M"_W>-,[,13?M,'ZC!4]MZ3V^^>F^?#XZLS7 K#A5"+]L@%FN**2%>)7Q9857 ME&;\=0:OV0K17/*GCET_.!0SKY4&"X&>0!7]XEW G RW0WP/5@SD-XE@LJFK M'S^OE[8W2I^V*]7U2G5W KG?<[DR:-HEYZ:[^^*B^V:40QXJ;/PJ'?@%S/_C MP^(_E][Z#^="B'%\JVFNW)R7AS'0G/&E>R8_Z(=T_*>9DY:6ZIT4\_PC^<88 MHM(OJSO5TE9I8ZNR6OFTM?JY!&'-]DYYM;JU7?GSG?G)A,0GYG,_47[&MY/# M:YFS?\3B?\]6!#'PNF>2@;=ZH5G"*Z]$P2_ML05U3)TZ-J[R8(M-V(I:EL^B MC%F1E^\G-OWT8-I"E)XD2O0[:J*MMDSCHIL7(^K7A/ZIW?*#E1'IG)W0[3=ZQ2G; M)V'PV DP_2N(W8+IIRV19))4_U:]<;KPQA>*=4.Q4G7;KRFA/^\54U %:\,/ MC='W1/J-=K>?)EZ-;?=[H\GGG;Q[O/#9%P+W H&C>.&T_S23LX73OE"L&XJE M<4JQ;?4Z( 4%BW_IM%WPB;@7#O="FEX@32^EZ='S$G^^U**/JP#,HBV+2;N% M3@]UFHTF[;9*V]5_K^],8L9N5N1K84ZF+7H3]?K?ZOC-8C9UH5BW%$LN??@< M#DUCX.X7FU8MIE(7]VBGLS0VUZXV@N1>Y'(393,WZJO_7K)+ M7>SXU2RQ]6 O1%#F'>R=IV7]H MY>W.#1)?>-\+L7J)6"V\[YG.65EXW_.I67KI0QE^!J\[!G"V;V0;+CSKA3B] M1)P6GO48B)I/V;-^[@9&"^5Z?>7"9.G#=K&WQ59K4+P*3E^XTPM!>HD@+=SI M,;"T6+C3"\VZI5E\Z3VW^6(]_4)^7B8_SV/F12+Q+RDG:NG#+B!C>L^. MU!>IPPMA>[ZPT1^N_7YZB>.QE&\=%8C%Z)$*L0_N<35ZPJ(<["3+P?X0BI_3 MX6=4O7ZP=M\#9:\_K>ZE-1FK.[529;NZ7MI9WUS=6=NJ;)8VMG>^P'$^+VCL@ HV+TDXX@2-%(6^3M[KIO#/3\5FCW3[.!QNR M#FM2%1NY%C<(I68PK7Q0<3Q]W0C 5O"\[G5Z2,.<=9>'&POEK=-VXQ2N2CM] M=O+N\2![I-]R8(C@J<4%T/;4C'X#S)])F\RV^YT2M+\/]^T,*Z?TVB6?QPAO M"N\=.KEIP!O$3KL)5[>[J>)Y'&Y6.VSG]]]FI;3Q_3<]#*WT/G!S!QUJ [ < M_)[''.YL+XHM<(=O?M9.>]6FJC $_1'.3^#IR\4W_,?HUVX]O=3=7^&M0^O> MKZGV@,M/H"%WCYSEC<;=WTXZ[:,''M@T%_=^2H)S[_)V+[V5N;YONS,ZEN0A M;_7#Z$C":R!CW1PDV("LA4ZSFZXX-0!$4GHAGF'#5TIK%\;GKK25**]5M!->&+ZZ ME>7B H@.2]V^[>8^AQ0R7]OGC?:-"PLV]T[E YB@M! M33OP8^DT#V<%;$G9FE>=.]BS&5IV4ES0+@ZWKVH6+5\U.EUY]7/Q:L,WOM[< M^<:[_U#G[I/$\AV& *D:B& ^PZ.V7#1A@8,\+X2C]1GG79CI52M M!^C"T:5#*5LNV7ZO$+L$7@-D-I%'K[U<^@W_/J*!$OAEK78S=\NEDW8C+USG MXEV;@^(?;E3EJ?M'Z3?R^X"X;-Y("7/0=X.[],)P3X;_]/-B[]!.V_<=>#9P MUG+JA\$%RVE3T<'?ZWY;AD=T>W#68%[P6A>]Z9E2*[C0[9I.\3!G.O A528I M9+MYTA@ FMID\_9)W< M7>@/7@)@#*;CZL7)MM\%V>IV2Q"2#,%,NT?TPB&H M3]Z"-RPW+T+HIN:WDKR 6L 7#^\_ *$X MVY_F7?@"=V7W[GK=_J(U?9?>-/8'Q#QZT3N #_0K[_BTJU:2F^&1VR_KPVEH MM$^*>T.(!"8PM8#?:T';%N^5MBYOY. W=0<*?'VOPTX8"#!<+NY=WDRRFVZ0 M?@_G8)F3U)OB/0HQ&\HN6(ZB,T8';KS!Q4"$4X]>/;7=.03[>SE4NW3[5,KU M-O[IB5<7#"U%8=[3D6X 57N@K^ EY._%IMRAEQ/3"Q:;U\/3DL9!HS7X3$!]_4'H41J$]@.-@N>!!ON$;]IN99 6 MV[VY/; +<(U/NZLDL<_]D!X'1 Z6)AL*4G=@57_#Z/<[O.8')FW \W?$^Z1O MX7I0 '-JP,"FK1MBGOH -&M :G7)$QLOA#H07& M;I8PROXG/09:5%B&=(L[J<"CO8^*+6;R08_^-KS][OJGX5U_3X)3+D22R.%& M,P6Z-Y[T]=Z3UC\-+KLHZ<$U*Z5O862G2Q?M_L"@#BUB.&RG+FB LB6(@$/@ MY=,NS5?DAJ\DVLAG;Y%KP@U_WNR'[=:56[!:>"!(.$#)XY:&;_9-C0D9V_ MU:[4T"$A#+X7E:R&305>++QC>%P2^>20W>O )[CJRZ5&8MC4!^;*RMUT@]KI MBGH.)PW>YD>N?7CQ78?JG9#K%-9DZ,$_%AN408P2&4$$$X8>3@(*W+LZ>-+0 MLB$[!;]\BRT+CC0GN4\6*NE#NG%HG>:==L%K*Z7MA,KPBM27=7.:O))."0Q) M>O'TJM"=+A3Z'#L&J!'\A!'_#%V.]%8AO7 1\4$;?7L8:S7-,6ADWBMZ,P<* M*Y0?)"CUW2LCE'R5PE9UKNW6%;FO%,'J('B#7NJ I@_0@4"V M,%CI[\"?'BG821MHH""H@=&YZ6#"%4.Q+0'2(W^O!2>ZP0N!9A6D7B\$,%F_ M!'JC<26$(U4<>2WM ;-!.#^\_Z _"K^]N&0YG0)=;_-!&%#HY^!FR]"TBZ$L M/S/DO.63/Q0DW R@0_&4PI-[!/)"LB^XJ]$-9X76MQ^C_A$A_RR/#S$:4$FA">:JFY-G"'(7 MDGN6HI [>/\P!KD*/JY<\Y72KS D5 -3.)23I(#@K5T,;,&/C%OWE@&Y-EHC M2[#: $GO']:3^!:&K_"FAO;VEF%YQO!+85E @KL0C@-%%#P+FI]:?1U 7UOU M08MN6X'N]\U ($) M)[W4?5:BV<7%A3O[T(!>B@7:!3&DDV][#LE3OLUR _8?>'#=TE6\P-&73GZ:Q.>&$_\9_@R% M="<43,:@W]8/7%:^]R^)3P9F%/0$I M6:%(:T9>MB<@P2N<:(;):^S;)]D*DX@K]3,;]TUAS[*G3_5_)ZEX=F]@+]K=< ).G0V=$D6#@=0G=.841'T![;.A70MNB"PND%6/[SF\@'B, M.]I.FQQ_VVN9OD]92+\O=/J7 'SU(;BGMSQ_KMARM=L-=T8V7F6K[)]6C5_G M^=-;LCQ77OBG86*.*23X_8M$>+(;MOPZSY\Q\L4K9&97WG\RW4$^K4L?TCSX MJ6G<&VV^CM"G8+AFH)?^S^OV1B$1CW3'0&H& R/3[HX_\_.TXG4CY32GZ>9^ M*^_MI"6._:Y?*N:JX=V*'W(B8D 2J8B,958P$Y2EU ED2>22N8.M%/TB3=%2 MR0>7-TVC^Z\E^#+(B(([G/?>M_I-W^X-#R^56J89TK.R0V-.WB<)7FWY]&?] M6GQ7>Y]2(C7TW-^FT0^@^]"SH;AS,;/AZ=\7=JU]^IGLG-9HN>^/UD_W-_71 M]E&EOKU9)A52IN7J7WGEO56NLLEGFE;7R1:W:."YO5NJUH_+99UIIU"[; ME[5J_:ARY(\JE^L7M2.':LUULKVV<[1=_7I9;J[S_;6/1[5O6Y?E#76^O:N; MKKG1@N.SVOD*RI7OY[5CG8:Y-[:/5L_+1WNT?.F/]X_*\-R=?+M:XY4CN*ZY?EY>VR+[W[:@#1_ST37P MK/X^V1/EM?6+2M5=5LA.LWQ9J5BOO+SY5ZQ\ M0N>?J^N]\BXZ.]"".T<$S:0P(6,6L\P$BC*IF?4\&A>D6?K EH4@RY3(/]_= MEHT/__P'%NB/6=&?&>&3ASMEVF[G@N)G043GCN(I,D8X&I4%0A>.:!DMBMX@ MYX,"8B\H7F%"\8+B9XCB+Z\H7@5L*?8LBP'C#""DF8V(9(A9%247DI&X] 'H M78EEBMF"XE](\3,66<]R6+);;W=Z65IZ/$R@+]8<=&_4O?Z.Z23C[LZG"-YW MS.O<,?GK.^O_#@U?;9?3&FTZ!PPEB*K/6N8Q% MX3*%&;CIUG(N;:1.@YM.T;+4=)E),@$2?YDNS10-_82?/HFQM079S;3;NB"[ ML9+=MBN\_?I.Z@C*G2LD%XS] L;.;[BGV"#/I9.9 M$$#;C&"<60__..V)#5HJA]C2!T(YT#5:###,[QCR@N/FPS==<-R8..[:*Q66 M>(NESKPD(F/2N,Q$3S,O(G:!F^@BA.!$LV6RX+B9'V7= 3E-5U70F_!V"]@[(L;7JG3-@!C^RQZAC+&A,J4QCP#R(PC@"+W M:ND#PVI9,[X81%B,F/[:-/?Z7NF"YL9'<]>.J4ECHA9\4DNUSY@U)C/"ZHP' MXY$6'BN6]O &FI-L$K/[;Y/F%F.ESQ@K=>U4=-"<+T9+Y]XU'8!9->?A!FTO MR/H99+U],]\6.^LU%SQ#2&@@:XHSA3C*@C1(1AZ)M''I@UYF2"S&$!;CI+\V MNTUBG'3!;C_-;M>N*,6:T6A))K'$:>9>99H'ER'OK3*&22O9T@>.Q+(2"WZ; M)5?TC8Z1?NF$$Y/[[^XML1@PG5FO]#)TVMYTZR/*]A4'^ M6 PI+$9.?VV^>ST_=4%ZKTUZ-R;X,>96.Y=IKPF0GHR9QE9G$3LE#(O8>[GT M@7"ZS-@DG->W27J+<=1G.Z^ISG_:C^K&/EON5GF2Q=CJS'JQ/QQ]& *\/L!W MM>6W$[B#HDD+.G\^G9>KJXG*!W[LZ@'C2$@K4.:) "_62Y)IC5FFO$!1I;(' MBJ7=NM-HA%J,1BQ&6W]MOGO]T=8%W[T"WUU<\1WV5'*N6!940!FSS&162IH9 M0B%P-U01!WR')5E&:!*+IMXFW\W8Z.NL.J_5=MHD=C)^ZO,BI9\I2CIWI#Z! MW-4%?;^8OM=ONJLQ8)+6$6364Y8QBG&FI ;O-6(PS-9PPI.[*I893_]-PF-] M!<6:*9):#,K^HK0X@5S7!2W^#"U>>[4,<\X,%UD@D6;,6)XI8F.&K &7EL)A M[Y8^,+(LF5I&?/9*G[P)6GS$Z_U_['UI4QO)LO9?41#WPTR$RE/[,G,N$0S@ MN=QW -LPQ]?^XJC5M"TDCA;;^->_62T)";.818A&U%DP:.FNSLQZ\LFEJJ8' M!^5)>S+?=Y* MEAI+D?%NJ_?%V8@1OX4M,8Y/5\JL9[2GF4$@5F'>(X M>>0H]2@*X[F4+A%!UM9)6Q#>)H*57'NI+3YOP%M(ON7'CN""=0^'=;/\BS?1 MR2 ",B$"UG%*D2.YG\)'$B.AG!F^S%[@U42ZA@6[3X6Q+G&A\2K&ATUBK)>KCI"?CJ\8*GC"-R''*(327&&EC(TI&,954 )IJ"M8UD:ZN:(*U M[G$M"S6>-#>=ZU,N*'U'E'XWSTB9UBD&;Q 102(>0D*& 50SX;VRGB8B4D;I M-F7+:.A8S9Q"R9ZN", ]/"$M +<0@)O14.&%H29*1%W.FE)#D#.2HQ"\32XX MDG @*-MPDP!N :QT,?K$%(/NQ3C<@:Z-%'=KBNL ?:VT!.#'ZQC],GYLF4M M2"G.ZU;.R\^S6P)/?X ILKYJ0=?G&KF#)F!(8?>R'7BPM-HW\/NO[ M-ZS VU2W,UG?W>K,K/QNJ^^6"Z>/70-Z'@6>FZZ^6X'D?)/3\DUN#CD[P_/$ MGE[6O/QX9*(!PGG$'$LC\:112?:)X;X:VVW9Y^0.:95/Y[9_PD1%XXE'V@:" MN,4:.2$3LI$'J@DCEJJU=458FYER6FE)JA=,?UZ8OKSC60NFWP_3YW9DE4G: MW 7D%<.(:Y*0T4RC%#3EX)@=D7E+/VS:6.*"Z0UJ UK19G28XOU1G!TI4!K2 MGRS]SGJ<2ZX6M+X+6N^<.R_ ?T6UB,:\TZ#@AAD'=!P[R6C4?D$Q'MMG2O< M)F095 M5'TJBC%MH>Y*3"#$48HBU@%Q3"TRDGJ42-!6R2A2 MLFOKAK7I4D!]-1,-#4@>%[Q[&M2UX-U#X-W<-A]!1*6E1#&I?%@KQ1"K*X6L M)R;JP#'/ZRL))VV,FWVW8'\6+2;\SN]SHALUY MJRP\Z%8\Z-QFD=HZHX.1R 'M1-Q8C&R0!N6>'"R)PB3&K/=^D^S>L ^ZJL8;JRX]#.MF:^LOW] M_L'0#F/XM^V,XNSNA8O<@HM\'NYN3KC(IL'O_^\(^^-_=^U;,]K_Y.GN7^_R M^-B[M]ML#\:]_]<[\>[[-MG_Z^71[N'>)[@VWWO[\OC_OF]_W3_\3'8/M^GN M)\]W#S]_H,)++[5")'J-N',,&1XP"I@%QKCA3.'KRPI7&-3=*J_%H)ZZ03DI M4S IHA1R0[GS$1D7$N+!!4($P9;QM?47 (3D$KK\PPNM$]MO??V)Q#OW&!=[ST%SC\& V M\@+)MX'D[QO70/+N=X!8\OY3IX+Q?GV_!>,^!CG]]>\.P/'Q^\-_ONY^__AU M=^LU^1&2][;\!VV-Q#P0) FE ,3PPYH0D6 NX^,O-:][N/=B7JME M7M9#U,TD0SQI@GB,$5D,/-)[PSC8@XX4**1H T[F____S: MZX=![-[$&'<&@U$QQ$Q, M-;?))L;];0WLT<"K&%CS#$Q+K#RQ$@6='" 89T@#I"$M%,:>&$',K0WLT1"L M>,=&V9;!FL7@.!*68,2](LC%2!&UCD2=2#".KJV#7<6?,[0;9&ZJ6OMU0U9O MAC0_R>*4'3@>>ZW+]]CO!3LXNGZ"UZG7,K-O.[-G34PI)4:#!7BGTB"NM$>. M4?C3,.T]L D54FY!UI30/QK7S-W(2G!9R+*ZT+:0M2H%VAX0VN;68GMGP/T ML> 0'W'A$@)(4TC$Q+31W!'E"K0U<2UVZ:>H@3&W4/:Z]VFF6%CM>SR44OA> M'%1M7Q-?;7_=_^O=Z>Y;D,_6WO&[3Z_)N^,=O@?7V=_Z1[P'6;VCVV+_\1B2H%:A*FBMZIDV)AK3G%FIZ0-7D=8G0: M62\$XC02I(6E2#KGL94\BD3K-HJ%=E%P;(1^GDN!?IV+F&=+S__/[P9?7N[39]P[UC("2??B =<+^-#YISHJ6(2)D(%#8FBXQ-&+'(.1.Q2 M$QN%BFTUW[928IS9*)#E4B-N@X7PR!@4M/764&7 ,M;6R;A'Z*9]0I,BTQUA M[U%,LU1%FV.6WW<^A$"EDLDAI4GN8,,&.84#-0PQ(R H5D4C4$ZE MCG33R5VJ]G>:T',G1GAMDI8&"4^ CP3,D$L)2$FTH/\D05=LPH/+86>E'^F9 M8]LR3HPHV'8_;)MU)%'J%=?1( 9T%G$G C(,^(447!,=0I(L36*M@FTKTI#4 MY"/.-F!,V;9LIW5BJX"J;LO;DVIH.^4\LZ?)1&<:?04*W>ENCM590/M6H'WN M"+,@G?+>,40C38@3RY#Q4B%+-!;.,IUH/L),M!57;2G+,6;E&+-G#G-+.(&W MP-QB8&[&30GX(P:(AK2':)L;A9$VWJ'(2: 6N"KU F".MYD&PV 7JZ(%YE;J M\+(Z$=FX%J/#?K2#4?]TVA0_*3<=Q4YHV2'(KO?]F%L__=] M]W3_\".!Z_']K=WO^X?;'X@A,CDB4(Q.Y#T[*+(P+Q"+WCAMC!,^-+'EJ%A6 MTRTK&6LC90GY1,"S$AZ1#@G^U,10J:5-P:RM$PH@RMKBDF-!+Y:92KGHEG[X MET9%Z>?F;,FJWFFRS@)TQY/ G!G$*'&(6Q.0EBHBAAE.+'!/B(3YI=N&FK8A MXL)TNG <3TFJEH+1JJ+;PP?G!=WNCVZSN%P1+8)3%GAIWM20"84TO(2L,(YK M99R/H:!;\T+R52T9>3\Z'G7R>EV AU3Y:EAJ1=MJ2YN!O38[:LWFEV-0JV2AGVFV/CP*=J"C??'QAG3Q5Q%R9Q&@G-@ND0& MI%W@*'''@S2>^-PARFF;"](F\N+2_8*-#>7"#Y NN*'DU,-RX4YE7=6IAA5< M,Z]*O3DW7IHXKS7*R9N3NS%X/_1&KA.O]@D-,-K_>KR =C'"?*+^].%CC;]G MTVFC&XIWO:=W]?.1AV6@(@&.U8M\,+#,WA6"$$2EURYQR7T:;U B* $/NPSO M^GASKR%(ULP,?'%-Q34U09B-"O6*:UJT:YH%?EP;(!36(A9RB8,IA;2B(I^E MHW#0%%/,(?!C;89Q6^-EK.DNKNF*R/"WH86Q3UNFY[;7K455=4/L#G]G$H8Y M)SL/+\;^]+'6_^7ZOZV?[[V^W86.;?]CU9V*E-#&;>1+QZMLCF++>M\[AH&= M@H9;W=XP!XI]>+G;JN!1/O;K->/]8=[N:'@4!Q%0SHY"E?N" .%J2ZJ;A%+5 MM5U?U?47>.$8!#%X\3 RO$H_-:Q]P!^H6%OD+2]#1>NS21,*/]C.R"9[D=]OY:D\':[^=>^";"O,ZW7X:#895.KVE/:W"K%>7 MZV?KW<;6SF9K9^]P^\W>QN'._M[&WVWX<_-%:V-OJW7PSY\'.UL[&V]VM@]6 M"0.OD,;F_M[!_M\[6QN'V_#LA_#/[O;>X4%K_V5K_]7VFUH^!ZUG((A?_ID" M^Z_7/^TU#R?'SU:[X.EW)I^HHR [&O:F7QFSB?J5"0.!Y^O8DT'\??K+A3!M M7MKYL4(U..G8T]^K;OU ]7TG*&',"V.RH&JLF.2+)T.:X,B+\7L_T+'QFTR\ M$(IA8Z[^R+7?O_Y-]@(8HU3ZCM_'+\AU;VK*F*%W_'H9^),>^$^J(S=$F@R!+WQ ^FEZ V(H9+-P, M]++-H&BZ3/@RX9LRX5=K:<*#R>U-_!*[HSCX_>'[?)=G90]767WT 4RUU-"F M[&(LQ5B>I+$4X?QL< WK;V[R)A5OXB#:OC^J6YL#>-A.[R07GEO]L;=]M)[F MTOIUS3+;I]>\%0V1$@<7N.$(37_9[ MQYLPA#RXM]7P:',T #G&_O8WWQEE46X,!A'^%P[MMZ8T=IWNG35V[< U=_#> MVW]_WMOZ=[6[]>;H'7TMX#MT[]->]>[XY='>7__@W>\?YQJ[0N?]IZ-J]_O& M]SWZ[^K=IS>?]H[?B?VM_ZW@?D?P^_?]K;UJ[^W["XU=\/GC_;]@#%N[[/U; M>"YXQO>?/O/=XSR.;?A]E^_2'?+^^'_365/7 ?[Z@3,/7UKG@;=' GJY&(O(S;Q@NN+]*N$^Q#389D@AS/%KLHE-!"A8P MTY8Z7N.^GN*^+KC?:-S_?H;[U#/0* U(A1 0EWF-N\41A:"5(CH9%G0^_I&V MC2S[WQ?<+[C_O'"?<4PE2YX .^3$"? !6&-M".""(I9,^#XI?/\IX#Z9\7VI MB%.4(1T!_+G5"1DB(F(NB$A<\)(#[I,VY:H-&B_(7Y"_(/^S0G[@^(Y$90Q. MD1.B++,DP*_,!&*]D!/&3PKC?PK(S\Z07WK-&'<.">PIXB8D9!,'1Q",52Q( MJPA?6Y=8MX4J!_L]T,XLT^4&N9S0I)I_*4PN5#>EHOQ$%7?O FHQHF)$*V9$ M16@KTL;0U+[ S=Y@.-Z:+7X[B=W!73L$'T\T!4 ?ZP""8@_%'LK]'_?^#6M_ M;W*WWMC5]5*K?\NVO3.YEA,!GT876];T?OJKUPOU7F2Q_Z7R<7#0ZX22PKQ% M"G.OFF]6B]I1)C#"+'+$&:/(,F61YT$3[)F7MMX>D[)$=>YT/F&+/(*6F1%-1+ZGSR MSJ^M"V+:C#7OA+FG@G8-J\ U.35YU4+B+!_IG,#24H^,,!"A$QN054(@#/X+2VF%IFIMG2O9EJP 7@&\ M9PYX2UU!60!O88 W2TG&2'"*42(KO$/PT$:)3-99VOKM,T$:1M1 M(*] WC.'O*4N'2R0MS#(FV4E(W9:1JF V;$('"]2Y$(@ 'DI*!JBD7D[*-*6 M@K<5*0[WDCWQ(REP7Y'A+Y9BE,Q2PUS@F$X3?$C4K(1DH0$8D%9Y2, MSJZM:ZK:DM&"? 7YGC?R+2&!69#O(9&/S7&^P'U4% GG(=JUSB.3H9QC-XCIP,0V$ \LC8P1+S1"L)Y%H6J M85S(-C&E(%5J\,\<]);89UE ;Z&@-\M7!L$HL4$CD:B#J#TFI#7#2 'RF1!< MHGZ\%I*RMES*VN\">@7T&@QZ2^RU+*"W4-";I2I=(CHJ"59A-49<,($LQ1Q% M#2!(L,1,T;5UWF:"MPU?QI+( GH%]!H,>DOLMBR@MU#0FV4I ]/1@1Z1%%8A M[E1$1F(!@2YC5C#""25KZZQ-F6X3OHS:]&J"7NFWO+'T7O;Z<(=NRX_Z_=CU MIZWX+1YUS")X?W2SZK)^]L/"EG#0J8WPK,M^>3G)X9%IC5*+%(M,DH]J&Z,95M&XTQYJ.]L^VQO^L$'+)Y_L4A+P/0LZE/TD, M+% "N&@#XA'3O*V<1 :TR11E0A&;$1)SWL9F&1G0@I %(5<2(9=\)E!!R'L@ MY%QB% O%&%,<.6/S+G3Y+" J!;(N.$YY8%'FK=7;PO V:>#&FP4A"T(^$81< M\BE"!2'O@Y S#DF"H-9J@P(-$G$%]-'R%) EQ(&I.&.L7%N7;]"!CN0\\+G6@31I+$5H1VM,26BD8W<@MY!IP*_5[ MQZW>2\X9FT7VGHKVKH[7QQRV%I# MO$-",@ZTU5ID:(C(:!<,E8 NM*?S[4G%RL]O]:5CJ5L/VYX-UC-, 7O%L MWLW"=)>L3A&" MH]&]X-W]\6ZN<&.5PC$IC*B5#/$8%;)8:A3J\&[ M@G?/!N\>HZ&]X-T"\&ZN#(.]"3PY% F$LIQPB8R,$>G M1%$)8OUVKIHYPW6 M"<$%[TJ1I:2^B]":-)8BM%)D65"1Y<'6)K[>9ZG-, M0B?]0'N];F_*3O?BL-#26]'2?^;++-H3&YP*R)J\JYP('#FF-<(D>)9$HH&; MO+!R+?$]3$%^1X ^>9*+YIX+8(%O$O2(&Y)0EHH MC%3R@H2D722Y]*)46UW26%.0KR#?LT*^):Y[*%H@AC YR/ M1(QTC!Q9:9*C6 :?[-JZY*J1*V&>"O(]SSI,&4L92QG+4L>R6C61AUUXXB*P MD#@IB[2&]EO9J>RYK$R9-?!L#(?]RHV&UG7B8>^5[<=NX9.WXY-^OGHB' F. M&HMB8!%QG/MYK R(.Y*<#,QH4Y^^*(UN,WTQB_B(33TKL:SZV<;8SPLT'V-Y M2P'-Q8+F7!#.=0A>.I2XIHA+'9%3C*,4(O&Y)U+0E$%3,-/FIE&=WP4T"V@^ M%=!\C#4R!307"IIS-9L@7!1<422TXXA;S?,!$!IY%B,CDE)&:-[%1T@-P%F8 M9@'- II/9*%- 76TP%4AC&9-*E 0L\YH;HH!I MT@*:I1!4QE+&4L;RY,:R6H6@!X/H5_W>EVJ0*1"0DP:6@IX$G7RT=3+?8[\7 M[.#HJD$Z1(QH) M#C$X1ITO.%=PKN#<@DHJ!=$> M'FZB1")\ S3Y!,6@!SPP:Y&!)B! OK> @^ M G,S^.(&.P7-"IH]*S1;[+J6PMH>&./FRAI$JRB$1U2[O'XO:F3!V2!M4G) MP!5CIK"V52M>/+:('G\ 4^W\U!D5W13=-+)8\>AJ>O0!%#LI8RG%OF6L^MJ+ MPU:G-[A0VEN:F&[7.=8 09Q8@;II!S&B/'!#/>XS&6>A:/ M<2^/,8LQC-?1IK593QH--TS_MH/(MVPVM4'5& MPQA:W4F;1NLD]D%RQ\<0M0R.;/_"T86/)\D&R.T1@^ G%^>^BOV#;$"+[<*@ M<_'N^:!VV_:[(*#!]+ZUC6]TP];8PDN8>ZLP=W>^^<)(RZC#%@RH;KX@'&G+ M&8+0US+%K<4\KJV#45P\K**<%U[2G@745QW4[]DH44!]:: ^RUTRPSSVSB/K MA$0\*(R,I!K19*.GF%D<< 'U NH%U)\IJ-^SEZ& ^K) ?:Z%@7J7E*(<<

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htm IDEA: XBRL DOCUMENT v3.19.3
Subsequent Events
 9 Months Ended
Sep. 30, 2019
Subsequent Events [Abstract]  
Subsequent Events Subsequent Events
For purpose of disclosure in the consolidated financial statements, the Company has evaluated subsequent events through November 13, 2019, the date the consolidated financial statements were available to be issued. Management is not aware of any material events that have occurred subsequent to the balance sheet date that would require adjustment to, or disclosure in the accompanying financial statements.
On November 12, 2019, the Company entered into an amendment (the “Amendment”) to the Employment Agreement between the Company and Mark A. Emalfarb, dated as of June 16, 2016, as previously amended (the “Agreement”). The Amendment contains a technical correction clarifying the exercise period and date of grant of certain stock awarded, or to be awarded, to Mr. Emalfarb.

XML 38 R17.htm IDEA: XBRL DOCUMENT v3.19.3
Share-Based Compensation (Tables)
 9 Months Ended
Sep. 30, 2019
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Schedule of valuation assumptions The assumptions used in the Black-Scholes option pricing model for stock options granted through the nine months ended September 30, 2019 are as follows:
Risk-Free interest rate
1.69% - 2.50%
Expected dividend yield— %
Expected stock price volatility
28.59% - 37.29%
Expected life of options
2 - 6.25 Years
Discount for lack of marketability
0.0% - 8.48%
Schedule of stock option activity
The following table summarizes the stock option activities for the nine months ended September 30, 2019: 
SharesWeighted-Average Exercise PriceWeighted-Average Remaining Contractual Term (Years)Aggregate Intrinsic Value
Outstanding at December 31, 20183,552,890  $1.575.06$1,149,461
Granted (1)
1,089,000  2.26  
Exercised (2)
(635,500) 1.62  
Expired—  —  
Canceled —  —  
Outstanding at September 30, 20194,006,390  $1.755.89$17,556,185
Exercisable at September 30, 20192,764,073  $1.644.65$12,408,351
_________________
Notes:
(1) Represents the following stock options granted:
•Annual share-based compensation awards on January 2, 2019, including: (a) 600,000 stock options with an exercise price of $1.87 per share granted to executives and key personnel, vesting upon grant, or one year anniversary, or vest annually in equal installments over four years, (b) 300,000 stock options with an exercise price of $1.87 per share granted to the Board of Directors, vesting 25% upon grant and the remaining 75% will vest annually in equal installments over four years, and (c) 24,000 stock options with an exercise price of $1.87 per share granted to employees, vesting annually in equal installments over four years. 
•One-time awards granted on (a) January 2, 2019 of 50,000 stock options with an exercise price of $1.87 per share granted to a contractor, vesting upon one year anniversary, (b) March 7, 2019 of 15,000 stock options with an exercise price of $3.00 per share granted to a contractor, vesting upon one year anniversary, (c) June 25, 2019 of 75,000 stock options with an exercise price of $5.83 per share granted to three members of the Board of Directors, vesting upon one year anniversary, and (d) June 28, 2019 of 25,000 stock options with an exercise price of $6.26 per share granted to the Chief Financial Officer, vesting immediately.
(2) Represents the following stock options exercised:
•A total of 635,500 stock options exercised with a weighted average market price of $1.62, including (a) net share exercise of 440,000 stock options resulting in the issuance of 304,171 shares of common stock, and surrender of 135,829 shares, and (b)195,500 stock options exercised with cash payment.
Schedule of non-cash stock option compensation expense Total non-cash stock option compensation expense was allocated among the following expense categories: 
Three Months Ended September 30,Nine Months Ended September 30,
2019201820192018
General and administrative$118,754  $51,887  $957,843  $356,024  
Research and development25,426  18,733  76,503  57,616  
Total $144,180  $70,620  $1,034,346  $413,640  
XML 39 dyai-20190930_htm.xml IDEA: XBRL DOCUMENT 0001213809 2019-01-01 2019-09-30 0001213809 2019-11-12 0001213809 2019-09-30 0001213809 2018-12-31 0001213809 2019-07-01 2019-09-30 0001213809 2018-07-01 2018-09-30 0001213809 2018-01-01 2018-09-30 0001213809 us-gaap:CommonStockMember 2018-12-31 0001213809 us-gaap:TreasuryStockMember 2018-12-31 0001213809 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001213809 us-gaap:RetainedEarningsMember 2018-12-31 0001213809 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-09-30 0001213809 us-gaap:CommonStockMember 2019-01-01 2019-09-30 0001213809 us-gaap:RetainedEarningsMember 2019-01-01 2019-09-30 0001213809 us-gaap:CommonStockMember 2019-09-30 0001213809 us-gaap:TreasuryStockMember 2019-09-30 0001213809 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001213809 us-gaap:RetainedEarningsMember 2019-09-30 0001213809 2017-12-31 0001213809 2018-09-30 0001213809 dyai:DuPontDaniscoMember dyai:IndustrialTechnologyBusinessMember 2015-12-31 2015-12-31 0001213809 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-07-01 2019-09-30 0001213809 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-07-01 2018-09-30 0001213809 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-09-30 0001213809 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-09-30 0001213809 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-09-30 0001213809 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0001213809 us-gaap:NonUsMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-07-01 2019-09-30 0001213809 us-gaap:NonUsMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-09-30 0001213809 country:US us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-07-01 2018-09-30 0001213809 country:US us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-09-30 0001213809 us-gaap:NonUsMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2019-07-01 2019-09-30 0001213809 us-gaap:NonUsMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2019-09-30 0001213809 country:US us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0001213809 us-gaap:BilledRevenuesMember 2019-09-30 0001213809 us-gaap:BilledRevenuesMember 2018-12-31 0001213809 us-gaap:UnbilledRevenuesMember 2019-09-30 0001213809 us-gaap:UnbilledRevenuesMember 2018-12-31 0001213809 2017-12-22 2017-12-22 0001213809 us-gaap:CashMember 2019-09-30 0001213809 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2019-09-30 0001213809 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2019-09-30 0001213809 us-gaap:CashMember 2018-12-31 0001213809 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2018-12-31 0001213809 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0001213809 us-gaap:CorporateDebtSecuritiesMember 2019-07-01 2019-09-30 0001213809 us-gaap:CorporateDebtSecuritiesMember 2018-07-01 2018-09-30 0001213809 us-gaap:CorporateDebtSecuritiesMember 2019-01-01 2019-09-30 0001213809 us-gaap:CorporateDebtSecuritiesMember 2018-01-01 2018-09-30 0001213809 us-gaap:CorporateDebtSecuritiesMember 2018-01-01 2018-12-31 0001213809 2017-06-30 2017-06-30 0001213809 dyai:ResearchServicesAgreementMember 2017-06-30 2017-06-30 0001213809 dyai:BDIHoldingsMember dyai:ResearchServicesAgreementMember 2017-06-30 2017-06-30 0001213809 dyai:VLPbioMember dyai:ResearchServicesAgreementMember 2017-06-30 2017-06-30 0001213809 dyai:BDIMember dyai:ResearchServicesAgreementMember 2017-06-30 0001213809 dyai:BDIMember dyai:ResearchServicesAgreementMember 2017-06-30 2017-06-30 0001213809 srt:MinimumMember dyai:ResearchServicesAgreementMember 2017-06-30 2017-06-30 0001213809 srt:MaximumMember dyai:ResearchServicesAgreementMember 2017-06-30 2017-06-30 0001213809 dyai:BDIMember srt:MinimumMember dyai:ResearchServicesAgreementMember 2017-06-30 2017-06-30 0001213809 dyai:BDIMember srt:MaximumMember dyai:ResearchServicesAgreementMember 2017-06-30 2017-06-30 0001213809 dyai:ResearchServicesAgreementMember 2017-06-30 0001213809 dyai:ServiceFrameworkAgreementMember 2017-06-30 0001213809 dyai:ServiceFrameworkAgreementMember 2017-06-30 2017-06-30 0001213809 dyai:ServiceFrameworkAgreementMember 2019-09-30 0001213809 dyai:NovovetMember 2019-04-26 0001213809 dyai:AlphazymeMember 2019-05-05 0001213809 dyai:AlphazymeMember us-gaap:CollaborativeArrangementMember 2019-05-05 2019-05-05 0001213809 dyai:SerumMember us-gaap:CollaborativeArrangementMember 2019-05-07 0001213809 dyai:SerumMember us-gaap:CollaborativeArrangementMember 2019-05-07 2019-05-07 0001213809 dyai:SerumMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-09-30 0001213809 dyai:SerumMember us-gaap:CollaborativeArrangementMember 2019-07-01 2019-09-30 0001213809 dyai:SerumMember us-gaap:CollaborativeArrangementMember 2019-09-30 0001213809 dyai:JupiterFloridaHeadquartersLeaseMember 2019-09-30 0001213809 dyai:JupiterFloridaHeadquartersLeaseMember 2019-01-01 2019-09-30 0001213809 dyai:NetherlandsOfficeLeaseMember 2019-09-30 0001213809 dyai:NetherlandsOfficeLeaseMember 2019-01-01 2019-09-30 0001213809 dyai:NetherlandsOfficeLeaseMember 2019-02-01 0001213809 dyai:NetherlandsOfficeLeaseMember 2019-02-01 2019-02-01 0001213809 dyai:VTTTechnicalResearchCentreofFinlandLtdMember 2019-06-28 0001213809 dyai:VTTTechnicalResearchCentreofFinlandLtdMember 2019-06-28 2019-06-28 0001213809 dyai:VTTTechnicalResearchCentreofFinlandLtdMember us-gaap:SubsequentEventMember 2019-10-25 0001213809 dyai:VTTTechnicalResearchCentreofFinlandLtdMember us-gaap:SubsequentEventMember 2019-10-25 2019-10-25 0001213809 dyai:A2006PlanMember 2019-09-30 0001213809 dyai:A2011PlanMember 2019-09-30 0001213809 dyai:A2011PlanMember 2019-01-01 2019-01-01 0001213809 dyai:A2011PlanMember 2018-12-31 0001213809 us-gaap:EmployeeStockOptionMember dyai:A2011PlanMember 2019-01-01 2019-09-30 0001213809 us-gaap:EmployeeStockOptionMember dyai:A2011PlanMember us-gaap:ChiefExecutiveOfficerMember 2019-01-01 2019-09-30 0001213809 us-gaap:EmployeeStockOptionMember dyai:A2011PlanMember dyai:ContractorMember 2019-01-01 2019-09-30 0001213809 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0001213809 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0001213809 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0001213809 2018-01-01 2018-12-31 0001213809 us-gaap:EmployeeStockOptionMember dyai:ExecutivesandKeyPersonnelMember 2019-01-02 2019-01-02 0001213809 dyai:ExecutivesandKeyPersonnelMember 2019-01-02 2019-01-02 0001213809 us-gaap:DirectorMember 2019-01-02 2019-01-02 0001213809 us-gaap:EmployeeStockOptionMember us-gaap:DirectorMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2019-01-02 2019-01-02 0001213809 us-gaap:EmployeeStockOptionMember us-gaap:DirectorMember dyai:SharebasedCompensationAwardTrancheTwothroughFiveMember 2019-01-02 2019-01-02 0001213809 dyai:EmployeeMember 2019-01-02 2019-01-02 0001213809 us-gaap:EmployeeStockOptionMember dyai:EmployeeMember 2019-01-02 2019-01-02 0001213809 us-gaap:EmployeeStockOptionMember dyai:ContractorMember 2019-01-02 0001213809 dyai:ContractorMember 2019-01-02 2019-01-02 0001213809 us-gaap:EmployeeStockOptionMember dyai:ContractorMember 2019-03-07 0001213809 dyai:ContractorMember 2019-03-07 2019-03-07 0001213809 us-gaap:EmployeeStockOptionMember us-gaap:DirectorMember 2019-06-25 0001213809 us-gaap:DirectorMember 2019-06-25 2019-06-25 0001213809 2019-06-25 0001213809 us-gaap:EmployeeStockOptionMember us-gaap:ChiefFinancialOfficerMember 2019-06-28 0001213809 us-gaap:ChiefFinancialOfficerMember 2019-06-28 2019-06-28 0001213809 us-gaap:GeneralAndAdministrativeExpenseMember 2019-07-01 2019-09-30 0001213809 us-gaap:GeneralAndAdministrativeExpenseMember 2018-07-01 2018-09-30 0001213809 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-09-30 0001213809 us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-09-30 0001213809 us-gaap:ResearchAndDevelopmentExpenseMember 2019-07-01 2019-09-30 0001213809 us-gaap:ResearchAndDevelopmentExpenseMember 2018-07-01 2018-09-30 0001213809 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-09-30 0001213809 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-09-30 0001213809 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001213809 2019-01-01 2019-03-31 0001213809 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001213809 us-gaap:CommonStockMember 2019-03-31 0001213809 us-gaap:TreasuryStockMember 2019-03-31 0001213809 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001213809 us-gaap:RetainedEarningsMember 2019-03-31 0001213809 2019-03-31 0001213809 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001213809 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001213809 2019-04-01 2019-06-30 0001213809 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001213809 us-gaap:CommonStockMember 2019-06-30 0001213809 us-gaap:TreasuryStockMember 2019-06-30 0001213809 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001213809 us-gaap:RetainedEarningsMember 2019-06-30 0001213809 2019-06-30 0001213809 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001213809 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001213809 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0001213809 us-gaap:CommonStockMember 2017-12-31 0001213809 us-gaap:TreasuryStockMember 2017-12-31 0001213809 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001213809 us-gaap:RetainedEarningsMember 2017-12-31 0001213809 us-gaap:TreasuryStockMember 2018-01-01 2018-03-31 0001213809 2018-01-01 2018-03-31 0001213809 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0001213809 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0001213809 us-gaap:CommonStockMember 2018-03-31 0001213809 us-gaap:TreasuryStockMember 2018-03-31 0001213809 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0001213809 us-gaap:RetainedEarningsMember 2018-03-31 0001213809 2018-03-31 0001213809 us-gaap:AdditionalPaidInCapitalMember 2018-04-01 2018-06-30 0001213809 2018-04-01 2018-06-30 0001213809 us-gaap:RetainedEarningsMember 2018-04-01 2018-06-30 0001213809 us-gaap:CommonStockMember 2018-06-30 0001213809 us-gaap:TreasuryStockMember 2018-06-30 0001213809 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0001213809 us-gaap:RetainedEarningsMember 2018-06-30 0001213809 2018-06-30 0001213809 us-gaap:TreasuryStockMember 2018-07-01 2018-09-30 0001213809 us-gaap:AdditionalPaidInCapitalMember 2018-07-01 2018-09-30 0001213809 us-gaap:CommonStockMember 2018-07-01 2018-09-30 0001213809 us-gaap:RetainedEarningsMember 2018-07-01 2018-09-30 0001213809 us-gaap:CommonStockMember 2018-09-30 0001213809 us-gaap:TreasuryStockMember 2018-09-30 0001213809 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0001213809 us-gaap:RetainedEarningsMember 2018-09-30 0001213809 2016-02-16 2016-02-16 0001213809 2016-02-16 0001213809 2017-08-16 2017-08-16 0001213809 2017-08-16 0001213809 2016-01-12 2016-01-12 0001213809 dyai:PubliclyAnnouncedRepurchasePlansMember 2016-01-12 2016-01-12 0001213809 2017-01-11 2017-01-11 0001213809 dyai:PubliclyAnnouncedRepurchasePlansMember 2017-01-11 2017-01-11 0001213809 2017-01-01 2017-02-28 0001213809 dyai:PubliclyAnnouncedRepurchasePlansMember 2017-01-01 2017-02-28 0001213809 2017-02-28 0001213809 2017-09-01 2017-12-31 0001213809 dyai:PubliclyAnnouncedRepurchasePlansMember 2017-09-01 2017-12-31 0001213809 2018-01-01 2018-08-31 0001213809 dyai:PubliclyAnnouncedRepurchasePlansMember 2018-01-01 2018-08-31 0001213809 2018-08-31 0001213809 2016-01-01 2018-12-31 0001213809 dyai:PubliclyAnnouncedRepurchasePlansMember 2016-01-01 2018-12-31 shares iso4217:USD iso4217:USD shares dyai:segment dyai:customer pure iso4217:EUR dyai:collaboration_project dyai:antibody_and_vaccine dyai:protein utr:sqft dyai:board_of_director 0001213809 2019-09-30 2019 Q3 false 140 Intracoastal Pointe Drive Suite 404 Jupiter FL true false --12-31 P2Y P1Y P1Y P1Y 10-Q true 2019-09-30 false 000-55264 DYADIC INTERNATIONAL, INC. DE 45-0486747 140 Intracoastal Pointe Drive Suite 404 Jupiter FL 33477 561 743-8333 Yes Yes Non-accelerated Filer true false false Common Stock, par value $0.001 per share DYAI NASDAQ 27213157 4662327 2386314 30793472 38816441 235440 294240 418945 318744 9406 506866 0 253446 336868 172001 36456458 42748052 1514153 0 500616 500616 50232 52139 38521459 43300807 713395 309060 470117 399576 93276 141002 1276788 849638 0.0001 0.0001 5000000 5000000 0 0 0 0 0 0 0.001 0.001 100000000 100000000 39466659 38966988 27213157 26713486 39467 38967 95747666 94385230 12253502 12253502 18929915 18929915 -39612547 -33043113 37244671 42451169 38521459 43300807 454507 262960 1247908 608576 384803 243406 1034934 519331 841343 476633 2351953 1654716 101849 288175 827632 1021573 1056196 1023606 4354941 3238145 -13727 -12279 -24693 -1921 2397918 2044099 8594153 6435686 -1943411 -1781139 -7346245 -5827110 245027 241644 777711 647686 -1698384 -1539495 -6568534 -5179424 0 0 900 0 -1698384 -1539495 -6569434 -5179424 -0.06 -0.06 -0.24 -0.19 27181003 27774436 26909205 27996754 38966988 38967 -12253502 -18929915 94385230 -33043113 42451169 1034346 1034346 499671 500 328090 328590 -6569434 -6569434 39466659 39467 -12253502 -18929915 95747666 -39612547 37244671 -6569434 -5179424 1034346 413640 141362 598464 -24693 -1921 -58800 -176617 110807 -66574 -497460 0 -253446 -705836 164590 39732 429955 35345 70541 92616 -47726 51786 0 -102000 -4381954 -3178357 37585548 39320144 43953000 40739000 6367452 1418856 0 2304042 328590 4500 328590 -2299542 -38075 -12600 2276013 -4071643 2386314 5786348 4662327 1714705 506866 0 Organization and Summary of Significant Accounting Policies<div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Description of Business</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our” or the “Company”) is a global biotechnology platform company based in Jupiter, Florida with operations in the United States, a satellite office in the Netherlands and research organizations performing services under contract to Dyadic in Finland and Spain. Over the past two decades, the Company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has previously licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Myceliophthora thermophila</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> fungus, which the Company named C1. The C1 technology is a robust and versatile fungal expression system for the development and production of enzymes and other proteins.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">On December 31, 2015, the Company sold its industrial technology business to DuPont Danisco (“DuPont”), the industrial biosciences business of DuPont (NYSE: DD) for $75 million (the “DuPont Transaction”). As part of the DuPont Transaction, Dyadic retained co-exclusive rights to the C1 technology for use in all human and animal pharmaceutical applications, and currently has the exclusive ability to enter into sub-license agreements (subject to the terms of the license and to certain exceptions). DuPont retained certain rights to utilize the C1 technology in pharmaceutical applications, including the development and production of pharmaceutical products, for which it will be required to make royalty payments to Dyadic upon commercialization. In certain circumstances, Dyadic may owe a royalty to either DuPont or certain licensors of DuPont, depending upon whether Dyadic elects to utilize certain patents either owned by DuPont or licensed in by DuPont.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">After the DuPont Transaction, the Company has been focused on the biopharmaceutical industry, specifically in further improving and applying the proprietary C1 technology into a safe and efficient gene expression platform to help accelerate the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. We believe that the C1 technology could be beneficial in the development and manufacturing of human and animal vaccines (such as virus-like particles (VLPs) and antigens), monoclonal antibodies (mAbs), Bi-Specific antibodies, Fab antibody fragments, Fc-Fusion proteins, metabolites, and other therapeutic enzymes and proteins. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Effective April 17, 2019, our common stock began trading on the NASDAQ Stock Market LLC’s NASDAQ Capital Market, under the symbol “DYAI”. Prior to the Company’s uplisting to the NASDAQ, the Company’s common stock traded on the OTCQX market.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Summary of Significant Accounting Policies</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Presentation </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The accompanying unaudited condensed consolidated financial statements, including the accounts of the Company and its wholly owned subsidiaries, have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and footnote disclosures normally included in consolidated financial statements have been condensed or omitted pursuant to such rules and regulations. All significant intra-entity transactions and balances have been eliminated in consolidation. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and footnotes as of and for the year ended December 31, 2018, included in our Form 10-K which was filed with the SEC on March 27, 2019.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"> </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In the opinion of management, the accompanying unaudited interim consolidated financial statements reflect all adjustments, which are of a normal recurring nature, considered necessary for a fair presentation of all periods presented. The results of the Company’s operations for any interim periods are not necessarily indicative of the results of operations for any other interim period or for a full fiscal year. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Since concluding the DuPont Transaction, the Company has conducted business in one operating segment, which is identified by the Company based on how resources are allocated, and operating decisions are made. Management evaluates performance and allocates resources based on the Company as a whole.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The preparation of these consolidated financial statements in accordance with GAAP requires management to make estimates and judgments that affect the reported amount of assets and liabilities and related disclosure of contingent assets and liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the applicable period. Actual results may differ from these estimates under different assumptions or conditions. Such differences could be material to the consolidated financial statements.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Concentrations</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company’s financial instruments that are potentially subject to concentrations of credit risk consist primarily of cash and cash equivalents, and investment securities. At times, the Company has cash, cash equivalents, and investment securities at financial institutions exceeding the Federal Depository Insurance Company (“FDIC”) and the Securities Investor Protection Corporation (“SIPC”) insured limit on domestic currency and the Netherlands’ FDIC counterpart for foreign currency. The Company only deals with reputable financial institutions and has not experienced any losses in such accounts. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">For the three months ended September 30, 2019 and 2018, the Company’s revenue was generated from five and four customers, respectively. For the nine months ended September 30, 2019 and 2018, the Company’s revenue was generated from eight and five customers, respectively. As of September 30, 2019 and December 31, 2018, the Company’s accounts receivable was from three and four customers, respectively. The loss of business from one or a combination of the Company’s customers could adversely affect its operations. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company generates a portion of its revenues from customers that are located outside of the United States. For the three months ended September 30, 2019, the Company had three customers outside of the United States (i.e. European and Indian customers) that accounted for approximately 77.0% or $351,000 of total revenue. For the nine months ended September 30, 2019 the Company had three customers outside of the United States that accounted for approximately 73.6% or $918,000 of total revenue. For the three and nine months ended September 30, 2018, 100% of the Company’s revenue was from the United States.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">As of September 30, 2019, the Company had one customer outside of the United States that accounted for approximately 79.3% or $332,000 of accounts receivable. As of December 31, 2018, 100% of the Company’s accounts receivable was from the United States.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash and Cash Equivalents</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We treat highly liquid investments with original maturities of three months or less when purchased as cash equivalents, including money market funds, which are unrestricted for withdrawal or use. </span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Investment Securities</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company invests excess cash balances in short-term and long-term investment grade securities. Short-term investment securities mature within 12 months or less, and long-term investment securities mature between 12 and 18 months from the applicable reporting date. Management determines the appropriate classification of its investments at the time of purchase and reevaluates the classifications at each balance sheet date. The Company’s investments in debt securities have been classified and accounted for as held-to-maturity. Held-to-maturity securities are those securities that the Company has the ability and intent to hold until maturity. Held-to-maturity securities are recorded at amortized cost, adjusted for the amortization or accretion of premiums or discounts. Premiums and discounts are amortized over the life of the related held-to-maturity security. When a debt security is purchased at a premium, both the face value of the debt and premium amount are reflected as investing outflow. Other-than-temporary impairment charges, if incurred, will be included in other income (expense).</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company’s investments in money market funds have been classified and accounted for as available-for-sale securities and presented as cash equivalents on the consolidated balance sheets. As of September 30, 2019 and December 31, 2018, all of our money market funds were invested in U.S. Government money market funds. The Company did not have any investment securities classified as trading as of September 30, 2019 or December 31, 2018.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accounts Receivable</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Accounts receivable consist of billed receivables currently due from customers and unbilled receivables. Unbilled receivables represent the excess of contract revenue (or amounts reimbursable under contracts) over billings to date. Such amounts become billable in accordance with the contract terms, which usually consider the passage of time, achievement of certain milestones or completion of the project. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Outstanding account balances are reviewed individually for collectability. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing accounts receivable. Substantially all of our accounts receivable were current and include unbilled amounts that will be billed and collected over the next twelve months. There was no allowance for doubtful accounts as of September 30, 2019 and December 31, 2018.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Accounts receivable consist of the following:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"><tr><td style="width:1.0%;"/><td style="width:61.836018%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.569546%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.824890%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.569546%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(Unaudited)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(Audited)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Billed receivable </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">66,988 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">193,065 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Unbilled receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">351,957 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">125,679 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">418,945 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">318,744 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Prepaid Expenses and Other Current Assets</span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Prepaid expenses and other current assets consist of the following:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"><tr><td style="width:1.0%;"/><td style="width:61.836018%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.569546%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.824890%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.569546%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(Unaudited)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(Audited)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses - various</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">81,320 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">91,725 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid insurance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">254,997 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">77,249 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">551 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,027 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">336,868 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">172,001 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Equity Method Investment</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company follows Accounting Standards Codification (“ASC”) Subtopic 323-10, Investments - Equity Methods and Joint Ventures, which requires the accounting for investments where the Company can exercise significant influence, but not control of a joint venture or equity investment. See Note 3 for the Company’s investments recorded under the equity method of accounting. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Equity method investments are assessed for impairment whenever events or changes in circumstances indicate that the carrying amount of the investment may not be recoverable. If the decline in value is considered to be other than temporary, the investment is written down to its estimated fair value, which establishes a new cost basis in the investment. </span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accounts Payable</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Accounts payable consist of the following:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"><tr><td style="width:1.0%;"/><td style="width:61.836018%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.569546%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.824890%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.569546%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(Unaudited)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(Audited)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">636,428 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">240,064 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Legal expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">17,283 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">59,684 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">68,996 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">713,395 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">309,060 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accrued Expenses</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Accrued expenses consist of the following:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"><tr><td style="width:1.0%;"/><td style="width:61.836018%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.569546%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.824890%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.569546%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(Unaudited)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(Audited)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Employee wages and benefits</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">353,552 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">268,287 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">77,855 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">49,666 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">38,710 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">81,623 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">470,117 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">399,576 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue Recognition </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company has no pharmaceutical products approved for sale at this point, and all of our revenue to date has been research revenue from third-party collaborations and government grants. The Company is expected to generate future revenue from license agreements and collaborative arrangements, which may include upfront payments for licenses or options to obtain a license, payment for research and development services and milestone payments, in the form of cash or non-cash considerations (e.g., minority equity interest).</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue related to research collaborations and agreements: </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company typically performs research and development services as specified in each respective agreement on a best efforts basis, and recognizes revenue from research funding under collaboration agreements in accordance with the 5-step process outlined in ASC Topic 606 (“Topic 606”): (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We recognize revenue when we satisfy a performance obligation by transferring control of the service to a customer in an amount that reflects the consideration that we expect to receive. Since the performance obligation under our collaboration agreements is generally satisfied over time, we elected to use the input method under Topic 606 to measure the progress toward complete satisfaction of a performance obligation. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Under the input methods, revenue will be recognized on the basis of the entity’s efforts or inputs to the satisfaction of a performance obligation (e.g., resources consumed, labor hours expended, costs incurred, or time elapsed) relative to the total expected inputs to the satisfaction of that performance obligation. The Company believes that the cost-based input method is the best measure of progress to reflect how the Company transfers its performance obligation to a customer. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to budgeted costs to fulfill the performance obligation. These costs consist primarily of full-time equivalent effort and third-party contract costs. Revenue will be recognized based on actual costs incurred as a percentage of total budgeted costs as the Company completes its performance obligations. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company’s performance obligations. In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete the Company’s performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue related to sublicensing agreements: </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">If the sublicense to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue allocated to the license when technology is transferred to the customer and the customer is able to use and benefit from the license.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Milestone payments: </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Company evaluates whether the achievement of the milestones is considered probable and estimates the amount to be included in the transaction price. If the milestone payment is in exchange for a sublicense and is based on the sublicensee’s subsequent sale of product, the Company recognizes milestone payment by applying the accounting guidance for royalties. To date, the Company has not recognized any milestone payment revenue resulting from any of its sublicensing arrangements.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Royalties: </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">With respect to licenses deemed to be the predominant item to which the</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">sales-based royalties relate, including milestone payments based on the level of sales, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or </span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its sublicensing arrangements.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We invoice customers based on our contractual arrangements with each customer, which may not be consistent with the period that revenues are recognized. When there is a timing difference between when we invoice customers and when revenues are recognized, we record either a contract asset (unbilled accounts receivable) or a contract liability (deferred research and development obligations), as appropriate. If upfront fees or considerations related to sublicensing agreement are received prior to the technology transfer, the Company will record the amount received as deferred revenue from licensing agreement. </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">We are not required to disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">The Company adopted a practical expedient to expense sales commissions when incurred because the amortization period would be one year or less.</span></div><div><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and Development Costs </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Research and development (“R&amp;D”) costs are expensed as incurred. R&amp;D costs are for the Company’s internally funded pharmaceutical programs and other governmental and commercial projects. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Research and development costs consist of personnel-related costs, facilities, research-related overhead, services from independent contract research organizations, and other external costs. Research and development costs, including related party, during the three and nine months ended September 30, 2019 and 2018 were as follows: </span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:32.941520%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:13.643275%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.823392%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.643275%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.643275%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.643275%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(Unaudited)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(Unaudited)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(Unaudited)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(Unaudited)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Outside contracted services</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">730,190 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">365,689 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,974,176 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,316,581 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Contracted services - related party</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">101,849 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">288,175 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">827,632 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,021,573 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Personnel related costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">95,269 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">87,307 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">312,321 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">277,856 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Facilities, overhead and other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">15,884 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">23,637 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">65,456 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">60,279 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">943,192 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">764,808 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,179,585 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,676,289 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-indent:18pt;margin-bottom:12pt;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Foreign Currency Transaction Gain or Loss</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company’s foreign subsidiary uses the U.S. dollar as its functional currency, and it initially measures the foreign currency denominated assets and liabilities at the transaction date. Monetary assets and liabilities are then re-measured at exchange rates in effect at the end of each period, and property and non-monetary assets and liabilities are converted at historical rates. </span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Fair Value Measurements</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company applies fair value accounting for certain financial instruments that are recognized or disclosed at fair value in the financial statements. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">Level 1</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> – Quoted prices in active markets for identical assets or liabilities.</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">Level 2</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> – Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">Level 3</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> – Inputs that are generally unobservable and typically reflect management’s estimate of assumptions that market participants would use in pricing the asset or liability.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Certain assets and liabilities on the balance sheets are measured at carrying values, which approximate fair values due to the short-term nature of these balances. Such items include cash and cash equivalents, accounts receivable, accounts payable, prepaid expenses, and accrued expenses. Investments in debt securities are recorded at amortized cost, and their estimated fair value amounts are provided by the third-party broker service for disclosure purposes. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company utilized various methods, including income, cost and market approaches to determine the fair value of its investments in equity interest, which may fall into Level 3 of the fair value hierarchy because of the significant unobservable inputs utilized in these valuation approaches. These inputs can be readily observable, market corroborated, or generally unobservable inputs. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. Our key inputs included, but were not limited to, significant management judgments and estimates, including projections of the timing and amount of the project’s cash flows, determination of a discount rate for the income approach, market multipliers, probability weighting of potential outcomes of legal and regulatory proceedings, and weighting of the valuations produced by the income, cost and market approaches.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Income Taxes</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Tax Cuts and Jobs Act (“TCJA”) was enacted on December 22, 2017 and became effective January 1, 2018. The TCJA contains several key provisions, including a reduction in the U.S. Federal corporate income tax rate from 35% to 21% and a change to the corporate alternative minimum tax (“AMT”). The TCJA’s reduction in the U.S. statutory tax rate had no additional impact on the consolidated financial statement for the year ended December 31, 2018.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> The TCJA eliminated the corporate AMT and permits existing AMT credit carryforwards to be used to reduce the regular tax obligation in 2018, 2019, and 2020. Any AMT credit carryforwards that do not reduce regular taxes are eligible for a 50% refund in 2018 through 2020, and a 100% refund in 2021. Accordingly, we reclassified the balance of the AMT credit from the deferred tax asset to an income tax receivable in 2018. The corresponding balance in the valuation allowance has been reversed into income tax benefit in the amount of $1,001,233. As of September 30, 2019, we have received 50% or approximately $0.5 million refund for tax year 2018 and expect to receive the remaining 50% for tax years 2019 through 2021.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">For the nine months ended September 30, 2019, the Company recorded a provision for income taxes of $900. There were no unrecognized tax benefits as of September 30, 2019 and December 31, 2018. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Deferred tax assets as of September 30, 2019 and December 31, 2018 were approximately $6.9 million and $4.6 million, respectively. Due to the Company’s history of operating losses and the uncertainty regarding our ability to generate taxable income in the future, the Company has established a 100% valuation allowance against deferred tax assets as of September 30, 2019 and December 31, 2018.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">On June 20, 2019, the Company received a letter from the United States Internal Revenue Service (the “IRS”) informing the Company that its 2016 federal tax return was selected for examination. In August 2019, the Company had a meeting with the IRS agent and provided the IRS with all requested information. Thus far, the Company has not been informed of any assessment. As the IRS audit is still in progress, we are unable to predict when the audit will be concluded or whether any assessment will be proposed. </span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Comprehensive Income (Loss)</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Comprehensive income (loss) includes net income (loss) and other revenue, expenses, gains and losses that are recorded as an element of shareholders’ equity but are excluded from net income (loss) under GAAP. The Company does not have any significant transactions that are required to be reported in other comprehensive income (loss), and therefore, does not separately present a statement of comprehensive income (loss) in its consolidated financial statements.</span></div><div><span><br/></span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock-Based Compensation</span></div><div style="text-indent:18pt;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We recognize all share-based payments to employees and our board of directors (“Board of Directors”), as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statement of operations based on the grant date fair values of such payments. Stock-based compensation expense recognized each period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are recorded as they occur.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Net Loss Per Share</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common stock outstanding during the reporting period. Diluted net loss per share adjusts the weighted average number of common stock outstanding for the potential dilution that could occur if common stock equivalents, such as stock options were exercised or converted into common stock, calculated by applying the treasury stock method. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">For each of the three and nine months ended September 30, 2019 and 2018, the effect of the potential exercise of options to purchase 4,006,390 and 3,411,890 shares of common stock, respectively, were excluded from the computation of diluted net loss per share as their effect would have been anti-dilutive.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Pronouncements Not Adopted as of September 30, 2019 </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which modifies the measurement of expected credit losses of certain financial instruments. ASU 2016-13 will be effective for the Company beginning in the first quarter of 2020. The Company is currently evaluating the impact, if any, of this newly issued guidance.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820) which modifies the disclosure requirements on fair value measurements. The effective date for the standard is fiscal years beginning after December 15, 2019, which for the Company is January 1, 2020. Early adoption is permitted. The new disclosure requirements for changes in unrealized gains and losses in other comprehensive income for recurring Level 3 measurements, the range and weighted average of significant unobservable inputs and the amended requirements for the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively. The Company does not expect ASU 2018-13 to have a material impact on our consolidated financial statements.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Other pronouncements issued by the FASB or other authoritative accounting standards group with future effective dates are either not applicable or not significant to our consolidated financial statements. </span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recently Adopted Accounting Pronouncements</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). Under the new guidance, lessees will be required to recognize the assets and liabilities that arise from operating leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. Companies are required to recognize and measure leases using a modified retrospective approach at either the beginning of the earliest comparative period presented or the beginning of the reporting period in which the entity first applies the new standard. ASU 2016-02 was effective for the Company beginning in the first quarter of 2019. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements and related disclosures, as the Company’s leases are one year or less and not required to recognize lease assets or liabilities under the new guidance.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In March 2017, the FASB issued ASU 2017-08, Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization of Purchased Callable Debt Securities. The amendments in this ASU shorten the amortization period for certain callable debt securities held at a premium. The amendments require the premium to be amortized to the earliest call date. The amendments do not require an accounting change for securities held at a discount; the discount continues to be amortized to maturity. The Company adopted the standard on January 1, 2019. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements and related disclosures.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In February 2018, the FASB issued ASU 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. The new guidance allows a reclassification from accumulated other comprehensive income to retained earnings for any stranded tax effects resulting from TCJA that was enacted on December 22, 2017. The new guidance will be effective for the Company beginning in the first quarter of 2019. The Company adopted the standard on January 1, 2019. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements and related disclosures.</span></div>In June 2018, the FASB issued ASU 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Non-employee Share-based Payment Accounting. The standard expands the scope of Topic 718 to include share-based payments issued to non-employees for goods or services, simplifying the accounting for share-based payments to non-employees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years with early adoption permitted, including adoption in an interim period. The Company adopted the standard on January 1, 2019. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements and related disclosures. 75000000 <div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Presentation </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The accompanying unaudited condensed consolidated financial statements, including the accounts of the Company and its wholly owned subsidiaries, have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and footnote disclosures normally included in consolidated financial statements have been condensed or omitted pursuant to such rules and regulations. All significant intra-entity transactions and balances have been eliminated in consolidation. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and footnotes as of and for the year ended December 31, 2018, included in our Form 10-K which was filed with the SEC on March 27, 2019.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"> </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In the opinion of management, the accompanying unaudited interim consolidated financial statements reflect all adjustments, which are of a normal recurring nature, considered necessary for a fair presentation of all periods presented. The results of the Company’s operations for any interim periods are not necessarily indicative of the results of operations for any other interim period or for a full fiscal year. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Since concluding the DuPont Transaction, the Company has conducted business in one operating segment, which is identified by the Company based on how resources are allocated, and operating decisions are made. Management evaluates performance and allocates resources based on the Company as a whole.</span></div> 1 Use of EstimatesThe preparation of these consolidated financial statements in accordance with GAAP requires management to make estimates and judgments that affect the reported amount of assets and liabilities and related disclosure of contingent assets and liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the applicable period. Actual results may differ from these estimates under different assumptions or conditions. Such differences could be material to the consolidated financial statements. ConcentrationsThe Company’s financial instruments that are potentially subject to concentrations of credit risk consist primarily of cash and cash equivalents, and investment securities. At times, the Company has cash, cash equivalents, and investment securities at financial institutions exceeding the Federal Depository Insurance Company (“FDIC”) and the Securities Investor Protection Corporation (“SIPC”) insured limit on domestic currency and the Netherlands’ FDIC counterpart for foreign currency. The Company only deals with reputable financial institutions and has not experienced any losses in such accounts. 5 4 8 5 3 4 3 3 0.770 351000 3 3 0.736 918000 1 1 1 0.793 332000 1 Cash and Cash EquivalentsWe treat highly liquid investments with original maturities of three months or less when purchased as cash equivalents, including money market funds, which are unrestricted for withdrawal or use. <div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Investment Securities</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company invests excess cash balances in short-term and long-term investment grade securities. Short-term investment securities mature within 12 months or less, and long-term investment securities mature between 12 and 18 months from the applicable reporting date. Management determines the appropriate classification of its investments at the time of purchase and reevaluates the classifications at each balance sheet date. The Company’s investments in debt securities have been classified and accounted for as held-to-maturity. Held-to-maturity securities are those securities that the Company has the ability and intent to hold until maturity. Held-to-maturity securities are recorded at amortized cost, adjusted for the amortization or accretion of premiums or discounts. Premiums and discounts are amortized over the life of the related held-to-maturity security. When a debt security is purchased at a premium, both the face value of the debt and premium amount are reflected as investing outflow. Other-than-temporary impairment charges, if incurred, will be included in other income (expense).</span></div>The Company’s investments in money market funds have been classified and accounted for as available-for-sale securities and presented as cash equivalents on the consolidated balance sheets. <div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accounts Receivable</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Accounts receivable consist of billed receivables currently due from customers and unbilled receivables. Unbilled receivables represent the excess of contract revenue (or amounts reimbursable under contracts) over billings to date. Such amounts become billable in accordance with the contract terms, which usually consider the passage of time, achievement of certain milestones or completion of the project. </span></div>Outstanding account balances are reviewed individually for collectability. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing accounts receivable. Substantially all of our accounts receivable were current and include unbilled amounts that will be billed and collected over the next twelve months. 0 0 <div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Accounts receivable consist of the following:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"><tr><td style="width:1.0%;"/><td style="width:61.836018%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.569546%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.824890%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.569546%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(Unaudited)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(Audited)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Billed receivable </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">66,988 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">193,065 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Unbilled receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">351,957 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">125,679 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">418,945 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">318,744 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 66988 193065 351957 125679 418945 318744 <div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Prepaid expenses and other current assets consist of the following:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"><tr><td style="width:1.0%;"/><td style="width:61.836018%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.569546%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.824890%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.569546%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(Unaudited)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(Audited)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses - various</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">81,320 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">91,725 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid insurance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">254,997 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">77,249 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">551 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,027 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">336,868 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">172,001 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 81320 91725 254997 77249 551 3027 336868 172001 <div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Equity Method Investment</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company follows Accounting Standards Codification (“ASC”) Subtopic 323-10, Investments - Equity Methods and Joint Ventures, which requires the accounting for investments where the Company can exercise significant influence, but not control of a joint venture or equity investment. See Note 3 for the Company’s investments recorded under the equity method of accounting. </span></div>Equity method investments are assessed for impairment whenever events or changes in circumstances indicate that the carrying amount of the investment may not be recoverable. If the decline in value is considered to be other than temporary, the investment is written down to its estimated fair value, which establishes a new cost basis in the investment. <div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Accounts payable consist of the following:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"><tr><td style="width:1.0%;"/><td style="width:61.836018%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.569546%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.824890%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.569546%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(Unaudited)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(Audited)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">636,428 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">240,064 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Legal expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">17,283 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">59,684 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">68,996 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">713,395 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">309,060 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 636428 240064 17283 0 59684 68996 713395 309060 Accrued expenses consist of the following:<table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"><tr><td style="width:1.0%;"/><td style="width:61.836018%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.569546%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.824890%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.569546%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(Unaudited)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(Audited)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Employee wages and benefits</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">353,552 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">268,287 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">77,855 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">49,666 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">38,710 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">81,623 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">470,117 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">399,576 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table> 353552 268287 77855 49666 38710 81623 470117 399576 <div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue Recognition </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company has no pharmaceutical products approved for sale at this point, and all of our revenue to date has been research revenue from third-party collaborations and government grants. The Company is expected to generate future revenue from license agreements and collaborative arrangements, which may include upfront payments for licenses or options to obtain a license, payment for research and development services and milestone payments, in the form of cash or non-cash considerations (e.g., minority equity interest).</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue related to research collaborations and agreements: </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company typically performs research and development services as specified in each respective agreement on a best efforts basis, and recognizes revenue from research funding under collaboration agreements in accordance with the 5-step process outlined in ASC Topic 606 (“Topic 606”): (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We recognize revenue when we satisfy a performance obligation by transferring control of the service to a customer in an amount that reflects the consideration that we expect to receive. Since the performance obligation under our collaboration agreements is generally satisfied over time, we elected to use the input method under Topic 606 to measure the progress toward complete satisfaction of a performance obligation. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Under the input methods, revenue will be recognized on the basis of the entity’s efforts or inputs to the satisfaction of a performance obligation (e.g., resources consumed, labor hours expended, costs incurred, or time elapsed) relative to the total expected inputs to the satisfaction of that performance obligation. The Company believes that the cost-based input method is the best measure of progress to reflect how the Company transfers its performance obligation to a customer. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to budgeted costs to fulfill the performance obligation. These costs consist primarily of full-time equivalent effort and third-party contract costs. Revenue will be recognized based on actual costs incurred as a percentage of total budgeted costs as the Company completes its performance obligations. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company’s performance obligations. In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete the Company’s performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue related to sublicensing agreements: </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">If the sublicense to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue allocated to the license when technology is transferred to the customer and the customer is able to use and benefit from the license.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Milestone payments: </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Company evaluates whether the achievement of the milestones is considered probable and estimates the amount to be included in the transaction price. If the milestone payment is in exchange for a sublicense and is based on the sublicensee’s subsequent sale of product, the Company recognizes milestone payment by applying the accounting guidance for royalties. To date, the Company has not recognized any milestone payment revenue resulting from any of its sublicensing arrangements.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Royalties: </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">With respect to licenses deemed to be the predominant item to which the</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">sales-based royalties relate, including milestone payments based on the level of sales, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or </span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its sublicensing arrangements.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We invoice customers based on our contractual arrangements with each customer, which may not be consistent with the period that revenues are recognized. When there is a timing difference between when we invoice customers and when revenues are recognized, we record either a contract asset (unbilled accounts receivable) or a contract liability (deferred research and development obligations), as appropriate. If upfront fees or considerations related to sublicensing agreement are received prior to the technology transfer, the Company will record the amount received as deferred revenue from licensing agreement. </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">We are not required to disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">The Company adopted a practical expedient to expense sales commissions when incurred because the amortization period would be one year or less.</span></div> Research and Development Costs Research and development (“R&amp;D”) costs are expensed as incurred. R&amp;D costs are for the Company’s internally funded pharmaceutical programs and other governmental and commercial projects. Research and development costs, including related party, during the three and nine months ended September 30, 2019 and 2018 were as follows: <table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:32.941520%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:13.643275%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.823392%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.643275%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.643275%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.643275%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(Unaudited)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(Unaudited)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(Unaudited)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(Unaudited)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Outside contracted services</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">730,190 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">365,689 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,974,176 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,316,581 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Contracted services - related party</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">101,849 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">288,175 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">827,632 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,021,573 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Personnel related costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">95,269 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">87,307 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">312,321 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">277,856 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Facilities, overhead and other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">15,884 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">23,637 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">65,456 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">60,279 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">943,192 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">764,808 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,179,585 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,676,289 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table> 730190 365689 1974176 1316581 101849 288175 827632 1021573 95269 87307 312321 277856 15884 23637 65456 60279 943192 764808 3179585 2676289 Foreign Currency Transaction Gain or LossThe Company’s foreign subsidiary uses the U.S. dollar as its functional currency, and it initially measures the foreign currency denominated assets and liabilities at the transaction date. Monetary assets and liabilities are then re-measured at exchange rates in effect at the end of each period, and property and non-monetary assets and liabilities are converted at historical rates. <div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Fair Value Measurements</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company applies fair value accounting for certain financial instruments that are recognized or disclosed at fair value in the financial statements. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">Level 1</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> – Quoted prices in active markets for identical assets or liabilities.</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">Level 2</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> – Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">Level 3</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> – Inputs that are generally unobservable and typically reflect management’s estimate of assumptions that market participants would use in pricing the asset or liability.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Certain assets and liabilities on the balance sheets are measured at carrying values, which approximate fair values due to the short-term nature of these balances. Such items include cash and cash equivalents, accounts receivable, accounts payable, prepaid expenses, and accrued expenses. Investments in debt securities are recorded at amortized cost, and their estimated fair value amounts are provided by the third-party broker service for disclosure purposes. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company utilized various methods, including income, cost and market approaches to determine the fair value of its investments in equity interest, which may fall into Level 3 of the fair value hierarchy because of the significant unobservable inputs utilized in these valuation approaches. These inputs can be readily observable, market corroborated, or generally unobservable inputs. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. Our key inputs included, but were not limited to, significant management judgments and estimates, including projections of the timing and amount of the project’s cash flows, determination of a discount rate for the income approach, market multipliers, probability weighting of potential outcomes of legal and regulatory proceedings, and weighting of the valuations produced by the income, cost and market approaches.</span></div> Income TaxesThe Tax Cuts and Jobs Act (“TCJA”) was enacted on December 22, 2017 and became effective January 1, 2018. The TCJA contains several key provisions, including a reduction in the U.S. Federal corporate income tax rate from 35% to 21% and a change to the corporate alternative minimum tax (“AMT”). 1001233 500000 900 0 0 6900000 4600000 1 1 <div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Comprehensive Income (Loss)</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Comprehensive income (loss) includes net income (loss) and other revenue, expenses, gains and losses that are recorded as an element of shareholders’ equity but are excluded from net income (loss) under GAAP. The Company does not have any significant transactions that are required to be reported in other comprehensive income (loss), and therefore, does not separately present a statement of comprehensive income (loss) in its consolidated financial statements.</span></div> <div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock-Based Compensation</span></div><div style="text-indent:18pt;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We recognize all share-based payments to employees and our board of directors (“Board of Directors”), as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statement of operations based on the grant date fair values of such payments. Stock-based compensation expense recognized each period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are recorded as they occur.</span></div> Net Loss Per ShareBasic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common stock outstanding during the reporting period. Diluted net loss per share adjusts the weighted average number of common stock outstanding for the potential dilution that could occur if common stock equivalents, such as stock options were exercised or converted into common stock, calculated by applying the treasury stock method. 4006390 4006390 3411890 3411890 <div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Pronouncements Not Adopted as of September 30, 2019 </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which modifies the measurement of expected credit losses of certain financial instruments. ASU 2016-13 will be effective for the Company beginning in the first quarter of 2020. The Company is currently evaluating the impact, if any, of this newly issued guidance.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820) which modifies the disclosure requirements on fair value measurements. The effective date for the standard is fiscal years beginning after December 15, 2019, which for the Company is January 1, 2020. Early adoption is permitted. The new disclosure requirements for changes in unrealized gains and losses in other comprehensive income for recurring Level 3 measurements, the range and weighted average of significant unobservable inputs and the amended requirements for the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively. The Company does not expect ASU 2018-13 to have a material impact on our consolidated financial statements.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Other pronouncements issued by the FASB or other authoritative accounting standards group with future effective dates are either not applicable or not significant to our consolidated financial statements. </span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recently Adopted Accounting Pronouncements</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). Under the new guidance, lessees will be required to recognize the assets and liabilities that arise from operating leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. Companies are required to recognize and measure leases using a modified retrospective approach at either the beginning of the earliest comparative period presented or the beginning of the reporting period in which the entity first applies the new standard. ASU 2016-02 was effective for the Company beginning in the first quarter of 2019. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements and related disclosures, as the Company’s leases are one year or less and not required to recognize lease assets or liabilities under the new guidance.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In March 2017, the FASB issued ASU 2017-08, Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization of Purchased Callable Debt Securities. The amendments in this ASU shorten the amortization period for certain callable debt securities held at a premium. The amendments require the premium to be amortized to the earliest call date. The amendments do not require an accounting change for securities held at a discount; the discount continues to be amortized to maturity. The Company adopted the standard on January 1, 2019. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements and related disclosures.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In February 2018, the FASB issued ASU 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. The new guidance allows a reclassification from accumulated other comprehensive income to retained earnings for any stranded tax effects resulting from TCJA that was enacted on December 22, 2017. The new guidance will be effective for the Company beginning in the first quarter of 2019. The Company adopted the standard on January 1, 2019. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements and related disclosures.</span></div>In June 2018, the FASB issued ASU 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Non-employee Share-based Payment Accounting. The standard expands the scope of Topic 718 to include share-based payments issued to non-employees for goods or services, simplifying the accounting for share-based payments to non-employees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years with early adoption permitted, including adoption in an interim period. The Company adopted the standard on January 1, 2019. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements and related disclosures. Cash, Cash Equivalent, and Investments <div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company’s investments in debt securities are classified as held-to-maturity and are recorded at amortized cost, and its investments in money market funds are classified as cash equivalents. The following table shows the Company’s cash, available-for-sale securities, and short-term and long-term investment securities by major security type as of September 30, 2019 and December 31, 2018:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"><tr><td style="width:1.0%;"/><td style="width:33.871157%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:4.442167%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532064%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.884334%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.824890%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.469985%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.824890%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.055637%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.824890%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.469985%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2019 (Unaudited)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Gross</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Gross</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Level</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:6.5pt;font-weight:700;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Holding Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Holding Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Adjusted Cost</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and Cash Equivalents</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">552,569 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">552,569 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Money Market Funds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4,109,758 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4,109,758 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4,662,327 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4,662,327 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Short-Term Investment Securities </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:6.5pt;font-weight:700;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Corporate Bonds </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(4)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">30,794,626 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">16,862 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(15,708)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">30,793,472 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Long-Term Investment Securities </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:6.5pt;font-weight:700;line-height:100%;vertical-align:top;">(3)</sup></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Corporate Bonds </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(4)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,527,865 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">13,712 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,514,153 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">36,984,818 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">30,574 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(15,708)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">36,969,952 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:33.818713%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:4.432749%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.865497%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.823392%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.450292%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.823392%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.035088%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.823392%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.450292%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619883%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619883%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018 (Audited)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Gross</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Gross</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Level</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:6.5pt;font-weight:700;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Holding Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Holding Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Adjusted Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and Cash Equivalents</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,048,272 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,048,272 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Money Market Funds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,338,042 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,338,042 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,386,314 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,386,314 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Short-Term Investment Securities </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:6.5pt;font-weight:700;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Corporate Bonds </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(4)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">38,731,120 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(85,321)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">38,816,441 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">41,117,434 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(85,321)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">41,202,755 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">_________________</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Notes:</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">(1) Definition of the three-level fair value hierarchy:</span></div><div style="text-indent:-13.5pt;padding-left:31.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities</span></div><div style="text-indent:-13.5pt;padding-left:31.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">Level 2 - Other inputs that are directly or indirectly observable in the markets</span></div><div style="text-indent:-13.5pt;padding-left:31.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">Level 3 - Inputs that are generally unobservable </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">(2) Short-term investment securities will mature within 12 months or less, from the applicable reporting date.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">(3) Long-term investment securities will mature between 12 and 18 months, from the applicable reporting date.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">(4) The premium paid to purchase held-to-maturity investment securities was $54,385 and $0 for the three months ended September 30, 2019 and 2018, respectively. The premium paid to purchase held-to-maturity investment securities was $158,548 </span></div>and $205,038 for the nine months ended September 30, 2019 and 2018, respectively. The premium paid to purchase held-to-maturity investment securities was $378,681 for the year ended December 31, 2018.The Company considers the declines in market value of its investment portfolio to be temporary in nature. The Company’s investment policy requires investment securities to be investment grade and held to maturity with the primary objective to maintain a high degree of liquidity while maximizing yield. When evaluating an investment for other-than-temporary impairment, the Company reviews factors such as the length of time and extent to which fair value has been below its cost basis, the financial condition of the issuer and any changes thereto, changes in market interest rates, and whether it is more likely than not the Company will be required to sell the investment before recovery of the investment’s cost basis. As of September 30, 2019, the Company does not consider any of its investments to be other-than-temporarily impaired. The following table shows the Company’s cash, available-for-sale securities, and short-term and long-term investment securities by major security type as of September 30, 2019 and December 31, 2018:<div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"><tr><td style="width:1.0%;"/><td style="width:33.871157%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:4.442167%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532064%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.884334%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.824890%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.469985%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.824890%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.055637%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.824890%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.469985%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2019 (Unaudited)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Gross</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Gross</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Level</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:6.5pt;font-weight:700;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Holding Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Holding Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Adjusted Cost</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and Cash Equivalents</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">552,569 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">552,569 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Money Market Funds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4,109,758 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4,109,758 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4,662,327 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4,662,327 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Short-Term Investment Securities </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:6.5pt;font-weight:700;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Corporate Bonds </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(4)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">30,794,626 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">16,862 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(15,708)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">30,793,472 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Long-Term Investment Securities </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:6.5pt;font-weight:700;line-height:100%;vertical-align:top;">(3)</sup></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Corporate Bonds </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(4)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,527,865 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">13,712 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,514,153 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">36,984,818 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">30,574 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(15,708)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">36,969,952 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:33.818713%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:4.432749%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.865497%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.823392%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.450292%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.823392%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.035088%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.823392%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.450292%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619883%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619883%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018 (Audited)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Gross</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Gross</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Level</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:6.5pt;font-weight:700;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Holding Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Holding Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Adjusted Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and Cash Equivalents</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,048,272 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,048,272 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Money Market Funds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,338,042 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,338,042 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,386,314 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,386,314 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Short-Term Investment Securities </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:6.5pt;font-weight:700;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Corporate Bonds </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(4)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">38,731,120 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(85,321)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">38,816,441 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">41,117,434 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(85,321)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">41,202,755 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">_________________</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Notes:</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">(1) Definition of the three-level fair value hierarchy:</span></div><div style="text-indent:-13.5pt;padding-left:31.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities</span></div><div style="text-indent:-13.5pt;padding-left:31.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">Level 2 - Other inputs that are directly or indirectly observable in the markets</span></div><div style="text-indent:-13.5pt;padding-left:31.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">Level 3 - Inputs that are generally unobservable </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">(2) Short-term investment securities will mature within 12 months or less, from the applicable reporting date.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">(3) Long-term investment securities will mature between 12 and 18 months, from the applicable reporting date.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">(4) The premium paid to purchase held-to-maturity investment securities was $54,385 and $0 for the three months ended September 30, 2019 and 2018, respectively. The premium paid to purchase held-to-maturity investment securities was $158,548 </span></div>and $205,038 for the nine months ended September 30, 2019 and 2018, respectively. The premium paid to purchase held-to-maturity investment securities was $378,681 for the year ended December 31, 2018. 552569 552569 4109758 4109758 4662327 4662327 30794626 16862 15708 30793472 1527865 13712 0 1514153 36984818 30574 15708 36969952 1048272 1048272 1338042 1338042 2386314 2386314 38731120 0 85321 38816441 41117434 0 85321 41202755 54385 0 158548 205038 378681 Research Collaboration and Sub-licensing Agreements<div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">BDI Agreements</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">On June 30, 2017, the Company entered into a strategic Research Services Agreement (the “RSA”) with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U. (“BDI Pharma”), and a Service Framework Agreement (the “SFA”, and together with the RSA, the “R&amp;D Agreements”), with VLP The Vaccines Company, S.L.U. (“VLPbio”), both of which are subsidiaries of Biotechnology Developments for Industry, S.L., a Spanish biotechnology company (“BDI Holdings” and together with BDI Pharma and VLPbio, “BDI”). </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The R&amp;D Agreements provide a framework under which the parties will engage in a research and development collaboration encompassing several different projects over approximately a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNhOGM2N2M3MTJiNzRiYTY4NGM5NDMyYTlkMGNhYjMwL3NlYzozYThjNjdjNzEyYjc0YmE2ODRjOTQzMmE5ZDBjYWIzMF80Ni9mcmFnOmMwOGVjYTNkNWQ1MTQxNDhhZTllYTk5YWEwMmRlOTNhL3RleHRyZWdpb246YzA4ZWNhM2Q1ZDUxNDE0OGFlOWVhOTlhYTAyZGU5M2FfNzcx_cfb5843b-f985-4f17-839d-04b0499eadd0">two</span>-year period, with a focus on advancing Dyadic’s proprietary C1 technology in the development of next generation biological vaccines and drugs. Dyadic expects to leverage the BDI team’s previous C1 gene expression and industrial fermentation scale-up and commercialization experience with yeast and filamentous fungi processes to further advance Dyadic’s proprietary C1 technology with the potential to commercialize certain biopharmaceutical product(s). All of the data and any products developed from the funded research projects will be owned by Dyadic. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Upon closing of the BDI transaction, the Company paid EUR €1 million (the “RSA Initial Payment”) in cash to engage BDI to develop designated C1 based product candidates and further improve the C1 manufacturing process, in consideration of which Dyadic also received a 16.1% equity interest in BDI Holdings and a 3.3% equity interest in VLPbio. BDI is obligated to spend a minimum amount of EUR €936,000 over two years in the conduct of the research and development project under the RSA. If the research and development activities produce a product that is selected for additional development and commercialization, then Dyadic expects to share with BDI a range of between 50% and 75% of the net income from such selected product, depending upon the amount of BDI’s aggregate spend in the development of the selected product, with a minimum aggregate spend by BDI of EUR €1 million for a 50% share and EUR €8 million for a 75% share. If BDI does not enter into an agreement with Dyadic for such additional development and commercialization of the selected product, then Dyadic will pay to BDI EUR €1.5 million of the net income from Dyadic’s commercialization, if any, of the selected product. In addition, under the SFA, Dyadic agreed to purchase from BDI at least USD $1 million (the “SFA Commitment”) in contract research services specified by Dyadic over two years since the closing of the BDI transaction. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">The Company has concluded that BDI is not a Variable Interest Entity (“VIE”), because BDI has sufficient equity to finance its activities without additional subordinated financial support and its at-risk equity holders have the characteristics of a controlling financial interest. Additionally, Dyadic is not the primary beneficiary of BDI as Dyadic does not have the power to control or direct the activities of BDI or its operations. As a result, the Company does not consolidate its investments in BDI, and the financial results of BDI are not included in the Company’s consolidated financial results. Dyadic has fulfilled its SFA commitment, however it is and may in the future continue to provide funding to BDI for certain research and commercialization projects. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company performed a valuation analysis of the components of the transaction and allocated the consideration based on the relative fair value of each component. As the fair value of BDI equity interest was considered immaterial, the RSA Initial Payment of approximately USD $1.1 million (EUR €1 million) was accounted for as a prepaid research and development collaboration payment on our consolidated balance sheet, and both the collaboration payment under the RSA and the remaining SFA Commitment of USD $1 million paid by Dyadic will be expensed as the related research services are performed by BDI. BDI has completed its services under the RSA in June 2019, and the entire amount of the RSA Initial Payment was expensed. Under the SFA, there were four research projects completed and three research projects in progress, and we do not have any outstanding commitment under the SFA as of September 30, 2019.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">As of September 30, 2019 and December 31, 2018, the prepaid research and development collaboration related to BDI recorded on our consolidated balance sheets were none and approximately $0.3 million, respectively. For the three months ended September 30, 2019 and 2018, research and development expenses related to BDI were recorded as research and development - related party in our consolidated statements of operations in the amount of approximately $0.1 million and $0.3 million, respectively. For the nine months ended September 30, 2019 and 2018, research and development expenses related to BDI were recorded as research and development - related party in our consolidated statements of operations in the amount of approximately $0.8 million and $1.0 million, respectively.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Novovet and Luina Bio Sub-License Agreement</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">On April 26, 2019, the Company entered into a sub-license agreement (the “Luina Bio Sub-License Agreement”) with Luina Bio Pty Ltd. (“Luina Bio”) and Novovet Pty Ltd (“Novovet”). Under the terms of the Luina Bio Sub-License Agreement, the Company has granted to Novovet, subject to the terms of the license agreement entered into between the Company and Danisco US, Inc. on December 31, 2015, a worldwide sub-license to certain patent rights and know-how related to Dyadic’s proprietary C1 gene expression platform for the exclusive and sole purpose of commercializing certain targeted antigen and biological products for the prevention and treatment of various ailments for companion animals.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In consideration of the license granted pursuant to the Luina Bio Sub-License Agreement, Dyadic received a 20% equity interest in Novovet (“Novovet Up-Front Consideration”) in accordance with the terms of Novovet’s Shareholder Agreement (“Shareholders Agreement”), and will receive a percentage of royalties on future net sales and non-sales revenue, if any, which incorporates Dyadic's proprietary C1 gene expression platform. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company evaluated the nature of its equity interest investment in Novovet and determined that Novovet is a Variable Interest Entity (“VIE”), because Novovet does not have sufficient equity to finance its activities without additional financial support from third party investors or lenders. However, the Company is not the primary beneficiary of Novovet as Dyadic does not have the power to control or direct the activities of Novovet that most significantly impact the VIE. As a result, the Company will not consolidate its investment in Novovet, but account for under the equity method investment, given that it has the ability to exercise significant influence, but not control, over Novovet. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">As of September 30, 2019, the technology transfer of the Company’s C1 platform has not been completed and Novovet has not raised sufficient capital to support its required research and drug development activities. Therefore, the Novovet Up-Front Consideration received under the Luina Bio Sub-License Agreement, in the form of a 20% equity interest in Novovet, does not yet meet the revenue recognition criteria under ASC 606. The Company will account for its investment in Novovet and the related income under the equity method of accounting, once the transfer of its C1 technology is completed and Novovet receives adequate financing required to commence its research and development activities.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Shareholder Agreement provides that, for as long as the Company has a respective proportion of Novovet equal to or more than 20% it may designate one individual to serve on the Board of Directors of Novovet. The Dyadic appointee is Mark Emalfarb, Dyadic’s CEO. Pursuant to the terms of the Shareholders Agreement, the Company agreed, subject to certain exceptions, not to sell, transfer, assign, convey or otherwise dispose of its interests in Novovet. In addition, the Company is entitled to or subject to, as applicable, anti-dilution rights, tag along rights and drag along rights, each as described in the Shareholders Agreement.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Alphazyme Sub-License Agreement</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">On May 5, 2019, the Company entered into a sub-license agreement (the “Alphazyme Sub-License Agreement”) with Alphazyme, LLC (“Alphazyme”). Under the terms of the Alphazyme Sub-License Agreement, the Company has granted to Alphazyme, subject to the terms of the license agreement entered into between the Company and Danisco US, Inc. on December 31, 2015, a sub-license to certain patent rights and know-how related to Dyadic’s proprietary C1 gene expression platform for the purpose of commercializing certain pharmaceutical products that are used as reagents to catalyze a chemical reaction to detect, measure, or be used as a process intermediate to produce a nucleic acid as a therapeutic or diagnostic agent.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In consideration of the license granted pursuant to the Alphazyme Sub-License Agreement, Dyadic will receive a 7.5% ownership interest in Alphazyme (“Alphazyme Up-Front Consideration”) upon the successful transfer of C1 technology, additional milestone payments and a percentage of royalties on net sales, if any, which incorporate Dyadic's proprietary C1 gene expression platform. The Alphazyme Sub-License Agreement has an initial exclusivity period of 18 months (“Exclusivity Period”) beginning on the date the technology transfer has been completed. Following the Exclusivity Period, the sub-license will be nonexclusive. At any time prior to the expiration of the Exclusivity Period, </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Alphazyme has the option to extend the Exclusivity Period for an additional twelve (12) months in return for an additional 2.5% ownership interest in Alphazyme.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company evaluated the nature of its equity interest investment in Alphazyme and determined that Alphazyme is a Variable Interest Entity (“VIE”) due to the capital structure of the entity. However, the Company is not the primary beneficiary of Alphazyme as Dyadic does not have the power to control or direct the activities of Alphazyme that most significantly impact the VIE. As a result, the Company does not consolidate its investments in Alphazyme. The Company will account for its investment in Alphazyme under the equity method, given that it has the ability to exercise significant influence, but not control, over Alphazyme. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">As of September 30, 2019, the technology transfer of the C1 platform has not completed and Dyadic has not received the Alphazyme Up-Front Consideration. Therefore, no revenue form the Alphazyme Sub-Licensing Agreement was recorded at September 30, 2019.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Upon receipt of the Alphazyme Up-Front Consideration, Dyadic will become a party to the Alphazyme Limited Liability Company Agreement pursuant to which the Company will agree to certain customary rights, covenants and obligations.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and Commercialization Collaboration with Serum</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">On May 7, 2019, the Company entered into a research and commercialization collaboration with Serum Institute of India Pvt., Ltd (“Serum”). Under the terms of this collaboration, Serum anticipates applying Dyadic’s C1 technology to express up to twelve (12) antibodies and vaccines and will undertake commercially best efforts to fully develop and commercialize the proteins expressed from Dyadic’s C1 technology. Dyadic has agreed to grant Serum the option to obtain an exclusive commercial sub-license for each of the twelve (12) proteins in return for certain research funding, milestone payments and royalties for 15 years from the date of the first commercial sale.</span></div>For the three and nine month ended September 30, 2019, the Company recognized approximately $13,000 in research revenue from Serum. As of September 30, 2019, the Company has approximately $70,000 in deferred revenue related to this agreement. 1000000 0.161 0.033 936000 P2Y 0.50 0.75 1000000 0.50 8000000 0.75 1500000 1000000 P2Y 1100000 1000000 1000000 4 3 0 300000 100000 300000 800000 1000000.0 0.20 0.20 0.075 P18M P12M 0.025 12 12 P15Y 13000 13000 70000 Commitments and Contingencies<div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Leases</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Jupiter, Florida Headquarters</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company’s corporate headquarters are located in Jupiter, Florida. The Company occupies approximately 4,900 square feet with a monthly rental rate and common area maintenance charges of approximately $9,700. The lease expires on June 30, 2020, and thereafter, the Company will reconsider the square footage of the leased space to align with the staffing requirements of the future operations of the Company. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">The Netherlands Office</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company maintains a small satellite office in Wageningen, The Netherlands. In 2018, the Company occupied approximately 258 square feet with annual rentals and common area maintenance charges of approximately $4,700. The lease expired on January 31, 2019, and thereafter, the Company entered into a new lease with the same lessor (the “New Lease”). The New Lease has a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNhOGM2N2M3MTJiNzRiYTY4NGM5NDMyYTlkMGNhYjMwL3NlYzozYThjNjdjNzEyYjc0YmE2ODRjOTQzMmE5ZDBjYWIzMF81Mi9mcmFnOjA5ZTFmMGU4NGNmZTQ0MjE5MmM2MTMxNmQwNDQ3YjFmL3RleHRyZWdpb246MDllMWYwZTg0Y2ZlNDQyMTkyYzYxMzE2ZDA0NDdiMWZfODUw_ea74b704-850b-4351-81f6-fde731371d7e">one</span>-year term and includes a flexible office space with annual rentals of approximately $4,000. </span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">VTT Research Contract Extension</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">On June 28, 2019, the Company extended its research contract (“Contract”) through June 2022 with VTT Technical Research Centre of Finland Ltd. (“VTT”). Under the terms of this Contract, Dyadic will pay VTT a total of EUR €2.52 million over the next three years to continue developing Dyadic’s C1 fungal expression system for therapeutic protein production, including C1 host system improvement, glycoengineering, and management of third-party target protein projects. VTT is subject to an additional success bonus up to EUR €450,000 based on the technical targets stipulated in the Contract. Dyadic and its sublicensees will also have the right to use synthetic promoters developed by VTT with an access fee. On October 25, 2019, the Company expanded the Contract to pay an additional EUR €690,000 over the next 1.5 years to reinforce the glycoengineering work. Dyadic retains the right to terminate the Contract with 90 days’ notice.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Legal Proceedings</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. The Company does not believe that any of these claims or proceedings against us is likely to have, individually or in the aggregate, a material adverse effect on the financial condition or results of operations.</span></div> 4900 9700 258 4700 4000 2520000 P3Y 450000 690000 P1Y6M P90D Share-Based Compensation<div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Description of Equity Plans</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The 2011 Equity Incentive Plan (the “2011 Plan”) was adopted by the Company’s Board of Directors on April 28, 2011 and approved by the Company’s stockholders on June 15, 2011. The 2011 Plan serves as the successor to the Company’s 2006 Stock Option Plan (the “2006 Plan”). Since the effective date of the 2011 Plan, all equity awards were made from the 2011 Plan, and no additional awards will be granted under the 2006 plan. Under the 2011 Plan, 3,000,000 shares of the Company’s common stock have been initially reserved for issuance pursuant to a variety of share-based compensation awards, plus any shares available for issuance under the 2006 Plan or are subject to awards under the 2006 Plan which are forfeited or lapse unexercised and which following the effective date are not issued under the 2006 Plan. In accordance with the provisions of the 2011 Plan, the Board of Directors approved an increase of 1,500,000 shares to the plan on January 1, 2019. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">As of September 30, 2019, the Company had 4,006,390 stock options outstanding and an additional 1,547,211 shares of common stock available for grant under the 2011 Plan. As of December 31, 2018, there were 3,552,890 stock options outstanding and 1,136,211 shares of common stock available for grant under the 2011 Plan. </span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock Options </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Options are granted to purchase common stock at prices that are equal to the fair value of the common stock on the date the option is granted. Vesting is determined by the Board of Directors at the time of grant. The term of any stock option awards under the Company’s 2011 Plan is no more than ten years except for qualified options granted to the CEO (five years) and certain contractors (two years).</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The grant-date fair value of each option grant is estimated using the Black-Scholes option pricing model and amortized on a straight-line basis over the requisite service period, which is generally the vesting period, for each separately vesting portion of the award as if the award was, in substance, multiple awards. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs, including the following:</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Risk-free interest rate</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">. The risk-free interest rate is based on U.S. Treasury rates with securities approximating the expected lives of options at the date of grant. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected dividend yield</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">. The expected dividend yield is zero, as the Company has never paid dividends to common shareholders and does not currently anticipate paying any in the foreseeable future. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected stock price volatility.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> The expected stock price volatility was calculated based on the Company’s own volatility after the DuPont Transaction. The Company reviews its volatility assumption on an annual basis and has used the Company’s historical volatility since 2016, as the DuPont Transaction resulted in significant changes in the Company’s business and capital structure. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected life of option. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The expected life of option was based on the contractual term of the option and expected employee exercise and post-vesting employment termination behavior. The Company uses the weighted average vesting period and contractual term of the option as the best estimate of the expected life of a new option, except for the qualified options granted to the CEO (i.e., 5 years) and certain contractors (i.e., 2 years). </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Discount for lack of marketability.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> The Company applied a discount to reflect the lack of marketability due to the holding period restriction of its shares under Rule 144 prior to its April 2019 uplisting to the NASDAQ. The discount for lack of marketability is no longer applicable since the uplisting of the Company’s common stock.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The assumptions used in the Black-Scholes option pricing model for stock options granted through the nine months ended September 30, 2019 are as follows:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"><tr><td style="width:1.0%;"/><td style="width:58.761347%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:37.238653%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-Free interest rate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">1.69% - 2.50%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Expected dividend yield</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Expected stock price volatility</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">28.59% - 37.29%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Expected life of options</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">2 - 6.25 Years</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Discount for lack of marketability</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">0.0% - 8.48%</span></div></td></tr></table></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the stock option activities for the nine months ended September 30, 2019: </span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:41.859649%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.304094%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.823392%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.304094%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.823392%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.304094%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.823392%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.304094%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average Exercise Price</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December 31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,552,890 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$1.57</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5.06</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$1,149,461</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Granted</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"> (1)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,089,000 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2.26 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Exercised </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(635,500)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.62 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Expired</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Canceled </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at September 30, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4,006,390 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$1.75</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5.89</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$17,556,185</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable at September 30, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,764,073 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$1.64</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4.65</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$12,408,351</span></td></tr></table></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">_________________</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Notes:</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">(1) Represents the following stock options granted:</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Annual share-based compensation awards on January 2, 2019, including: (a) 600,000 stock options with an exercise price of $1.87 per share granted to executives and key personnel, vesting upon grant, or one year anniversary, or vest annually in equal installments over four years, (b) 300,000 stock options with an exercise price of $1.87 per share granted to the Board of Directors, vesting 25% upon grant and the remaining 75% will vest annually in equal installments over four years, and (c) 24,000 stock options with an exercise price of $1.87 per share granted to employees, vesting annually in equal installments over four years. </span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">One-time awards granted on (a) January 2, 2019 of 50,000 stock options with an exercise price of $1.87 per share granted to a contractor, vesting upon one year anniversary, (b) March 7, 2019 of 15,000 stock options with an exercise price of $3.00 per share granted to a contractor, vesting upon one year anniversary, (c) June 25, 2019 of 75,000 stock options with an exercise price of $5.83 per share granted to three members of the Board of Directors, vesting upon one year anniversary, and (d) June 28, 2019 of 25,000 stock options with an exercise price of $6.26 per share granted to the Chief Financial Officer, vesting immediately.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">(2) Represents the following stock options exercised:</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">A total of 635,500 stock options exercised with a weighted average market price of $1.62, including (a) net share exercise of 440,000 stock options resulting in the issuance of 304,171 shares of common stock, and surrender of 135,829 shares, and (b)195,500 stock options exercised with cash payment. </span></div><div><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Compensation Expenses</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We recognize all share-based payments to employees and our Board of Directors, as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statement of operations, and these charges had no impact on the Company’s reported cash flows. Stock-based compensation expense is calculated on the grant date fair values of such awards, and recognized each period based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are recorded as they occur.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Total non-cash stock option compensation expense was allocated among the following expense categories: </span></div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"/><td style="width:25.419355%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.595308%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.595308%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.595308%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.595308%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">118,754 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">51,887 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">957,843 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">356,024 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">25,426 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">18,733 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">76,503 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">57,616 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">144,180 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">70,620 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,034,346 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">413,640 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table> 0 3000000 1500000 4006390 1547211 3552890 1136211 P10Y P5Y P2Y 0 P5Y P2Y The assumptions used in the Black-Scholes option pricing model for stock options granted through the nine months ended September 30, 2019 are as follows:<table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"><tr><td style="width:1.0%;"/><td style="width:58.761347%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:37.238653%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-Free interest rate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">1.69% - 2.50%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Expected dividend yield</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Expected stock price volatility</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">28.59% - 37.29%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Expected life of options</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">2 - 6.25 Years</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Discount for lack of marketability</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">0.0% - 8.48%</span></div></td></tr></table> 0.0169 0.0250 0 0.2859 0.3729 P2Y P6Y3M 0.000 0.0848 <div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the stock option activities for the nine months ended September 30, 2019: </span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:41.859649%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.304094%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.823392%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.304094%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.823392%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.304094%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.823392%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.304094%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average Exercise Price</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December 31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,552,890 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$1.57</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5.06</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$1,149,461</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Granted</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"> (1)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,089,000 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2.26 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Exercised </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(635,500)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.62 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Expired</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Canceled </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at September 30, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4,006,390 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$1.75</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5.89</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$17,556,185</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable at September 30, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,764,073 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$1.64</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4.65</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$12,408,351</span></td></tr></table></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">_________________</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Notes:</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">(1) Represents the following stock options granted:</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Annual share-based compensation awards on January 2, 2019, including: (a) 600,000 stock options with an exercise price of $1.87 per share granted to executives and key personnel, vesting upon grant, or one year anniversary, or vest annually in equal installments over four years, (b) 300,000 stock options with an exercise price of $1.87 per share granted to the Board of Directors, vesting 25% upon grant and the remaining 75% will vest annually in equal installments over four years, and (c) 24,000 stock options with an exercise price of $1.87 per share granted to employees, vesting annually in equal installments over four years. </span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">One-time awards granted on (a) January 2, 2019 of 50,000 stock options with an exercise price of $1.87 per share granted to a contractor, vesting upon one year anniversary, (b) March 7, 2019 of 15,000 stock options with an exercise price of $3.00 per share granted to a contractor, vesting upon one year anniversary, (c) June 25, 2019 of 75,000 stock options with an exercise price of $5.83 per share granted to three members of the Board of Directors, vesting upon one year anniversary, and (d) June 28, 2019 of 25,000 stock options with an exercise price of $6.26 per share granted to the Chief Financial Officer, vesting immediately.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">(2) Represents the following stock options exercised:</span></div>•A total of 635,500 stock options exercised with a weighted average market price of $1.62, including (a) net share exercise of 440,000 stock options resulting in the issuance of 304,171 shares of common stock, and surrender of 135,829 shares, and (b)195,500 stock options exercised with cash payment. 3552890 1.57 P5Y21D 1149461 1089000 2.26 635500 1.62 0 0 0 0 4006390 1.75 P5Y10M20D 17556185 2764073 1.64 P4Y7M24D 12408351 600000 1.87 P1Y P4Y 300000 1.87 0.25 0.75 P4Y 24000 1.87 P4Y 50000 1.87 P1Y 15000 3.00 P1Y 75000 5.83 3 P1Y 25000 6.26 635500 1.62 440000 304171 135829 195500 Total non-cash stock option compensation expense was allocated among the following expense categories: <table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"/><td style="width:25.419355%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.595308%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.595308%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.595308%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.595308%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">118,754 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">51,887 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">957,843 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">356,024 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">25,426 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">18,733 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">76,503 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">57,616 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">144,180 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">70,620 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,034,346 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">413,640 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table> 118754 51887 957843 356024 25426 18733 76503 57616 144180 70620 1034346 413640 Shareholders’ Equity<div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Issuances of Common Stock</span></div><div style="text-indent:54pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">For the nine months ended September 30, 2019, there were 499,671 shares of the Company’s common stock issued as a result of the exercise of stock options with a weighted average issue price of $1.62 per share. For the nine months ended September 30, 2018, no shares were issued. </span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.830409%;"><tr><td style="width:1.0%;"/><td style="width:20.633136%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.835503%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.792899%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.835503%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.792899%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.835503%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.792899%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.835503%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.792899%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.835503%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.017751%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="26" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30, 2019 (Unaudited)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Treasury Stock </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Additional Paid-In Capital </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated Deficit </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">January 1, 2019</span></td><td colspan="2" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">38,967 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(18,929,915)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">94,385,230 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(33,043,113)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">42,451,169 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">309,563 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">309,563 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(2,175,258)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(2,175,258)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">38,967 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(18,929,915)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">94,694,793 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(35,218,371)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">40,585,474 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Stock issued</span></td><td colspan="2" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">398 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">148,782 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">149,180 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">580,603 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">580,603 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(2,695,792)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(2,695,792)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2019</span></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">39,365 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(18,929,915)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">95,424,178 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(37,914,163)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">38,619,465 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Stock issued</span></td><td colspan="2" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">102 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">179,308 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">179,410 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">144,180 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">144,180 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,698,384)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,698,384)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2019</span></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">39,467 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(18,929,915)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">95,747,666 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(39,612,547)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">37,244,671 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="26" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30, 2018 (Unaudited)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Treasury Stock </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Additional Paid-In Capital </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated Deficit </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">January 1, 2018</span></td><td colspan="2" style="background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">38,937 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(16,625,873)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">93,913,557 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(27,351,357)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">49,975,264 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Stock repurchased</span></td><td colspan="2" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(374,820)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(374,820)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">269,596 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">269,596 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(2,043,292)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(2,043,292)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2018</span></td><td colspan="2" style="background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">38,937 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(17,000,693)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">94,183,153 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(29,394,649)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">47,826,748 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">73,425 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">73,425 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,596,637)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,596,637)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">38,937 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(17,000,693)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">94,256,578 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(30,991,286)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">46,303,536 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Stock repurchased</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,929,222)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,929,222)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">70,619 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">70,619 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Stock issued</span></td><td colspan="2" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">30 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4,470 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4,500 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,539,495)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,539,495)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2018</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">38,967 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(18,929,915)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">94,331,667 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(32,530,781)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">42,909,938 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock Repurchase Programs </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">On February 16, 2016, the Board of Directors authorized a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNhOGM2N2M3MTJiNzRiYTY4NGM5NDMyYTlkMGNhYjMwL3NlYzozYThjNjdjNzEyYjc0YmE2ODRjOTQzMmE5ZDBjYWIzMF82NC9mcmFnOjdlOTNlZGQ4ZTk2NjQ5MmM5NDBmNzY0MzAzODU2ZTIwL3RleHRyZWdpb246N2U5M2VkZDhlOTY2NDkyYzk0MGY3NjQzMDM4NTZlMjBfNDA3_66c5c6c9-00df-40ae-96e1-b11867a04abd">one</span>-year stock repurchase program, under which the Company was authorized to repurchase up to $15,000,000 of its outstanding common stock (the “2016 Stock Repurchase Program”). The 2016 Stock Repurchase Program ended on February 15, 2017.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">On August 16, 2017, the Board of Directors authorized a new <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNhOGM2N2M3MTJiNzRiYTY4NGM5NDMyYTlkMGNhYjMwL3NlYzozYThjNjdjNzEyYjc0YmE2ODRjOTQzMmE5ZDBjYWIzMF82NC9mcmFnOjdlOTNlZGQ4ZTk2NjQ5MmM5NDBmNzY0MzAzODU2ZTIwL3RleHRyZWdpb246N2U5M2VkZDhlOTY2NDkyYzk0MGY3NjQzMDM4NTZlMjBfNjk2_12bfbf5e-9e02-4b9d-9e7e-6ea003e72b7b">one</span>-year stock repurchase program, under which the Company may repurchase up to $5,000,000 of its outstanding common stock (the “2017 Stock Repurchase Program”). On August 6, 2018, the Board of Directors authorized an extension of this stock repurchase program through August 15, 2019. The 2017 Stock Repurchase Program ended on August 15, 2019. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the Company’s stock repurchase activities: </span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:95.175439%;"><tr><td style="width:1.0%;"/><td style="width:31.333333%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.568049%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.517665%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.568049%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.755760%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.568049%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.517665%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.568049%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.517665%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.568049%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.517665%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Period</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total Number of Shares Purchased</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Average Price Paid per Share</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total Number of Treasury Shares Purchased as Part of Publicly Announced Plan</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Maximum Dollar Value of Shares that May Yet Be Purchased Under the Plan</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Privately Negotiated Transactions:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">January 12, 2016 - Abengoa repurchased and retired shares</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,136,752 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.35 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,884,615 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">N/A</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">January 11, 2017 - Pinnacle Family Office Investments L.P. repurchased shares</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,363,590 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.54 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,639,929 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,363,590 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">15,000,000 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">2016 Stock Repurchase Program:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">January through February 2017</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">7,863,980 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.58 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">12,448,283 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">7,863,980 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,551,717 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2017 Stock Repurchase Program:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5,000,000 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">September through December 2017</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">381,607 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.41 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">537,661 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">381,607 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4,462,339 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">January through August 2018</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,644,325 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.40 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,304,042 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,644,325 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,158,297 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total open market and privately negotiated purchases</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">14,390,254 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.52 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">21,814,530 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">12,253,502 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Treasury Stock </span></div>As of September 30, 2019 and December 31, 2018, there were 12,253,502 shares of common stock held in treasury, at a cost of approximately $18.9 million, representing the purchase price on the date the shares were surrendered to the Company. 499671 1.62 0 <table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.830409%;"><tr><td style="width:1.0%;"/><td style="width:20.633136%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.835503%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.792899%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.835503%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.792899%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.835503%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.792899%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.835503%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.792899%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.835503%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.017751%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="26" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30, 2019 (Unaudited)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Treasury Stock </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Additional Paid-In Capital </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated Deficit </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">January 1, 2019</span></td><td colspan="2" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">38,967 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(18,929,915)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">94,385,230 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(33,043,113)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">42,451,169 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">309,563 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">309,563 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(2,175,258)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(2,175,258)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">38,967 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(18,929,915)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">94,694,793 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(35,218,371)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">40,585,474 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Stock issued</span></td><td colspan="2" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">398 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">148,782 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">149,180 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">580,603 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">580,603 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(2,695,792)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(2,695,792)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2019</span></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">39,365 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(18,929,915)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">95,424,178 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(37,914,163)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">38,619,465 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Stock issued</span></td><td colspan="2" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">102 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">179,308 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">179,410 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">144,180 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">144,180 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,698,384)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,698,384)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2019</span></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">39,467 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(18,929,915)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">95,747,666 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(39,612,547)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">37,244,671 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="26" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30, 2018 (Unaudited)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Treasury Stock </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Additional Paid-In Capital </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated Deficit </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">January 1, 2018</span></td><td colspan="2" style="background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">38,937 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(16,625,873)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">93,913,557 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(27,351,357)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">49,975,264 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Stock repurchased</span></td><td colspan="2" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(374,820)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(374,820)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">269,596 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">269,596 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(2,043,292)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(2,043,292)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2018</span></td><td colspan="2" style="background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">38,937 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(17,000,693)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">94,183,153 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(29,394,649)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">47,826,748 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">73,425 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">73,425 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,596,637)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,596,637)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">38,937 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(17,000,693)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">94,256,578 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(30,991,286)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">46,303,536 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Stock repurchased</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,929,222)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,929,222)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">70,619 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">70,619 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Stock issued</span></td><td colspan="2" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">30 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4,470 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4,500 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,539,495)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,539,495)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2018</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">38,967 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(18,929,915)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">94,331,667 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(32,530,781)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">42,909,938 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table> 38967 -18929915 94385230 -33043113 42451169 309563 309563 -2175258 -2175258 38967 -18929915 94694793 -35218371 40585474 398 148782 149180 580603 580603 -2695792 -2695792 39365 -18929915 95424178 -37914163 38619465 102 179308 179410 144180 144180 -1698384 -1698384 39467 -18929915 95747666 -39612547 37244671 38937 -16625873 93913557 -27351357 49975264 374820 374820 269596 269596 -2043292 -2043292 38937 -17000693 94183153 -29394649 47826748 73425 73425 -1596637 -1596637 38937 -17000693 94256578 -30991286 46303536 1929222 1929222 70619 70619 30 4470 4500 -1539495 -1539495 38967 -18929915 94331667 -32530781 42909938 15000000 5000000 <div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the Company’s stock repurchase activities: </span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:95.175439%;"><tr><td style="width:1.0%;"/><td style="width:31.333333%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.568049%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.517665%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.568049%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.755760%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.568049%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.517665%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.568049%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.517665%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.568049%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.517665%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Period</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total Number of Shares Purchased</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Average Price Paid per Share</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total Number of Treasury Shares Purchased as Part of Publicly Announced Plan</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Maximum Dollar Value of Shares that May Yet Be Purchased Under the Plan</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Privately Negotiated Transactions:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">January 12, 2016 - Abengoa repurchased and retired shares</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,136,752 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.35 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,884,615 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">N/A</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">January 11, 2017 - Pinnacle Family Office Investments L.P. repurchased shares</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,363,590 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.54 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,639,929 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,363,590 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">15,000,000 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">2016 Stock Repurchase Program:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">January through February 2017</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">7,863,980 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.58 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">12,448,283 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">7,863,980 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,551,717 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2017 Stock Repurchase Program:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5,000,000 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">September through December 2017</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">381,607 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.41 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">537,661 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">381,607 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4,462,339 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">January through August 2018</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,644,325 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.40 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,304,042 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,644,325 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,158,297 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total open market and privately negotiated purchases</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">14,390,254 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.52 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">21,814,530 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">12,253,502 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div> 2136752 1.35 2884615 0 2363590 1.54 3639929 2363590 15000000 7863980 1.58 12448283 7863980 2551717 5000000 381607 1.41 537661 381607 4462339 1644325 1.40 2304042 1644325 2158297 14390254 1.52 21814530 12253502 12253502 12253502 18900000 18900000 Subsequent Events <div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">For purpose of disclosure in the consolidated financial statements, the Company has evaluated subsequent events through November 13, 2019, the date the consolidated financial statements were available to be issued. Management is not aware of any material events that have occurred subsequent to the balance sheet date that would require adjustment to, or disclosure in the accompanying financial statements.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">On November 12, 2019, the Company entered into an amendment (the “Amendment”) to the Employment Agreement between the Company and Mark A. Emalfarb, dated as of June 16, 2016, as previously amended (the “Agreement”). The Amendment contains a technical correction clarifying the exercise period and date of grant of certain stock awarded, or to be awarded, to Mr. Emalfarb.</span></div> XML 40 R6.htm IDEA: XBRL DOCUMENT v3.19.3
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Cash flows from operating activities    
Net loss $ (6,569,434) $ (5,179,424)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation expense 1,034,346 413,640
Amortization of held-to-maturity securities, net 141,362 598,464
Foreign currency exchange loss (gain), net 24,693 1,921
Changes in operating assets and liabilities:    
Interest receivable 58,800 176,617
Accounts receivable (110,807) 66,574
Income tax receivable 497,460 0
Prepaid research and development 253,446 705,836
Prepaid expenses and other current assets (164,590) (39,732)
Accounts payable 429,955 35,345
Accrued expenses 70,541 92,616
Deferred research and development obligation (47,726) 51,786
Income taxes payable 0 (102,000)
Net cash used in operating activities (4,381,954) (3,178,357)
Cash flows from investing activities    
Purchases of held-to-maturity investment securities (37,585,548) (39,320,144)
Proceeds from maturities of investment securities 43,953,000 40,739,000
Net cash provided by investing activities 6,367,452 1,418,856
Cash flows from financing activities    
Repurchases of common stock 0 (2,304,042)
Proceeds from exercise of options 328,590 4,500
Net cash provided by (used in) financing activities 328,590 (2,299,542)
Effect of exchange rate changes on cash (38,075) (12,600)
Net increase (decrease) in cash and cash equivalents 2,276,013 (4,071,643)
Cash and cash equivalents at beginning of period 2,386,314 5,786,348
Cash and cash equivalents at end of period 4,662,327 1,714,705
Supplemental cash flow information    
Cash received from income tax refund $ 506,866 $ 0
XML 41 R2.htm IDEA: XBRL DOCUMENT v3.19.3
CONSOLIDATED BALANCE SHEETS - USD ($)
Sep. 30, 2019
Dec. 31, 2018
Current assets:    
Cash and cash equivalents $ 4,662,327 $ 2,386,314
Short-term investment securities 30,793,472 38,816,441
Interest receivable 235,440 294,240
Accounts receivable 418,945 318,744
Income tax receivable 9,406 506,866
Prepaid research and development 0 253,446
Prepaid expenses and other current assets 336,868 172,001
Total current assets 36,456,458 42,748,052
Non-current assets:    
Long-term investment securities 1,514,153 0
Long-term income tax receivable 500,616 500,616
Other assets 50,232 52,139
Total assets 38,521,459 43,300,807
Current liabilities:    
Accounts payable 713,395 309,060
Accrued expenses 470,117 399,576
Deferred research and development obligations 93,276 141,002
Total current liabilities 1,276,788 849,638
Commitments and contingencies (See Note 4)
Stockholders’ equity:    
Preferred stock 0 0
Common stock 39,467 38,967
Additional paid-in capital 95,747,666 94,385,230
Treasury stock, shares held at cost (18,929,915) (18,929,915)
Accumulated deficit (39,612,547) (33,043,113)
Total stockholders’ equity 37,244,671 42,451,169
Total liabilities and stockholders’ equity $ 38,521,459 $ 43,300,807
XML 42 R29.htm IDEA: XBRL DOCUMENT v3.19.3
Share-Based Compensation - Assumptions (Details) - Stock Option
 9 Months Ended
Sep. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Risk-Free interest rate, minimum 1.69%
Risk-Free interest rate, maximum 2.50%
Expected dividend rate 0.00%
Expected stock price volatility, minimum 28.59%
Expected stock price volatility, maximum 37.29%
Minimum  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Expected life of options 2 years
Discount for lack of marketability 0.00%
Maximum  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Expected life of options 6 years 3 months
Discount for lack of marketability 8.48%
XML 43 R21.htm IDEA: XBRL DOCUMENT v3.19.3
Organization and Summary of Significant Accounting Policies - Prepaid Expenses and Other Current Assets (Details) - USD ($)
Sep. 30, 2019
Dec. 31, 2018
Accounting Policies [Abstract]    
Prepaid expenses - various $ 81,320 $ 91,725
Prepaid insurance 254,997 77,249
Prepaid taxes 551 3,027
Prepaid expenses and other current assets $ 336,868 $ 172,001
XML 44 R25.htm IDEA: XBRL DOCUMENT v3.19.3
Cash, Cash Equivalent, and Investments (Details) - USD ($)
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Dec. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash and Cash Equivalents $ 4,662,327   $ 4,662,327   $ 2,386,314
Short term investments, adjusted cost 30,793,472   30,793,472   38,816,441
Long term investments, adjusted cost 1,514,153   1,514,153   0
Cash and Investment, fair value 36,984,818   36,984,818   41,117,434
Investment, gross unrealized holding gain 30,574   30,574   0
Investment, gross unrealized holding losses (15,708)   (15,708)   (85,321)
Cash and Investment, adjusted cost 36,969,952   36,969,952   41,202,755
Cash          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash and Cash Equivalents 552,569   552,569   1,048,272
Money Market Funds | Level 1          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash and Cash Equivalents 4,109,758   4,109,758   1,338,042
Corporate bonds          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Held-to-maturity, premium paid on purchase 54,385 $ 0 158,548 $ 205,038 378,681
Corporate bonds | Level 2          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Short term investments, fair value 30,794,626   30,794,626   38,731,120
Short term investments, gross unrealized holding gain 16,862   16,862   0
Short term investments, gross unrealized holding loss (15,708)   (15,708)   (85,321)
Short term investments, adjusted cost 30,793,472   30,793,472   $ 38,816,441
Long term Investments, fair value 1,527,865   1,527,865    
Long term Investments, gross unrealized holding gain 13,712   13,712    
Long term Investments, gross unrealized holding loss 0   0    
Long term investments, adjusted cost $ 1,514,153   $ 1,514,153    
XML 45 R7.htm IDEA: XBRL DOCUMENT v3.19.3
Organization and Summary of Significant Accounting Policies
 9 Months Ended
Sep. 30, 2019
Accounting Policies [Abstract]  
Organization and Summary of Significant Accounting Policies Organization and Summary of Significant Accounting Policies
Description of Business
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our” or the “Company”) is a global biotechnology platform company based in Jupiter, Florida with operations in the United States, a satellite office in the Netherlands and research organizations performing services under contract to Dyadic in Finland and Spain. Over the past two decades, the Company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has previously licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Myceliophthora thermophila fungus, which the Company named C1. The C1 technology is a robust and versatile fungal expression system for the development and production of enzymes and other proteins.
On December 31, 2015, the Company sold its industrial technology business to DuPont Danisco (“DuPont”), the industrial biosciences business of DuPont (NYSE: DD) for $75 million (the “DuPont Transaction”). As part of the DuPont Transaction, Dyadic retained co-exclusive rights to the C1 technology for use in all human and animal pharmaceutical applications, and currently has the exclusive ability to enter into sub-license agreements (subject to the terms of the license and to certain exceptions). DuPont retained certain rights to utilize the C1 technology in pharmaceutical applications, including the development and production of pharmaceutical products, for which it will be required to make royalty payments to Dyadic upon commercialization. In certain circumstances, Dyadic may owe a royalty to either DuPont or certain licensors of DuPont, depending upon whether Dyadic elects to utilize certain patents either owned by DuPont or licensed in by DuPont.
After the DuPont Transaction, the Company has been focused on the biopharmaceutical industry, specifically in further improving and applying the proprietary C1 technology into a safe and efficient gene expression platform to help accelerate the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. We believe that the C1 technology could be beneficial in the development and manufacturing of human and animal vaccines (such as virus-like particles (VLPs) and antigens), monoclonal antibodies (mAbs), Bi-Specific antibodies, Fab antibody fragments, Fc-Fusion proteins, metabolites, and other therapeutic enzymes and proteins.
Effective April 17, 2019, our common stock began trading on the NASDAQ Stock Market LLC’s NASDAQ Capital Market, under the symbol “DYAI”. Prior to the Company’s uplisting to the NASDAQ, the Company’s common stock traded on the OTCQX market.
Summary of Significant Accounting Policies
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements, including the accounts of the Company and its wholly owned subsidiaries, have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and footnote disclosures normally included in consolidated financial statements have been condensed or omitted pursuant to such rules and regulations. All significant intra-entity transactions and balances have been eliminated in consolidation. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and footnotes as of and for the year ended December 31, 2018, included in our Form 10-K which was filed with the SEC on March 27, 2019.
In the opinion of management, the accompanying unaudited interim consolidated financial statements reflect all adjustments, which are of a normal recurring nature, considered necessary for a fair presentation of all periods presented. The results of the Company’s operations for any interim periods are not necessarily indicative of the results of operations for any other interim period or for a full fiscal year.
Since concluding the DuPont Transaction, the Company has conducted business in one operating segment, which is identified by the Company based on how resources are allocated, and operating decisions are made. Management evaluates performance and allocates resources based on the Company as a whole.
Use of Estimates
The preparation of these consolidated financial statements in accordance with GAAP requires management to make estimates and judgments that affect the reported amount of assets and liabilities and related disclosure of contingent assets and liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the applicable period. Actual results may differ from these estimates under different assumptions or conditions. Such differences could be material to the consolidated financial statements.
Concentrations
The Company’s financial instruments that are potentially subject to concentrations of credit risk consist primarily of cash and cash equivalents, and investment securities. At times, the Company has cash, cash equivalents, and investment securities at financial institutions exceeding the Federal Depository Insurance Company (“FDIC”) and the Securities Investor Protection Corporation (“SIPC”) insured limit on domestic currency and the Netherlands’ FDIC counterpart for foreign currency. The Company only deals with reputable financial institutions and has not experienced any losses in such accounts.
For the three months ended September 30, 2019 and 2018, the Company’s revenue was generated from five and four customers, respectively. For the nine months ended September 30, 2019 and 2018, the Company’s revenue was generated from eight and five customers, respectively. As of September 30, 2019 and December 31, 2018, the Company’s accounts receivable was from three and four customers, respectively. The loss of business from one or a combination of the Company’s customers could adversely affect its operations.
The Company generates a portion of its revenues from customers that are located outside of the United States. For the three months ended September 30, 2019, the Company had three customers outside of the United States (i.e. European and Indian customers) that accounted for approximately 77.0% or $351,000 of total revenue. For the nine months ended September 30, 2019 the Company had three customers outside of the United States that accounted for approximately 73.6% or $918,000 of total revenue. For the three and nine months ended September 30, 2018, 100% of the Company’s revenue was from the United States.
As of September 30, 2019, the Company had one customer outside of the United States that accounted for approximately 79.3% or $332,000 of accounts receivable. As of December 31, 2018, 100% of the Company’s accounts receivable was from the United States.
Cash and Cash Equivalents
We treat highly liquid investments with original maturities of three months or less when purchased as cash equivalents, including money market funds, which are unrestricted for withdrawal or use.
Investment Securities
The Company invests excess cash balances in short-term and long-term investment grade securities. Short-term investment securities mature within 12 months or less, and long-term investment securities mature between 12 and 18 months from the applicable reporting date. Management determines the appropriate classification of its investments at the time of purchase and reevaluates the classifications at each balance sheet date. The Company’s investments in debt securities have been classified and accounted for as held-to-maturity. Held-to-maturity securities are those securities that the Company has the ability and intent to hold until maturity. Held-to-maturity securities are recorded at amortized cost, adjusted for the amortization or accretion of premiums or discounts. Premiums and discounts are amortized over the life of the related held-to-maturity security. When a debt security is purchased at a premium, both the face value of the debt and premium amount are reflected as investing outflow. Other-than-temporary impairment charges, if incurred, will be included in other income (expense).
The Company’s investments in money market funds have been classified and accounted for as available-for-sale securities and presented as cash equivalents on the consolidated balance sheets. As of September 30, 2019 and December 31, 2018, all of our money market funds were invested in U.S. Government money market funds. The Company did not have any investment securities classified as trading as of September 30, 2019 or December 31, 2018.
Accounts Receivable
Accounts receivable consist of billed receivables currently due from customers and unbilled receivables. Unbilled receivables represent the excess of contract revenue (or amounts reimbursable under contracts) over billings to date. Such amounts become billable in accordance with the contract terms, which usually consider the passage of time, achievement of certain milestones or completion of the project.
Outstanding account balances are reviewed individually for collectability. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing accounts receivable. Substantially all of our accounts receivable were current and include unbilled amounts that will be billed and collected over the next twelve months. There was no allowance for doubtful accounts as of September 30, 2019 and December 31, 2018.
Accounts receivable consist of the following:
September 30, 2019December 31, 2018
(Unaudited)(Audited)
Billed receivable $66,988  $193,065  
Unbilled receivable351,957  125,679  
$418,945  $318,744  
Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets consist of the following:
September 30, 2019December 31, 2018
(Unaudited) (Audited) 
Prepaid expenses - various$81,320  $91,725  
Prepaid insurance254,997  77,249  
Prepaid taxes551  3,027  
$336,868  $172,001  
Equity Method Investment
The Company follows Accounting Standards Codification (“ASC”) Subtopic 323-10, Investments - Equity Methods and Joint Ventures, which requires the accounting for investments where the Company can exercise significant influence, but not control of a joint venture or equity investment. See Note 3 for the Company’s investments recorded under the equity method of accounting.
Equity method investments are assessed for impairment whenever events or changes in circumstances indicate that the carrying amount of the investment may not be recoverable. If the decline in value is considered to be other than temporary, the investment is written down to its estimated fair value, which establishes a new cost basis in the investment.
Accounts Payable
Accounts payable consist of the following:
September 30, 2019December 31, 2018
(Unaudited) (Audited) 
Research and development expenses$636,428  $240,064  
Legal expenses17,283  —  
Other59,684  68,996  
$713,395  $309,060  
Accrued Expenses
Accrued expenses consist of the following:
September 30, 2019December 31, 2018
(Unaudited) (Audited) 
Employee wages and benefits$353,552  $268,287  
Research and development expenses77,855  49,666  
Other38,710  81,623  
$470,117  $399,576  

Revenue Recognition
The Company has no pharmaceutical products approved for sale at this point, and all of our revenue to date has been research revenue from third-party collaborations and government grants. The Company is expected to generate future revenue from license agreements and collaborative arrangements, which may include upfront payments for licenses or options to obtain a license, payment for research and development services and milestone payments, in the form of cash or non-cash considerations (e.g., minority equity interest).
Revenue related to research collaborations and agreements: The Company typically performs research and development services as specified in each respective agreement on a best efforts basis, and recognizes revenue from research funding under collaboration agreements in accordance with the 5-step process outlined in ASC Topic 606 (“Topic 606”): (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We recognize revenue when we satisfy a performance obligation by transferring control of the service to a customer in an amount that reflects the consideration that we expect to receive. Since the performance obligation under our collaboration agreements is generally satisfied over time, we elected to use the input method under Topic 606 to measure the progress toward complete satisfaction of a performance obligation.
Under the input methods, revenue will be recognized on the basis of the entity’s efforts or inputs to the satisfaction of a performance obligation (e.g., resources consumed, labor hours expended, costs incurred, or time elapsed) relative to the total expected inputs to the satisfaction of that performance obligation. The Company believes that the cost-based input method is the best measure of progress to reflect how the Company transfers its performance obligation to a customer. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to budgeted costs to fulfill the performance obligation. These costs consist primarily of full-time equivalent effort and third-party contract costs. Revenue will be recognized based on actual costs incurred as a percentage of total budgeted costs as the Company completes its performance obligations.
A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company’s performance obligations. In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete the Company’s performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.
Revenue related to sublicensing agreements: If the sublicense to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue allocated to the license when technology is transferred to the customer and the customer is able to use and benefit from the license.
Milestone payments: At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Company evaluates whether the achievement of the milestones is considered probable and estimates the amount to be included in the transaction price. If the milestone payment is in exchange for a sublicense and is based on the sublicensee’s subsequent sale of product, the Company recognizes milestone payment by applying the accounting guidance for royalties. To date, the Company has not recognized any milestone payment revenue resulting from any of its sublicensing arrangements.
Royalties: With respect to licenses deemed to be the predominant item to which the sales-based royalties relate, including milestone payments based on the level of sales, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or
partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its sublicensing arrangements.
We invoice customers based on our contractual arrangements with each customer, which may not be consistent with the period that revenues are recognized. When there is a timing difference between when we invoice customers and when revenues are recognized, we record either a contract asset (unbilled accounts receivable) or a contract liability (deferred research and development obligations), as appropriate. If upfront fees or considerations related to sublicensing agreement are received prior to the technology transfer, the Company will record the amount received as deferred revenue from licensing agreement.
We are not required to disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.

The Company adopted a practical expedient to expense sales commissions when incurred because the amortization period would be one year or less.

Research and Development Costs
Research and development (“R&D”) costs are expensed as incurred. R&D costs are for the Company’s internally funded pharmaceutical programs and other governmental and commercial projects.
Research and development costs consist of personnel-related costs, facilities, research-related overhead, services from independent contract research organizations, and other external costs. Research and development costs, including related party, during the three and nine months ended September 30, 2019 and 2018 were as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2019201820192018
(Unaudited) (Unaudited) (Unaudited) (Unaudited) 
Outside contracted services$730,190  $365,689  $1,974,176  $1,316,581  
Contracted services - related party101,849  288,175  827,632  1,021,573  
Personnel related costs95,269  87,307  312,321  277,856  
Facilities, overhead and other15,884  23,637  65,456  60,279  
$943,192  $764,808  $3,179,585  $2,676,289  

Foreign Currency Transaction Gain or Loss
The Company’s foreign subsidiary uses the U.S. dollar as its functional currency, and it initially measures the foreign currency denominated assets and liabilities at the transaction date. Monetary assets and liabilities are then re-measured at exchange rates in effect at the end of each period, and property and non-monetary assets and liabilities are converted at historical rates.
Fair Value Measurements
The Company applies fair value accounting for certain financial instruments that are recognized or disclosed at fair value in the financial statements. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:
•Level 1 – Quoted prices in active markets for identical assets or liabilities.
•Level 2 – Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
•Level 3 – Inputs that are generally unobservable and typically reflect management’s estimate of assumptions that market participants would use in pricing the asset or liability.

Certain assets and liabilities on the balance sheets are measured at carrying values, which approximate fair values due to the short-term nature of these balances. Such items include cash and cash equivalents, accounts receivable, accounts payable, prepaid expenses, and accrued expenses. Investments in debt securities are recorded at amortized cost, and their estimated fair value amounts are provided by the third-party broker service for disclosure purposes.
The Company utilized various methods, including income, cost and market approaches to determine the fair value of its investments in equity interest, which may fall into Level 3 of the fair value hierarchy because of the significant unobservable inputs utilized in these valuation approaches. These inputs can be readily observable, market corroborated, or generally unobservable inputs. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. Our key inputs included, but were not limited to, significant management judgments and estimates, including projections of the timing and amount of the project’s cash flows, determination of a discount rate for the income approach, market multipliers, probability weighting of potential outcomes of legal and regulatory proceedings, and weighting of the valuations produced by the income, cost and market approaches.
Income Taxes
The Tax Cuts and Jobs Act (“TCJA”) was enacted on December 22, 2017 and became effective January 1, 2018. The TCJA contains several key provisions, including a reduction in the U.S. Federal corporate income tax rate from 35% to 21% and a change to the corporate alternative minimum tax (“AMT”). The TCJA’s reduction in the U.S. statutory tax rate had no additional impact on the consolidated financial statement for the year ended December 31, 2018.
The TCJA eliminated the corporate AMT and permits existing AMT credit carryforwards to be used to reduce the regular tax obligation in 2018, 2019, and 2020. Any AMT credit carryforwards that do not reduce regular taxes are eligible for a 50% refund in 2018 through 2020, and a 100% refund in 2021. Accordingly, we reclassified the balance of the AMT credit from the deferred tax asset to an income tax receivable in 2018. The corresponding balance in the valuation allowance has been reversed into income tax benefit in the amount of $1,001,233. As of September 30, 2019, we have received 50% or approximately $0.5 million refund for tax year 2018 and expect to receive the remaining 50% for tax years 2019 through 2021.
For the nine months ended September 30, 2019, the Company recorded a provision for income taxes of $900. There were no unrecognized tax benefits as of September 30, 2019 and December 31, 2018.
Deferred tax assets as of September 30, 2019 and December 31, 2018 were approximately $6.9 million and $4.6 million, respectively. Due to the Company’s history of operating losses and the uncertainty regarding our ability to generate taxable income in the future, the Company has established a 100% valuation allowance against deferred tax assets as of September 30, 2019 and December 31, 2018.
On June 20, 2019, the Company received a letter from the United States Internal Revenue Service (the “IRS”) informing the Company that its 2016 federal tax return was selected for examination. In August 2019, the Company had a meeting with the IRS agent and provided the IRS with all requested information. Thus far, the Company has not been informed of any assessment. As the IRS audit is still in progress, we are unable to predict when the audit will be concluded or whether any assessment will be proposed.
Comprehensive Income (Loss)
Comprehensive income (loss) includes net income (loss) and other revenue, expenses, gains and losses that are recorded as an element of shareholders’ equity but are excluded from net income (loss) under GAAP. The Company does not have any significant transactions that are required to be reported in other comprehensive income (loss), and therefore, does not separately present a statement of comprehensive income (loss) in its consolidated financial statements.

Stock-Based Compensation

We recognize all share-based payments to employees and our board of directors (“Board of Directors”), as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statement of operations based on the grant date fair values of such payments. Stock-based compensation expense recognized each period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are recorded as they occur.
Net Loss Per Share
Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common stock outstanding during the reporting period. Diluted net loss per share adjusts the weighted average number of common stock outstanding for the potential dilution that could occur if common stock equivalents, such as stock options were exercised or converted into common stock, calculated by applying the treasury stock method.
For each of the three and nine months ended September 30, 2019 and 2018, the effect of the potential exercise of options to purchase 4,006,390 and 3,411,890 shares of common stock, respectively, were excluded from the computation of diluted net loss per share as their effect would have been anti-dilutive.
Recent Accounting Pronouncements Not Adopted as of September 30, 2019
In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which modifies the measurement of expected credit losses of certain financial instruments. ASU 2016-13 will be effective for the Company beginning in the first quarter of 2020. The Company is currently evaluating the impact, if any, of this newly issued guidance.
In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820) which modifies the disclosure requirements on fair value measurements. The effective date for the standard is fiscal years beginning after December 15, 2019, which for the Company is January 1, 2020. Early adoption is permitted. The new disclosure requirements for changes in unrealized gains and losses in other comprehensive income for recurring Level 3 measurements, the range and weighted average of significant unobservable inputs and the amended requirements for the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively. The Company does not expect ASU 2018-13 to have a material impact on our consolidated financial statements.
Other pronouncements issued by the FASB or other authoritative accounting standards group with future effective dates are either not applicable or not significant to our consolidated financial statements.
Recently Adopted Accounting Pronouncements
In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). Under the new guidance, lessees will be required to recognize the assets and liabilities that arise from operating leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. Companies are required to recognize and measure leases using a modified retrospective approach at either the beginning of the earliest comparative period presented or the beginning of the reporting period in which the entity first applies the new standard. ASU 2016-02 was effective for the Company beginning in the first quarter of 2019. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements and related disclosures, as the Company’s leases are one year or less and not required to recognize lease assets or liabilities under the new guidance.
In March 2017, the FASB issued ASU 2017-08, Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization of Purchased Callable Debt Securities. The amendments in this ASU shorten the amortization period for certain callable debt securities held at a premium. The amendments require the premium to be amortized to the earliest call date. The amendments do not require an accounting change for securities held at a discount; the discount continues to be amortized to maturity. The Company adopted the standard on January 1, 2019. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements and related disclosures.
In February 2018, the FASB issued ASU 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. The new guidance allows a reclassification from accumulated other comprehensive income to retained earnings for any stranded tax effects resulting from TCJA that was enacted on December 22, 2017. The new guidance will be effective for the Company beginning in the first quarter of 2019. The Company adopted the standard on January 1, 2019. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements and related disclosures.
In June 2018, the FASB issued ASU 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Non-employee Share-based Payment Accounting. The standard expands the scope of Topic 718 to include share-based payments issued to non-employees for goods or services, simplifying the accounting for share-based payments to non-employees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years with early adoption permitted, including adoption in an interim period. The Company adopted the standard on January 1, 2019. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements and related disclosures.
XML 46 R3.htm IDEA: XBRL DOCUMENT v3.19.3
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Sep. 30, 2019
Dec. 31, 2018
Statement of Financial Position [Abstract]    
Preferred stock, par value (USD per share) $ 0.0001 $ 0.0001
Preferred stock, shares authorized (in shares) 5,000,000 5,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (USD per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 100,000,000 100,000,000
Common stock, shares issued (in shares) 39,466,659 38,966,988
Common stock, shares outstanding (in shares) 27,213,157 26,713,486
Treasury stock (in shares) 12,253,502 12,253,502
XML 47 R20.htm IDEA: XBRL DOCUMENT v3.19.3
Organization and Summary of Significant Accounting Policies - Accounts Receivable (Details) - USD ($)
Sep. 30, 2019
Dec. 31, 2018
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
Accounts receivable $ 418,945 $ 318,744
Billed receivable    
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
Accounts receivable 66,988 193,065
Unbilled receivable    
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
Accounts receivable $ 351,957 $ 125,679
XML 49 R24.htm IDEA: XBRL DOCUMENT v3.19.3
Organization and Summary of Significant Accounting Policies - Research and Development Costs (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Accounting Policies [Abstract]        
Outside contracted services $ 730,190 $ 365,689 $ 1,974,176 $ 1,316,581
Contracted services - related party 101,849 288,175 827,632 1,021,573
Personnel related costs 95,269 87,307 312,321 277,856
Facilities, overhead and other 15,884 23,637 65,456 60,279
Research and development expense, related party, net $ 943,192 $ 764,808 $ 3,179,585 $ 2,676,289
XML 50 R28.htm IDEA: XBRL DOCUMENT v3.19.3
Share-Based Compensation - Textual (Details) - shares
 9 Months Ended
Jan. 01, 2019
Sep. 30, 2019
Mar. 07, 2019
Jan. 02, 2019
Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Outstanding (in shares)   4,006,390     3,552,890
Stock Option | Contractor          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Number of shares available for grant (in shares)     15,000 50,000  
2006 Plan          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Number of shares available for grant (in shares)   0      
2011 Plan          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Number of shares available for grant (in shares)   1,547,211     1,136,211
Common stock reserved for future issuance (in shares)   3,000,000      
Approved (in shares) 1,500,000        
2011 Plan | Stock Option          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Expiration period   10 years      
2011 Plan | Stock Option | Chief Executive Officer          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Expiration period   5 years      
Expected life of options   5 years      
2011 Plan | Stock Option | Contractor          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Expiration period   2 years      
XML 51 R35.htm IDEA: XBRL DOCUMENT v3.19.3
Shareholders' Equity - Stock Repurchase (Details) - USD ($)
 2 Months Ended 4 Months Ended 8 Months Ended 36 Months Ended
Jan. 11, 2017
Jan. 12, 2016
Feb. 28, 2017
Dec. 31, 2017
Aug. 31, 2018
Dec. 31, 2018
Aug. 16, 2017
Feb. 16, 2016
Equity, Class of Treasury Stock [Line Items]                
Total Number of Shares Purchased (in shares) 2,363,590 2,136,752 7,863,980 381,607 1,644,325 14,390,254    
Average Price Paid per Share (in usd per share) $ 1.54 $ 1.35 $ 1.58 $ 1.41 $ 1.40 $ 1.52    
Amount $ 3,639,929 $ 2,884,615 $ 12,448,283 $ 537,661 $ 2,304,042 $ 21,814,530    
Maximum Dollar Value of Shares that May Yet Be Purchased Under the Plan     $ 2,551,717 $ 4,462,339 $ 2,158,297   $ 5,000,000 $ 15,000,000
Publicly Announced Repurchase Plans                
Equity, Class of Treasury Stock [Line Items]                
Total Number of Shares Purchased (in shares) 2,363,590 0 7,863,980 381,607 1,644,325 12,253,502    
XML 52 R31.htm IDEA: XBRL DOCUMENT v3.19.3
Share-Based Compensation - Stock Option Activity - Textual (Details)
 9 Months Ended
Jun. 28, 2019
$ / shares
shares
Jun. 25, 2019
board_of_director
$ / shares
shares
Mar. 07, 2019
$ / shares
shares
Jan. 02, 2019
$ / shares
shares
Sep. 30, 2019
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Options granted (in shares)         1,089,000
Weighted average exercise price, granted (USD per share) | $ / shares         $ 2.26
Number of board of directors | board_of_director   3      
Exercise of stock options (in shares)         635,500
Weighted average exercise price, exercised (in USD per share) | $ / shares         $ 1.62
Exercise of stock options, net (in shares)         440,000
Exercise of stock options, common stock (in shares)         304,171
Exercise of stock options, forfeited (in shares)         135,829
Exercise of stock options, cash (in shares)         195,500
Executives and Key Personnel          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Weighted average exercise price, granted (USD per share) | $ / shares       $ 1.87  
Award requisite service period       1 year  
Board of Directors          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Options granted (in shares)       300,000  
Weighted average exercise price, granted (USD per share) | $ / shares   $ 5.83   $ 1.87  
Award requisite service period   1 year      
Employee          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Options granted (in shares)       24,000  
Weighted average exercise price, granted (USD per share) | $ / shares       $ 1.87  
Contractor          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Weighted average exercise price, granted (USD per share) | $ / shares     $ 3.00 $ 1.87  
Award requisite service period     1 year 1 year  
Chief Financial Officer          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Weighted average exercise price, granted (USD per share) | $ / shares $ 6.26        
Stock Option | Executives and Key Personnel          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Options granted (in shares)       600,000  
Award vesting period       4 years  
Stock Option | Board of Directors          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Number of shares available for grant (in shares)   75,000      
Stock Option | Board of Directors | Share-based Compensation Award, Tranche One          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Percentage of options that will vest       25.00%  
Stock Option | Board of Directors | Share-based Compensation Award, Tranche Two through Five          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Award vesting period       4 years  
Percentage of options that will vest       75.00%  
Stock Option | Employee          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Award vesting period       4 years  
Stock Option | Contractor          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Number of shares available for grant (in shares)     15,000 50,000  
Stock Option | Chief Financial Officer          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Number of shares available for grant (in shares) 25,000        
XML 54 R12.htm IDEA: XBRL DOCUMENT v3.19.3
Shareholders' Equity
 9 Months Ended
Sep. 30, 2019
Equity [Abstract]  
Stockholders' Equity Shareholders’ Equity
Issuances of Common Stock
For the nine months ended September 30, 2019, there were 499,671 shares of the Company’s common stock issued as a result of the exercise of stock options with a weighted average issue price of $1.62 per share. For the nine months ended September 30, 2018, no shares were issued.
Nine Months Ended September 30, 2019 (Unaudited) 
Common Stock  Treasury Stock  Additional Paid-In Capital  Accumulated Deficit  Total  
January 1, 2019$38,967  $(18,929,915) $94,385,230  $(33,043,113) $42,451,169  
Stock-based compensation—  —  309,563  —  309,563  
Net loss—  —  —  (2,175,258) (2,175,258) 
March 31, 201938,967  (18,929,915) 94,694,793  (35,218,371) 40,585,474  
Stock issued398  —  148,782  —  149,180  
Stock-based compensation—  —  580,603  —  580,603  
Net loss—  —  —  (2,695,792) (2,695,792) 
June 30, 201939,365  (18,929,915) 95,424,178  (37,914,163) 38,619,465  
Stock issued102  —  179,308  —  179,410  
Stock-based compensation—  —  144,180  —  144,180  
Net loss—  —  —  (1,698,384) (1,698,384) 
September 30, 2019$39,467  $(18,929,915) $95,747,666  $(39,612,547) $37,244,671  
Nine Months Ended September 30, 2018 (Unaudited) 
Common Stock  Treasury Stock  Additional Paid-In Capital  Accumulated Deficit  Total
January 1, 2018$38,937  $(16,625,873) $93,913,557  $(27,351,357) $49,975,264  
Stock repurchased—  (374,820) —  —  (374,820) 
Stock-based compensation—  —  269,596  —  269,596  
Net loss—  —  —  (2,043,292) (2,043,292) 
March 31, 201838,937  (17,000,693) 94,183,153  (29,394,649) 47,826,748  
Stock-based compensation—  —  73,425  —  73,425  
Net loss—  —  —  (1,596,637) (1,596,637) 
June 30, 201838,937  (17,000,693) 94,256,578  (30,991,286) 46,303,536  
Stock repurchased(1,929,222) —  (1,929,222) 
Stock-based compensation—  70,619  —  70,619  
Stock issued30  —  4,470  4,500  
Net loss—  —  —  (1,539,495) (1,539,495) 
September 30, 2018$38,967  $(18,929,915) $94,331,667  $(32,530,781) $42,909,938  
Stock Repurchase Programs
On February 16, 2016, the Board of Directors authorized a one-year stock repurchase program, under which the Company was authorized to repurchase up to $15,000,000 of its outstanding common stock (the “2016 Stock Repurchase Program”). The 2016 Stock Repurchase Program ended on February 15, 2017.
On August 16, 2017, the Board of Directors authorized a new one-year stock repurchase program, under which the Company may repurchase up to $5,000,000 of its outstanding common stock (the “2017 Stock Repurchase Program”). On August 6, 2018, the Board of Directors authorized an extension of this stock repurchase program through August 15, 2019. The 2017 Stock Repurchase Program ended on August 15, 2019.
The following table summarizes the Company’s stock repurchase activities: 
PeriodTotal Number of Shares PurchasedAverage Price Paid per ShareAmountTotal Number of Treasury Shares Purchased as Part of Publicly Announced PlanMaximum Dollar Value of Shares that May Yet Be Purchased Under the Plan
Privately Negotiated Transactions:
January 12, 2016 - Abengoa repurchased and retired shares2,136,752  $1.35  $2,884,615  —  N/A
January 11, 2017 - Pinnacle Family Office Investments L.P. repurchased shares2,363,590  1.54  3,639,929  2,363,590  N/A
$15,000,000  
2016 Stock Repurchase Program:
January through February 20177,863,980  1.58  12,448,283  7,863,980  $2,551,717  
2017 Stock Repurchase Program:$5,000,000  
September through December 2017381,607  1.41  537,661  381,607  $4,462,339  
January through August 20181,644,325  1.40  2,304,042  1,644,325  $2,158,297  
Total open market and privately negotiated purchases14,390,254  $1.52  $21,814,530  12,253,502  

Treasury Stock
As of September 30, 2019 and December 31, 2018, there were 12,253,502 shares of common stock held in treasury, at a cost of approximately $18.9 million, representing the purchase price on the date the shares were surrendered to the Company.
XML 55 R16.htm IDEA: XBRL DOCUMENT v3.19.3
Cash, Cash Equivalent, and Investments (Tables)
 9 Months Ended
Sep. 30, 2019
Cash and Cash Equivalents [Abstract]  
Schedule of Cash, Available-for-sale Securities, Short-term and Long-term Investment Securities The following table shows the Company’s cash, available-for-sale securities, and short-term and long-term investment securities by major security type as of September 30, 2019 and December 31, 2018:
September 30, 2019 (Unaudited)
GrossGross
LevelUnrealizedUnrealized
(1)
Fair ValueHolding GainsHolding LossesAdjusted Cost
Cash and Cash Equivalents
Cash$552,569  $—  $—  $552,569  
Money Market Funds1  4,109,758  —  —  4,109,758  
Subtotal4,662,327  —  —  4,662,327  
Short-Term Investment Securities (2)
Corporate Bonds (4)
2  30,794,626  16,862  (15,708) 30,793,472  
Long-Term Investment Securities (3)
Corporate Bonds (4)
2  1,527,865  13,712  —  1,514,153  
Total$36,984,818  $30,574  $(15,708) $36,969,952  

December 31, 2018 (Audited)
GrossGross
LevelUnrealizedUnrealized
(1)
Fair ValueHolding GainsHolding LossesAdjusted Cost
Cash and Cash Equivalents
Cash$1,048,272  $—  $—  $1,048,272  
Money Market Funds1  1,338,042  —  —  1,338,042  
Subtotal2,386,314  —  —  2,386,314  
Short-Term Investment Securities (2)
Corporate Bonds (4)
2  38,731,120  —  (85,321) 38,816,441  
Total$41,117,434  $—  $(85,321) $41,202,755  
_________________
Notes:
(1) Definition of the three-level fair value hierarchy:
•Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities
•Level 2 - Other inputs that are directly or indirectly observable in the markets
•Level 3 - Inputs that are generally unobservable
(2) Short-term investment securities will mature within 12 months or less, from the applicable reporting date.
(3) Long-term investment securities will mature between 12 and 18 months, from the applicable reporting date.
(4) The premium paid to purchase held-to-maturity investment securities was $54,385 and $0 for the three months ended September 30, 2019 and 2018, respectively. The premium paid to purchase held-to-maturity investment securities was $158,548
and $205,038 for the nine months ended September 30, 2019 and 2018, respectively. The premium paid to purchase held-to-maturity investment securities was $378,681 for the year ended December 31, 2018.

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